
<html lang="en"     class="pb-page"  data-request-id="c4cbbbb4-afa5-4884-85f1-d3e3b1fc31c8"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2020.63.issue-17;article:article:10.1021/acs.jmedchem.0c00691;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Systematic Variation of Pyrrolobenzodiazepine (PBD)-Dimer Payload Physicochemical Properties Impacts Efficacy and Tolerability of the Corresponding Antibody–Drug Conjugates" /></meta><meta name="dc.Creator" content="Leanna R.  Staben" /></meta><meta name="dc.Creator" content="Jinhua  Chen" /></meta><meta name="dc.Creator" content="Josefa dela  Cruz-Chuh" /></meta><meta name="dc.Creator" content="Geoff  del Rosario" /></meta><meta name="dc.Creator" content="Mary Ann  Go" /></meta><meta name="dc.Creator" content="Jun  Guo" /></meta><meta name="dc.Creator" content="S. Cyrus  Khojasteh" /></meta><meta name="dc.Creator" content="Katherine R.  Kozak" /></meta><meta name="dc.Creator" content="Guangmin  Li" /></meta><meta name="dc.Creator" content="Carl  Ng" /></meta><meta name="dc.Creator" content="Gail D.  Lewis Phillips" /></meta><meta name="dc.Creator" content="Thomas H.  Pillow" /></meta><meta name="dc.Creator" content="Rebecca K.  Rowntree" /></meta><meta name="dc.Creator" content="John  Wai" /></meta><meta name="dc.Creator" content="BinQing  Wei" /></meta><meta name="dc.Creator" content="Keyang  Xu" /></meta><meta name="dc.Creator" content="Zijin  Xu" /></meta><meta name="dc.Creator" content="Shang-Fan  Yu" /></meta><meta name="dc.Creator" content="Donglu  Zhang" /></meta><meta name="dc.Creator" content="Peter S.  Dragovich" /></meta><meta name="dc.Description" content="Cytotoxic pyrrolobenzodiazepine (PBD)-dimer molecules are frequently utilized as payloads for antibody–drug conjugates (ADCs), and many examples are currently in clinical development. In order to f..." /></meta><meta name="Description" content="Cytotoxic pyrrolobenzodiazepine (PBD)-dimer molecules are frequently utilized as payloads for antibody–drug conjugates (ADCs), and many examples are currently in clinical development. In order to f..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="July 31, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c00691" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00691" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c00691" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00691" /></link>
        
    
    

<title>Systematic Variation of Pyrrolobenzodiazepine (PBD)-Dimer Payload Physicochemical Properties Impacts Efficacy and Tolerability of the Corresponding Antibody–Drug Conjugates | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c00691" /></meta><meta property="og:title" content="Systematic Variation of Pyrrolobenzodiazepine (PBD)-Dimer Payload Physicochemical Properties Impacts Efficacy and Tolerability of the Corresponding Antibody–Drug Conjugates" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/large/jm0c00691_0020.jpeg" /></meta><meta property="og:description" content="Cytotoxic pyrrolobenzodiazepine (PBD)-dimer molecules are frequently utilized as payloads for antibody–drug conjugates (ADCs), and many examples are currently in clinical development. In order to further explore this ADC payload class, the physicochemical properties of various PBD-dimer molecules were modified by the systematic introduction of acidic and basic moieties into their chemical structures. The impact of these changes on DNA binding, cell membrane permeability, and in vitro antiproliferation potency was, respectively, determined using a DNA alkylation assay, PAMPA assessments, and cell-based cytotoxicity measurements conducted with a variety of cancer lines. The modified PBD-dimer compounds were subsequently incorporated into CD22-targeting ADCs, and these entities were profiled in a variety of in vitro and in vivo experiments. The introduction of a strongly basic moiety into the PBD-dimer scaffold afforded a conjugate with dramatically worsened mouse tolerability properties relative to ADCs derived from related payloads, which lacked the basic group." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c00691"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00691">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c00691&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c00691&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c00691&amp;href=/doi/10.1021/acs.jmedchem.0c00691" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 17</span><span class="cit-fg-pageRange">, 9603-9622</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/17" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c00665" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c00768" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Systematic Variation of Pyrrolobenzodiazepine (PBD)-Dimer Payload Physicochemical Properties Impacts Efficacy and Tolerability of the Corresponding Antibody–Drug Conjugates</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Leanna R. Staben</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Leanna R. Staben</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Leanna+R.++Staben">Leanna R. Staben</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jinhua Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jinhua Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">WuXi AppTec Co., Ltd, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jinhua++Chen">Jinhua Chen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Josefa dela Cruz-Chuh</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Josefa dela Cruz-Chuh</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Josefa+dela++Cruz-Chuh">Josefa dela Cruz-Chuh</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Geoff del Rosario</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Geoff del Rosario</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Geoff++del+Rosario">Geoff del Rosario</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mary Ann Go</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mary Ann Go</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mary+Ann++Go">Mary Ann Go</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jun Guo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jun Guo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jun++Guo">Jun Guo</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">S. Cyrus Khojasteh</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">S. Cyrus Khojasteh</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=S.+Cyrus++Khojasteh">S. Cyrus Khojasteh</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Katherine R. Kozak</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Katherine R. Kozak</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Katherine+R.++Kozak">Katherine R. Kozak</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Guangmin Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Guangmin Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Guangmin++Li">Guangmin Li</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Carl Ng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Carl Ng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Carl++Ng">Carl Ng</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Gail D. Lewis Phillips</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gail D. Lewis Phillips</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gail+D.++Lewis+Phillips">Gail D. Lewis Phillips</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Thomas H. Pillow</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Thomas H. Pillow</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Thomas+H.++Pillow">Thomas H. Pillow</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rebecca K. Rowntree</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rebecca K. Rowntree</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rebecca+K.++Rowntree">Rebecca K. Rowntree</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">John Wai</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">John Wai</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">WuXi AppTec Co., Ltd, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=John++Wai">John Wai</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">BinQing Wei</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">BinQing Wei</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=BinQing++Wei">BinQing Wei</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Keyang Xu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Keyang Xu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Keyang++Xu">Keyang Xu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zijin Xu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zijin Xu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">WuXi AppTec Co., Ltd, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zijin++Xu">Zijin Xu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Shang-Fan Yu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shang-Fan Yu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shang-Fan++Yu">Shang-Fan Yu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Donglu Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Donglu Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Donglu++Zhang">Donglu Zhang</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Peter S. Dragovich</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Peter S. Dragovich</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Tel: 650-467-6854. Email: <a href="/cdn-cgi/l/email-protection#d6b2a4b7b1b9a0bfb5bef8a6b3a2b3a496b1b3b8b3f8b5b9bb"><span class="__cf_email__" data-cfemail="aecadccfc9c1d8c7cdc680decbdacbdceec9cbc0cb80cdc1c3">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Peter+S.++Dragovich">Peter S. Dragovich</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7372-2862" title="Orcid link">http://orcid.org/0000-0001-7372-2862</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00691&amp;href=/doi/10.1021%2Facs.jmedchem.0c00691" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 17</span><span class="cit-pageRange">, 9603–9622</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">July 31, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>6 May 2020</li><li><span class="item_label"><b>Published</b> online</span>31 July 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 10 September 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c00691" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00691</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D9603%26pageCount%3D20%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DLeanna%2BR.%2BStaben%252C%2BJinhua%2BChen%252C%2BJosefa%2Bdela%2BCruz-Chuh%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D17%26contentID%3Dacs.jmedchem.0c00691%26title%3DSystematic%2BVariation%2Bof%2BPyrrolobenzodiazepine%2B%2528PBD%2529-Dimer%2BPayload%2BPhysicochemical%2BProperties%2BImpacts%2BEfficacy%2Band%2BTolerability%2Bof%2Bthe%2BCorresponding%2BAntibody%25E2%2580%2593Drug%2BConjugates%26numPages%3D20%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D9622%26publicationDate%3DSeptember%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c00691"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1000</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c00691" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Systematic Variation of Pyrrolobenzodiazepine (PBD)-Dimer Payload Physicochemical Properties Impacts Efficacy and Tolerability of the Corresponding Antibody–Drug Conjugates&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Leanna&quot;,&quot;last_name&quot;:&quot;R. Staben&quot;},{&quot;first_name&quot;:&quot;Jinhua&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Josefa&quot;,&quot;last_name&quot;:&quot;dela Cruz-Chuh&quot;},{&quot;first_name&quot;:&quot;Geoff&quot;,&quot;last_name&quot;:&quot;del Rosario&quot;},{&quot;first_name&quot;:&quot;Mary&quot;,&quot;last_name&quot;:&quot;Ann Go&quot;},{&quot;first_name&quot;:&quot;Jun&quot;,&quot;last_name&quot;:&quot;Guo&quot;},{&quot;first_name&quot;:&quot;S.&quot;,&quot;last_name&quot;:&quot;Cyrus Khojasteh&quot;},{&quot;first_name&quot;:&quot;Katherine&quot;,&quot;last_name&quot;:&quot;R. Kozak&quot;},{&quot;first_name&quot;:&quot;Guangmin&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Carl&quot;,&quot;last_name&quot;:&quot;Ng&quot;},{&quot;first_name&quot;:&quot;Gail&quot;,&quot;last_name&quot;:&quot;D. Lewis Phillips&quot;},{&quot;first_name&quot;:&quot;Thomas&quot;,&quot;last_name&quot;:&quot;H. Pillow&quot;},{&quot;first_name&quot;:&quot;Rebecca&quot;,&quot;last_name&quot;:&quot;K. Rowntree&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;Wai&quot;},{&quot;first_name&quot;:&quot;BinQing&quot;,&quot;last_name&quot;:&quot;Wei&quot;},{&quot;first_name&quot;:&quot;Keyang&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Zijin&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Shang-Fan&quot;,&quot;last_name&quot;:&quot;Yu&quot;},{&quot;first_name&quot;:&quot;Donglu&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Peter&quot;,&quot;last_name&quot;:&quot;S. Dragovich&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;07&quot;,&quot;day&quot;:&quot;31&quot;,&quot;issue&quot;:&quot;17&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;9603-9622&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c00691&quot;},&quot;abstract&quot;:&quot;Cytotoxic pyrrolobenzodiazepine (PBD)-dimer molecules are frequently utilized as payloads for antibody–drug conjugates (ADCs), and many examples are currently in clinical development. In order to further explore this ADC payload class, the physicochemical properties of various PBD-dimer molecules were modified by the systematic introduction of acidic and basic moieties into their chemical structures. The impact of these changes on DNA binding, cell membrane permeability, and in vitro antiproliferation potency was, respectively, determined using a DNA alkylation assay, PAMPA assessments, and cell-based cytotoxicity measurements conducted with a variety of cancer lines. The modified PBD-dimer compounds were subsequently incorporated into CD22-targeting ADCs, and these entities were profiled in a variety of in vitro and in vivo experiments. The introduction of a strongly basic moiety into the PBD-dimer scaffold afforded a conjugate with dramatically worsened mouse tolerability properties relative to ADCs derived&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00691&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00691" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00691&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00691" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00691&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00691" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00691&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00691&amp;href=/doi/10.1021/acs.jmedchem.0c00691" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c00691" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c00691" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c00691%26sid%3Dliteratum%253Aachs%26pmid%3D32787101%26genre%3Darticle%26aulast%3DStaben%26date%3D2020%26atitle%3DSystematic%2BVariation%2Bof%2BPyrrolobenzodiazepine%2B%2528PBD%2529-Dimer%2BPayload%2BPhysicochemical%2BProperties%2BImpacts%2BEfficacy%2Band%2BTolerability%2Bof%2Bthe%2BCorresponding%2BAntibody%25E2%2580%2593Drug%2BConjugates%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D17%26spage%3D9603%26epage%3D9622%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (3)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a>,</li><li><a href="/action/doSearch?ConceptID=291754" title="Molecules">Molecules</a>,</li><li><a href="/action/doSearch?ConceptID=292149" title="Testing and assessment">Testing and assessment</a>,</li><li><a href="/action/doSearch?ConceptID=292504" title="Permeability">Permeability</a>,</li><li><a href="/action/doSearch?ConceptID=291290" title="Conjugate acid-base pairs">Conjugate acid-base pairs</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/17" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/jmcmar.2020.63.issue-17/20200910/jmcmar.2020.63.issue-17.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/medium/jm0c00691_0020.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/large/jm0c00691_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00691&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Cytotoxic pyrrolobenzodiazepine (PBD)-dimer molecules are frequently utilized as payloads for antibody–drug conjugates (ADCs), and many examples are currently in clinical development. In order to further explore this ADC payload class, the physicochemical properties of various PBD-dimer molecules were modified by the systematic introduction of acidic and basic moieties into their chemical structures. The impact of these changes on DNA binding, cell membrane permeability, and <i>in vitro</i> antiproliferation potency was, respectively, determined using a DNA alkylation assay, PAMPA assessments, and cell-based cytotoxicity measurements conducted with a variety of cancer lines. The modified PBD-dimer compounds were subsequently incorporated into CD22-targeting ADCs, and these entities were profiled in a variety of <i>in vitro</i> and <i>in vivo</i> experiments. The introduction of a strongly basic moiety into the PBD-dimer scaffold afforded a conjugate with dramatically worsened mouse tolerability properties relative to ADCs derived from related payloads, which lacked the basic group.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76782" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76782" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Pyrrolobenzodiazepine (PBD)-dimers are compounds that form covalent DNA interstrand cross-links in a sequence-dependent manner and that exhibit broad-spectrum subnanomolar antiproliferative activities against a variety of cancer cell lines.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Because of their exceptional cell potencies, PBD-dimers have been extensively employed as antibody–drug conjugate (ADC) payloads, and ADCs bearing such entities have been studied in advanced preclinical experiments and/or human clinical trials.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> For example, SG2057 {(11aS,11a′S)-8,8′-(pentane-1,5-diylbis(oxy))bis(7-methoxy-2-methylene-1,2,3,11a-tetrahydro-5<i>H</i>-benzo[<i>e</i>]pyrrolo[1,2-<i>a</i>][1,4]diazepin-5-one), compound <b>1</b>} was incorporated into ADCs designed to treat acute myeloid leukemia (AML)<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> or HER2-expressing cancers,<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> while SG3199 {(11aS,11a′<i>S</i>)-8,8′-(pentane-1,5-diylbis(oxy))bis(7-methoxy-2-methyl-1,11a-dihydro-5<i>H</i>-benzo[<i>e</i>]pyrrolo[1,2-<i>a</i>][1,4]diazepin-5-one), compound <b>2</b>} was employed as a component of rovalpituzumab tesirine (“Rova-T”), which progressed to phase 3 clinical trials for the treatment of small-cell lung cancer.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> In addition, SG1882 {(<i>S</i>)-2-(4-aminophenyl)-7-methoxy-8-(3-(((<i>S</i>)-7-methoxy-2-(4-methoxyphenyl)-5-oxo-5,11a-dihydro-1<i>H</i>-benzo[<i>e</i>]pyrrolo[1,2-<i>a</i>][1,4]diazepin-8-yl)oxy)-propoxy)-1,11a-dihydro-5<i>H</i>-benzo[<i>e</i>]pyrrolo[1,2-<i>a</i>][1,4]diazepin-5-one, compound <b>3</b>} was the cytotoxic payload associated with vadastuximab talirine that was assessed in phase 3 trials to treat acute myeloid leukemia (AML).<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Several additional PBD-dimer-containing ADCs are currently undergoing clinical evaluation against a variety of cancers including loncastuximab tesirine (ADCT-402),<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> ADCT-601,<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> MEDI-2228,<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> and camidanlumab tesirine (ADCT-301).<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> In spite of these advancements, the late-stage clinical failures of both Rova-T<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> and vadastuximab talirine<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> suggest that additional optimization of the PBD-dimer entities may be required in order to fully realize the therapeutic potential of this ADC payload class (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/medium/jm0c00691_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/large/jm0c00691_0001.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Representative cytotoxic PBD-dimers employed as ADC payloads.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/large/jm0c00691_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00691&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">As part of our own explorations of PBD-dimer-containing ADCs, which also employed linkers that afforded lysosomal cleavage,<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2,3)</a> we wished to better understand how modifications to the physicochemical properties of the cytotoxic payloads impacted the <i>in vitro</i> and <i>in vivo</i> performance of the associated conjugates. In particular, we were curious to learn how the incorporation of acidic or basic moieties into the chemical structures of typical PBD-dimers might alter the efficacy and/or tolerability outcomes associated with ADCs constructed from the modified payloads. We also desired to understand how the results of these alterations compared to those associated with other well-known ADC payload classes. Prior studies of related ADC payload modifications include a comparison of cell-permeable and cell-impermeable auristatin derivatives (MMAE and MMAF, respectively),<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> modification of maytansinoid-derived payload physicochemical properties,<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> and examination of topoisomerase inhibitor payloads with varying cell-permeability characteristics.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> However, there are currently few published examples that study the impact of physicochemical property modification of the PBD-dimer ADC payload class.<a onclick="showRef(event, 'ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref15 ref16">(15,16)</a> In this report, we describe our efforts to systematically modify PBD-dimer physicochemical properties via the introduction of various ionizable functional groups as part of a focused effort to better understand such impacts. We also detail <i>in vitro</i> and <i>in vivo</i> testing results of antibody–drug conjugates derived from the new PBD-dimer entities that explore how these payload modifications alter ADC bioactivity in both <i>in vitro</i> and <i>in vivo</i> settings. In addition, we compare the physicochemical property effects observed for the modified PBD-dimers and associated conjugates with those previously reported for other ADC payload classes.<a onclick="showRef(event, 'ref12 ref13 ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14 ref15">(12−15)</a></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56525" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56525" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">We began our explorations by identifying a location within the PBD-dimer chemical structure that could be employed for the introduction of the desired diverse ionizable functionalities without significantly impacting the ability of the molecules to bind to the DNA minor groove and subsequently cross-link the nucleic acid.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> We were inspired by our previous studies that examined ADCs constructed from noncleavable linker drugs bearing a centrally located phenyl moiety in the PBD-dimer structure (e.g., compound <b>4</b>, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Such ADCs were highly active in both <i>in vitro</i> and <i>in vivo</i> experiments, and these results indicated that the alkyne/PEG fragment, which would remain attached to the PBD-dimer core structure following lysosomal catabolism of the associated antibody, did not significantly impede DNA binding and/or alkylation by the cytotoxic compound. We, therefore, sought to utilize a related alkyne-based attachment strategy to derivatize the PBD-dimer core structure with the desired ionizable functional groups. Accordingly, we designed compounds <b>5</b>–<b>9</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) in which the various structural changes were incorporated at the terminus of the phenyl-alkyne moiety present in the center of the PBD-dimer molecules. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, the functionalities employed in <b>5</b>–<b>9</b> were purposely selected to span a range of acidic and basic moieties with the methyl group present in <b>7</b> serving as a nonionizable (neutral) comparator. In addition, the degree to which these acidic and basic groups ionized was expected to vary as the compounds transitioned between various biological environments as a result of their antibody-mediated intracellular delivery (e.g., compound <b>6</b> was anticipated to be predominantly ionized in the neutral cytosol but significantly less so in the weakly acidic lysosome). As part of these designs, we also envisioned subsequently connecting the new PBD-dimer entities to antibodies using well-precedented dipeptide-containing linkers that could be attached to the N-10 positions of the PBD structures (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/medium/jm0c00691_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/large/jm0c00691_0002.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Alkyne-containing PBD-dimer linker drug employed in our previous studies (ref <a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/large/jm0c00691_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00691&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Structures and Physicochemical and Biological Properties of Compounds <b>5</b>–<b>9</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/medium/jm0c00691_0016.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/medium/jm0c00691_0017.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Percent of unalkylated single-strand DNA remaining following independent exposure of double-stranded DNA to 100 μM of each compound for 1 h. 0 = strong alkylation observed, 100 = no (weak) alkylation observed.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">PAMPA effective permeability determined for each compound at indicated pH; >20 = high, 10–20 = medium, <10 = low.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">Antiproliferation activity determined in cell-culture experiments using the indicated cell line. Data are presented as geometric means (<i>n</i> = 4 per group); 95% confidence intervals are listed in <a href="/doi/suppl/10.1021/acs.jmedchem.0c00691/suppl_file/jm0c00691_si_001.pdf" class="ext-link">Table S1</a>.</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last">p<i>K</i><sub>a</sub> value of the R-group appended to each compound calculated using the MoKa software package (version 2.6.6).</p></div><div class="footnote" id="t1fn5"><sup><sup>e</sup></sup><p class="last">Average of antiproliferation values determined for each compound using a panel of 5–7 cell lines. See <a href="/doi/suppl/10.1021/acs.jmedchem.0c00691/suppl_file/jm0c00691_si_001.pdf" class="ext-link">Table S2</a> for more details.</p></div><div class="footnote" id="t1fn6"><sup><sup>f</sup></sup><p class="last">pH = 6.2.</p></div><div class="footnote" id="t1fn7"><sup><sup>g</sup></sup><p class="last">Value does not include two tested cell lines with IC<sub>50</sub> outcomes >100 000 pM.</p></div><div class="footnote" id="t1fn8"><sup><sup>h</sup></sup><p class="last">Conjugate acid. NA = not applicable. ND = not determined.</p></div></div><div></div></div><div class="NLM_p">As was observed in our prior work,<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> modeling studies performed with <b>5</b>–<b>9</b> suggested that the alkyne fragments would protrude away from the DNA minor groove into the solvent and thereby minimize the impact of the various terminal functional groups on the ability of the new molecules to bind to DNA (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). To confirm that this was indeed the case, we assessed the ability of each compound to alkylate a fragment of double-stranded DNA that contained a sequence known to be efficiently recognized by this class of cytotoxic agents.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> In this semiquantitative assessment, the methyl-containing compound <b>7</b> exhibited DNA alkylation activity that was somewhat weaker than that displayed by the reference compound <b>1</b>, which lacked the centrally located phenyl-alkyne moiety (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). This outcome likely reflects altered interactions of the two PBD-dimers with the double-stranded oligonucleotide that presumably result from the different linkers used to connect the PBD-monomer units.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/medium/jm0c00691_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/large/jm0c00691_0003.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Composite model of compounds <b>5</b>–<b>9</b> binding to the DNA minor groove. The pink atom indicates the location of ionizable groups attached to the terminus of the central phenyl-alkyne moiety.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/large/jm0c00691_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00691&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We then compared the DNA alkylation properties of compounds <b>5</b>, <b>6</b>, <b>8</b>, and <b>9</b> to those of <b>7</b> to determine the impact of the various ionizable groups that resided in the former molecules. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, the weakly basic pyridine-containing compound <b>8</b> was equipotent with <b>7</b>, while the strongly basic <b>9</b> was more active (similar to reference compound <b>1</b>). In contrast, the strongly acidic molecule <b>5</b> was somewhat less active than <b>7</b>. These outcomes suggested that the positioning of the strongly ionizable moieties present in <b>5</b> and <b>9</b> by the designed alkyne fragment did not completely eliminate electrostatic interactions between those entities and the negatively charged phosphate backbone of the test oligonucleotide. The weaker alkylation activity exhibited by compound <b>8</b> relative to <b>9</b> likely results from only minimal ionization of the pyridine moiety at the neutral pH of the assay as compared to the considerable protonation expected for the dimethylamino group. Somewhat surprisingly, the tetrazole-containing compound <b>6</b> displayed strong DNA alkylation properties that were analogous to those exhibited by reference compound <b>1</b>. The origin of this activity is not known at this time but may involve the interaction of the (presumably ionized) tetrazole moiety with the test oligonucleotide and/or its associated water network in a manner that somehow compensates for the anticipated unfavorable electrostatic interactions with the DNA phosphates.</div><div class="NLM_p">An important caveat associated with the above assessments is that a single fragment of test DNA was used to compare the molecules, and this fragment may not perfectly represent all nucleic acid sequences that are expected to be targeted by the molecules in cells. The semiquantitative nature of the alkylation assay employed also adds some uncertainty to the described comparisons. In spite of these limitations, the DNA-binding assessments indicated that compounds <b>5</b>–<b>9</b> all retained measurable DNA alkylation properties that were considerably differentiated from a minor groove binding reference compound that was incapable of covalently modifying the nucleic acid (compound <b>10</b>, <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). For this reason, we chose to continue with the assessment of <b>5</b>–<b>9</b> as ADC payloads, and the associated biological data will be reported later in this work. However, although we attempted to normalize DNA affinity among the new PBD-dimer molecules via the above assessments, this variable may still partially contribute to the <i>in vitro</i> and <i>in vivo</i> outcomes described for the associated compounds and conjugates (see below for specific instances where this situation may apply).</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/medium/jm0c00691_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/large/jm0c00691_0004.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Reference compound <b>10</b> employed in DNA alkylation assessments as an inactive control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/large/jm0c00691_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00691&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We expected the ionizable groups present in compounds <b>5</b>, <b>6</b>, <b>8</b>, and <b>9</b> to impact their cell membrane permeability relative to the nonionizable methyl fragment incorporated into compound <b>7</b>. Given the nature and diversity of the ionizable moieties, we also expected the pH of the assay media to influence the outcomes. Accordingly, we employed PAMPA testing<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> as a surrogate for cell membrane permeability and assessed the new molecules at two different pH values. The first value (pH 4.0) was selected to mimic the lysosomal environment that the molecules were expected to encounter shortly after their release from a catabolized antibody–drug conjugate. The second value (pH 7.4) was intended to duplicate the cellular cytosol as well as the extracellular environment. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, the measured PAMPA Pe parameters correlated well with the calculated p<i>K</i><sub>a</sub> data for the various compounds at both pH values tested. In particular, the strongly acidic <b>5</b> exhibited low PAMPA Pe outcomes relative to neutral compound <b>7</b> at both pH 4.0 and 7.4. In contrast, the weakly acidic <b>6</b> displayed a much larger Pe at the former pH compared to the latter value that was consistent with its reduced ionization under the more acidic conditions. PAMPA results for the two basic molecules <b>8</b> and <b>9</b> were also predictably influenced by the pH employed in the assessments with both compounds exhibiting smaller Pe values at the more acidic pH relative to neutral conditions. Collectively, the PAMPA data indicated that PBD-dimers <b>5</b>–<b>9</b> might exhibit differing permeabilities toward biological membranes and that such differences would likely be dependent on the pH of the associated biological environment.</div><div class="NLM_p">We then assessed the ability of compounds <b>5</b>–<b>9</b> to exhibit antiproliferation effects in <i>in vitro</i> cell-based experiments. This testing was conducted at near-neutral pH (7.4), and two diverse cell lines were employed: the B-cell-derived BJAB line and the KPL4 breast cancer line. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, compound <b>5</b>, which contained the most acidic functional group and which displayed the lowest PAMPA Pe values, was not active in the cell-based assessments when tested to relatively high concentrations (20 nM). In stark contrast, the neutral molecule <b>7</b> exhibited picomolar antiproliferation effects in both cell lines that were similar to those displayed by the well-characterized control compound <b>1</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). These data suggested that, as a result of sulfonic acid ionization at physiological pH, compound <b>5</b> was not able to effectively transition through the outer membranes of either employed cell line (differences in DNA binding/alkylation between <b>5</b> and <b>7</b> may also have contributed somewhat to the observed outcomes). The weakly acidic <b>6</b> also exhibited significantly impaired activity in these cell assays relative to compound <b>7</b> but was surprisingly more active than compound <b>5</b> in spite of a similarly low pH 7.4 PAMPA Pe value. The improved DNA alkylation properties of <b>6</b> relative to <b>5</b> may have contributed to the latter outcome. In contrast, the molecules bearing basic functional groups (<b>8</b> and <b>9</b>) displayed only slightly attenuated antiproliferation potencies relative to <b>7</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). The latter results were consistent with both <b>8</b> and <b>9</b> exhibiting PAMPA values at pH 7.4 that were predictive of good or moderate membrane permeability characteristics. In addition, the stronger DNA alkylation properties of <b>9</b> as compared to <b>7</b> may have helped compensate for the lower pH 7.4 PAMPA Pe value (and presumed poorer cell membrane permeability) displayed by the former molecule. Reassuringly, the BJAB and KPL4 outcomes also paralleled antiproliferation results obtained by testing compounds <b>5</b>–<b>9</b> against panels of five, six, or seven additional diverse cancer cell lines (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.0c00691/suppl_file/jm0c00691_si_001.pdf" class="ext-link">Supporting Information</a>).</div><div class="NLM_p">Having profiled the new PBD-dimer compounds in the various <i>in vitro</i> assessments described above in unconjugated form, we sought to attach them to antibodies to further characterize their biological properties. Accordingly, we prepared CD22-targeting antibody conjugates <b>11a</b>–<b>15a</b> and the corresponding HER2 ADCs <b>11b</b>–<b>15b</b> (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). The well-known Valine-Citrulline (Val-Cit) protease-cleavable dipeptide trigger was incorporated into the design of these conjugates, and the PBD-dimer payloads were connected to this moiety via an N10 carbamate functional group and a <i>para</i>-amino-benzyloxy (PAB) self-immolative spacer.<a onclick="showRef(event, 'ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref21 ref22">(21,22)</a> ADCs bearing related PBD-dimer payloads that were linked to the antibodies via similar N10 carbamates displayed strong antigen-dependent anticancer activity in both <i>in vitro</i> and <i>in vivo</i> assessments.<a onclick="showRef(event, 'ref4 ref22'); return false;" href="javascript:void(0);" class="ref ref4 ref22">(4,22)</a> These prior outcomes suggested that efficient delivery of the associated PBD-dimer payloads occurred following treatment of cells and tumors with the conjugates, and we were therefore confident that equally favorable delivery outcomes would occur with the new molecules under study. In addition, the new conjugates <b>11a</b>–<b>15a</b> and <b>11b</b>–<b>15b</b> were constructed via maleimide derivatization of cysteine residues that were engineered into the LC-K149 location of the antibody structures [drug–antibody ratios (DARs) of ∼2.0].<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> This location and connection approach were known from our prior studies to afford conjugates that exhibited highly favorable <i>in vitro</i> and <i>in vivo</i> stability properties.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Significant retro-Michael-related deconjugation was therefore not expected to be observed with the new ADCs. In addition, the CD22 antigen was known to be highly expressed on BJAB cells,<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> and conjugates that target this entity had previously shown strong <i>in vitro</i> and <i>in vivo</i> biological activities.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Similarly, HER2 was well-precedented as an ADC target, and the antigen was highly expressed on KPL4 breast cancer cells (IHC 3+).<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Conversely, the CD22 antigen was not highly expressed on KPL4 cells, and the HER2 receptor was not significantly present on the surface of B-cell lines (e.g., BJAB). These differential expression patterns enabled the CD22 and HER2 conjugates to serve as respective negative (i.e., nontargeted) controls for KPL4 and B-cell ADC experiments.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Structures and Biological Properties of Conjugates <b>11a</b>–<b>15a</b> and <b>11b</b>–<b>15b</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/medium/jm0c00691_0018.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/medium/jm0c00691_0019.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">p<i>K</i><sub>a</sub> value of the R-group appended to each PBD-dimer payload calculated using the MoKa software package (version 2.6.6).</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Drug–antibody ratio.</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">Antiproliferation activity determined in cell-culture experiments using the indicated cell line. As these assessments were not all simultaneously performed, an appropriate control conjugate (<b>16a</b> or <b>16b</b>) was included in every determination to serve as an activity benchmark. Data are presented as geometric means (<i>n</i> = 4 per group); 95% confidence intervals are listed in <a href="/doi/suppl/10.1021/acs.jmedchem.0c00691/suppl_file/jm0c00691_si_001.pdf" class="ext-link">Table S3</a>. The targeted antigen expressed by each cell line (CD22 or HER2) is listed at the top of each column.</p></div><div class="footnote" id="t2fn4"><sup><sup>d</sup></sup><p class="last">Control ADC (<b>16a</b>) IC<sub>50</sub> was weaker than typically observed (BJAB = 74 ng/mL; WSU-DLCL2 = 20 ng/mL).</p></div><div class="footnote" id="t2fn5"><sup><sup>e</sup></sup><p class="last">Conjugate acid.</p></div><div class="footnote" id="t2fn6"><sup><sup>f</sup></sup><p class="last">Control ADC, which releases compound <b>1</b> PBD-dimer payload (see <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>).</p></div><div class="footnote" id="t2fn7"><sup><sup>g</sup></sup><p class="last">LC-V205 antibody attachment site; the alternate attachment site is not anticipated to impact <i>in vitro</i> potency relative to the LC-K149 site. NA = not applicable. ND = not determined. Star symbol = second copy of the attached linker drug.</p></div></div><div></div></div><div class="NLM_p">As shown in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> and <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>, all of the CD22-targeting conjugates <b>11a</b>–<b>15a</b> exhibited strong antiproliferation activities when tested against the BJAB cell lines that were similar to the potency displayed by a control conjugate that incorporated the well-known PBD-dimer <b>1</b> (<b>16a</b>, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). In contrast, the corresponding HER2 conjugates <b>11b</b>–<b>15b</b> afforded drastically weaker outcomes in the BJAB assessments (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). These results were consistent with the antigen-selective delivery of the new PBD-dimer payloads to the BJAB cells via the CD22-targeting ADCs. Related antiproliferation outcomes were also observed when the conjugates were tested against a second B-cell-derived and CD22-expressing cell line (WSU-DLCL2, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>; see <a href="/doi/suppl/10.1021/acs.jmedchem.0c00691/suppl_file/jm0c00691_si_001.pdf" class="ext-link">Figure S1</a> for CD22 expression in WSU-DLCL2 cells). The near-equal activity of ADCs <b>11a</b>–<b>15a</b> against the B-cell lines was notable, given the disparate antiproliferation potencies of the unconjugated PBD-dimer payloads depicted in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> above (see <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a> as well). The strong activities of conjugates <b>11a</b> and <b>12a</b> against the BJAB line were particularly striking in light of the dramatically attenuated potencies observed for the corresponding unconjugated payloads against the same cell line (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>, <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). The described results paralleled those reported earlier for the auristatin-derived, acid-containing ADC payload MMAF, which is a relatively weak <i>in vitro</i> antiproliferative agent in unconjugated form but which exhibits significantly more potent cell-based activity when appropriately conjugated to an antibody.<a onclick="showRef(event, 'cit12a'); return false;" href="javascript:void(0);" class="ref cit12a">(12a)</a> Note that <b>12a</b> exhibited anti-BJAB activity that was similar to control conjugate <b>16a</b> when both conjugates were tested side-by-side in the same antiproliferation assessment (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Thus, when normalized based on the activity of control compound <b>1</b>, <b>12a</b> is believed to be approximately equipotent with <b>11a</b> and <b>13a</b>–<b>15a</b> against the B-cell lines.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/medium/jm0c00691_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/large/jm0c00691_0005.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. <i>In vitro</i> antiproliferation activities of PBD-dimer conjugates as a function of cell line. Antiproliferation data are taken from <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>. The targeted antigen expressed by each cell line (CD22 or HER2) is listed below each name. p<i>K</i><sub>a</sub> values refer to the R-group appended to each PBD-dimer payload and were calculated using the MoKa software package (version 2.6.6); red = acidic, blue = basic (conjugate acid). (*) Control ADC (<b>16a</b>) IC<sub>50</sub> was weaker than typically observed; see <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> for additional details.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/large/jm0c00691_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00691&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/medium/jm0c00691_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/large/jm0c00691_0006.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Structure of control conjugates <b>16a</b> (CD22) and <b>16b</b> (HER2). Star symbol = second copy of the attached linker drug.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/large/jm0c00691_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00691&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/medium/jm0c00691_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/large/jm0c00691_0007.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. BJAB or KPL4 <i>in vitro</i> antiproliferation activities of PBD-dimer conjugates as a function of free payload <i>in vitro</i> antiproliferation potency. Antiproliferation data are taken from <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>. The targeted antigen expressed by each cell line (CD22 or HER2) is listed below each name. p<i>K</i><sub>a</sub> values refer to the R-group appended to each PBD-dimer payload and were calculated using the MoKa software package (version 2.6.6); red = acidic, blue = basic (conjugate acid). (*) Control ADC (<b>16a</b>) IC<sub>50</sub> was weaker than typically observed; see <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> for additional details.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/large/jm0c00691_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00691&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">These results suggested that the PBD-dimer payloads containing acidic functional groups (including highly ionizable moieties such as the sulfonic acid present in <b>5</b>) were able to efficiently transition from the cellular lysosome to the cytosol and/or nucleus following antibody-mediated delivery. In the case of <b>5</b>, this transition occurred in spite of the payload exhibiting a low PAMPA Pe value at lysosomal pH that was suggestive of poor membrane permeability (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). The origin of the potent <i>in vitro</i> antiproliferation activity of conjugates <b>11a</b> and <b>12a</b> is not known with certainty at this time. Some possibilities include (1) active transport of the released payloads across the lysosomal membrane,<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> (2) the lysosomal membrane being a more porous barrier with respect to small-molecule passive permeability relative to the outer cell membrane, and (3) underestimation of payload membrane permeability properties via the PAMPA assessment. Additional experiments are thus required to further define the precise mechanism(s) by which these modified PBD-dimer ADC payloads exert their <i>in vitro</i> biological activities.</div><div class="NLM_p">Strong <i>in vitro</i> antiproliferation potencies were also noted for the CD22-targeting conjugates whose PBD-dimer payloads contained added basic moieties. Both ADCs <b>14a</b> and <b>15a</b> were equipotent with conjugate <b>13a</b> for which the payload was the control molecule bearing the neutral methyl R-group (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a> and <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>). As with conjugate <b>11a</b> above, the <i>in vitro</i> activity of <b>15a</b> was unexpected since the corresponding unconjugated payload associated with the latter ADC exhibited a low PAMPA Pe value at lysosomal pH (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Like conjugate <b>11a</b>, the potent activity of <b>15a</b> suggested efficient transition of the released payload from the lysosome to the cellular cytosol and/or nucleus following antibody-mediated delivery by mechanisms that are not fully understood at this time (see above for some possibilities).</div><div class="NLM_p">Importantly, potent antigen-dependent antiproliferation activities were also observed when the HER2-targeting conjugates <b>11b</b>–<b>15b</b> were tested against the KPL4 cell line (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). The majority of the ADCs whose payloads contained ionizable groups were equipotent in the KPL4 assessments to the conjugate for which the payload lacked any added ionizable functionality (compare <b>12b</b>, <b>14b</b>, and <b>15b</b>, with <b>13b</b>; <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). The one possible exception to this trend was conjugate <b>11b</b>, which exhibited an approximately 10-fold weaker KPL4 IC<sub>50</sub> value relative to <b>13b</b> (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). This result may reflect reduced lysosome-cytosol transition efficiency in the KPL4 cells for the sulfonic acid-containing PBD-dimer payload (<b>5</b>) corresponding to <b>11b</b> relative to what was observed in the BJAB line. However, the outcome may also be related to the reduced DNA alkylation activity displayed by payload <b>5</b> compared to the PBD-dimer associated with conjugate <b>13b</b> (compound <b>7</b>, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). The described data mirrored results observed previously with maytansine-containing trastuzumab-MCC-DM1 (T-DM1), which generates a cell-impermeable catabolite, but is nevertheless highly potent against the KPL4 cell line.<a onclick="showRef(event, 'cit27c ref29'); return false;" href="javascript:void(0);" class="ref cit27c ref29">(27c,29)</a> Importantly, the KPL4 outcomes also confirmed that the potent <i>in vitro</i> antiproliferation activities displayed by conjugates bearing the new PBD-dimer payloads were associated with cancers in addition to those of B-cell origin. Reassuringly, none of the tested conjugates were particularly active when tested against the Jurkat cell line, which did not express either the CD22 or HER2 antigen to a significant degree (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>).<a onclick="showRef(event, 'ref25 ref30'); return false;" href="javascript:void(0);" class="ref ref25 ref30">(25,30)</a></div><div class="NLM_p">We were curious to understand how the <i>in vitro</i> biological activities observed for the ADCs described above would translate into <i>in vivo</i> antitumor efficacy studies. As shown in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A, single intravenous administration of CD22-targeting conjugate <b>13a</b> (0.3 mg/kg) to mice bearing WSU-DLCL2 xenografts afforded strong and durable antitumor efficacy over an extended observation time period. Alternatively, the administration of a matched dose of ADC <b>12a</b> resulted in considerably weaker <i>in vivo</i> activity against the same WSU-DLCL2 model. These outcomes contrasted with the <i>in vitro</i> studies described in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> above in which the two conjugates exhibited highly similar WSU-DLCL2 antiproliferation potencies (when normalized relative to control conjugate activity). One possibility for the differing <i>in vitro</i> and <i>in vivo</i> anticancer results is a greater dependency on bystander effects for efficacy in the xenograft studies relative to the cell-culture environment. Based on the PAMPA (pH 7.4) and antiproliferation characterizations depicted in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, the PBD-dimer released from <b>12a</b> (compound <b>6</b>) was not expected to permeate from cell to cell as effectively as the corresponding payload delivered by <b>13a</b> (compound <b>7</b>). Such intercellular transition differences may be magnified in the environment of the WSU-DLCL2 tumors relative to cell-culture assessments since a greater proportion of the xenografted tumor cells are likely not exposed to direct contact by the administered ADCs. Encouragingly, the <i>in vivo</i> WSU-DLCL2 efficacy of conjugate <b>12a</b> could be increased by administering a higher dose to the test animals (compare 1.0 mg/kg efficacy outcomes with the 0.3 mg/kg results, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A). Consistent with the involvement of bystander effects in WSU-DLCL2 efficacy outcomes, the activity of conjugate <b>11a</b> (bearing the least cell-permeable PBD-dimer payload <b>5</b>; cf., <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) was attenuated relative to that observed for ADC <b>12a</b> when 1.0 mg/kg doses of the two conjugates were compared (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A). Importantly, all the conjugates tested in these initial <i>in vivo</i> assessments exhibited minimal effects on mouse body weights during the course of the studies (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>B).</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/medium/jm0c00691_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/large/jm0c00691_0008.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. <i>In vivo</i> activity of conjugates <b>11a</b>, <b>12a</b>, and <b>13a</b> in the WSU-DLCL2 xenograft model. (A) Efficacy (tumor growth inhibition). (B) Impact on mouse body weights. Blue traces, <b>11a</b>; red traces, <b>12a</b>; green traces, <b>13a</b>; black traces, vehicle control. Numbers next to traces indicate doses of each conjugate (in mg/kg) that were administered once IV at the day 0 time point. Group mean tumor volumes or body weight changes (±SEM) are plotted over the duration of the study (<i>n</i> = 8/group). See <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a> for additional details.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/large/jm0c00691_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00691&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Intrigued by the above observations, we further probed the impact of the payload modifications on <i>in vivo</i> activity by conducting a second xenograft study using the WSU-DLCL2 model. <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>A depicts the efficacy outcomes that were observed when conjugates <b>11a</b> and <b>13a</b> were tested at the 1.0 mg/kg dose level in this new experiment. As was observed in our initial <i>in vivo</i> assessment of the two conjugates, the antitumor efficacy displayed by <b>11a</b> (bearing the less cell-permeable payload) was attenuated relative to the activity exhibited by <b>13a</b>. We also compared the performance of HER2-targeting control conjugates <b>11b</b> and <b>13b</b> in this experiment (both administered at 1.0 mg/kg) and were surprised to observe the highly disparate outcomes depicted in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>A for the two ADCs. Specifically, strong <i>in vivo</i> efficacy was noted for <b>13b</b> that was similar to that observed for ADC <b>13a</b> at the later time points of the study. In contrast, the HER2-targeting <b>11b</b> displayed no <i>in vivo</i> efficacy, and the poor performance of this conjugate was easily distinguished from that of the related and much-more-active CD22-targeting ADC (<b>11a</b>). Stability assessments performed with conjugates <b>11a</b> and <b>13a</b> confirmed minimal deconjugation of the attached linker drugs 7 days after their administration to mice (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00691/suppl_file/jm0c00691_si_001.pdf" class="ext-link">Figure S2</a>). In addition, no obvious biotransformations of the PBD-dimer payloads were observed in these studies. Similar excellent <i>in vivo</i> stability properties are expected to be associated with all conjugates described in this work. Collectively, these data suggested that the permeability differences associated with the PBD-dimer payloads delivered by conjugates <b>11a</b> and <b>13a</b> (compounds <b>5</b> and <b>7</b>, respectively; <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) may have influenced the antigen-independent activities of the corresponding HER2 conjugates (<b>11b</b> and <b>13b</b>) in this WSU-DLCL2 <i>in vivo</i> experiment. However, we did not compare the <i>in vivo</i> activities of <b>11b</b> and <b>13b</b> at lower doses (a 0.3 mg/kg dose of the related CD22 conjugate <b>13a</b> is sufficient to regress the WSU-DLCL2 tumor model; <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A), and we cannot rule out that the outcomes observed with <b>13b</b> are simply a result of overdosing the conjugate. As was the case with our initial assessments in this tumor model with conjugates <b>11a</b>, <b>12a</b>, and <b>13a</b>, it is possible that bystander effects contributed to the observed nonspecific outcomes shown in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a> and such phenomena were minimized by the poor cell permeability associated with the PBD-dimer payload delivered by conjugates <b>11a</b> and <b>11b</b>. Interestingly, the activity displayed by conjugates <b>11b</b> and <b>13b</b> in the <i>in vivo</i> experiment paralleled the <i>in vitro</i> antiproliferation outcomes observed for the ADCs (and the corresponding CD22-targeting conjugates) in nonspecific activity assessments employing Jurkat cells that did not express either the HER2 or CD22 antigens (i.e., <b>13a</b>/<b>13b</b> were more potent than <b>11a</b>/<b>11b</b>, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). As was also observed in our initial <i>in vivo</i> assessments, all the conjugates tested in these subsequent WSU-DLCL2 experiments did not significantly impact mouse body weights over the duration of the studies (although minor body weight loss was noted for conjugate <b>13a</b> when administered at the 1.0 mg/kg dose level, <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>B).</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/medium/jm0c00691_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/large/jm0c00691_0009.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. <i>In vivo</i> activity of conjugates <b>11a</b>, <b>11b</b>, <b>13a</b>, and <b>13b</b> in the WSU-DLCL2 xenograft model. (A) Efficacy (tumor growth inhibition). (B) Impact on mouse body weights. Blue traces (solid line), <b>11a</b>; blue traces (dotted line), <b>11b</b>; green traces (solid line), <b>13a</b>; green traces (dotted line), <b>13b</b>; black traces, vehicle control. Numbers next to traces indicate doses of each conjugate (in mg/kg) that were administered once IV at the day 0 time point. Group mean tumor volumes (± SEM) are plotted over the duration of the study (<i>n</i> = 5/group). See <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a> for additional details.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/large/jm0c00691_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00691&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To complete our <i>in vivo</i> assessments of the conjugates bearing the new PBD-dimer payloads, we profiled ADCs <b>13a</b>, <b>14a</b>, and <b>15a</b> in the WSU-DLCL2 xenograft model. All of the tested conjugates exhibited strong efficacy in these assessments following single IV administrations at relatively low doses (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>A). Consistent with the efficacy outcomes associated with ADCs whose PBD-dimer payloads contained acidic functional groups, conjugate <b>15a</b> (bearing the least-permeable and strongly basic PBD-dimer) displayed somewhat attenuated <i>in vivo</i> antitumor activity relative to <b>13a</b> and <b>14a</b> at the 0.3 mg/kg dose (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>A; cf., <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). More strikingly, conjugate <b>15a</b> also had a much more deleterious impact on mouse body weights as compared to <b>13a</b> and <b>14a</b> when the ADCs were administered at the 1.0 mg/kg dose level (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>B and <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a>B). Collectively, these data indicated that the introduction of a strongly basic moiety into the PBD-dimer payload structure simultaneously worsened the <i>in vivo</i> efficacy and mouse tolerability outcomes of the corresponding ADCs as compared to conjugates bearing unmodified (neutral) PBD-dimer molecules. These outcomes may be related to the propensity of strongly basic small-molecules to indiscriminately bind to acidic tissue constituents (e.g., membrane phospholipids) and/or accumulate in acidic cellular compartments such as the lysosome.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Similarly, basic radioactive labels were observed to be widely distributed to the tissues of xenografted mice following administration of the corresponding radiolabeled antibodies.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Additional studies involving other PBD-dimer scaffolds, alternate <i>in vivo</i> efficacy models, and more-complete toxicology assessments are required to fully assess the generality of these observations. However, the current data suggest that improvements in the preclinical performance of PBD-dimer-containing ADCs can be realized by not including strongly basic moieties in the associated payloads.</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/medium/jm0c00691_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/large/jm0c00691_0010.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. <i>In vivo</i> activity of conjugates <b>13a</b>, <b>14a</b>, and <b>15a</b> in the WSU-DLCL2 xenograft model. (A) Efficacy (tumor growth inhibition). (B) Impact on mouse body weights. Green traces, <b>13a</b>; orange traces, <b>14a</b>; purple traces, <b>15a</b>; black traces, vehicle control. Numbers next to traces indicate doses of each conjugate (in mg/kg) that were administered once IV at the day 0 time point. Group mean tumor volumes (± SEM) are plotted over the duration of the study (<i>n</i> = 5/group). See <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a> for additional details.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/large/jm0c00691_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00691&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The unconjugated PBD-dimers described in this work were prepared by the methods depicted in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. For the synthesis of compounds <b>6</b>, <b>8</b>, and <b>9</b>, iodo-containing intermediate <b>17</b> (prepared as depicted in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>) was coupled to various alkynes (<b>19</b>–<b>21</b>) using well-precedented protocols.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Subsequent removal of the Boc-protecting groups present in the coupling products (<b>22</b>–<b>24</b>) afforded the desired PBD-dimers. The 1-dimethylamino-2-propyne (<b>19</b>) required for the synthesis of <b>22</b> was obtained from commercial sources, while the preparations of alkynes <b>20</b> [5-(but-3-yn-1-yl)-1<i>H</i>-tetrazole] and <b>21</b> [4-(but-3-yn-1-yl)pyridine] are described in <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a> below. Alternatively, the known THP-containing intermediate <b>18</b><a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> was similarly coupled to commercially available propargyl alcohol (<b>25</b>) or 1-butyne (<b>26</b>) to, respectively, give products <b>27</b> and <b>28</b>. The latter entity was deprotected under acidic conditions to afford PBD-dimer <b>7</b>. The former compound was transformed into sulfonic acid <b>29</b> (via propargyl bromide <b>28</b>), and the THP moieties present in <b>29</b> were subsequently removed to give PBD-dimer <b>5</b>.</div><figure id="sch1" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/medium/jm0c00691_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/large/jm0c00691_0011.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Unconjugated PBD-Dimers <b>5</b>–<b>9</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/large/jm0c00691_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00691&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) alkyne, Et<sub>2</sub>NH, Pd(Ph<sub>3</sub>P)<sub>4</sub>, CuI, DMF, 100 °C, 10–20 min, 40–67%; (b) TFA, 0–15 °C, 1 h, 15–80%; (c) Et<sub>3</sub>N, MsCl, DCM, 15 °C, 0.5 h; (d) LiBr, THF, 10 °C, 16 h, 94%; (e) Na<sub>2</sub>SO<sub>3</sub>, 3:1 MeOH/H<sub>2</sub>O, 60 °C, 6 h, 31%. THP = 2-tetrahydropyran.</p></p></figure><div class="NLM_p">The ADCs described in this work were prepared by conjugating anti-CD22 10F4v3 LC-K149C or anti-HER2 7C2 LC-K149C mAbs to linker drugs <b>31</b>–<b>35</b> via the engineered LC-K149C cysteine residues according to previously published protocols (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>).<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> ADCs produced using the conjugation reaction conditions and purification schemes typically afforded protein yields from 25 to 95%. All of the conjugates were characterized in regards to aggregation (SEC HPLC), drug to antibody ratio (LC–MS), and amount of unconjugated (free) drug present in the final conjugates (LC–MS). Detailed characterization data for each conjugate are provided in Table S4 (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00691/suppl_file/jm0c00691_si_001.pdf" class="ext-link">Supporting Information</a>).</div><figure id="sch2" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/medium/jm0c00691_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/large/jm0c00691_0012.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Preparation of Antibody–Drug Conjugates <b>11a</b>–<b>15a</b> and <b>11b</b>–<b>15b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/large/jm0c00691_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00691&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) DMF, Tris pH 6.5 to 7.5, 25 °C, 3–24 h.</p></p></figure><div class="NLM_p">The linker drugs required for the preparation of the ADCs described in this work were synthesized by the methods depicted in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>. The nitro groups present in intermediate <b>36</b> (prepared as shown in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>) were reduced to afford the corresponding bis-aniline compound (<b>37</b>), and this entity was monoprotected in moderate yield by exposure to one equivalent of di-<i>tert</i>-butyl dicarbonate to give <b>38</b>. Transformation of the unprotected aniline contained in <b>38</b> to the corresponding isocyanate (or possibly the carbamic chloride) followed by condensation with commercially available Boc-Val-Cit-PAB–OH afforded carbamate <b>39</b> in reasonable yield. The silyl-protecting groups present in <b>39</b> were removed under acidic conditions to generate diol <b>40</b>, and this intermediate was oxidized with IBX<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> to give compound <b>41</b>. As detailed in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> for the unconjugated PBD-dimers, the coupling of <b>41</b> with alkynes <b>19</b>, <b>20</b>, <b>21</b>, and <b>25</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>) was accomplished using Sonogoshira protocols<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> to afford compounds <b>43b</b>–<b>43e</b> in good-to-moderate yields. The sulfonic acid-containing linker drug <b>43a</b> was prepared by directly coupling prop-2-yne-1-sulfonic acid <b>42</b> (prepared as described in <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a> below) to <b>41</b> in contrast to the related multistep synthesis employed in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> to generate the corresponding unconjugated PBD-dimer <b>5</b>. Removal of the Boc-protecting groups present in compounds <b>43a</b>–<b>43e</b> followed by coupling of the deprotected intermediates (not shown) to commercially available 6-maleimidocaproic acid <i>N</i>-hydroxysuccinate ester afforded the desired linker drugs <b>31</b>–<b>35</b> in low-to-moderate yield following purification by preparative HPLC methods.</div><figure id="sch3" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/medium/jm0c00691_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/large/jm0c00691_0013.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Preparation of Linker Drugs <b>31</b>–<b>35</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/large/jm0c00691_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00691&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Fe, NH<sub>4</sub>Cl, 2:1 EtOH/H<sub>2</sub>O, 80 °C, 2 h, 100%; (b) Boc<sub>2</sub>O, THF, 75 °C, 3 h, 36%; (c) Et<sub>3</sub>N, triphosgene, 4 Å sieves, DCM, 25 °C, 1 h, then Boc-Val-Cit-PAB–OH, DMF, 25 °C, 16 h, 81%; (d) HOAc, 3:1 THF/H<sub>2</sub>O, 25 °C, 16 h, 79%; (e) IBX, DMSO, 38 °C, 16 h, 43%; (f) alkyne, Et<sub>2</sub>NH, Pd(Ph<sub>3</sub>P)<sub>4</sub>, CuI, DMF, 25 °C, 12–48 h, 25–61%; (g) TFA, 0 °C, 1 h; (h) MC-OSu, (<i>i</i>-Pr)<sub>2</sub>NEt, DMF, 25 °C, 10–72 h, 15–32%. TBS = Si(CH<sub>3</sub>)<sub>2</sub>tBu.</p></p></figure><figure id="sch4" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/medium/jm0c00691_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/large/jm0c00691_0014.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Preparation of Intermediates <b>17</b> and <b>36</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/large/jm0c00691_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00691&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaBH<sub>4</sub>, CaCl<sub>2</sub>, EtOH, 0–25 °C, 2 h, 72%; (b) CBr<sub>4</sub>, PPh<sub>3</sub>, DCM, 0–25 °C, 12 h, 35%; (c) <i>n</i>-Bu<sub>4</sub>NI, K<sub>2</sub>CO<sub>3</sub>, DMF, 60 °C, 6 h, 63%; (d) NaClO<sub>2</sub>, NaH<sub>2</sub>PO<sub>4</sub>·2H<sub>2</sub>O, H<sub>2</sub>O<sub>2</sub>, THF, 25–45 °C, 4 h, 93%; (e) HNO<sub>3</sub>, 25 °C, 16 h, 58%; (f) oxalyl chloride, DCM, 25 °C, 4 h, then <b>50</b>, Et<sub>3</sub>N, −40 to 0 °C, crude; (g) LiOH·2H<sub>2</sub>O, 1:1 THF/H<sub>2</sub>O, 25 °C, 3 h, 50% over 2 steps; (h) TBSCl, imidazole, DMF, 0–25 °C, 3 h, 67%; (i) Fe, NH<sub>4</sub>Cl, 2:1 EtOH/H<sub>2</sub>O, 90 °C, 2 h, 78%; (j) Boc<sub>2</sub>O, THF, 90 °C, 6 h, 99%; (k) HOAc, 2:1 THF/H<sub>2</sub>O, 18 °C, 48 h, 90%; (l) DMP, DCM, 14 °C, 16 h, 53%. TBS = Si(CH<sub>3</sub>)<sub>2</sub>tBu.</p></p></figure><div class="NLM_p">The syntheses of intermediates <b>17</b> and <b>36</b> required for the preparation of unconjugated PBD-dimers and related linker drugs described above are illustrated in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>. Commercially available diester <b>44</b> was reduced to afford diol <b>45</b>, which was subsequently transformed into dibromide <b>46</b> in a moderate overall yield on >100 g scale.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Coupling of <b>46</b> with commercially available 4-hydroxy-3-methoxybenzaldehyde (vanillin) provided intermediate <b>47</b>, and this entity was oxidized via the combination of NaClO<sub>2</sub>, NaH<sub>2</sub>PO<sub>4</sub>·2H<sub>2</sub>O, and H<sub>2</sub>O<sub>2</sub> to give diacid <b>48</b> in good yield. Nitration of <b>48</b> proceeded smoothly to afford the dinitro-diacid <b>49</b> in moderate yield. This entity was converted to the corresponding diacid-chloride (not shown), which was then coupled with trifluoroacetic acid salt <b>50</b> (prepared from the corresponding Boc-protected pyrrolidine;<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> not shown) to give intermediate <b>51</b>. The acetate-protecting groups present in the crude material thus obtained were removed via mild basic hydrolysis, and the resulting diol (<b>52</b>) was subsequently converted to the bis-<i>tert</i>-butyl-dimethylsilyl ether (intermediate <b>36</b>). Reduction of the nitro groups present in <b>36</b> followed by protection of the resulting anilines as the corresponding Boc-derivatives afforded intermediate <b>53</b> in good overall yield. Removal of the silyl-protecting groups present in <b>53</b> followed by oxidation of the resulting diol (not shown) with the Dess–Martin periodinane<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> provided intermediate <b>17</b> in moderate yield after purification by preparative thin-layer chromatography.<named-content content-type="anchor" rid="sch5" type="simple"></named-content></div><figure id="sch5" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/medium/jm0c00691_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/large/jm0c00691_0015.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Preparation of Alkynes <b>20</b>, <b>21</b>, and <b>42</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/large/jm0c00691_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00691&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaI, DMSO, 0–20 °C, 2 h, then NaCN, 80 °C, 2 h, 54%; (b) Et<sub>3</sub>N·HCl, NaN<sub>3</sub>, toluene, 25–115 °C, 10 h, 52%; (c) <i>n</i>-BuLi, (<i>i</i>-Pr)<sub>2</sub>NH, THF, −78 to 50 °C, 45 min, then (3-bromoprop-1-yn-1-yl)trimethylsilane, 20 °C, 3 h, 23%; (d) <i>n</i>-Bu<sub>4</sub>NF, THF, 20 °C, 20 min, 99%; (e) Na<sub>2</sub>SO<sub>3</sub>, 1:1 MeOH/H<sub>2</sub>O, 80 °C, 8 h, 98%.</p></p></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23530" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23530" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">This work describes the systematic variation of PBD-dimer physicochemical properties in an effort to better understand how such modifications impact the <i>in vitro</i> and <i>in vivo</i> performance of antibody–drug conjugates derived from the new compounds. The presented results complement a recent disclosure by others that explored PBD-dimer lipophilicity modulation as a means to improve conjugation efficiencies.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> As demonstrated by the conducted experiments and resulting data, alterations that significantly ameliorated the antiproliferation activities of the unconjugated PBD-dimer molecules (presumably due to poor cell membrane permeability properties) had relatively little impact on the <i>in vitro</i> cell potencies of the corresponding ADCs. These results paralleled those reported previously for other ADC payload classes such as auristatins and maytansinoids. A greater influence of these changes was noted <i>in vivo</i> with conjugates bearing low-permeable PBD-dimers exhibiting reduced xenograft efficacy relative to ADCs derived from payloads, which exhibited more favorable membrane permeability characteristics. The former conjugates also displayed the largest activity differences when compared to the corresponding nontargeting control ADCs in the <i>in vivo</i> assessments. In spite of their attenuated potencies, conjugates derived from PBD-dimer payload <b>5</b> (containing the sulfonic acid moiety) were nevertheless active in both <i>in vitro</i> and <i>in vivo</i> assessments. Such conjugates, along with related new entities derived from <b>5</b>, thus enable the biological exploration of PBD-dimer-containing ADCs, which release free payloads that are devoid of bystander effects. Importantly, the introduction of a strongly basic amine moiety into the PBD-dimer payload structure significantly worsened mouse tolerability outcomes of the related ADCs relative to conjugates derived from less-basic PBD-dimer molecules. It is expected that this collective information will enable the design of new PBD-dimer-containing ADCs with improved therapeutic potential relative to existing entities.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41177" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41177" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> General Chemistry Methods</h3><div class="NLM_p last">Unless otherwise indicated, all reagents and solvents were purchased from commercial sources and were used without further purification. Moisture- or oxygen-sensitive reactions were conducted under an atmosphere of argon or nitrogen gas. Unless otherwise stated, <sup>1</sup>H NMR spectra were recorded at 300 or 400 MHz using Varian or Bruker instruments operating at the indicated frequencies. Chemical shifts are expressed in ppm (δ) relative to an internal standard; tetramethylsilane (ppm = 0.00). The following abbreviations are used: br = broad signal, s = singlet, d = doublet, dd = doublet of doublets, t = triplet, q = quartet, p = pentet, m = multiplet. Purification by silica gel chromatography was carried out using Biotage systems with prepacked cartridges. Chemical purities were ≥95% for all final compounds as assessed by LC–MS analysis at UV 220 nm.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Molecular Modeling</h3><div class="NLM_p last">Based on the solution structure of PBD-monomer covalently bound to a standard B-DNA helix (PBD entry 2KTT),<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> models of PBD-dimer variants (<b>5</b>–<b>9</b>) bound in the DNA minor groove were created as previously described.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> For example, in the model for <b>7</b>, two covalent bonds (bond length 1.47–1.49 Å) between the C11/C11′ atom of two PBD-monomers and the exocyclic N2 atom of two deoxyguanines, which are separated by four base pairs on opposite DNA strands, serve to anchor the PBD-dimer snugly inside the minor groove.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> PAMPA Testing</h3><div class="NLM_p">PAMPA permeability for DNA alkylators was determined using a previously published method (Pion, Inc.). The compound concentration was 50 μM dissolved in 100 mM phosphate buffer before filtering. The receiver pH was 7.4, and the donor pH was either 4 or 7.4. The incubation was performed at 37 °C for 4 h. The amount of compound permeated through the membrane was quantified by relative UV absorbance at 250–500 nm, and the permeability Pe was calculated using the formula below.<span class="NLM_disp-formula" id="ueq1"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/medium/jm0c00691_m001.gif" alt="" id="_i16" /></img></span><i>P</i><sub>e</sub> = permeability (cm/s)</div><div class="NLM_p"><i>V</i><sub>D</sub> = donor volume (0.3 mL)</div><div class="NLM_p"><i>V</i><sub>A</sub> = donor volume (0.2 mL)</div><div class="NLM_p"><i>C</i><sub>equilibrium</sub> = [(<i>C</i><sub>D</sub> × <i>V</i><sub>D</sub>) – (<i>C</i><sub>A</sub> × <i>V</i><sub>A</sub>)]/<i>V</i><sub>D</sub> – <i>V</i><sub>A</sub></div><div class="NLM_p"><i>S</i> = membrane area (0.3 cm<sup>2</sup>)</div><div class="NLM_p last"><i>t</i> = incubation time (sec)</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> DNA Alkylation Assessments</h3><div class="NLM_p last">Two complementary single-strand DNA oligonucleotides (Oligo 1:5′-TATAGAAATCTATA-3′ and Oligo 2:3′-ATATCTTTAGATAT-5′) were synthesized at Genentech as designed previously.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> The compounds <b>1</b> and <b>5</b>–<b>10</b> were incubated at 100 μM with double-stranded DNA Oligos 1 and 2 (100 μM) for 1 h in Bis-Tris buffer pH 7.1 (10 mM) at 37 °C. The samples were analyzed by LC–MS/UV (210–450 nm) on a Sciex TripleTOF 5600 mass spectrometer. The LC conditions were as follows: Hypersil Gold C18 column (100 × 2.1 mm, 1.9 μm, Thermo Scientific), flow rate of 0.4 mL/min and mobile phases A (50 mM hexafluoro-isopropanol and 15 mM diethylamine) and B (50% A and 50% of 1:1 methanol/acetonitrile) with a gradient of 5% B 0–0.5 min, 5–25% B 0.5–25 min, 25–95% B 25–40 min, and 95% B 40–42 min. The measured percent remaining value determined for each compound was an average of the starting DNA oligos remaining in incubations (<i>n</i> = 2) compared to those in the control incubations of compound <b>10</b> (variability was <10% between measurements). The products were characterized by LC–MS in a negative ESI ion mode. Under these conditions, all small molecules were eluted in the column wash after the gradient.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Antiproliferation Experiments (Unconjugated Compounds)</h3><div class="NLM_p last">Cells were seeded in 384-well plates and treated with unconjugated compounds 24 h later. After 4 days of continuous drug incubation, the cell viabilities were determined using CellTiter Glo II reagent (Promega; Madison, WI). The luminescent intensities were measured on a PerkinElmer Envision reader. The relative cell viabilities were calculated by normalizing to nondrug treatment controls and were graphed using the KleidaGraph software package. The IC<sub>50</sub> values were determined as the concentrations required to obtain 50% of the maximum cell killing.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Antiproliferation Experiments (Conjugates)</h3><div class="NLM_p">On day 0, suspension cell lines, BJAB (CD22-positive) and WSU-DLCL2 (CD22-positive) cells and Jurkat (CD22 and HER2-negative) cells, were seeded at 4000 cells per well in 40 μL RPMI-1640 culture media supplemented with 10% fetal bovine serum, 2 mM glutamine, 50 μM cystine, and 0.015 g/L <span class="smallcaps smallerCapital">l</span>-methionine in 384-well flat clear bottom white polystyrene tissue culture-treated microplates (Corning, NY). Antibody–drug conjugates, 2 mg/mL in 20 mM histidine acetate, 240 mM sucrose, 0.02% PS20 pH 5.5 buffer, were transferred to cells seeded in 384-well plates using ECHO acoustic liquid handling technology (Labcyte Inc., Sunnyvale, CA) to create a 10-point dose–response curve in triplicate starting from 20 μg/mL with 1:3× serial dilution. Cells were cultured in a humidified incubator set at 37 °C and maintaining an atmosphere of 5% CO<sub>2</sub>. On day 4, cells were equilibrated to room temperature, then 40 μL/well CellTiter Glo II reagent (Promega; Madison, WI) was added, and plates were shaken for 10 min then incubated for 30 min at RT in the dark. Luminescence was read using an EnVision 2101 Multilabel Reader (PerkinElmer, Waltham, MA). Normalized luminescence intensity data were analyzed using GraphPad Prism 6, and IC<sub>50</sub> values were calculated using a four-parameter sigmoidal fit.</div><div class="NLM_p last">KPL4 (HER2-positive) cells were plated in black-walled 96-well plates and allowed to adhere overnight at 37 °C in a humidified atmosphere of 5% CO<sub>2</sub>. The medium was then removed and replaced by a fresh culture medium containing different concentrations of antibody–drug conjugates. After 5 days, CellTiter Glo reagent (Promega Corp.) was added to the wells for 10 min at room temperature, and the luminescent signal was measured using EnVision Multilabel Plate Reader (PerkinElmer).</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> <i>In Vivo</i> Efficacy Studies</h3><div class="NLM_p">All animal studies were carried out in compliance with the National Institutes of Health guidelines for the care and use of laboratory animals and were approved by the Institutional Animal Care and Use Committee at Genentech, Inc.</div><div class="NLM_p">The efficacy of the anti-CD22-drug conjugates was evaluated in a mouse xenograft model of CD22-expressing WSU-DLCL2 human non-Hodgkin’s lymphoma. The WSU-DLCL2 cell line was obtained from DSMZ (German Collection of Microorganisms and Cell Cultures; Braunschweig, Germany). To set up the xenograft model, tumor cells (20 million cells in 0.2 mL Hank’s Balanced Salt Solution; Hyclone) were inoculated subcutaneously into the flanks of female C.B-17 SCID mice (Charles Rivers Laboratories). When tumors reached the desired volume (∼200 mm<sup>3</sup>), animals were divided into groups of 5–8 mice with similar mean tumor size and received a single intravenous injection of antibody–drug conjugates through the tail vein (referred to as Day 0). The treatment information was not blinded during tumor measurement. Tumors were measured in two dimensions (length and width) using calipers, and the tumor volume was calculated using the formula: tumor size (mm<sup>3</sup>) = 0.5 (length × width × width). Changes in mouse body weights were reported as a percentage relative to the starting weight. Tumor sizes and mouse weights were recorded over the course of the study. Mice whose tumor volumes exceeded 2000 mm<sup>3</sup> or whose body weight losses were 20% of their starting weight were promptly euthanized per IACUC guidelines. Results were plotted as mean (±SEM) tumor volume or body weight change of each group over time.</div><div class="NLM_p last">Blood samples were collected via retro-orbital bleeds from animals and were used to derive plasma for <i>in vivo</i> ADC stability assessments. All blood samples were collected into tubes containing lithium heparin and were allowed to sit on wet ice until centrifugation (within 15 min of collection). Samples were centrifuged at 10 000 rpm for 5 min at 4 °C. Plasma was then collected, placed on dry ice, and stored in a freezer set at −70 °C until analysis.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Compound Syntheses</h3><div class="NLM_p">The preparation of unconjugated PBD-dimer <b>9</b> is provided below as a representative example of the syntheses of compounds <b>6</b>, <b>8</b>, and <b>9</b>. Characterization data for compounds <b>6</b> and <b>8</b> are provided following the information associated with <b>9</b>. The preparations of the required noncommercial alkynes (<b>20</b> and <b>21</b>; <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>) are described at the end of the compound synthesis section.</div><div id="sec4_8_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> Di-<i>tert</i>-butyl 8,8′-(((5-(3-(Dimethylamino)prop-1-yn-1-yl)-1,3-phenylene)bis(methylene))-bis(oxy))(11S,11aS,11′S,11a′S)-bis(11-hydroxy-7-methoxy-2-methylene-5-oxo-2,3,11,11a-tetrahydro-1<i>H</i>-benzo[<i>e</i>]pyrrolo[1,2-<i>a</i>][1,4]diazepine-10(5<i>H</i>)-carboxylate) (<b>22</b>)</h4><div class="NLM_p last">Pd(PPh<sub>3</sub>)<sub>4</sub> (25.9 mg, 0.02 mmol) was added to a mixture of compound <b>17</b> (110 mg, 0.11 mmol), 1-dimethylamino-2-propyne (<b>19</b>, 47 mg, 0.56 mmol), Et<sub>2</sub>NH (164 mg, 2.24 mmol), CuI (4.3 mg, 0.02 mmol) and 4 Å MS (30 mg) in anhydrous DMF (3 mL). The reaction mixture was heated via microwave irradiation at 100 °C under N<sub>2</sub> for 10 min then was cooled to 25 °C. The mixture was filtered, and the filtrate was concentrated <i>in vacuo</i> to remove the solvent. The residue was then diluted with EtOAc (100 mL), and the resulting solution was washed with brine (30 mL × 4), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The crude material thus obtained was purified by prep-HPLC (acetonitrile 35–65/10 mM NH<sub>4</sub>HCO<sub>3</sub> in water) to give compound <b>22</b> (70 mg, 67%) as a white solid. LC–MS (5–95, AB, 1.5 min): RT = 0.80 min, [M + H]<sup>+</sup> 936.7.</div></div><div id="sec4_8_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> (11aS,11a′S)-8,8′-(((5-(3-(Dimethylamino)prop-1-yn-1-yl)-1,3-phenylene)bis(methylene))bis(oxy))bis(7-methoxy-2-methylene-1,2,3,11a-tetrahydro-5<i>H</i>-benzo[<i>e</i>]pyrrolo[1,2-<i>a</i>][1,4]diazepin-5-one) (<b>9</b>)</h4><div class="NLM_p last">A solution of compound <b>22</b> (70 mg, 0.07 mmol) in TFA (3 mL) was stirred at 15 °C for 1 h. The solution was added dropwise to saturated aqueous NaHCO<sub>3</sub> solution (200 mL) at 0 °C, and the resulting mixture was extracted with DCM (40 mL × 3). The combined DCM layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. Purification of the residue by prep-TLC (10% MeOH in DCM, <i>R</i><sub><i>f</i></sub> = 0.5) afforded compound <b>9</b> (43 mg, 80%) as a white solid. LC–MS (5–95, AB, 1.5 min): RT = 0.73 min, [M + H]<sup>+</sup> 700.3. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.65 (d, <i>J</i> = 4.0 Hz, 2H), 7.52 (s, 2H), 7.47–7.44 (m, 3H), 6.80 (s, 2H), 5.19–5.10 (m, 8H), 4.28 (s, 4H), 3.96 (s, 6H), 3.88–3.86 (m, 2H), 3.49 (s, 2H), 3.14–3.08 (m, 2H), 2.95–2.91 (m, 2H), 2.38 (s, 6H).</div></div><div id="sec4_8_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> (11aS,11a′S)-8,8′-(((5-(4-(1<i>H</i>-Tetrazol-5-yl)but-1-yn-1-yl)-1,3-phenylene)bis(methylene))bis(oxy))bis(7-methoxy-2-methylene-1,2,3,11a-tetrahydro-5H-benzo[<i>e</i>]pyrrolo[1,2-<i>a</i>][1,4]diazepin-5-one) (<b>6</b>)</h4><div class="NLM_p last">LC–MS (5–95, AB, 1.5 min): RT = 0.783 min, [M + H]<sup>+</sup> 739.3.</div></div><div id="sec4_8_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> (11aS,11a′S)-8,8′-(((5-(4-(Pyridin-4-yl)but-1-yn-1-yl)-1,3-phenylene)bis(methylene))-bis(oxy))bis(7-methoxy-2-methylene-1,2,3,11a-tetrahydro-5<i>H</i>-benzo[<i>e</i>]pyrrolo[1,2-<i>a</i>][1,4]diazepin-5-one) (<b>8</b>)</h4><div class="NLM_p">LC–MS (5–95, AB, 1.5 min): RT = 0.755 min, [M + H]<sup>+</sup> 748.4. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.53 (d, <i>J</i> = 5.6 Hz, 2H), 7.66 (d, <i>J</i> = 4.8 Hz, 2H), 7.53 (s, 2H), 7.42 (s, 1H), 7.38 (s, 2H), 7.21 (d, <i>J</i> = 5.6 Hz, 2), 6.80 (s, 2H), 5.19–5.09 (m, 8H), 4.28 (s, 4H), 3.96 (s, 6H), 3.89–3.86 (m, 2H), 3.10–3.08 (m, 2H), 2.95–2.91 (m, 4H), 2.74–2.70 (m, 2H).</div><div class="NLM_p last">The preparation of unconjugated PBD-dimer <b>5</b> is provided below to illustrate the synthesis of this compound as well as compound <b>7</b>. Characterization data for compound <b>7</b> follow the information associated with <b>5</b>.</div></div><div id="sec4_8_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> Di-<i>tert</i>-butyl 8,8′-(((5-(3-Hydroxyprop-1-yn-1-yl)-1,3-phenylene)bis(methylene))bis(oxy))-(11S,11aS,11′S,11a′S)-bis(7-methoxy-2-methylene-5-oxo-11-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)-2,3,11,11a-tetrahydro-1<i>H</i>-benzo[<i>e</i>]pyrrolo[1,2-<i>a</i>][1,4]diazepine-10(5<i>H</i>)-carboxylate) (<b>27</b>)</h4><div class="NLM_p last">Pd(PPh<sub>3</sub>)<sub>4</sub> (40 mg, 0.03 mmol) was added to a mixture of compound <b>18</b><a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> (200 mg, 0.17 mmol), propargyl alcohol (<b>26</b>, 256 mg, 3.08 mmol), Et<sub>2</sub>NH (254 mg, 3.48 mmol), CuI (6.6 mg, 0.03 mmol), and 4 Å MS (50 mg) in anhydrous DMF (3 mL). The reaction mixture was heated via microwave irradiation at 100 °C under N<sub>2</sub> for 15 min then was cooled to 25 °C. The mixture was filtered, and the filtrate was concentrated <i>in vacuo</i>. The residue was diluted with EtOAc (50 mL), and the resulting solution was washed with H<sub>2</sub>O (30 mL × 4), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated <i>in vacuo</i>. The residue was purified by prep-TLC (5% MeOH in DCM, <i>R</i><sub><i>f</i></sub> = 0.5) to give compound <b>27</b> (120 mg, 60%) as a white solid. LC–MS (5–95, AB, 1.5 min): RT = 1.02 min, [M + Na]<sup>+</sup> 1099.8.</div></div><div id="sec4_8_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> Di-<i>tert</i>-butyl 8,8′-(((5-(3-Bromoprop-1-yn-1-yl)-1,3-phenylene)bis(methylene))bis(oxy))-(11S,11aS,11′S,11a′S)-bis(7-methoxy-2-methylene-5-oxo-11-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)-2,3,11,11a-tetrahydro-1<i>H</i>-benzo[<i>e</i>]pyrrolo[1,2-<i>a</i>][1,4]diazepine-10(5<i>H</i>)-carboxylate) (<b>29</b>)</h4><div class="NLM_p last">To a 15 °C solution of compound <b>27</b> (120 mg, 0.11 mmol) in anhydrous DCM (10 mL) was added Et<sub>3</sub>N (338 mg, 3.34 mmol) followed by dropwise addition of methanesulfonyl chloride (280 mg, 2.44 mmol). The reaction solution was stirred at 15 °C for 0.5 h then was diluted with DCM (50 mL). The resulting mixture was washed with H<sub>2</sub>O (20 mL × 3), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated <i>in vacuo</i> to give the crude mesylate (128 mg, 94%). To a solution of this crude material in anhydrous THF (10 mL) at 10 °C was added LiBr (48 mg, 0.55 mmol). The reaction solution was stirred at that temperature for 16 h whereupon it was diluted with DCM (50 mL). The resulting mixture was washed with H<sub>2</sub>O (20 mL × 3), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated <i>in vacuo</i> to give crude compound <b>29</b> (126 mg, 94%). LC–MS (5–95, AB, 1.5 min): RT = 1.11 min, [M + Na]<sup>+</sup> 1161.2. This material was used in the next step without further purification.</div></div><div id="sec4_8_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> 3-(3,5-Bis((((11S,11aS)-10-(<i>tert</i>-butoxycarbonyl)-7-methoxy-2-methylene-5-oxo-11-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)-2,3,5,10,11,11a-hexahydro-1<i>H</i>-benzo[<i>e</i>]pyrrolo[1,2-<i>a</i>][1,4]diazepin-8-yl)oxy)methyl)phenyl)prop-2-yne-1-sulfonic acid (<b>30</b>)</h4><div class="NLM_p last">To a mixture of compound <b>29</b> (126 mg, 0.11 mmol) in MeOH (15 mL)/water (5 mL) at 25 °C was added Na<sub>2</sub>SO<sub>3</sub> (139 mg, 1.11 mmol). The reaction mixture was stirred at 60 °C for 6 h. After cooling to 25 °C, the mixture was concentrated <i>in vacuo</i> to remove MeOH. The remaining aqueous slurry was then extracted with DCM (50 mL × 4). The combined DCM layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The residue was purified by prep-TLC (10% MeOH in DCM, <i>R</i><sub><i>f</i></sub> = 0.3) followed by prep-HPLC (acetonitrile 40–70/10 mM NH<sub>4</sub>HCO<sub>3</sub> in water) to afford compound <b>30</b> (40 mg, 31%) as a white solid. LC–MS (5–95, AB, 1.5 min): RT = 0.98 min, [M-2Boc-2THP-2H<sub>2</sub>O + H]<sup>+</sup> 737.1.</div></div><div id="sec4_8_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> 3-(3,5-Bis((((<i>S</i>)-7-methoxy-2-methylene-5-oxo-2,3,5,11a-tetrahydro-1<i>H</i>-benzo[<i>e</i>]pyrrolo-[1,2-<i>a</i>][1,4]diazepin-8-yl)oxy)methyl)phenyl)prop-2-yne-1-sulfonic Acid (<b>5</b>)</h4><div class="NLM_p last">A solution of compound <b>30</b> (25 mg, 0.02 mmol) in TFA (2 mL)/water (0.10 mL) was stirred at 15 °C for 1 h. The solution was concentrated <i>in vacuo</i> to remove the solvent, and the residue was first pH-adjusted to 9.0 by the addition of saturated aqueous NaHCO<sub>3</sub> solution (2 mL) and then was further diluted with H<sub>2</sub>O (8.0 mL). The resulting solution was purified by prep-HPLC (acetonitrile 20–50% in water) to afford compound <b>5</b> (sodium salt, 5 mg, 27%) as a white solid. LC–MS (5–95, AB, 1.5 min): RT = 0.75 min, [M + H]<sup>+</sup> 737.3.</div></div><div id="sec4_8_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> (11aS,11a′S)-8,8′-(((5-(But-1-yn-1-yl)-1,3-phenylene)bis(methylene))bis(oxy))bis(7-methoxy-2-methylene-1,2,3,11a-tetrahydro-5<i>H</i>-benzo[<i>e</i>]pyrrolo[1,2-<i>a</i>][1,4]diazepin-5-one) (<b>7</b>)</h4><div class="NLM_p">LC–MS (5–95, AB, 1.5 min): RT = 0.88 min, [M + H]<sup>+</sup> 671.4.</div><div class="NLM_p last">The preparation of linker drug <b>35</b> is provided below as a representative example of the syntheses of compounds <b>31</b>–<b>35</b>. As part of these preparations, intermediate <b>41</b> was derivatized with the appropriate alkyne to afford compounds <b>43a</b>–<b>43e</b>. The required alkynes were commercially available [1-dimethylamino-2-propyne (<b>19</b>) and but-1-yne (<b>25</b>); <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>] or were synthesized as described at the end of the chemical synthesis section (<b>20</b>, <b>21</b>, and <b>42</b>; <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>). Characterization data for compounds <b>31</b>–<b>34</b> are provided following the information associated with <b>35</b>.</div></div><div id="sec4_8_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> ((((5-Iodo-1,3-phenylene)bis(methylene))bis(oxy))bis(2-amino-5-methoxy-4,1-phenylene))bis(((<i>S</i>)-2-(((<i>tert</i>-butyldimethylsilyl)oxy)methyl)-4-methylenepyrrolidin-1-yl)methanone) (<b>37</b>)</h4><div class="NLM_p last">To a mixture of compound <b>36</b> (preparation described below; 5.00 g, 4.66 mmol) in EtOH (50 mL)/water (25 mL) was added iron (2.60 g, 47 mmol), followed by NH<sub>4</sub>Cl (4.98 g, 93 mmol). The reaction mixture was stirred at 80 °C for 2 h and then was concentrated to remove most of the EtOH. The residue was filtered and washed with EtOAc (60 mL), and the filtrate was diluted with H<sub>2</sub>O (40 mL). The resulting mixture was extracted with EtOAc (60 mL × 3), and the combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to afford compound <b>37</b> (4.70 g, 100%) as a pale yellow solid. LC–MS (5–95, AB, 1.5 min): RT = 1.16 min, [M + H]<sup>+</sup> 1013.4.</div></div><div id="sec4_8_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> <i>tert</i>-Butyl (5-((3-((5-Amino-4-((<i>S</i>)-2-(((<i>tert</i>-butyldimethylsilyl)oxy)methyl)-4-methylenepyrrolidine-1-carbonyl)-2-methoxyphenoxy)methyl)-5-iodobenzyl)oxy)-2-((<i>S</i>)-2-(((<i>tert</i>-butyldimethylsilyl)oxy)methyl)-4-methylenepyrrolidine-1-carbonyl)-4-methoxyphenyl)carbamate (<b>38</b>)</h4><div class="NLM_p last">To a 25 °C solution of compound <b>37</b> (4.70 g, 4.64 mmol) in anhydrous THF (100 mL) was added Boc<sub>2</sub>O (1.01 g, 4.64 mmol). The reaction solution was stirred at 75 °C for 3 h, then cooled to 25 °C, and was concentrated under a vacuum. The residue was purified by chromatography on silica gel (10–60% EtOAc in petroleum ether) to afford compound <b>38</b> (2.00 g, 36%) as a pale yellow solid. LC–MS (5–95, AB, 1.5 min): RT = 1.15 min, [M + H]<sup>+</sup> 1113.3. A portion of starting material <b>37</b> (2.3 g) was also recovered by subsequently eluting the silica gel column with a more polar solvent mixture (0–40% MeOH in DCM).</div></div><div id="sec4_8_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> <i>tert</i>-Butyl (5-((3-((5-((((4-((<i>S</i>)-2-((<i>S</i>)-2-((<i>tert</i>-Butoxycarbonyl)amino)-3-methylbutanamido)-5-ureidopentanamido)benzyl)oxy)carbonyl)amino)-4-((<i>S</i>)-2-(((<i>tert</i>-butyldimethylsilyl)oxy)methyl)-4-methylenepyrrolidine-1-carbonyl)-2-methoxyphenoxy)methyl)-5-iodobenzyl)oxy)-2-((<i>S</i>)-2-(((<i>tert</i>-butyldimethylsilyl)oxy)methyl)-4-methylenepyrrolidine-1-carbonyl)-4-methoxyphenyl)carbamate (<b>39</b>)</h4><div class="NLM_p last">A solution of compound <b>38</b> (400 mg, 0.36 mmol) and Et<sub>3</sub>N (182 mg, 1.8 mmol) in anhydrous DCM (10 mL) was added dropwise to a 25 °C solution of triphosgene (106 mg, 0.36 mmol) and 4 Å MS (30 mg) in anhydrous DCM (20 mL). The reaction mixture was stirred at 25 °C for 1 h and then was concentrated under a vacuum. The crude product thus obtained was used directly in the next step without further purification. To the above crude product (409 mg, 0.36 mmol) in anhydrous DCM (8.0 mL) was added Et<sub>3</sub>N (109 mg, 1.08 mmol) followed by a solution of commercially available <i>tert</i>-butyl ((<i>S</i>)-1-(((<i>S</i>)-1-((4-(hydroxymethyl)phenyl)amino)-1-oxo-5-ureidopentan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)carbamate (Boc-Val-Cit-PAB–OH, 258 mg, 0.54 mmol) in anhydrous DMF (8.0 mL). After the reaction mixture was stirred at 20 °C for 16 h, it was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (0–15% MeOH in DCM) to give compound <b>39</b> (500 mg, 81%) as a white solid. LC–MS (5–95, AB, 1.5 min): RT = 1.14 min, [(M – 100)/2 + H]<sup>+</sup> 759.7.</div></div><div id="sec4_8_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> <i>tert</i>-Butyl (5-((3-((5-((((4-((<i>S</i>)-2-((<i>S</i>)-2-((<i>tert</i>-Butoxycarbonyl)amino)-3-methylbutanamido)-5-ureidopentanamido)benzyl)oxy)carbonyl)amino)-4-((<i>S</i>)-2-(hydroxymethyl)-4-methylenepyrrolidine-1-carbonyl)-2-methoxyphenoxy)methyl)-5-iodobenzyl)oxy)-2-((<i>S</i>)-2-(hydroxymethyl)-4-methylenepyrrolidine-1-carbonyl)-4-methoxyphenyl)carbamate (<b>40</b>)</h4><div class="NLM_p last">To a solution of compound <b>39</b> (500 mg, 0.31 mmol) in THF (3.0 mL)/water (1.5 mL) was added HOAc (4.5 mL, 0.31 mmol). The reaction solution was stirred at 25 °C for 16 h then was concentrated under a vacuum. The residue was purified by chromatography on silica gel (0–15% MeOH in DCM) to afford compound <b>40</b> (390 mg, 79%) as a pale yellow solid. LC–MS (5–95, AB, 1.5 min): RT = 0.94 min, [M + H]<sup>+</sup> 1390.7.</div></div><div id="sec4_8_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 4-((<i>S</i>)-2-((<i>S</i>)-2-((<i>tert</i>-Butoxycarbonyl)amino)-3-methylbutanamido)-5-ureidopentanamido)benzyl(11S,11aS)-8-((3-((((11S,11aS)-10-(<i>tert</i>-butoxycarbonyl)-11-hydroxy-7-methoxy-2-methylene-5-oxo-2,3,5,10,11,11a-hexahydro-1<i>H</i>-benzo[<i>e</i>]pyrrolo[1,2-<i>a</i>][1,4]diazepin-8-yl)oxy)methyl)-5-iodobenzyl)oxy)-11-hydroxy-7-methoxy-2-methylene-5-oxo-2,3,11,11a-tetrahydro-1<i>H</i>-benzo[<i>e</i>]pyrrolo[1,2-<i>a</i>][1,4]diazepine-10(5<i>H</i>)-carboxylate (<b>41</b>)</h4><div class="NLM_p last">To a solution of compound <b>40</b> (100 mg, 0.07 mmol) in DMSO (8.0 mL) was added IBX (161 mg, 0.58 mmol) at 25 °C. The reaction was warmed to 38 °C and was stirred at that temperature for 16 h. The mixture was cooled to 25 °C and was poured into ice–water (15 mL). The resulting precipitate was collected by vacuum filtration and was purified by chromatography on silica gel (0–12% MeOH in DCM) to give a semipure product. This material was further purified by prep-TLC (10% MeOH in DCM, <i>R</i><sub><i>f</i></sub> = 0.5) to give compound <b>41</b> (45 mg, 43%) as a white solid. LC–MS (5–95, AB, 1.5 min): RT = 0.89 min, [M + Na]<sup>+</sup> 1408.5.</div></div><div id="sec4_8_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 4-((<i>S</i>)-2-((<i>S</i>)-2-((<i>tert</i>-Butoxycarbonyl)amino)-3-methylbutanamido)-5-ureidopentanamido)benzyl (11S,11aS)-8-((3-((((11S,11aS)-10-(<i>tert</i>-butoxycarbonyl)-11-hydroxy-7-methoxy-2-methylene-5-oxo-2,3,5,10,11,11a-hexahydro-1<i>H</i>-benzo[<i>e</i>]pyrrolo[1,2-<i>a</i>][1,4]diazepin-8-yl)oxy)methyl)-5-(3-(dimethylamino)prop-1-yn-1-yl)benzyl)oxy)-11-hydroxy-7-methoxy-2-methylene-5-oxo-2,3,11,11a-tetrahydro-1<i>H</i>-benzo[<i>e</i>]pyrrolo[1,2-<i>a</i>][1,4]diazepine-10(5<i>H</i>)-carboxylate (<b>43e</b>)</h4><div class="NLM_p last">Pd(Ph<sub>3</sub>P)<sub>4</sub> (20 mg, 0.02 mmol) was added to a mixture of compound <b>41</b> (120 mg, 0.090 mmol), Et<sub>2</sub>NH (0.18 mL, 1.73 mmol), 1-dimethylamino-2-propyne (<b>19</b>, 36 mg, 0.43 mmol), and CuI (16 mg, 0.09 mmol) in anhydrous DMF (6.0 mL) at 25 °C. The reaction solution was stirred at 25 °C under N<sub>2</sub> for 16 h and then was concentrated under a vacuum. The residue was purified by prep-TLC (12% MeOH in DCM, <i>R</i><sub><i>f</i></sub> = 0.5) to afford compound <b>43e</b> (50 mg, 41%) as a brown solid. LC–MS (5–95, AB, 1.5 min): RT = 0.81 min, [(M+H]<sup>+</sup> 1342.6.</div></div><div id="sec4_8_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 4-((<i>S</i>)-2-((<i>S</i>)-2-(6-(2,5-Dioxo-2,5-dihydro-1<i>H</i>-pyrrol-1-yl)hexanamido)-3-methylbutanamido)-5-ureidopentanamido)benzyl (11S,11aS)-8-((3-(3-(dimethylamino)prop-1-yn-1-yl)-5-((((<i>S</i>)-7-methoxy-2-methylene-5-oxo-2,3,5,11a-tetrahydro-1<i>H</i>-benzo[<i>e</i>]pyrrolo[1,2-<i>a</i>][1,4]diazepin-8-yl)oxy)methyl)benzyl)oxy)-11-hydroxy-7-methoxy-2-methylene-5-oxo-2,3,11,11a-tetrahydro-1<i>H</i>-benzo[<i>e</i>]pyrrolo[1,2-<i>a</i>][1,4]diazepine-10(5<i>H</i>)-carboxylate (<b>35</b>)</h4><div class="NLM_p last">(Part 1) A solution of compound <b>43e</b> (25 mg, 0.020 mmol) in TFA (1.5 mL, 0.02 mmol) was stirred at 0 °C for 1 h. The solution was added dropwise into saturated aqueous NaHCO<sub>3</sub> solution (40 mL) at 0 °C, and the resulting mixture was extracted with DCM/MeOH (10:1, 30 mL × 3). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude deprotected product (structure not shown, 20 mg, 76%) as a brown solid. LC–MS (5–95, AB, 1.5 min): RT = 0.72 min, [M/2 + H]<sup>+</sup> 562.5. (Part 2) To a solution of the crude material prepared above (20 mg, 0.02 mmol) and commercially available 2,5-dioxopyrrolidin-1-yl 6-(2,5-dioxo-2,5-dihydro-1<i>H</i>-pyrrol-1-yl)hexanoate (MC-OSu, 27 mg, 0.09 mmol) in anhydrous DMF (4.0 mL) was added (<i>i</i>-Pr)<sub>2</sub>NEt (11 mg, 0.09 mmol) at 25 °C. The reaction solution was stirred at that temperature for 48 h and then was concentrated under a vacuum. The residue was purified by prep-TLC (12% MeOH in DCM, <i>R</i><sub><i>f</i></sub> = 0.4) to give a semipure product. This material was combined with another batch of a semipure product (prepared on the same scale from <b>43e</b> as described above), and the combined lots were again purified by prep-TLC (12% MeOH in DCM, <i>R</i><sub><i>f</i></sub> = 0.4) to afford compound <b>35</b> (12.5 mg) as a white solid. LC–MS (5–95, AB, 1.5 min): RT = 0.78 min, [M/2 + H]<sup>+</sup> 659.1.</div></div><div id="sec4_8_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> 3-(3-((((11S,11aS)-10-(((4-((<i>S</i>)-2-((<i>S</i>)-2-(6-(2,5-Dioxo-2,5-dihydro-1<i>H</i>-pyrrol-1-yl)hexanamido)-3-methylbutanamido)-5-ureidopentanamido)benzyl)oxy)carbonyl)-11-hydroxy-7-methoxy-2-methylene-5-oxo-2,3,5,10,11,11a-hexahydro-1<i>H</i>-benzo[<i>e</i>]pyrrolo[1,2-<i>a</i>][1,4]diazepin-8-yl)oxy)methyl)-5-((((<i>S</i>)-7-methoxy-2-methylene-5-oxo-2,3,5,11a-tetrahydro-1<i>H</i>-benzo[<i>e</i>]pyrrolo[1,2-<i>a</i>][1,4]diazepin-8-yl)oxy)methyl)phenyl)prop-2-yne-1-sulfonic Acid (<b>31</b>)</h4><div class="NLM_p last">LC–MS (10–80, AB, 7.0 min): RT = 3.03 min, [M/2 + H]<sup>+</sup> 677.8.</div></div><div id="sec4_8_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 4-((<i>S</i>)-2-((<i>S</i>)-2-(6-(2,5-Dioxo-2,5-dihydro-1<i>H</i>-pyrrol-1-yl)hexanamido)-3-methylbutanamido)-5-ureidopentanamido)benzyl (11S,11aS)-8-((3-(4-(1<i>H</i>-tetrazol-5-yl)but-1-yn-1-yl)-5-((((<i>S</i>)-7-methoxy-2-methylene-5-oxo-2,3,5,11a-tetrahydro-1<i>H</i>-benzo[<i>e</i>]pyrrolo[1,2-<i>a</i>][1,4]diazepin-8-yl)oxy)methyl)benzyl)oxy)-11-hydroxy-7-methoxy-2-methylene-5-oxo-2,3,11,11a-tetrahydro-1<i>H</i>-benzo[<i>e</i>]pyrrolo[1,2-<i>a</i>][1,4]diazepine-10(5<i>H</i>)-carboxylate (<b>32</b>)</h4><div class="NLM_p last">LC–MS (5–95, AB, 1.5 min): RT = 0.70 min, [M + Na]<sup>+</sup> 1377.4.</div></div><div id="sec4_8_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 4-((<i>S</i>)-2-((<i>S</i>)-2-(6-(2,5-Dioxo-2,5-dihydro-1<i>H</i>-pyrrol-1-yl)hexanamido)-3-methylbutanamido)-5-ureidopentanamido)benzyl (11S,11aS)-8-((3-(but-1-yn-1-yl)-5-((((<i>S</i>)-7-methoxy-2-methylene-5-oxo-2,3,5,11a-tetrahydro-1<i>H</i>-benzo[<i>e</i>]pyrrolo[1,2-<i>a</i>][1,4]diazepin-8-yl)oxy)methyl)benzyl)oxy)-11-hydroxy-7-methoxy-2-methylene-5-oxo-2,3,11,11a-tetrahydro-1<i>H</i>-benzo[<i>e</i>]pyrrolo[1,2-<i>a</i>][1,4]diazepine-10(5<i>H</i>)-carboxylate (<b>33</b>)</h4><div class="NLM_p last">LC–MS (10–80, AB, 7.0 min): RT = 3.84 min, [M/2 + H]<sup>+</sup> 644.6.</div></div><div id="sec4_8_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 4-((<i>S</i>)-2-((<i>S</i>)-2-(6-(2,5-Dioxo-2,5-dihydro-1<i>H</i>-pyrrol-1-yl)hexanamido)-3-methylbutanamido)-5-ureidopentanamido)benzyl (11S,11aS)-11-hydroxy-7-methoxy-8-((3-((((<i>S</i>)-7-methoxy-2-methylene-5-oxo-2,3,5,11a-tetrahydro-1<i>H</i>-benzo[<i>e</i>]pyrrolo[1,2-<i>a</i>][1,4]diazepin-8-yl)oxy)methyl)-5-(4-(pyridin-4-yl)but-1-yn-1-yl)benzyl)oxy)-2-methylene-5-oxo-2,3,11,11a-tetrahydro-1<i>H</i>-benzo[<i>e</i>]pyrrolo[1,2-<i>a</i>][1,4]diazepine-10(5<i>H</i>)-carboxylate (<b>34</b>)</h4><div class="NLM_p last">LC–MS (5–95, AB, 1.5 min): RT = 0.78 min, [M/2 + H]<sup>+</sup> 682.9.</div></div><div id="sec4_8_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> (5-Iodo-1,3-phenylene)dimethanol (<b>45</b>)</h4><div class="NLM_p last">To a 10 L four-necked round-bottom flask was placed ethanol (2000 mL) at 0 °C followed by sequential addition of NaBH<sub>4</sub> (252 g, 6.66 mol) portionwise and commercially available 1,3-dimethyl-5-iodobenzene-1,3-dicarboxylate (<b>44</b>, 520 g, 1.62 mol) at the same temperature. To this mixture was added a solution of CaCl<sub>2</sub> (362 g) in ethanol (3000 mL) dropwise with stirring at 0 °C. The resulting solution was stirred at room temperature for 2 h and then was quenched by the addition of 2000 mL of 0 °C water. The mixture was concentrated under a vacuum, and the residue was diluted with water (1000 mL) and extracted with EtOAc (2000 mL × 3). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under a vacuum to afford compound <b>45</b> (310 g, 72%) as a white solid.</div></div><div id="sec4_8_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 1,3-Bis(bromomethyl)-5-iodobenzene (<b>46</b>)</h4><div class="NLM_p last">To a 5000 mL four-necked round-bottom flask purged and maintained with an inert atmosphere of nitrogen was placed a solution of compound <b>45</b> (310 g, 1.17 mol) in DCM (2000 mL) and CBr<sub>4</sub> (856 g) followed by the addition of a solution of triphenylphosphine (640 g, 2.45 mol) in DCM (1000 mL) dropwise with stirring at 0 °C. The resulting solution was stirred at room temperature overnight then was concentrated under a vacuum. The residue was purified by chromatography on silica gel (5% EtOAc in petroleum ether) to afford compound <b>46</b> (160 g, 35%) as a white solid.</div></div><div id="sec4_8_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 4,4′-(((5-Iodo-1,3-phenylene)bis(methylene))bis(oxy))bis(3-methoxybenzaldehyde) (<b>47</b>)</h4><div class="NLM_p last">To a 3000 mL four-necked round-bottom flask was placed a solution of commercially available 4-hydroxy-3-methoxybenzaldehyde (vanillin, 80 g, 0.53 mol) in DMF (2000 mL), K<sub>2</sub>CO<sub>3</sub> (74 g, 0.54 mol), TBAI (10 g, 27 mmol), and compound <b>46</b> (104 g, 0.27 mol). The resulting solution was stirred at 60 °C for 3 h, then additional portions of 4-hydroxy-3-methoxybenzaldehyde, K<sub>2</sub>CO<sub>3</sub>, and TBAI (same amounts as described previously) were sequentially added, and stirring was continued at 60 °C for another 3 h. The reaction mixture was cooled to room temperature with a water bath and was quenched by the addition of water (1000 mL). The resulting mixture was extracted with EtOAc (1000 mL × 3), and the combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under a vacuum. Purification of the residue by chromatography on silica gel (16–50% EtOAc in DCM) afforded compound <b>47</b> (177 g, 63%) as a white solid.</div></div><div id="sec4_8_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 4,4′-(((5-Iodo-1,3-phenylene)bis(methylene))bis(oxy))bis(3-methoxybenzoic acid) (<b>48</b>)</h4><div class="NLM_p last">To a 5000 mL four-necked round-bottom flask was placed a solution of NaClO<sub>2</sub> (78 g,) in water (1400 mL) and NaH<sub>2</sub>PO<sub>4</sub>·2H<sub>2</sub>O (52 g) followed by the addition of a solution of compound <b>47</b> (177 g, 333 mmol) in THF (2000 mL) dropwise with stirring at 25 °C. To this mixture was added H<sub>2</sub>O<sub>2</sub> (30%, 887 mL) dropwise with stirring. The resulting solution was stirred at 45 °C for 4 h, then was cooled to at 25 °C, and the pH was adjusted to 3 via the addition of aqueous HCl (1 N). The resulting solution was extracted with EtOAc (1000 mL × 3), and the combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under a vacuum to afford compound <b>48</b> (175 g, 93%) as a white solid.</div></div><div id="sec4_8_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 4,4′-(((5-Iodo-1,3-phenylene)bis(methylene))bis(oxy))bis(5-methoxy-2-nitrobenzoic acid) (<b>49</b>)</h4><div class="NLM_p last">To a 5000 mL four-necked round-bottom flask was placed concentrated HNO<sub>3</sub> (2500 mL) followed by the addition of compound <b>48</b> (78 g, 137 mmol) in portions at 25 °C. The resulting solution was stirred at that temperature overnight and then was quenched by the addition of 5 L of water/ice. The resulting solids were collected by vacuum filtration to afford compound <b>49</b> as a yellow solid. The reaction was repeated on the same scale to afford a second batch of <b>49</b> (combined yield = 104 g, 58%).</div></div><div id="sec4_8_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> (<i>S</i>)-(4-Methylenepyrrolidin-2-yl)methyl Acetate Trifluoroacetic Acid Salt (<b>50</b>)</h4><div class="NLM_p last">To a 1000 mL three-necked round-bottom flask purged and maintained with an inert atmosphere of nitrogen was placed a solution of <i>tert</i>-butyl (2<i>S</i>)-2-[(acetyloxy)methyl]-4-methylidenepyrrolidine-1-carboxylate<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> (64 g, 250 mmol) in DCM (500 mL) followed by the addition of TFA (128 mL) dropwise with stirring at 0 °C. The resulting solution was then stirred at room temperature for 2 h, after which it was concentrated under a vacuum to afford 110 g of crude <b>50</b> as a brown oil. This material was used without additional purification in the next step below.</div></div><div id="sec4_8_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> ((2<i>R</i>,2′<i>R</i>)-(4,4′-(((5-Iodo-1,3-phenylene)bis(methylene))bis(oxy))bis(5-methoxy-2-nitrobenzoyl))bis(4-methylenepyrrolidine-1,2-diyl))bis(methylene) Diacetate (<b>51</b>)</h4><div class="NLM_p last">To a 3000 mL four-necked round-bottom flask was placed compound <b>49</b> (77 g, 118 mmol) in DCM (1000 mL) followed by the addition of oxalyl chloride (70 g) dropwise with stirring at 25 °C. The resulting solution was stirred at that temperature for 4 h and then was concentrated under a vacuum. The residue was dissolved in DCM (1500 mL) to provide “solution A”. To a separate 3000 mL four-necked round-bottom flask purged and maintained with an inert atmosphere of nitrogen was placed a solution of crude compound <b>50</b> (116 g, 430 mmol) in DCM (1000 mL) followed by the addition of Et<sub>3</sub>N (168 g, 1.66 mol) dropwise with stirring at −40 °C. To this mixture was added “solution A” prepared above at −40 °C. The reaction was allowed to warm to 0 °C over 2 h and then was quenched by the addition of 0 °C water (1000 mL). The resulting mixture was extracted with DCM (2000 mL × 3), and the combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under a vacuum to afford crude compound <b>51</b> (130 g) as a yellow solid. This material was used in subsequent transformations without additional purification.</div></div><div id="sec4_8_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> ((((5-Iodo-1,3-phenylene)bis(methylene))bis(oxy))bis(5-methoxy-2-nitro-4,1-phenylene))bis(((<i>S</i>)-2-(hydroxymethyl)-4-methylenepyrrolidin-1-yl)methanone) (<b>52</b>)</h4><div class="NLM_p last">To a 2000 mL four-necked round-bottom flask was placed a solution of compound <b>51</b> (130 g, 140 mmol) in THF/H<sub>2</sub>O (500 mL/500 mL) and LiOH·2H<sub>2</sub>O (23 g, 540 mmol). The resulting solution was stirred at 25 °C for 3 h then was extracted with EtOAc (500 mL × 3). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under a vacuum. The residue was purified by chromatography on silica gel (9% MeOH in DCM) to afford compound <b>52</b> (60 g, 50%) as a yellow solid.</div></div><div id="sec4_8_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> ((((5-Iodo-1,3-phenylene)bis(methylene))bis(oxy))bis(5-methoxy-2-nitro-4,1-phenylene))bis(((<i>S</i>)-2-(((<i>tert</i>-butyldimethylsilyl)oxy)methyl)-4-methylenepyrrolidin-1-yl)methanone) (<b>36</b>)</h4><div class="NLM_p last">To a 3000 mL four-necked round-bottom flask purged and maintained with an inert atmosphere of nitrogen was placed a solution of compound <b>52</b> (60 g, 70 mmol) in DMF (1500 mL) followed by the addition of imidazole (57 g) in portions at 0 °C. To this mixture was added TBSCl (53.6 g) in portions at 0 °C. The resulting solution was stirred at 25 °C for 3 h and then was quenched by the addition of water (5000 mL). The quenched reaction was extracted with EtOAc (1000 mL × 3), and the combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under a vacuum. The residue was purified by chromatography on silica gel (33% EtOAc in petroleum ether) to afford compound <b>36</b> (51 g, 67%) as a light yellow solid. LC–MS (60–95, AB, 6.6 min): RT = 3.07 min [M + H]<sup>+</sup>, 1073.7. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.87–7.84 (m, 4H), 7.58 (s, 1H), 7.25 (s, 1H), 7.05 (s, 1H), 5.26–5.24 (m, 4H), 5.00 (s, 1H), 4.91 (s, 1 H), 4.39–4.21 (m, 2H), 3.94–3.93 (m, 6H), 3.86–3.83 (m, 4H), 3.79–3.47 (m, 3H), 3.39–3.32 (m, 1H), 2.72–2.60 (m, 2H), 2.50 (m, 1H), 0.88 (s, 12H), 0.73 (s, 6H), 0.084 (s, 8H), 0.07 (s, 4H), −0.16 (s, 2H), −0.21 (s, 2H).</div></div><div id="sec4_8_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> Di-<i>tert</i>-butyl ((((5-Iodo-1,3-phenylene)bis(methylene))bis(oxy))bis(6-((<i>S</i>)-2-(((<i>tert</i>-butyldimethylsilyl)oxy)methyl)-4-methylenepyrrolidine-1-carbonyl)-4-methoxy-3,1-phenylene))dicarbamate (<b>53</b>)</h4><div class="NLM_p last">To a mixture of compound <b>36</b> (3.00 g, 2.80 mmol) in EtOH (20 mL)/water (10 mL) was added iron (1.56 g, 28 mmol), followed by NH<sub>4</sub>Cl (2.99 g, 55.9 mmol). The reaction mixture was stirred at 90 °C for 2 h. The mixture was filtered, and the filtrate was diluted with H<sub>2</sub>O (50 mL) and extracted with EtOAc (80 mL × 3). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated <i>in vacuo</i> to give the bis-aniline-intermediate (structure not shown; 2.20 g, 78%) as a white solid. LC–MS (5–95, AB, 1.5 min): RT = 1.20 min, [M + H]<sup>+</sup> 1013.5. Boc<sub>2</sub>O (1.90 g, 8.69 mmol) was added to a solution of this crude material in anhydrous THF (50 mL), and the reaction solution was stirred at 90 °C for 6 h. The mixture was concentrated <i>in vacuo</i> to afford crude compound <b>53</b> (2.60 g, 99%) as a pale yellow solid. LC–MS (5–95, AB, 1.5 min): RT = 1.43 min, [M + H]<sup>+</sup> 1214.8.</div></div><div id="sec4_8_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> Di-<i>tert</i>-butyl 8,8′-(((5-Iodo-1,3-phenylene)bis(methylene))bis(oxy))(11S,11aS,11′S,11a′S)-bis(11-hydroxy-7-methoxy-2-methylene-5-oxo-2,3,11,11a-tetrahydro-1<i>H</i>-benzo[<i>e</i>]pyrrolo[1,2-<i>a</i>][1,4]diazepine-10(5<i>H</i>)-carboxylate) (<b>17</b>)</h4><div class="NLM_p last">A solution of crude compound <b>53</b> (2.60 g, 2.14 mmol) in HOAc (15 mL)/THF (10 mL)/water (5 mL) was stirred at 18 °C for 48 h. The solution was diluted with EtOAc (120 mL) and was washed sequentially with H<sub>2</sub>O (40 mL × 5) and saturated aqueous NaHCO<sub>3</sub> solution (30 mL × 2). The EtOAc layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The residue was purified by chromatography on silica gel (0–3.3% MeOH in DCM) to give the crude diol intermediate (1.90 g, 90%) as a yellow solid. LC–MS (5–95, AB, 1.5 min): RT = 1.01 min, [M + H]<sup>+</sup> 985.3. To a solution of a portion of this crude material (400 mg, 0.41 mmol) in anhydrous DCM (40 mL) at 14 °C was added DMP (450 mg, 1.06 mmol). After the reaction mixture was stirred at that temperature for 16 h, it was diluted with H<sub>2</sub>O (20 mL) followed by saturated aqueous Na<sub>2</sub>SO<sub>3</sub> solution (20 mL) and saturated aqueous NaHCO<sub>3</sub> solution (20 mL). The mixture was extracted with EtOAc (60 mL × 3), and the combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The residue was purified by prep-TLC (7% MeOH in DCM, <i>R</i><sub><i>f</i></sub> = 0.7) to give compound <b>17</b> (220 mg, 53%) as a white solid. LC–MS (5–95, AB, 1.5 min): RT = 0.93 min, [M + Na]<sup>+</sup> 1003.5.</div></div><div id="sec4_8_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> Pent-4-ynenitrile (<b>54</b>)</h4><div class="NLM_p last">NaI (560 mg, 3.76 mmol) was added to a solution of 4-bromo-1-butyne (500 mg, 3.76 mmol) in DMSO (4.0 mL) at 0 °C. The mixture was warmed to 20 °C and was stirred at that temperature for 2 h. NaCN (368 mg, 7.52 mmol) was then added, and the mixture was warmed to 80 °C and maintained at that temperature for 2 h. After cooling to 20 °C, the reaction was stirred for an additional 18 h and then was partitioned between EtOAc (20 mL) and water (10 mL). The organic layer was washed with water (5 mL × 4) and was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated to give crude <b>54</b> (160 mg, 54%) as a brown oil. This material was used directly in the next step.</div></div><div id="sec4_8_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 5-(But-3-yn-1-yl)-1<i>H</i>-tetrazole (<b>20</b>)</h4><div class="NLM_p last">Et<sub>3</sub>N·HCl (522 mg, 3.79 mmol) and NaN<sub>3</sub> (246 mg, 3.79 mmol) were added sequentially to a solution of crude compound <b>54</b> (100 mg, 1.26 mmol) in toluene (5 mL) at 25 °C. The mixture was heated to 115 °C and was stirred at that temperature for 10 h. After cooling to 25 °C, the reaction mixture was partitioned between EtOAc (20 mL) and water (20 mL). The aqueous layer was then acidified with HOAc and HCl (2.0 M) to pH = 1.0 and was subsequently extracted with EtOAc (20 mL × 4). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub> and were concentrated. The residue was purified by chromatography on silica gel (20% EtOAc in petroleum ether) to afford compound <b>20</b> (80 mg, 52%) as an orange solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 3.08 (t, <i>J</i> = 6.8 Hz, 2H), 2.84 (t, <i>J</i> = 2.8 Hz, 1H), 2.67–2.63 (m, 2H).</div></div><div id="sec4_8_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> 4-(4-(Trimethylsilyl)but-3-yn-1-yl)pyridine (<b>55</b>)</h4><div class="NLM_p last">A solution of <i>n</i>-BuLi in hexanes (0.94 mL, 2.36 mmol) was added dropwise to a solution of <i>N</i>,<i>N</i>-diisopropylamine (1.07 mL, 2.15 mmol) in anhydrous THF (10 mL) at −78 °C under N<sub>2</sub>. The solution was stirred at 0 °C for 10 min. 4-Methylpyridine (200 mg, 2.15 mmol) in anhydrous THF (5 mL) was added dropwise, and the mixture was then heated to 50 °C for 45 min. The mixture was cooled to 20 °C, and (3-bromoprop-1-yn-1-yl)trimethylsilane (328 mg, 1.72 mmol) in anhydrous THF (5 mL) was added. The resulting mixture was stirred for another 3 h at 20 °C and then was quenched with saturated NH<sub>4</sub>Cl solution (20 mL). The quenched reaction was extracted with EtOAc (30 mL × 3), and the combined EtOAc layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The residue was purified by prep-TLC (33% EtOAc in petroleum ether, <i>R</i><sub><i>f</i></sub> = 0.4) to afford compound <b>55</b> (100 mg, 23%) as a colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.52 (d, <i>J</i> = 6.0 Hz, 2H), 7.17 (d, <i>J</i> = 5.6 Hz, 2H), 2.82 (t, <i>J</i> = 7.6 Hz, 2H), 2.53 (t, <i>J</i> = 7.6 Hz, 2H), 0.12 (s, 9H).</div></div><div id="sec4_8_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> 4-(But-3-yn-1-yl)pyridine (<b>21</b>)</h4><div class="NLM_p last">TBAF (775 mg, 2.46 mmol) was added to a solution of compound <b>55</b> (100 mg, 0.490 mmol) in anhydrous THF (10 mL) at 20 °C. The reaction mixture was stirred at that temperature for 20 min and then was diluted with DCM (60 mL). The resulting solution was washed with H<sub>2</sub>O (30 mL × 3), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to afford crude 4-(but-3-yn-1-yl)pyridine <b>21</b> (64 mg, 99%) as a brown oil. This material was used in subsequent Sonogashira coupling reactions without additional purification.</div></div><div id="sec4_8_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> Sodium Prop-2-yne-1-sulfonate (<b>42</b>)</h4><div class="NLM_p last">A mixture of Na<sub>2</sub>SO<sub>3</sub> (5.72 g, 45 mmol) and propargyl bromide (4.0 mL, 36 mmol) in MeOH (14 mL) and water (14 mL) was heated to 80 °C for 8 h. MeOH (200 mL) was added, and the precipitate was filtered off. The filtrate was concentrated to about 10 mL; then acetone (200 mL) was added, and the resulting precipitate was collected by vacuum filtration to give the desired product <b>42</b> (5.00 g, 98%) as a white solid. <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O): δ 3.84 (t, <i>J</i> = 2.8 Hz, 2H), 2.70 (t, <i>J</i> = 2.8 Hz, 1H).</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i58"><a href="/doi/suppl/10.1021/acs.jmedchem.0c00691" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75701" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75701" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c00691?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00691</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">95% confidence intervals for <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> IC<sub>50</sub> data, antiproliferation activity of compounds <b>5</b>–<b>9</b> against a panel of cancer cell lines, 95% confidence intervals for <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> IC<sub>50</sub> data, CD22 expression in WSU-DLCL2 cells, <i>in vivo</i> stability for conjugates <b>11a</b> and <b>13a</b>, and conjugate characterization data (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00691/suppl_file/jm0c00691_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings of <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> compounds (<b>5</b>–<b>10</b>) (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00691/suppl_file/jm0c00691_si_002.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Molecular formula strings of new compounds in <a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a>–<a class="ref internalNav" href="#sch5" aria-label="5">5</a> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00691/suppl_file/jm0c00691_si_003.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00691/suppl_file/jm0c00691_si_001.pdf">jm0c00691_si_001.pdf (615.34 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00691/suppl_file/jm0c00691_si_002.csv">jm0c00691_si_002.csv (1.03 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00691/suppl_file/jm0c00691_si_003.csv">jm0c00691_si_003.csv (5.4 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c00691" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74826" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74826" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peter S. Dragovich</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7372-2862" title="Orcid link">http://orcid.org/0000-0001-7372-2862</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#0e6a7c6f696178676d66207e6b7a6b7c4e696b606b206d6163"><span class="__cf_email__" data-cfemail="a3c7d1c2c4ccd5cac0cb8dd3c6d7c6d1e3c4c6cdc68dc0ccce">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Leanna R. Staben</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jinhua Chen</span> - <span class="hlFld-Affiliation affiliation">WuXi
AppTec Co., Ltd, 288
Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Josefa dela Cruz-Chuh</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Geoff del Rosario</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mary Ann Go</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jun Guo</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">S. Cyrus Khojasteh</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Katherine R. Kozak</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Guangmin Li</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Carl Ng</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gail D. Lewis Phillips</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Thomas H. Pillow</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rebecca K. Rowntree</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John Wai</span> - <span class="hlFld-Affiliation affiliation">WuXi
AppTec Co., Ltd, 288
Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">BinQing Wei</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Keyang Xu</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zijin Xu</span> - <span class="hlFld-Affiliation affiliation">WuXi
AppTec Co., Ltd, 288
Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shang-Fan Yu</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Donglu Zhang</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e4476-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i59">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27200" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27200" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors would like to thank members of the Genentech and WuXi Biologics Conjugation Groups for the preparation and characterization of the antibody–drug conjugates described in this work.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">Boc<sub>2</sub>O</td><td class="NLM_def"><p class="first last">di-<i>tert</i>-butyl dicarbonate</p></td></tr><tr><td class="NLM_term">DAR</td><td class="NLM_def"><p class="first last">drug–antibody ratio</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">DHAA</td><td class="NLM_def"><p class="first last">dehydroascorbic acid</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylformamide</p></td></tr><tr><td class="NLM_term">DMP</td><td class="NLM_def"><p class="first last">Dess–Martin periodinane</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">DTT</td><td class="NLM_def"><p class="first last">dithiothreitol</p></td></tr><tr><td class="NLM_term">EtOAc</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">EtOH</td><td class="NLM_def"><p class="first last">ethyl alcohol</p></td></tr><tr><td class="NLM_term">HPLC</td><td class="NLM_def"><p class="first last">high-performance liquid chromatography</p></td></tr><tr><td class="NLM_term">IBX</td><td class="NLM_def"><p class="first last">2-iodoxybenzoic acid</p></td></tr><tr><td class="NLM_term">LC–MS</td><td class="NLM_def"><p class="first last">liquid chromatography–mass spectrometry</p></td></tr><tr><td class="NLM_term">MC-OSu</td><td class="NLM_def"><p class="first last">2,5-dioxopyrrolidin-1-yl 6-(2,5-dioxo-2,5-dihydro-1<i>H</i>-pyrrol-1-yl)hexanoate</p></td></tr><tr><td class="NLM_term">MeOH</td><td class="NLM_def"><p class="first last">methyl alcohol</p></td></tr><tr><td class="NLM_term">MS</td><td class="NLM_def"><p class="first last">molecular sieves</p></td></tr><tr><td class="NLM_term">MsCl</td><td class="NLM_def"><p class="first last">methanesulfonyl chloride</p></td></tr><tr><td class="NLM_term">PAMPA</td><td class="NLM_def"><p class="first last">parallel artificial membrane permeability assay</p></td></tr><tr><td class="NLM_term">PBD</td><td class="NLM_def"><p class="first last">pyrrolobenzodiazepine</p></td></tr><tr><td class="NLM_term">SEC</td><td class="NLM_def"><p class="first last">size-exclusion chromatography</p></td></tr><tr><td class="NLM_term">TBAF</td><td class="NLM_def"><p class="first last">tetra-<i>n</i>-butylammonium fluoride</p></td></tr><tr><td class="NLM_term">TBAI</td><td class="NLM_def"><p class="first last">tetra-<i>n</i>-butylammonium iodide</p></td></tr><tr><td class="NLM_term">TBSCl</td><td class="NLM_def"><p class="first last"><i>tert</i>-butyldimethylsilyl chloride</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">TLC</td><td class="NLM_def"><p class="first last">thin-layer chromatography</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i61">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74507" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74507" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 38 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mantaj, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, P. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurston, D. E.</span></span> <span> </span><span class="NLM_article-title">From anthramycin to pyrrolobenzodiazepine (PBD)-containing antibody–drug conjugates (ADCs)</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">462</span>– <span class="NLM_lpage">488</span>, <span class="refDoi"> DOI: 10.1002/anie.201510610</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1002%2Fanie.201510610" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVGitrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=462-488&author=J.+Mantajauthor=P.+J.+M.+Jacksonauthor=K.+M.+Rahmanauthor=D.+E.+Thurston&title=From+anthramycin+to+pyrrolobenzodiazepine+%28PBD%29-containing+antibody%E2%80%93drug+conjugates+%28ADCs%29&doi=10.1002%2Fanie.201510610"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">From Anthramycin to Pyrrolobenzodiazepine (PBD)-Containing Antibody-Drug Conjugates (ADCs)</span></div><div class="casAuthors">Mantaj, Julia; Jackson, Paul J. M.; Rahman, Khondaker M.; Thurston, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">462-488</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) are a family of sequence-selective DNA minor-groove binding agents that form a covalent aminal bond between their C11-position and the C2-NH2 groups of guanine bases.  The first example of a PBD monomer, the natural product anthramycin, was discovered in the 1960s, and the best known PBD dimer, SJG-136 (also known as SG2000, NSC 694501 or BN2629), was synthesized in the 1990s and has recently completed Phase II clin. trials in patients with leukemia and ovarian cancer.  More recently, PBD dimer analogs are being attached to tumor-targeting antibodies to create antibody-drug conjugates (ADCs), a no. of which are now in clin. trials, with many others in pre-clin. development.  This Review maps the development from anthramycin to the first PBD dimers, and then to PBD-contg. ADCs, and explores both structure-activity relationships (SARs) and the biol. of PBDs, and the strategies for their use as payloads for ADCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9tjTimo4Cv7Vg90H21EOLACvtfcHk0li7ajjUjvRqeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVGitrnO&md5=8a87ad3c033b2a20798c861accba46a6</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1002%2Fanie.201510610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201510610%26sid%3Dliteratum%253Aachs%26aulast%3DMantaj%26aufirst%3DJ.%26aulast%3DJackson%26aufirst%3DP.%2BJ.%2BM.%26aulast%3DRahman%26aufirst%3DK.%2BM.%26aulast%3DThurston%26aufirst%3DD.%2BE.%26atitle%3DFrom%2520anthramycin%2520to%2520pyrrolobenzodiazepine%2520%2528PBD%2529-containing%2520antibody%25E2%2580%2593drug%2520conjugates%2520%2528ADCs%2529%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2017%26volume%3D56%26spage%3D462%26epage%3D488%26doi%3D10.1002%2Fanie.201510610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">del Rosario, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leong, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, G. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vij, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, W.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalouni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadowsky, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendricks, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poon, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pillow, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schutten, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flygare, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polson, A. G.</span></span> <span> </span><span class="NLM_article-title">An Anti-CLL-1 antibody–drug conjugate for the treatment of acute myeloid leukemia</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1358</span>– <span class="NLM_lpage">1368</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-18-0333</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1158%2F1078-0432.CCR-18-0333" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=29959143" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlOmt7bE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2019&pages=1358-1368&author=B.+Zhengauthor=S.-F.+Yuauthor=G.+del+Rosarioauthor=S.+R.+Leongauthor=G.+Y.+Leeauthor=R.+Vijauthor=C.+Chiuauthor=W.-C.+Liangauthor=Y.+Wuauthor=C.+Chalouniauthor=J.+Sadowskyauthor=V.+Clarkauthor=A.+Hendricksauthor=K.+A.+Poonauthor=W.+Chuauthor=T.+Pillowauthor=M.+M.+Schuttenauthor=J.+Flygareauthor=A.+G.+Polson&title=An+Anti-CLL-1+antibody%E2%80%93drug+conjugate+for+the+treatment+of+acute+myeloid+leukemia&doi=10.1158%2F1078-0432.CCR-18-0333"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">An anti-CLL-I antibody-drug conjugate for the treatment of acute myeloid leukemia</span></div><div class="casAuthors">Zheng, Bing; Yu, Shang-Fan; del Rosario, Geoffrey; Leong, Steven R.; Lee, Genee Y.; Vij, Rajesh; Chiu, Cecilia; Liang, Wei-Ching; Wu, Yan; Chalouni, Cecile; Sadowsky, Jack; Clark, Vanessa; Hendricks, Angela; Poon, Kirsten Achilles; Chu, Wayne; Pillow, Thomas; Schutten, Melissa M.; Flygare, John; Polson, Andrew G.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1358</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The treatment of acute myeloid leukemia (AML) has not significantly changed in 40 years.  Cytarabine- and anthracycline-based chemotherapy induction regimens (7 + 3) remain the std. of care, and most patients have poor long-term survival.  The reapproval of Mylotarg, an anti-CD33-calicheamicin antibody-drug conjugate (ADC), has demonstrated ADCs as a clin. validated option to enhance the effectiveness of induction therapy.  We are interested in developing a next-generation ADC for AML to improve upon the initial success of Mylotarg.  Exptl. Design: The expression pattern of CLL-1 and its hematopoietic potential were investigated.  A novel anti-CLL-1-ADC, with a highly potent pyrrolobenzodiazepine (PBD) dimer conjugated through a self-immolative disulfide linker, was developed.  The efficacy and safety profiles of this ADC were evaluated in mouse xenograft models and in cynomolgus monkeys.  Results: We demonstrate that CLL-1 shares similar prevalence and trafficking properties that make CD33 an excellent ADC target for AML, but lacks expression on hematopoietic stem cells that hampers current CD33-targeted ADCs.  Our anti-CLL-1-ADC is highly effective at depleting tumor cells in AML xenograft models and lacks target independent toxicities at doses that depleted target monocytes and neutrophils in cynomolgus monkeys.  Conclusions: Collectively, our data suggest that an anti-CLL-1-ADC has the potential to become an effective and safer treatment for AML in humans, by reducing and allowing for faster recovery from initial cytopenias than the current generation of ADCs for AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJdzTurW_r4LVg90H21EOLACvtfcHk0lhhG-5H19Rakg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlOmt7bE&md5=c701a514d19baec87815539f0eaa9275</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-18-0333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-18-0333%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DB.%26aulast%3DYu%26aufirst%3DS.-F.%26aulast%3Ddel%2BRosario%26aufirst%3DG.%26aulast%3DLeong%26aufirst%3DS.%2BR.%26aulast%3DLee%26aufirst%3DG.%2BY.%26aulast%3DVij%26aufirst%3DR.%26aulast%3DChiu%26aufirst%3DC.%26aulast%3DLiang%26aufirst%3DW.-C.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DChalouni%26aufirst%3DC.%26aulast%3DSadowsky%26aufirst%3DJ.%26aulast%3DClark%26aufirst%3DV.%26aulast%3DHendricks%26aufirst%3DA.%26aulast%3DPoon%26aufirst%3DK.%2BA.%26aulast%3DChu%26aufirst%3DW.%26aulast%3DPillow%26aufirst%3DT.%26aulast%3DSchutten%26aufirst%3DM.%2BM.%26aulast%3DFlygare%26aufirst%3DJ.%26aulast%3DPolson%26aufirst%3DA.%2BG.%26atitle%3DAn%2520Anti-CLL-1%2520antibody%25E2%2580%2593drug%2520conjugate%2520for%2520the%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2019%26volume%3D25%26spage%3D1358%26epage%3D1368%26doi%3D10.1158%2F1078-0432.CCR-18-0333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pillow, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schutten, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadowsky, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poon, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solis, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Rosario, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Go, M. A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leipold, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamath, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masterson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregson, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunzner-Toste, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozak, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polakis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polson, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flygare, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Junutula, J. R.</span></span> <span> </span><span class="NLM_article-title">Modulating therapeutic activity and toxicity of pyrrolobenzodiazepine antibody–drug conjugates with self-immolative disulfide linkers</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">871</span>– <span class="NLM_lpage">878</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-16-0641</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1158%2F1535-7163.MCT-16-0641" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=28223423" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmvFemtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=871-878&author=T.+H.+Pillowauthor=M.+Schuttenauthor=S.-F.+Yuauthor=R.+Ohriauthor=J.+Sadowskyauthor=K.+A.+Poonauthor=W.+Solisauthor=F.+Zhongauthor=G.+Del+Rosarioauthor=M.+A.+T.+Goauthor=J.+Lauauthor=S.+Yeeauthor=J.+Heauthor=L.+Liuauthor=C.+Ngauthor=K.+Xuauthor=D.+D.+Leipoldauthor=A.+V.+Kamathauthor=D.+Zhangauthor=L.+Mastersonauthor=S.+J.+Gregsonauthor=P.+W.+Howardauthor=F.+Fangauthor=J.+Chenauthor=J.+Gunzner-Tosteauthor=K.+K.+Kozakauthor=S.+Spencerauthor=P.+Polakisauthor=A.+G.+Polsonauthor=J.+A.+Flygareauthor=J.+R.+Junutula&title=Modulating+therapeutic+activity+and+toxicity+of+pyrrolobenzodiazepine+antibody%E2%80%93drug+conjugates+with+self-immolative+disulfide+linkers&doi=10.1158%2F1535-7163.MCT-16-0641"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Modulating Therapeutic Activity and Toxicity of Pyrrolobenzodiazepine Antibody-Drug Conjugates with Self-Immolative Disulfide Linkers</span></div><div class="casAuthors">Pillow, Thomas H.; Schutten, Melissa; Yu, Shang-Fan; Ohri, Rachana; Sadowsky, Jack; Poon, Kirsten Achilles; Solis, Willy; Zhong, Fiona; Del Rosario, Geoffrey; Go, Mary Ann T.; Lau, Jeffrey; Yee, Sharon; He, Jintang; Liu, Luna; Ng, Carl; Xu, Keyang; Leipold, Douglas D.; Kamath, Amrita V.; Zhang, Donglu; Masterson, Luke; Gregson, Stephen J.; Howard, Philip W.; Fang, Fan; Chen, Jinhua; Gunzner-Toste, Janet; Kozak, Katherine K.; Spencer, Susan; Polakis, Paul; Polson, Andrew G.; Flygare, John A.; Junutula, Jagath R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">871-878</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A novel disulfide linker was designed to enable a direct connection between cytotoxic pyrrolobenzodiazepine (PBD) drugs and the cysteine on a targeting antibody for use in antibody-drug conjugates (ADCs).  ADCs composed of a cysteine-engineered antibody were armed with a PBD using a self-immolative disulfide linker.  Both the chem. linker and the antibody site were optimized for this new bioconjugation strategy to provide a highly stable and efficacious ADC.  This novel disulfide ADC was compared with a conjugate contg. the same PBD drug, but attached to the antibody via a peptide linker.  Both ADCs had similar efficacy in mice bearing human tumor xenografts.  Safety studies in rats revealed that the disulfide-linked ADC had a higher MTD than the peptide-linked ADC.  Overall, these data suggest that the novel self-immolative disulfide linker represents a valuable way to construct ADCs with equiv. efficacy and improved safety.  Mol Cancer Ther; 16(5); 871-8. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZP_imFtNeBrVg90H21EOLACvtfcHk0lhhG-5H19Rakg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmvFemtrw%253D&md5=6bf9501951de0cfad9d890a4ef9492b1</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-16-0641&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-16-0641%26sid%3Dliteratum%253Aachs%26aulast%3DPillow%26aufirst%3DT.%2BH.%26aulast%3DSchutten%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DS.-F.%26aulast%3DOhri%26aufirst%3DR.%26aulast%3DSadowsky%26aufirst%3DJ.%26aulast%3DPoon%26aufirst%3DK.%2BA.%26aulast%3DSolis%26aufirst%3DW.%26aulast%3DZhong%26aufirst%3DF.%26aulast%3DDel%2BRosario%26aufirst%3DG.%26aulast%3DGo%26aufirst%3DM.%2BA.%2BT.%26aulast%3DLau%26aufirst%3DJ.%26aulast%3DYee%26aufirst%3DS.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DNg%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DK.%26aulast%3DLeipold%26aufirst%3DD.%2BD.%26aulast%3DKamath%26aufirst%3DA.%2BV.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DMasterson%26aufirst%3DL.%26aulast%3DGregson%26aufirst%3DS.%2BJ.%26aulast%3DHoward%26aufirst%3DP.%2BW.%26aulast%3DFang%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DGunzner-Toste%26aufirst%3DJ.%26aulast%3DKozak%26aufirst%3DK.%2BK.%26aulast%3DSpencer%26aufirst%3DS.%26aulast%3DPolakis%26aufirst%3DP.%26aulast%3DPolson%26aufirst%3DA.%2BG.%26aulast%3DFlygare%26aufirst%3DJ.%2BA.%26aulast%3DJunutula%26aufirst%3DJ.%2BR.%26atitle%3DModulating%2520therapeutic%2520activity%2520and%2520toxicity%2520of%2520pyrrolobenzodiazepine%2520antibody%25E2%2580%2593drug%2520conjugates%2520with%2520self-immolative%2520disulfide%2520linkers%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2017%26volume%3D16%26spage%3D871%26epage%3D878%26doi%3D10.1158%2F1535-7163.MCT-16-0641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bankovich, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aujay, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bheddah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escarpe, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hampl, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laysang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Molina, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pysz, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slingerland, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torgov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foord, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jassem, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badzio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czapiewski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harpole, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowlati, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massion, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Travis, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietanza, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poirier, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudin, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stull, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dylla, S. J.</span></span> <span> </span><span class="NLM_article-title">A DLL3-targeted antibody–drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells <i>in vivo</i></span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">302ra136</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.aac9459</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1126%2Fscitranslmed.aac9459" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=26311731" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=302ra136&author=L.+R.+Saundersauthor=A.+J.+Bankovichauthor=W.+C.+Andersonauthor=M.+A.+Aujayauthor=S.+Bheddahauthor=K.+A.+Blackauthor=R.+Desaiauthor=P.+A.+Escarpeauthor=J.+Hamplauthor=A.+Laysangauthor=D.+Liuauthor=J.+Lopez-Molinaauthor=M.+Miltonauthor=A.+Parkauthor=M.+A.+Pyszauthor=H.+Shaoauthor=B.+Slingerlandauthor=M.+Torgovauthor=S.+A.+Williamsauthor=O.+Foordauthor=P.+Howardauthor=J.+Jassemauthor=A.+Badzioauthor=P.+Czapiewskiauthor=D.+H.+Harpoleauthor=A.+Dowlatiauthor=P.+P.+Massionauthor=W.+D.+Travisauthor=M.+C.+Pietanzaauthor=J.+T.+Poirierauthor=C.+M.+Rudinauthor=R.+A.+Stullauthor=S.+J.+Dylla&title=A+DLL3-targeted+antibody%E2%80%93drug+conjugate+eradicates+high-grade+pulmonary+neuroendocrine+tumor-initiating+cells+in+vivo&doi=10.1126%2Fscitranslmed.aac9459"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aac9459&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aac9459%26sid%3Dliteratum%253Aachs%26aulast%3DSaunders%26aufirst%3DL.%2BR.%26aulast%3DBankovich%26aufirst%3DA.%2BJ.%26aulast%3DAnderson%26aufirst%3DW.%2BC.%26aulast%3DAujay%26aufirst%3DM.%2BA.%26aulast%3DBheddah%26aufirst%3DS.%26aulast%3DBlack%26aufirst%3DK.%2BA.%26aulast%3DDesai%26aufirst%3DR.%26aulast%3DEscarpe%26aufirst%3DP.%2BA.%26aulast%3DHampl%26aufirst%3DJ.%26aulast%3DLaysang%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DLopez-Molina%26aufirst%3DJ.%26aulast%3DMilton%26aufirst%3DM.%26aulast%3DPark%26aufirst%3DA.%26aulast%3DPysz%26aufirst%3DM.%2BA.%26aulast%3DShao%26aufirst%3DH.%26aulast%3DSlingerland%26aufirst%3DB.%26aulast%3DTorgov%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DS.%2BA.%26aulast%3DFoord%26aufirst%3DO.%26aulast%3DHoward%26aufirst%3DP.%26aulast%3DJassem%26aufirst%3DJ.%26aulast%3DBadzio%26aufirst%3DA.%26aulast%3DCzapiewski%26aufirst%3DP.%26aulast%3DHarpole%26aufirst%3DD.%2BH.%26aulast%3DDowlati%26aufirst%3DA.%26aulast%3DMassion%26aufirst%3DP.%2BP.%26aulast%3DTravis%26aufirst%3DW.%2BD.%26aulast%3DPietanza%26aufirst%3DM.%2BC.%26aulast%3DPoirier%26aufirst%3DJ.%2BT.%26aulast%3DRudin%26aufirst%3DC.%2BM.%26aulast%3DStull%26aufirst%3DR.%2BA.%26aulast%3DDylla%26aufirst%3DS.%2BJ.%26atitle%3DA%2520DLL3-targeted%2520antibody%25E2%2580%2593drug%2520conjugate%2520eradicates%2520high-grade%2520pulmonary%2520neuroendocrine%2520tumor-initiating%2520cells%2520in%2520vivo%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2015%26volume%3D7%26spage%3D302ra136%26doi%3D10.1126%2Fscitranslmed.aac9459" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sutherland, M. S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walter, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffrey, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sussman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyon, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrington, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klussman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westendorf, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernstein, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senter, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benjamin, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drachman, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEarchern, J. A.</span></span> <span> </span><span class="NLM_article-title">SGN-CD33A: a novel CD33-targeting antibody–drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>122</i></span>,  <span class="NLM_fpage">1455</span>– <span class="NLM_lpage">1463</span>, <span class="refDoi"> DOI: 10.1182/blood-2013-03-491506</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1182%2Fblood-2013-03-491506" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=23770776" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVSqu73F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2013&pages=1455-1463&author=M.+S.+K.+Sutherlandauthor=R.+B.+Walterauthor=S.+C.+Jeffreyauthor=P.+J.+Burkeauthor=C.+Yuauthor=H.+Kostnerauthor=I.+Stoneauthor=M.+C.+Ryanauthor=D.+Sussmanauthor=R.+P.+Lyonauthor=W.+Zengauthor=K.+H.+Harringtonauthor=K.+Klussmanauthor=L.+Westendorfauthor=D.+Meyerauthor=I.+D.+Bernsteinauthor=P.+D.+Senterauthor=D.+R.+Benjaminauthor=J.+G.+Drachmanauthor=J.+A.+McEarchern&title=SGN-CD33A%3A+a+novel+CD33-targeting+antibody%E2%80%93drug+conjugate+using+a+pyrrolobenzodiazepine+dimer+is+active+in+models+of+drug-resistant+AML&doi=10.1182%2Fblood-2013-03-491506"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML</span></div><div class="casAuthors">Sutherland, May S. Kung; Walter, Roland B.; Jeffrey, Scott C.; Burke, Patrick J.; Yu, Changpu; Kostner, Heather; Stone, Ivan; Ryan, Maureen C.; Sussman, Django; Lyon, Robert P.; Zeng, Weiping; Harrington, Kimberly H.; Klussman, Kerry; Westendorf, Lori; Meyer, David; Bernstein, Irwin D.; Senter, Peter D.; Benjamin, Dennis R.; Drachman, Jonathan G.; McEarchern, Julie A.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1455-1463</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Outcomes in acute myeloid leukemia (AML) remain unsatisfactory, and novel treatments are urgently needed.  One strategy explores antibodies and their drug conjugates, particularly those targeting CD33.  Emerging data with gemtuzumab ozogamicin (GO) demonstrate target validity and activity in some patients with AML, but efficacy is limited by heterogeneous drug conjugation, linker instability, and a high incidence of multidrug resistance.  We describe here the development of SGN-CD33A, a humanized anti-CD33 antibody with engineered cysteines conjugated to a highly potent, synthetic DNA crosslinking pyrrolobenzodiazepine dimer via a protease-cleavable linker.  The use of engineered cysteine residues at the sites of drug linker attachment results in a drug loading of approx. 2 pyrrolobenzodiazepine dimers per antibody.  In preclin. testing, SGN-CD33A is more potent than GO against a panel of AML cell lines and primary AML cells in vitro and in xenotransplantation studies in mice.  Unlike GO, antileukemic activity is obsd. with SGN-CD33A in AML models with the multidrug-resistant phenotype.  Mechanistic studies indicate that the cytotoxic effects of SGN-CD33A involve DNA damage with ensuing cell cycle arrest and apoptotic cell death.  Together, these data suggest that SGN-CD33A has CD33-directed antitumor activity and support clin. testing of this novel therapeutic in patients with AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBSMYK90zZNrVg90H21EOLACvtfcHk0lg_oz6RZawmKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVSqu73F&md5=6f6d10edd544b91186ef2a8bfa9142dc</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1182%2Fblood-2013-03-491506&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2013-03-491506%26sid%3Dliteratum%253Aachs%26aulast%3DSutherland%26aufirst%3DM.%2BS.%2BK.%26aulast%3DWalter%26aufirst%3DR.%2BB.%26aulast%3DJeffrey%26aufirst%3DS.%2BC.%26aulast%3DBurke%26aufirst%3DP.%2BJ.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DKostner%26aufirst%3DH.%26aulast%3DStone%26aufirst%3DI.%26aulast%3DRyan%26aufirst%3DM.%2BC.%26aulast%3DSussman%26aufirst%3DD.%26aulast%3DLyon%26aufirst%3DR.%2BP.%26aulast%3DZeng%26aufirst%3DW.%26aulast%3DHarrington%26aufirst%3DK.%2BH.%26aulast%3DKlussman%26aufirst%3DK.%26aulast%3DWestendorf%26aufirst%3DL.%26aulast%3DMeyer%26aufirst%3DD.%26aulast%3DBernstein%26aufirst%3DI.%2BD.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26aulast%3DBenjamin%26aufirst%3DD.%2BR.%26aulast%3DDrachman%26aufirst%3DJ.%2BG.%26aulast%3DMcEarchern%26aufirst%3DJ.%2BA.%26atitle%3DSGN-CD33A%253A%2520a%2520novel%2520CD33-targeting%2520antibody%25E2%2580%2593drug%2520conjugate%2520using%2520a%2520pyrrolobenzodiazepine%2520dimer%2520is%2520active%2520in%2520models%2520of%2520drug-resistant%2520AML%26jtitle%3DBlood%26date%3D2013%26volume%3D122%26spage%3D1455%26epage%3D1463%26doi%3D10.1182%2Fblood-2013-03-491506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caimi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahl, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamadani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlo-Stella, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ungar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feingold, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ardeshna, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radford, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heffner, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, O. A.</span></span> <span> </span><span class="NLM_article-title">Safety and efficacy of ADCT-402 (loncastuximab tesirine), a novel antibody drug conjugate, in relapsed/refractory follicular lymphoma and mantle cell lymphoma: Interim results from the phase 1 first-in-human study</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>132</i></span> (<span class="NLM_issue">Suppl 1</span>),  <span class="NLM_fpage">2874</span>, <span class="refDoi"> DOI: 10.1182/blood-2018-99-118133</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1182%2Fblood-2018-99-118133" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2018&pages=2874&issue=Suppl+1&author=P.+Caimiauthor=B.+S.+Kahlauthor=M.+Hamadaniauthor=C.+Carlo-Stellaauthor=S.+Heauthor=D.+Ungarauthor=J.+Feingoldauthor=K.+M.+Ardeshnaauthor=J.+Radfordauthor=M.+Solhauthor=L.+Heffnerauthor=O.+A.+O%E2%80%99Connor&title=Safety+and+efficacy+of+ADCT-402+%28loncastuximab+tesirine%29%2C+a+novel+antibody+drug+conjugate%2C+in+relapsed%2Frefractory+follicular+lymphoma+and+mantle+cell+lymphoma%3A+Interim+results+from+the+phase+1+first-in-human+study&doi=10.1182%2Fblood-2018-99-118133"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1182%2Fblood-2018-99-118133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2018-99-118133%26sid%3Dliteratum%253Aachs%26aulast%3DCaimi%26aufirst%3DP.%26aulast%3DKahl%26aufirst%3DB.%2BS.%26aulast%3DHamadani%26aufirst%3DM.%26aulast%3DCarlo-Stella%26aufirst%3DC.%26aulast%3DHe%26aufirst%3DS.%26aulast%3DUngar%26aufirst%3DD.%26aulast%3DFeingold%26aufirst%3DJ.%26aulast%3DArdeshna%26aufirst%3DK.%2BM.%26aulast%3DRadford%26aufirst%3DJ.%26aulast%3DSolh%26aufirst%3DM.%26aulast%3DHeffner%26aufirst%3DL.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DO.%2BA.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520ADCT-402%2520%2528loncastuximab%2520tesirine%2529%252C%2520a%2520novel%2520antibody%2520drug%2520conjugate%252C%2520in%2520relapsed%252Frefractory%2520follicular%2520lymphoma%2520and%2520mantle%2520cell%2520lymphoma%253A%2520Interim%2520results%2520from%2520the%2520phase%25201%2520first-in-human%2520study%26jtitle%3DBlood%26date%3D2018%26volume%3D132%26issue%3DSuppl%25201%26spage%3D2874%26doi%3D10.1182%2Fblood-2018-99-118133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Zammarchi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Havenith, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chivers, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogg, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Britten, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dissanayake, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyrer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchinson, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masterson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartley, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Berkel, P. H.</span></span> <span> </span><span class="NLM_article-title">Preclinical activity of ADCT-601, a novel pyrrolobenzodiazepine (PBD) dimer-based antibody–drug conjugate (ADC) targeting AXL-expressing tumors</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span> (<span class="NLM_issue">13 Suppl</span>),  <span class="NLM_fpage">2792A</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2018-2792A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1158%2F1538-7445.AM2018-2792A" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=2792A&issue=13+Suppl&author=F.+Zammarchiauthor=K.+Havenithauthor=S.+Chiversauthor=P.+W.+Hoggauthor=C.+Brittenauthor=S.+Dissanayakeauthor=P.+Tyrerauthor=F.+Bertelliauthor=I.+Hutchinsonauthor=L.+Mastersonauthor=P.+Howardauthor=J.+A.+Hartleyauthor=P.+H.+van+Berkel&title=Preclinical+activity+of+ADCT-601%2C+a+novel+pyrrolobenzodiazepine+%28PBD%29+dimer-based+antibody%E2%80%93drug+conjugate+%28ADC%29+targeting+AXL-expressing+tumors&doi=10.1158%2F1538-7445.AM2018-2792A"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2018-2792A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2018-2792A%26sid%3Dliteratum%253Aachs%26aulast%3DZammarchi%26aufirst%3DF.%26aulast%3DHavenith%26aufirst%3DK.%26aulast%3DChivers%26aufirst%3DS.%26aulast%3DHogg%26aufirst%3DP.%2BW.%26aulast%3DBritten%26aufirst%3DC.%26aulast%3DDissanayake%26aufirst%3DS.%26aulast%3DTyrer%26aufirst%3DP.%26aulast%3DBertelli%26aufirst%3DF.%26aulast%3DHutchinson%26aufirst%3DI.%26aulast%3DMasterson%26aufirst%3DL.%26aulast%3DHoward%26aufirst%3DP.%26aulast%3DHartley%26aufirst%3DJ.%2BA.%26aulast%3Dvan%2BBerkel%26aufirst%3DP.%2BH.%26atitle%3DPreclinical%2520activity%2520of%2520ADCT-601%252C%2520a%2520novel%2520pyrrolobenzodiazepine%2520%2528PBD%2529%2520dimer-based%2520antibody%25E2%2580%2593drug%2520conjugate%2520%2528ADC%2529%2520targeting%2520AXL-expressing%2520tumors%26jtitle%3DCancer%2520Res.%26date%3D2018%26volume%3D78%26issue%3D13%2520Suppl%26spage%3D2792A%26doi%3D10.1158%2F1538-7445.AM2018-2792A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit7b"><span><span class="NLM_label">(b) </span> ADC Therapeutics
press release, January 16, 2019. <a href="https://www.globenewswire.com/news-release/2019/01/16/1696491/0/en/ADC-Therapeutics-Announces-First-Patient-Dosed-in-Phase-I-Clinical-Trial-of-ADCT-601-in-Advanced-Solid-Tumors.html" class="extLink">https://www.globenewswire.com/news-release/2019/01/16/1696491/0/en/ADC-Therapeutics-Announces-First-Patient-Dosed-in-Phase-I-Clinical-Trial-of-ADCT-601-in-Advanced-Solid-Tumors.html</a> (accessed July 7, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+ADC+Therapeutics%0Apress+release%2C+January+16%2C+2019.+https%3A%2F%2Fwww.globenewswire.com%2Fnews-release%2F2019%2F01%2F16%2F1696491%2F0%2Fen%2FADC-Therapeutics-Announces-First-Patient-Dosed-in-Phase-I-Clinical-Trial-of-ADCT-601-in-Advanced-Solid-Tumors.html+%28accessed+July+7%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kinneer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meekin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varkey, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurt, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flynn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hynes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezabeh, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wetzel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tai, Y.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbst, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tice, D.</span></span> <span> </span><span class="NLM_article-title">Preclinical evaluation of MEDI2228, a BCMA-targeting pyrrolobenzodiazepine-linked antibody drug conjugate for the treatment of multiple myeloma</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>130</i></span> (<span class="NLM_issue">Suppl 1</span>),  <span class="NLM_fpage">3153</span>, <span class="refDoi"> DOI: 10.1038/s41375-018-0278-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1038%2Fs41375-018-0278-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2019&pages=3153&issue=Suppl+1&author=K.+Kinneerauthor=J.+Meekinauthor=R.+Varkeyauthor=X.+Xiaoauthor=H.+Zhongauthor=S.+Breenauthor=E.+Hurtauthor=S.+Thomasauthor=M.+Flynnauthor=P.+Hynesauthor=B.+Bezabehauthor=C.+Chenauthor=L.+Wetzelauthor=R.+Chenauthor=Y.-T.+Taiauthor=K.+C.+Andersonauthor=R.+Herbstauthor=D.+Tice&title=Preclinical+evaluation+of+MEDI2228%2C+a+BCMA-targeting+pyrrolobenzodiazepine-linked+antibody+drug+conjugate+for+the+treatment+of+multiple+myeloma&doi=10.1038%2Fs41375-018-0278-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.1038%2Fs41375-018-0278-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41375-018-0278-7%26sid%3Dliteratum%253Aachs%26aulast%3DKinneer%26aufirst%3DK.%26aulast%3DMeekin%26aufirst%3DJ.%26aulast%3DVarkey%26aufirst%3DR.%26aulast%3DXiao%26aufirst%3DX.%26aulast%3DZhong%26aufirst%3DH.%26aulast%3DBreen%26aufirst%3DS.%26aulast%3DHurt%26aufirst%3DE.%26aulast%3DThomas%26aufirst%3DS.%26aulast%3DFlynn%26aufirst%3DM.%26aulast%3DHynes%26aufirst%3DP.%26aulast%3DBezabeh%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DWetzel%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DR.%26aulast%3DTai%26aufirst%3DY.-T.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26aulast%3DHerbst%26aufirst%3DR.%26aulast%3DTice%26aufirst%3DD.%26atitle%3DPreclinical%2520evaluation%2520of%2520MEDI2228%252C%2520a%2520BCMA-targeting%2520pyrrolobenzodiazepine-linked%2520antibody%2520drug%2520conjugate%2520for%2520the%2520treatment%2520of%2520multiple%2520myeloma%26jtitle%3DLeukemia%26date%3D2019%26volume%3D130%26issue%3DSuppl%25201%26spage%3D3153%26doi%3D10.1038%2Fs41375-018-0278-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit8b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group">ClinicalTrials.gov</span>, NCT03489525. <a href="https://clinicaltrials.gov/ct2/show/NCT03489525" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03489525</a> (accessed July 7, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+ClinicalTrials.gov%2C+NCT03489525.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03489525+%28accessed+July+7%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Flynn, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zammarchi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyrer, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akarca, A. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janghra, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Britten, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Havenith, C. E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, J.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiberghien, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masterson, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Hooge, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marafioti, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parren, P. W. H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Berkel, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartley, J. A.</span></span> <span> </span><span class="NLM_article-title">ADCT-301, a pyrrolobenzodiazepine (PBD) dimer-containing antibody–drug conjugate (ADC) Targeting CD25-expressing hematological malignancies</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">2709</span>– <span class="NLM_lpage">2721</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-16-0233</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1158%2F1535-7163.MCT-16-0233" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=27535974" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BC2sXovVOqsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=2709-2721&author=M.+J.+Flynnauthor=F.+Zammarchiauthor=P.+C.+Tyrerauthor=A.+U.+Akarcaauthor=N.+Janghraauthor=C.+E.+Brittenauthor=C.+E.+G.+Havenithauthor=J.-N.+Levyauthor=A.+Tiberghienauthor=L.+A.+Mastersonauthor=C.+Barryauthor=F.+D%E2%80%99Hoogeauthor=T.+Marafiotiauthor=P.+W.+H.+I.+Parrenauthor=D.+G.+Williamsauthor=P.+W.+Howardauthor=P.+H.+van+Berkelauthor=J.+A.+Hartley&title=ADCT-301%2C+a+pyrrolobenzodiazepine+%28PBD%29+dimer-containing+antibody%E2%80%93drug+conjugate+%28ADC%29+Targeting+CD25-expressing+hematological+malignancies&doi=10.1158%2F1535-7163.MCT-16-0233"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9aR"><div class="casContent"><span class="casTitleNuber">9a</span><div class="casTitle"><span class="NLM_cas:atitle">ADCT-301, a pyrrolobenzodiazepine (PBD) dimer-containing antibody-drug conjugate (ADC) targeting CD25-expressing hematological malignancies</span></div><div class="casAuthors">Flynn, Michael J.; Zammarchi, Francesca; Tyrer, Peter C.; Akarca, Ayse U.; Janghra, Narinder; Britten, Charles E.; Havenith, Carin E. G.; Levy, Jean-Noel; Tiberghien, Arnaud; Masterson, Luke A.; Barry, Conor; D'Hooge, Francois; Marafioti, Teresa; Parren, Paul W. H. I.; Williams, David G.; Howard, Philip W.; van Berkel, Patrick H.; Hartley, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2709-2721</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Despite the many advances in the treatment of hematol. malignancies over the past decade, outcomes in refractory lymphomas remain poor.  One potential strategy in this patient population is the specific targeting of IL2R-α (CD25), which is overexpressed on many lymphoma and leukemic cells, using antibody-drug conjugates (ADC).  ADCT-301 is an ADC composed of human IgG1 HuMax-TAC against CD25, stochastically conjugated through a dipeptide cleavable linker to a pyrrolobenzodiazepine (PBD) dimer warhead with a drug-antibody ratio (DAR) of 2.3.  ADCT-301 binds human CD25 with picomolar affinity.  ADCT-301 has highly potent and selective cytotoxicity against a panel of CD25-expressing human lymphoma cell lines.  Once internalized, the released warhead binds in the DNA minor groove and exerts its potent cytotoxic action via the formation of DNA interstrand cross-links.  A strong correlation between loss of viability and DNA cross-link formation is demonstrated.  DNA damage persists, resulting in phosphorylation of histone H2AX, cell-cycle arrest in G2-M, and apoptosis Bystander killing of CD25-neg. cells by ADCT-301 is also obsd.  In vivo, a single dose of ADCT-301 results in dose-dependent and targeted antitumor activity against both s.c. and disseminated CD25-pos. lymphoma models.  In xenografts of Karpas 299, which expressed both CD25 and CD30, marked superiority over brentuximab vedotin (Adcetris) is obsd.  Dose-dependent increases in DNA crosslinking, γ-H2AX, and PBD payload staining were obsd. in tumors in vivo indicating a role as relevant pharmacodynamic assays.  Together, these data support the clin. testing of this novel ADC in patients with CD25-expressing tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOYRWJCTYK9rVg90H21EOLACvtfcHk0lg5wKm_TyaRfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXovVOqsro%253D&md5=f43190787d13ef897602016b3a607bc3</span></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-16-0233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-16-0233%26sid%3Dliteratum%253Aachs%26aulast%3DFlynn%26aufirst%3DM.%2BJ.%26aulast%3DZammarchi%26aufirst%3DF.%26aulast%3DTyrer%26aufirst%3DP.%2BC.%26aulast%3DAkarca%26aufirst%3DA.%2BU.%26aulast%3DJanghra%26aufirst%3DN.%26aulast%3DBritten%26aufirst%3DC.%2BE.%26aulast%3DHavenith%26aufirst%3DC.%2BE.%2BG.%26aulast%3DLevy%26aufirst%3DJ.-N.%26aulast%3DTiberghien%26aufirst%3DA.%26aulast%3DMasterson%26aufirst%3DL.%2BA.%26aulast%3DBarry%26aufirst%3DC.%26aulast%3DD%25E2%2580%2599Hooge%26aufirst%3DF.%26aulast%3DMarafioti%26aufirst%3DT.%26aulast%3DParren%26aufirst%3DP.%2BW.%2BH.%2BI.%26aulast%3DWilliams%26aufirst%3DD.%2BG.%26aulast%3DHoward%26aufirst%3DP.%2BW.%26aulast%3Dvan%2BBerkel%26aufirst%3DP.%2BH.%26aulast%3DHartley%26aufirst%3DJ.%2BA.%26atitle%3DADCT-301%252C%2520a%2520pyrrolobenzodiazepine%2520%2528PBD%2529%2520dimer-containing%2520antibody%25E2%2580%2593drug%2520conjugate%2520%2528ADC%2529%2520Targeting%2520CD25-expressing%2520hematological%2520malignancies%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26volume%3D15%26spage%3D2709%26epage%3D2721%26doi%3D10.1158%2F1535-7163.MCT-16-0233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit9b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hamadani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samaniego, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spira, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radford, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caimi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menne, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boni, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feingold, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wuerthner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horwitz, S. M.</span></span> <span> </span><span class="NLM_article-title">Phase 1 study of ADCT-301 (camidanlumab tesirine), a novel pyrrolobenzodiazepine-based antibody drug conjugate, in relapsed/refractory classical Hodgkin lymphoma</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>132</i></span> (<span class="NLM_issue">Suppl 1</span>),  <span class="NLM_fpage">928</span>, <span class="refDoi"> DOI: 10.1182/blood-2018-99-118198</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1182%2Fblood-2018-99-118198" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2018&pages=928&issue=Suppl+1&author=M.+Hamadaniauthor=G.+P.+Collinsauthor=F.+Samaniegoauthor=A.+I.+Spiraauthor=A.+Daviesauthor=J.+Radfordauthor=P.+Caimiauthor=T.+Menneauthor=J.+Boniauthor=H.+Cruzauthor=J.+Feingoldauthor=S.+Heauthor=J.+Wuerthnerauthor=S.+M.+Horwitz&title=Phase+1+study+of+ADCT-301+%28camidanlumab+tesirine%29%2C+a+novel+pyrrolobenzodiazepine-based+antibody+drug+conjugate%2C+in+relapsed%2Frefractory+classical+Hodgkin+lymphoma&doi=10.1182%2Fblood-2018-99-118198"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1182%2Fblood-2018-99-118198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2018-99-118198%26sid%3Dliteratum%253Aachs%26aulast%3DHamadani%26aufirst%3DM.%26aulast%3DCollins%26aufirst%3DG.%2BP.%26aulast%3DSamaniego%26aufirst%3DF.%26aulast%3DSpira%26aufirst%3DA.%2BI.%26aulast%3DDavies%26aufirst%3DA.%26aulast%3DRadford%26aufirst%3DJ.%26aulast%3DCaimi%26aufirst%3DP.%26aulast%3DMenne%26aufirst%3DT.%26aulast%3DBoni%26aufirst%3DJ.%26aulast%3DCruz%26aufirst%3DH.%26aulast%3DFeingold%26aufirst%3DJ.%26aulast%3DHe%26aufirst%3DS.%26aulast%3DWuerthner%26aufirst%3DJ.%26aulast%3DHorwitz%26aufirst%3DS.%2BM.%26atitle%3DPhase%25201%2520study%2520of%2520ADCT-301%2520%2528camidanlumab%2520tesirine%2529%252C%2520a%2520novel%2520pyrrolobenzodiazepine-based%2520antibody%2520drug%2520conjugate%252C%2520in%2520relapsed%252Frefractory%2520classical%2520Hodgkin%2520lymphoma%26jtitle%3DBlood%26date%3D2018%26volume%3D132%26issue%3DSuppl%25201%26spage%3D928%26doi%3D10.1182%2Fblood-2018-99-118198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Abbvie
press release</span>, August 29, 2019. <a href="https://news.abbvie.com/news/press-releases/abbvie-discontinues-rovalpituzumab-tesirine-rova-t-research-and-development-program.htm" class="extLink">https://news.abbvie.com/news/press-releases/abbvie-discontinues-rovalpituzumab-tesirine-rova-t-research-and-development-program.htm</a> (accessed July 7, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Abbvie%0Apress+release%2C+August+29%2C+2019.+https%3A%2F%2Fnews.abbvie.com%2Fnews%2Fpress-releases%2Fabbvie-discontinues-rovalpituzumab-tesirine-rova-t-research-and-development-program.htm+%28accessed+July+7%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3D%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Seattle
Genetics press release</span>, June 19, 2017. <a href="https://investor.seattlegenetics.com/press-releases/news-details/2017/Seattle-Genetics-Discontinues-Phase-3-CASCADE-Trial-of-Vadastuximab-Talirine-SGN-CD33A-in-Frontline-Acute-Myeloid-Leukemia/default.aspx" class="extLink">https://investor.seattlegenetics.com/press-releases/news-details/2017/Seattle-Genetics-Discontinues-Phase-3-CASCADE-Trial-of-Vadastuximab-Talirine-SGN-CD33A-in-Frontline-Acute-Myeloid-Leukemia/default.aspx</a> (accessed July 7, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Seattle%0AGenetics+press+release%2C+June+19%2C+2017.+https%3A%2F%2Finvestor.seattlegenetics.com%2Fpress-releases%2Fnews-details%2F2017%2FSeattle-Genetics-Discontinues-Phase-3-CASCADE-Trial-of-Vadastuximab-Talirine-SGN-CD33A-in-Frontline-Acute-Myeloid-Leukemia%2Fdefault.aspx+%28accessed+July+7%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3D%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Doronina, S. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendelsohn, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bovee, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerveny, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alley, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oflazoglu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toki, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanderson, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zabinski, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wahl, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senter, P. D.</span></span> <span> </span><span class="NLM_article-title">Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: Effects of linker technology on efficacy and toxicity</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">114</span>– <span class="NLM_lpage">124</span>, <span class="refDoi"> DOI: 10.1021/bc0502917</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc0502917" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlars7%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2006&pages=114-124&author=S.+O.+Doroninaauthor=B.+A.+Mendelsohnauthor=T.+D.+Boveeauthor=C.+G.+Cervenyauthor=S.+C.+Alleyauthor=D.+L.+Meyerauthor=E.+Oflazogluauthor=B.+E.+Tokiauthor=R.+J.+Sandersonauthor=R.+F.+Zabinskiauthor=A.+F.+Wahlauthor=P.+D.+Senter&title=Enhanced+activity+of+monomethylauristatin+F+through+monoclonal+antibody+delivery%3A+Effects+of+linker+technology+on+efficacy+and+toxicity&doi=10.1021%2Fbc0502917"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12aR"><div class="casContent"><span class="casTitleNuber">12a</span><div class="casTitle"><span class="NLM_cas:atitle">Enhanced Activity of Monomethylauristatin F through Monoclonal Antibody Delivery: Effects of Linker Technology on Efficacy and Toxicity</span></div><div class="casAuthors">Doronina, Svetlana O.; Mendelsohn, Brian A.; Bovee, Tim D.; Cerveny, Charles G.; Alley, Stephen C.; Meyer, Damon L.; Oflazoglu, Ezogelin; Toki, Brian E.; Sanderson, Russell J.; Zabinski, Roger F.; Wahl, Alan F.; Senter, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">114-124</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We have previously shown that antibody-drug conjugates (ADCs) consisting of cAC10 (anti-CD30) linked to the antimitotic agent monomethylauristatin E (MMAE) lead to potent in vitro and in vivo activities against antigen pos. tumor models.  MMAF is a new antimitotic auristatin deriv. with a charged C-terminal phenylalanine residue that attenuates its cytotoxic activity compared to its uncharged counterpart, MMAE, most likely due to impaired intracellular access.  In vitro cytotoxicity studies indicated that mAb-maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl-MMAF (mAb-L1-MMAF) conjugates were >2200-fold more potent than free MMAF on a large panel of CD30 pos. hematol. cell lines.  As with cAC10-L1-MMAE, the corresponding MMAF ADC induced cures and regressions of established xenograft tumors at well tolerated doses.  To further optimize the ADC, several new linkers were generated in which various components within the L1 linker were either altered or deleted.  One of the most promising linkers contained a noncleavable maleimidocaproyl (L4) spacer between the drug and the mAb.  CAC10-L4-MMAF was approx. as potent in vitro as cAC10-L1-MMAF against a large panel of cell lines and was equally potent in vivo.  Importantly, cAC10-L4-MMAF was tolerated at >3 times the MTD of cAC10-L1-MMAF.  LCMS studies indicated that drug released from cAC10-L4-MMAF was the cysteine-L4-MMAF adduct, which likely arises from mAb degrdn. within the lysosomes of target cells.  This new linker technol. appears to be ideally suited for drugs that are both relatively cell-impermeable and tolerant of substitution with amino acids.  Thus, alterations of the linker have pronounced impacts on toxicity and lead to new ADCs with greatly improved therapeutic indexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfwQJyn8sp0LVg90H21EOLACvtfcHk0lhqBlKElntn-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlars7%252FL&md5=92da0266f0a83c7680006ef94956c879</span></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=10.1021%2Fbc0502917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc0502917%26sid%3Dliteratum%253Aachs%26aulast%3DDoronina%26aufirst%3DS.%2BO.%26aulast%3DMendelsohn%26aufirst%3DB.%2BA.%26aulast%3DBovee%26aufirst%3DT.%2BD.%26aulast%3DCerveny%26aufirst%3DC.%2BG.%26aulast%3DAlley%26aufirst%3DS.%2BC.%26aulast%3DMeyer%26aufirst%3DD.%2BL.%26aulast%3DOflazoglu%26aufirst%3DE.%26aulast%3DToki%26aufirst%3DB.%2BE.%26aulast%3DSanderson%26aufirst%3DR.%2BJ.%26aulast%3DZabinski%26aufirst%3DR.%2BF.%26aulast%3DWahl%26aufirst%3DA.%2BF.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26atitle%3DEnhanced%2520activity%2520of%2520monomethylauristatin%2520F%2520through%2520monoclonal%2520antibody%2520delivery%253A%2520Effects%2520of%2520linker%2520technology%2520on%2520efficacy%2520and%2520toxicity%26jtitle%3DBioconjugate%2520Chem.%26date%3D2006%26volume%3D17%26spage%3D114%26epage%3D124%26doi%3D10.1021%2Fbc0502917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit12b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Maderna, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leverett, C. A.</span></span> <span> </span><span class="NLM_article-title">Recent advances in the development of new auristatins: Structural modifications and application in antibody drug conjugates</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1798</span>– <span class="NLM_lpage">1812</span>, <span class="refDoi"> DOI: 10.1021/mp500762u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp500762u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtVaht7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=1798-1812&author=A.+Madernaauthor=C.+A.+Leverett&title=Recent+advances+in+the+development+of+new+auristatins%3A+Structural+modifications+and+application+in+antibody+drug+conjugates&doi=10.1021%2Fmp500762u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12bR"><div class="casContent"><span class="casTitleNuber">12b</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Advances in the Development of New Auristatins: Structural Modifications and Application in Antibody Drug Conjugates</span></div><div class="casAuthors">Maderna, Andreas; Leverett, Carolyn A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1798-1812</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review. Dolastatin 10 is a powerful antineoplastic agent and microtubule inhibitor that was discovered by Pettit et al. and published in 1987.  Since then, many research groups have engaged in SAR studies of synthetic analogs, termed "auristatins".  It was eventually discovered that auristatins are of great value as payloads in antibody drug conjugates (ADCs), which led to the FDA-approved ADC brentuximab vedotin (Seattle Genetics).  Currently, over 30 ADCs in clin. trials employ auristatins as payloads, and there is a great interest in the research community, both on academic and industrial sides, to further study these analogs.  This review will provide an overview of the recent advancements in auristatin development spanning a time frame of about the past ten years.  The main focus will be to describe structural changes made to the auristatin peptide and their resulting biol. activities in tumor cell proliferation assays.  Selected ADC examples will also be described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxfsjeci8BurVg90H21EOLACvtfcHk0lhqBlKElntn-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtVaht7o%253D&md5=6ad39fd9b6f8d0eff5be442037981c62</span></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=10.1021%2Fmp500762u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp500762u%26sid%3Dliteratum%253Aachs%26aulast%3DMaderna%26aufirst%3DA.%26aulast%3DLeverett%26aufirst%3DC.%2BA.%26atitle%3DRecent%2520advances%2520in%2520the%2520development%2520of%2520new%2520auristatins%253A%2520Structural%2520modifications%2520and%2520application%2520in%2520antibody%2520drug%2520conjugates%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2015%26volume%3D12%26spage%3D1798%26epage%3D1812%26doi%3D10.1021%2Fmp500762u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit12c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emmerton, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyamoto, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setter, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholas, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okeley, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyon, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benjamin, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Law, C.-L.</span></span> <span> </span><span class="NLM_article-title">Intracellular released payload influences potency and bystander-killing effects of antibody–drug conjugates in preclinical models</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">2710</span>– <span class="NLM_lpage">2719</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-15-1795</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1158%2F0008-5472.CAN-15-1795" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=26921341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BC28XntVers74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=2710-2719&author=F.+Liauthor=K.+K.+Emmertonauthor=M.+Jonasauthor=X.+Zhangauthor=J.+B.+Miyamotoauthor=J.+R.+Setterauthor=N.+D.+Nicholasauthor=N.+M.+Okeleyauthor=R.+P.+Lyonauthor=D.+R.+Benjaminauthor=C.-L.+Law&title=Intracellular+released+payload+influences+potency+and+bystander-killing+effects+of+antibody%E2%80%93drug+conjugates+in+preclinical+models&doi=10.1158%2F0008-5472.CAN-15-1795"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12cR"><div class="casContent"><span class="casTitleNuber">12c</span><div class="casTitle"><span class="NLM_cas:atitle">Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models</span></div><div class="casAuthors">Li, Fu; Emmerton, Kim K.; Jonas, Mechthild; Zhang, Xinqun; Miyamoto, Jamie B.; Setter, Jocelyn R.; Nicholas, Nicole D.; Okeley, Nicole M.; Lyon, Robert P.; Benjamin, Dennis R.; Law, Che-Leung</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2710-2719</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Antibody-drug conjugates (ADC) comprise targeting antibodies armed with potent small-mol. payloads.  ADCs demonstrate specific cell killing in clinic, but the basis of their antitumor activity is not fully understood.  In this study, we investigated the degree to which payload release predicts ADC activity in vitro and in vivo.  ADCs were generated to target different receptors on the anaplastic large cell lymphoma line L-82, but delivered the same cytotoxic payload (monomethyl auristatin E, MMAE), and we found that the intracellular concn. of released MMAE correlated with in vitro ADC-mediated cytotoxicity independent of target expression or drug:antibody ratios.  Intratumoral MMAE concns. consistently correlated with the extent of tumor growth inhibition in tumor xenograft models.  In addn., we developed a robust admixed tumor model consisting of CD30+ and CD30- cancer cells to study how heterogeneity of target antigen expression, a phenomenon often obsd. in cancer specimens, affects the treatment response.  CD30-targeting ADC delivering membrane permeable MMAE or pyrrolobenzodiazepine dimers demonstrated potent bystander killing of neighboring CD30- cells.  In contrast, a less membrane permeable payload, MMAF, failed to mediate bystander killing in vivo, suggesting local diffusion and distribution of released payloads represents a potential mechanism of ADC-mediated bystander killing.  Collectively, our findings establish that the biophys. properties and amt. of released payloads are chief factors detg. the overall ADC potency and bystander killing.  Cancer Res; 76(9); 2710-9. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoylCMD1xAFdLVg90H21EOLACvtfcHk0lhqBlKElntn-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntVers74%253D&md5=bb7e7c2e6b4ea6f92d522d6c086454d2</span></div><a href="/servlet/linkout?suffix=cit12c&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-15-1795&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-15-1795%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DF.%26aulast%3DEmmerton%26aufirst%3DK.%2BK.%26aulast%3DJonas%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DMiyamoto%26aufirst%3DJ.%2BB.%26aulast%3DSetter%26aufirst%3DJ.%2BR.%26aulast%3DNicholas%26aufirst%3DN.%2BD.%26aulast%3DOkeley%26aufirst%3DN.%2BM.%26aulast%3DLyon%26aufirst%3DR.%2BP.%26aulast%3DBenjamin%26aufirst%3DD.%2BR.%26aulast%3DLaw%26aufirst%3DC.-L.%26atitle%3DIntracellular%2520released%2520payload%2520influences%2520potency%2520and%2520bystander-killing%2520effects%2520of%2520antibody%25E2%2580%2593drug%2520conjugates%2520in%2520preclinical%2520models%26jtitle%3DCancer%2520Res.%26date%3D2016%26volume%3D76%26spage%3D2710%26epage%3D2719%26doi%3D10.1158%2F0008-5472.CAN-15-1795" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit12d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hingorani, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doan, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camargo, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aguilera, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pizzo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scanderbeg, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, E. E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowy, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Advani, S. J.</span></span> <span> </span><span class="NLM_article-title">Precision chemoradiotherapy for HER2 tumors using antibody conjugates of an auristatin derivative with reduced cell permeability</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">157</span>– <span class="NLM_lpage">167</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-18-1302</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1158%2F1535-7163.MCT-18-1302" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=31597712" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkvVOlt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2020&pages=157-167&author=D.+V.+Hingoraniauthor=M.+K.+Doanauthor=M.+F.+Camargoauthor=J.+Aguileraauthor=S.+M.+Songauthor=D.+Pizzoauthor=D.+J.+Scanderbegauthor=E.+E.+W.+Cohenauthor=A.+M.+Lowyauthor=S.+R.+Adamsauthor=S.+J.+Advani&title=Precision+chemoradiotherapy+for+HER2+tumors+using+antibody+conjugates+of+an+auristatin+derivative+with+reduced+cell+permeability&doi=10.1158%2F1535-7163.MCT-18-1302"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12dR"><div class="casContent"><span class="casTitleNuber">12d</span><div class="casTitle"><span class="NLM_cas:atitle">Precision chemoradiotherapy for HER2 tumors using antibody conjugates of an Auristatin derivative with reduced cell permeability</span></div><div class="casAuthors">Hingorani, Dina V.; Doan, Matthew K.; Camargo, Maria F.; Aguilera, Joseph; Song, Seung M.; Pizzo, Donald; Scanderbeg, Daniel J.; Cohen, Ezra E. W.; Lowy, Andrew M.; Adams, Stephen R.; Advani, Sunil J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">157-167</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The most successful therapeutic strategies for locally advanced cancers continue to combine decades-old classical radiosensitizing chemotherapies with radiotherapy.  Mol. targeted radiosensitizers offer the potential to improve the therapeutic ratio by increasing tumor-specific kill while minimizing drug delivery and toxicity to surrounding normal tissue.  Auristatins are a potent class of anti-tubulins that sensitize cells to ionizing radiation damage and are chem. amenable to antibody conjugation.  To achieve tumor-selective radiosensitization, we synthesized and tested anti-HER2 antibody-drug conjugates of two auristatin derivs. with ionizing radiation.  Monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF) were attached to the anti-HER2 antibodies trastuzumab and pertuzumab through a cleavable linker.  While MMAE is cell permeable, MMAF has limited cell permeability as free drug resulting in diminished cytotoxicity and radiosensitization.  However, when attached to trastuzumab or pertuzumab, MMAF was as efficacious as MMAE in blocking HER2-expressing tumor cells in G -M.  Moreover, MMAF anti-HER2 conjugates selectively killed and radiosensitized HER2-rich tumor cells.  Importantly, when conjugated to targeting antibody, MMAF had the advantage of decreased bystander and off-target effects compared with MMAE.  In murine xenograft models, MMAF anti-HER2 antibody conjugates had less drug accumulated in the normal tissue surrounding tumors compared with MMAE.  Therapeutically, systemically injected MMAF anti-HER2 conjugates combined with focal ionizing radiation increased tumor control and improved survival of mice with HER2-rich tumor xenografts.  In summary, our results demonstrate the potential of cell-impermeable radiosensitizing warheads to improve the therapeutic ratio of radiotherapy by leveraging antibody-drug conjugate technol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr40_zxT2Tip7Vg90H21EOLACvtfcHk0ljT3gGg81Eu-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkvVOlt7k%253D&md5=47f7c763a14a2f6ccb3fbfd71f17971b</span></div><a href="/servlet/linkout?suffix=cit12d&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-18-1302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-18-1302%26sid%3Dliteratum%253Aachs%26aulast%3DHingorani%26aufirst%3DD.%2BV.%26aulast%3DDoan%26aufirst%3DM.%2BK.%26aulast%3DCamargo%26aufirst%3DM.%2BF.%26aulast%3DAguilera%26aufirst%3DJ.%26aulast%3DSong%26aufirst%3DS.%2BM.%26aulast%3DPizzo%26aufirst%3DD.%26aulast%3DScanderbeg%26aufirst%3DD.%2BJ.%26aulast%3DCohen%26aufirst%3DE.%2BE.%2BW.%26aulast%3DLowy%26aufirst%3DA.%2BM.%26aulast%3DAdams%26aufirst%3DS.%2BR.%26aulast%3DAdvani%26aufirst%3DS.%2BJ.%26atitle%3DPrecision%2520chemoradiotherapy%2520for%2520HER2%2520tumors%2520using%2520antibody%2520conjugates%2520of%2520an%2520auristatin%2520derivative%2520with%2520reduced%2520cell%2520permeability%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2020%26volume%3D19%26spage%3D157%26epage%3D167%26doi%3D10.1158%2F1535-7163.MCT-18-1302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Widdison, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponte, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coccia, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanieri, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setiady, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skaletskaya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salomon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fishkin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maloney, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovtun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veale, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilhelm, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Audette, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costoplus, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chari, R. V. J.</span></span> <span> </span><span class="NLM_article-title">Development of anilino-maytansinoid ADCs that efficiently release cytotoxic metabolites in cancer cells and induce high levels of bystander killing</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">2261</span>– <span class="NLM_lpage">2278</span>, <span class="refDoi"> DOI: 10.1021/acs.bioconjchem.5b00430</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.bioconjchem.5b00430" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVyis7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2015&pages=2261-2278&author=W.+C.+Widdisonauthor=J.+F.+Ponteauthor=J.+A.+Cocciaauthor=L.+Lanieriauthor=Y.+Setiadyauthor=L.+Dongauthor=A.+Skaletskayaauthor=E.+E.+Hongauthor=R.+Wuauthor=Q.+Qiuauthor=R.+Singhauthor=P.+Salomonauthor=N.+Fishkinauthor=L.+Harrisauthor=E.+K.+Maloneyauthor=Y.+Kovtunauthor=K.+Vealeauthor=S.+D.+Wilhelmauthor=C.+A.+Audetteauthor=J.+A.+Costoplusauthor=R.+V.+J.+Chari&title=Development+of+anilino-maytansinoid+ADCs+that+efficiently+release+cytotoxic+metabolites+in+cancer+cells+and+induce+high+levels+of+bystander+killing&doi=10.1021%2Facs.bioconjchem.5b00430"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13a</span><div class="casTitle"><span class="NLM_cas:atitle">Development of anilino-maytansinoid ADCs that efficiently release cytotoxic metabolites in cancer cells and induce high levels of bystander killing</span></div><div class="casAuthors">Widdison, Wayne C.; Ponte, Jose F.; Coccia, Jennifer A.; Lanieri, Leanne; Setiady, Yulius; Dong, Ling; Skaletskaya, Anna; Hong, E. Erica; Wu, Rui; Qiu, Qifeng; Singh, Rajeeva; Salomon, Paulin; Fishkin, Nathan; Harris, Luke; Maloney, Erin K.; Kovtun, Yelena; Veale, Karen; Wilhelm, Sharon D.; Audette, Charlene A.; Costoplus, Juliet A.; Chari, Ravi V. J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2261-2278</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Antibody anilino maytansinoid conjugates (AaMCs) have been prepd. in which a maytansinoid bearing an aniline group was linked through the aniline amine to a dipeptide, which in turn was covalently attached to a desired monoclonal antibody.  Several such conjugates were prepd. utilizing different dipeptides in the linkage including Gly-Gly, L-Val-L-Cit, and all four stereoisomers of the Ala-Ala dipeptide.  The properties of AaMCs could be altered by the choice of dipeptide in the linker.  Each of the AaMCs, except the AaMC bearing a D-Ala-D-Ala peptide linker, displayed more bystander killing in vitro than maytansinoid ADCs that utilize disulfide linkers.  In mouse models, the anti-CanAg AaMC bearing a D-Ala-L-Ala dipeptide in the linker was shown to be more efficacious against heterogeneous HT-29 xenografts than maytansinoid ADCs that utilize disulfide linkers, while both types of the conjugates displayed similar tolerabilities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDe0CRN4quKLVg90H21EOLACvtfcHk0ljT3gGg81Eu-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVyis7rI&md5=b71d9ed21705a302f01c167ca662141a</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1021%2Facs.bioconjchem.5b00430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.bioconjchem.5b00430%26sid%3Dliteratum%253Aachs%26aulast%3DWiddison%26aufirst%3DW.%2BC.%26aulast%3DPonte%26aufirst%3DJ.%2BF.%26aulast%3DCoccia%26aufirst%3DJ.%2BA.%26aulast%3DLanieri%26aufirst%3DL.%26aulast%3DSetiady%26aufirst%3DY.%26aulast%3DDong%26aufirst%3DL.%26aulast%3DSkaletskaya%26aufirst%3DA.%26aulast%3DHong%26aufirst%3DE.%2BE.%26aulast%3DWu%26aufirst%3DR.%26aulast%3DQiu%26aufirst%3DQ.%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DSalomon%26aufirst%3DP.%26aulast%3DFishkin%26aufirst%3DN.%26aulast%3DHarris%26aufirst%3DL.%26aulast%3DMaloney%26aufirst%3DE.%2BK.%26aulast%3DKovtun%26aufirst%3DY.%26aulast%3DVeale%26aufirst%3DK.%26aulast%3DWilhelm%26aufirst%3DS.%2BD.%26aulast%3DAudette%26aufirst%3DC.%2BA.%26aulast%3DCostoplus%26aufirst%3DJ.%2BA.%26aulast%3DChari%26aufirst%3DR.%2BV.%2BJ.%26atitle%3DDevelopment%2520of%2520anilino-maytansinoid%2520ADCs%2520that%2520efficiently%2520release%2520cytotoxic%2520metabolites%2520in%2520cancer%2520cells%2520and%2520induce%2520high%2520levels%2520of%2520bystander%2520killing%26jtitle%3DBioconjugate%2520Chem.%26date%3D2015%26volume%3D26%26spage%3D2261%26epage%3D2278%26doi%3D10.1021%2Facs.bioconjchem.5b00430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit13b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Costoplus, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veale, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponte, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanieri, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setiady, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skaletskaya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartle, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salomon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maloney, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovtun, Y. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ab, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chari, R. V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widdison, W. C.</span></span> <span> </span><span class="NLM_article-title">Peptide-cleavable self-immolative maytansinoid antibody–drug conjugates designed to provide improved bystander killing</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1393</span>– <span class="NLM_lpage">1399</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00310</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00310" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVGgtLzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1393-1399&author=J.+A.+Costoplusauthor=K.+H.+Vealeauthor=Q.+Qiuauthor=J.+F.+Ponteauthor=L.+Lanieriauthor=Y.+Setiadyauthor=L.+Dongauthor=A.+Skaletskayaauthor=L.+M.+Bartleauthor=P.+Salomonauthor=R.+Wuauthor=E.+K.+Maloneyauthor=Y.+V.+Kovtunauthor=O.+Abauthor=K.+Laiauthor=R.+V.+J.+Chariauthor=W.+C.+Widdison&title=Peptide-cleavable+self-immolative+maytansinoid+antibody%E2%80%93drug+conjugates+designed+to+provide+improved+bystander+killing&doi=10.1021%2Facsmedchemlett.9b00310"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13b</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide-Cleavable Self-immolative Maytansinoid Antibody-Drug Conjugates Designed To Provide Improved Bystander Killing</span></div><div class="casAuthors">Costoplus, Juliet A.; Veale, Karen H.; Qiu, Qifeng; Ponte, Jose F.; Lanieri, Leanne; Setiady, Yulius; Dong, Ling; Skaletskaya, Anna; Bartle, Laura M.; Salomon, Paulin; Wu, Rui; Maloney, Erin K.; Kovtun, Yelena V.; Ab, Olga; Lai, Kate; Chari, Ravi V. J.; Widdison, Wayne C.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1393-1399</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new type of antibody-drug conjugate (ADC) has been prepd. that contains a sulfur-bearing maytansinoid attached to an antibody via a highly stable tripeptide linker.  Once internalized by cells, proteases in catabolic vesicles cleave the peptide of the ADC's linker causing self-immolation that releases a thiol-bearing metabolite, which is then S-methylated.  Conjugates were prepd. with peptide linkers contg. only alanyl residues, which were all L isomers or had a single D residue in one of the three positions.  A D-alanyl residue in the linker did not significantly impair a conjugate's cytotoxicity or bystander killing unless it was directly attached to the immolative moiety.  Increasing the no. of methylene units in the maytansinoid side chain of a conjugate did not typically affect an ADC's cytotoxicity to targeted cells but did increase bystander killing activity.  ADCs with the highest in vitro bystander killing were then evaluated in vivo in mice, where they displayed improved efficacy compared to previously described types of maytansinoid conjugates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVorbrpE2efbVg90H21EOLACvtfcHk0liqOtRd1JKlEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVGgtLzI&md5=5bbc21126af25e33a52971fbeef6be32</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00310%26sid%3Dliteratum%253Aachs%26aulast%3DCostoplus%26aufirst%3DJ.%2BA.%26aulast%3DVeale%26aufirst%3DK.%2BH.%26aulast%3DQiu%26aufirst%3DQ.%26aulast%3DPonte%26aufirst%3DJ.%2BF.%26aulast%3DLanieri%26aufirst%3DL.%26aulast%3DSetiady%26aufirst%3DY.%26aulast%3DDong%26aufirst%3DL.%26aulast%3DSkaletskaya%26aufirst%3DA.%26aulast%3DBartle%26aufirst%3DL.%2BM.%26aulast%3DSalomon%26aufirst%3DP.%26aulast%3DWu%26aufirst%3DR.%26aulast%3DMaloney%26aufirst%3DE.%2BK.%26aulast%3DKovtun%26aufirst%3DY.%2BV.%26aulast%3DAb%26aufirst%3DO.%26aulast%3DLai%26aufirst%3DK.%26aulast%3DChari%26aufirst%3DR.%2BV.%2BJ.%26aulast%3DWiddison%26aufirst%3DW.%2BC.%26atitle%3DPeptide-cleavable%2520self-immolative%2520maytansinoid%2520antibody%25E2%2580%2593drug%2520conjugates%2520designed%2520to%2520provide%2520improved%2520bystander%2520killing%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D1393%26epage%3D1399%26doi%3D10.1021%2Facsmedchemlett.9b00310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ogitani, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagihara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oitate, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naito, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agatsuma, T.</span></span> <span> </span><span class="NLM_article-title">Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody–drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity</span>. <i>Cancer Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">1039</span>– <span class="NLM_lpage">1046</span>, <span class="refDoi"> DOI: 10.1111/cas.12966</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1111%2Fcas.12966" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=27166974" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVahu7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2016&pages=1039-1046&author=Y.+Ogitaniauthor=K.+Hagiharaauthor=M.+Oitateauthor=H.+Naitoauthor=T.+Agatsuma&title=Bystander+killing+effect+of+DS-8201a%2C+a+novel+anti-human+epidermal+growth+factor+receptor+2+antibody%E2%80%93drug+conjugate%2C+in+tumors+with+human+epidermal+growth+factor+receptor+2+heterogeneity&doi=10.1111%2Fcas.12966"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity</span></div><div class="casAuthors">Ogitani, Yusuke; Hagihara, Katsunobu; Oitate, Masataka; Naito, Hiroyuki; Agatsuma, Toshinori</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1039-1046</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1349-7006</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Antibody-drug conjugates deliver anticancer agents selectively and efficiently to tumor tissue and have significant antitumor efficacy with a wide therapeutic window.  DS-8201a is a human epidermal growth factor receptor 2 (HER2)-targeting antibody-drug conjugate prepd. using a novel linker-payload system with a potent topoisomerase I inhibitor, exatecan deriv. (DX-8951 deriv., DXd).  It was effective against trastuzumab emtansine (T-DM1)-insensitive patient-derived xenograft models with both high and low HER2 expression.  In this study, the bystander killing effect of DS-8201a was evaluated and compared with that of T-DM1.  We confirmed that the payload of DS-8201a, DXd (1), was highly membrane-permeable whereas that of T-DM1, Lys-SMCC-DM1, had a low level of permeability.  Under a coculture condition of HER2-pos. KPL-4 cells and neg. MDA-MB-468 cells in vitro, DS-8201a killed both cells, whereas T-DM1 and an antibody-drug conjugate with a low permeable payload, anti-HER2-DXd (2), did not.  In vivo evaluation was carried out using mice inoculated with a mixt. of HER2-pos. NCI-N87 cells and HER2-neg. MDA-MB-468-Luc cells by using an in vivo imaging system.  In vivo, DS-8201a reduced the luciferase signal of the mice, indicating suppression of the MDA-MB-468-Luc population; however, T-DM1 and anti-HER2-DXd (2) did not.  Furthermore, it was confirmed that DS-8201a was not effective against MDA-MB-468-Luc tumors inoculated at the opposite side of the NCI-N87 tumor, suggesting that the bystander killing effect of DS-8201a is obsd. only in cells neighboring HER2-pos. cells, indicating low concern in terms of systemic toxicity.  These results indicated that DS-8201a has a potent bystander effect due to a highly membrane-permeable payload and is beneficial in treating tumors with HER2 heterogeneity that are unresponsive to T-DM1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroroEcCVHueLVg90H21EOLACvtfcHk0liqOtRd1JKlEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVahu7zO&md5=1e65fee32e1333a1c446aff844a7c67d</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1111%2Fcas.12966&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcas.12966%26sid%3Dliteratum%253Aachs%26aulast%3DOgitani%26aufirst%3DY.%26aulast%3DHagihara%26aufirst%3DK.%26aulast%3DOitate%26aufirst%3DM.%26aulast%3DNaito%26aufirst%3DH.%26aulast%3DAgatsuma%26aufirst%3DT.%26atitle%3DBystander%2520killing%2520effect%2520of%2520DS-8201a%252C%2520a%2520novel%2520anti-human%2520epidermal%2520growth%2520factor%2520receptor%25202%2520antibody%25E2%2580%2593drug%2520conjugate%252C%2520in%2520tumors%2520with%2520human%2520epidermal%2520growth%2520factor%2520receptor%25202%2520heterogeneity%26jtitle%3DCancer%2520Sci.%26date%3D2016%26volume%3D107%26spage%3D1039%26epage%3D1046%26doi%3D10.1111%2Fcas.12966" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="note"><p class="first last">For a related example that accomplishes indolinobenzodiazepine ADC payload modification via an attached linker, see:</p></div><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reid, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Archer, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shizuka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilhelm, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoder, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fishkin, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maloney, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salomon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ab, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sikka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chari, R. V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. L.</span></span> <span> </span><span class="NLM_article-title">Effect of linker stereochemistry on the activity of indolinobenzodiazepine containing antibody–drug conjugates (ADCs)</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1193</span>– <span class="NLM_lpage">1197</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00240</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00240" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlGjs7fP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1193-1197&author=E.+E.+Reidauthor=K.+E.+Archerauthor=M.+Shizukaauthor=A.+Wilhelmauthor=N.+C.+Yoderauthor=C.+Baiauthor=N.+E.+Fishkinauthor=L.+Harrisauthor=E.+K.+Maloneyauthor=P.+Salomonauthor=E.+Hongauthor=R.+Wuauthor=O.+Abauthor=S.+Jinauthor=K.+C.+Laiauthor=S.+Sikkaauthor=R.+V.+J.+Chariauthor=M.+L.+Miller&title=Effect+of+linker+stereochemistry+on+the+activity+of+indolinobenzodiazepine+containing+antibody%E2%80%93drug+conjugates+%28ADCs%29&doi=10.1021%2Facsmedchemlett.9b00240"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of Linker Stereochemistry on the Activity of Indolinobenzodiazepine Containing Antibody-Drug Conjugates (ADCs)</span></div><div class="casAuthors">Reid, Emily E.; Archer, Katie E.; Shizuka, Manami; Wilhelm, Alan; Yoder, Nicholas C.; Bai, Chen; Fishkin, Nathan E.; Harris, Luke; Maloney, Erin K.; Salomon, Paulin; Hong, Erica; Wu, Rui; Ab, Olga; Jin, Shan; Lai, Katharine C.; Sikka, Surina; Chari, Ravi V. J.; Miller, Michael L.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1193-1197</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Antibody-drug conjugates (ADCs) that incorporate potent indolinobenzodiazepine DNA alkylators as the payload component are currently undergoing clin. evaluation.  In one ADC design, the payload mols. are linked to the antibody through a peptidase-labile L-Ala-L-Ala linker.  In order to det. the role of amino acid stereochem. on antitumor activity and tolerability, we incorporated L- and D-alanyl groups in the dipeptide, synthesized all four diastereomers, and prepd. and tested the corresponding ADCs.  Results of our preclin. evaluation showed that the L-Ala-L-Ala configuration provided the ADC with the highest therapeutic index (antitumor activity vs toxicity).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5N94m19c_tLVg90H21EOLACvtfcHk0liqOtRd1JKlEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlGjs7fP&md5=72540be91ff42af39669c697c9b0f162</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00240&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00240%26sid%3Dliteratum%253Aachs%26aulast%3DReid%26aufirst%3DE.%2BE.%26aulast%3DArcher%26aufirst%3DK.%2BE.%26aulast%3DShizuka%26aufirst%3DM.%26aulast%3DWilhelm%26aufirst%3DA.%26aulast%3DYoder%26aufirst%3DN.%2BC.%26aulast%3DBai%26aufirst%3DC.%26aulast%3DFishkin%26aufirst%3DN.%2BE.%26aulast%3DHarris%26aufirst%3DL.%26aulast%3DMaloney%26aufirst%3DE.%2BK.%26aulast%3DSalomon%26aufirst%3DP.%26aulast%3DHong%26aufirst%3DE.%26aulast%3DWu%26aufirst%3DR.%26aulast%3DAb%26aufirst%3DO.%26aulast%3DJin%26aufirst%3DS.%26aulast%3DLai%26aufirst%3DK.%2BC.%26aulast%3DSikka%26aufirst%3DS.%26aulast%3DChari%26aufirst%3DR.%2BV.%2BJ.%26aulast%3DMiller%26aufirst%3DM.%2BL.%26atitle%3DEffect%2520of%2520linker%2520stereochemistry%2520on%2520the%2520activity%2520of%2520indolinobenzodiazepine%2520containing%2520antibody%25E2%2580%2593drug%2520conjugates%2520%2528ADCs%2529%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D1193%26epage%3D1197%26doi%3D10.1021%2Facsmedchemlett.9b00240" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Cailleau, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arora, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, G.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masterson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartley, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harper, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, P. W.</span></span> <span> </span><span class="NLM_article-title">Potentiation of PBD dimers by lipophilicity manipulation</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">741</span>– <span class="NLM_lpage">752</span>, <span class="refDoi"> DOI: 10.2174/1568026619666190401112517</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.2174%2F1568026619666190401112517" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=30931859" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVKksb%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=741-752&author=T.+Cailleauauthor=L.+R.+Adamsauthor=N.+Aroraauthor=G.-D.+Kangauthor=L.+Mastersonauthor=N.+Patelauthor=J.+A.+Hartleyauthor=S.+Maoauthor=J.+Harperauthor=P.+W.+Howard&title=Potentiation+of+PBD+dimers+by+lipophilicity+manipulation&doi=10.2174%2F1568026619666190401112517"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16aR"><div class="casContent"><span class="casTitleNuber">16a</span><div class="casTitle"><span class="NLM_cas:atitle">Potentiation of PBD Dimers by Lipophilicity Manipulation</span></div><div class="casAuthors">Cailleau, Thais; Adams, Lauren R.; Arora, Neha; Kang, Gyoung-Dong; Masterson, Luke; Patel, Neki; Hartley, John A.; Mao, Shenlan; Harper, Jay; Howard, Philip W.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">741-752</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Pyrrolobenzodiazepine (PBD) dimers are highly potent DNA crosslinking agents used as warheads in Antibody Drug Conjugates (ADCs) for cancer therapy.  We propose to investigate the correlation existing between the lipophilicity of those mols. and their activity (both in vitro and in vivo) as well as any effect obsd. during conjugation.  Reaction progress was monitored by Thin-Layer Chromatog. (TLC) using Merck Kieselgel 60 F254 silica gel, with a fluorescent indicator on aluminum plates.  Visualisation of TLC was achieved with UV light or iodine vapor unless otherwise stated.  Flash chromatog. was performed using Merck Kieselgel 60 F254 silica gel.  We have successfully designed and synthesized a novel PBD warhead (SG3312) with enhanced physicochem. properties.  The warhead also displayed increased potency in vitro.  After overcoming some epimerization issues, the synthesis of enantiomerically pure payload was achieved (SG3259) and fulfilled our criteria for a simplified and more efficient conjugation.  No addn. of propylene glycol was required, and high DAR and excellent monomeric purity were achieved.  The ADC (Herceptin-maia-SG3259) has been shown to release the active warhead (SG3312) upon exposure to Cathepsin B and demonstrated encouraging activity both in vitro and in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSrjP6i6JKr7Vg90H21EOLACvtfcHk0li6DXqgSDn6nA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVKksb%252FO&md5=eda97c8d8802c46b15b325c2ef2bbf33</span></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=10.2174%2F1568026619666190401112517&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026619666190401112517%26sid%3Dliteratum%253Aachs%26aulast%3DCailleau%26aufirst%3DT.%26aulast%3DAdams%26aufirst%3DL.%2BR.%26aulast%3DArora%26aufirst%3DN.%26aulast%3DKang%26aufirst%3DG.-D.%26aulast%3DMasterson%26aufirst%3DL.%26aulast%3DPatel%26aufirst%3DN.%26aulast%3DHartley%26aufirst%3DJ.%2BA.%26aulast%3DMao%26aufirst%3DS.%26aulast%3DHarper%26aufirst%3DJ.%26aulast%3DHoward%26aufirst%3DP.%2BW.%26atitle%3DPotentiation%2520of%2520PBD%2520dimers%2520by%2520lipophilicity%2520manipulation%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2019%26volume%3D19%26spage%3D741%26epage%3D752%26doi%3D10.2174%2F1568026619666190401112517" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit16b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kinneer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meekin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiberghien, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tai, Y.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phipps, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiefer, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rebelatto, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimasi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriarty, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadopoulos, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sridhar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregson, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wick, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masterson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbst, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tice, D. A.</span></span> <span> </span><span class="NLM_article-title">SLC46A3 as a potential predictive biomarker for antibody–drug conjugates bearing noncleavable linked maytansinoid and pyrrolobenzodiazepine warheads</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">6570</span>– <span class="NLM_lpage">6582</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-18-1300</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1158%2F1078-0432.CCR-18-1300" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=30131388" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1ait7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=6570-6582&author=K.+Kinneerauthor=J.+Meekinauthor=A.+C.+Tiberghienauthor=Y.-T.+Taiauthor=S.+Phippsauthor=C.+M.+Kieferauthor=M.+C.+Rebelattoauthor=N.+Dimasiauthor=A.+Moriartyauthor=K.+P.+Papadopoulosauthor=S.+Sridharauthor=S.+J.+Gregsonauthor=M.+J.+Wickauthor=L.+Mastersonauthor=K.+C.+Andersonauthor=R.+Herbstauthor=P.+W.+Howardauthor=D.+A.+Tice&title=SLC46A3+as+a+potential+predictive+biomarker+for+antibody%E2%80%93drug+conjugates+bearing+noncleavable+linked+maytansinoid+and+pyrrolobenzodiazepine+warheads&doi=10.1158%2F1078-0432.CCR-18-1300"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16bR"><div class="casContent"><span class="casTitleNuber">16b</span><div class="casTitle"><span class="NLM_cas:atitle">SLC46A3 as a potential predictive biomarker for antibody-drug conjugates bearing noncleavable linked maytansinoid and pyrrolobenzodiazepine warheads</span></div><div class="casAuthors">Kinneer, Krista; Meekin, John; Tiberghien, Arnaud C.; Tai, Yu-Tzu; Phipps, Sandrina; Kiefer, Christine Mione; Rebelatto, Marlon C.; Dimasi, Nazzareno; Moriarty, Alyssa; Papadopoulos, Kyriakos P.; Sridhar, Sriram; Gregson, Stephen J.; Wick, Michael J.; Masterson, Luke; Anderson, Kenneth C.; Herbst, Ronald; Howard, Philip W.; Tice, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6570-6582</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Antibody-drug conjugates (ADC) utilizing noncleavable linker drugs have been approved for clin. use, and several are in development targeting solid and hematol. malignancies including multiple myeloma.  Currently, there are no reliable biomarkers of activity for these ADCs other than presence of the targeted antigen.  We obsd. that certain cell lines are innately resistant to such ADCs, and sought to uncover the underlying mechanism of resistance.  Exptl. Design: The expression of 43 lysosomal membrane target genes was evaluated in cell lines resistant to ADCs bearing the noncleavable linker, pyrrolobenzodiazepine payload SG3376, in vitro.  The functional relevance of SLC46A3, a lysosomal transporter of noncleavable ADC catabolites whose expression uniquely correlated with SG3376 resistance, was assessed using EPHA2-, HER2-, and BCMA-targeted ADCs and isogenic cells overexpressing or genetically inactivated for SLC46A3.  SLC46A3 expression was also examd. in patient-derived xenograft and in vitro models of acquired T-DM1 resistance and multiple myeloma bone marrow samples by RT-PCR.  Results: Loss of SLC46A3 expression was found to be a mechanism of innate and acquired resistance to ADCs bearing DM1 and SG3376.  Sensitivity was restored in refractory lines upon introduction of SLC46A3, suggesting that expression of SLC46A3 may be more predictive of activity than target antigen levels alone.  Interrogation of primary multiple myeloma samples indicated a range of SLC46A3 expression, including samples with undetectable levels like multiple myeloma cell lines resistant to BCMA-targeting DM1 and SG3376 ADCs.  Conclusions: Our findings support SLC46A3 as a potential patient selection biomarker with immediate relevance to clin. trials involving these ADCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogMBCbYdUVXbVg90H21EOLACvtfcHk0li6DXqgSDn6nA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1ait7%252FI&md5=e3b5550bd7a96683d9f3ccac137eeb66</span></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-18-1300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-18-1300%26sid%3Dliteratum%253Aachs%26aulast%3DKinneer%26aufirst%3DK.%26aulast%3DMeekin%26aufirst%3DJ.%26aulast%3DTiberghien%26aufirst%3DA.%2BC.%26aulast%3DTai%26aufirst%3DY.-T.%26aulast%3DPhipps%26aufirst%3DS.%26aulast%3DKiefer%26aufirst%3DC.%2BM.%26aulast%3DRebelatto%26aufirst%3DM.%2BC.%26aulast%3DDimasi%26aufirst%3DN.%26aulast%3DMoriarty%26aufirst%3DA.%26aulast%3DPapadopoulos%26aufirst%3DK.%2BP.%26aulast%3DSridhar%26aufirst%3DS.%26aulast%3DGregson%26aufirst%3DS.%2BJ.%26aulast%3DWick%26aufirst%3DM.%2BJ.%26aulast%3DMasterson%26aufirst%3DL.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26aulast%3DHerbst%26aufirst%3DR.%26aulast%3DHoward%26aufirst%3DP.%2BW.%26aulast%3DTice%26aufirst%3DD.%2BA.%26atitle%3DSLC46A3%2520as%2520a%2520potential%2520predictive%2520biomarker%2520for%2520antibody%25E2%2580%2593drug%2520conjugates%2520bearing%2520noncleavable%2520linked%2520maytansinoid%2520and%2520pyrrolobenzodiazepine%2520warheads%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D24%26spage%3D6570%26epage%3D6582%26doi%3D10.1158%2F1078-0432.CCR-18-1300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Smellie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bose, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartley, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurston, D. E.</span></span> <span> </span><span class="NLM_article-title">Sequence-selective recognition of duplex DNA through covalent interstrand cross-linking: Kinetic and molecular modeling studies with pyrrolobenzodiazepine dimers</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">8232</span>– <span class="NLM_lpage">8239</span>, <span class="refDoi"> DOI: 10.1021/bi034313t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi034313t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BD3sXksF2kt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2003&pages=8232-8239&author=M.+Smellieauthor=D.+S.+Boseauthor=A.+S.+Thompsonauthor=T.+C.+Jenkinsauthor=J.+A.+Hartleyauthor=D.+E.+Thurston&title=Sequence-selective+recognition+of+duplex+DNA+through+covalent+interstrand+cross-linking%3A+Kinetic+and+molecular+modeling+studies+with+pyrrolobenzodiazepine+dimers&doi=10.1021%2Fbi034313t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17aR"><div class="casContent"><span class="casTitleNuber">17a</span><div class="casTitle"><span class="NLM_cas:atitle">Sequence-Selective Recognition of Duplex DNA through Covalent Interstrand Cross-Linking: Kinetic and Molecular Modeling Studies with Pyrrolobenzodiazepine Dimers</span></div><div class="casAuthors">Smellie, Melissa; Bose, Deravander S.; Thompson, Andrew S.; Jenkins, Terence C.; Hartley, John A.; Thurston, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">8232-8239</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Members of a homologous series of pyrrolo[2,1-c][1,4]benzodiazepine (PBD) dimers with C8-O-(CH2)n-O-C8' diether linkages (n = 3-6) have been studied for their ability to interact with oligonucleotide duplexes contg. potential target binding sites.  The results confirm earlier predictions that the n = 3 analog (DSB-120) will covalently bind to a 5'-Pu-GATC-Py sequence by crosslinking opposite-strand guanines sepd. by 2 bp.  Preference for this DNA sequence is shown using oligonucleotides with altered bases between and/or flanking these guanines.  The more extended PBD dimer (n = 5) can span an extra base pair and cross-link the 5'-Pu-GA(T/A)TC-Py sequence.  The ability of each homolog to cross-link linear plasmid DNA has been detd., with a rank order that correlates with the reported order of in vitro cytotoxicity: n = 3 > n = 5 > n = 6 > n = 4.  The n = 3 homolog is >300-fold more efficient at crosslinking DNA than the clin. used crosslinking agent melphalan under the same conditions.  Kinetic studies reveal that the n = 3 and 5 dimers achieve faster crosslinking to plasmid DNA (108 and 81% crosslinking h-1 μM-1 at 37°, resp.), whereas the n = 4 and 6 homologs are significantly less efficient at 10.3 and 23% crosslinking h-1 μM-1, resp.  Alternating activity for the odd n and even n dimers is probably due to configurational factors governed by the spatial sepn. of the PBD subunits and the flexible character of the tethering linkage.  Mol. modeling confirms the order of crosslinking reactivity, and highlights the role of linker length in dictating sequence recognition for this class of DNA-reactive agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZzUk-f-x3ebVg90H21EOLACvtfcHk0li6DXqgSDn6nA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXksF2kt78%253D&md5=ab688aab96a5be2bedb9e01933f80eed</span></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=10.1021%2Fbi034313t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi034313t%26sid%3Dliteratum%253Aachs%26aulast%3DSmellie%26aufirst%3DM.%26aulast%3DBose%26aufirst%3DD.%2BS.%26aulast%3DThompson%26aufirst%3DA.%2BS.%26aulast%3DJenkins%26aufirst%3DT.%2BC.%26aulast%3DHartley%26aufirst%3DJ.%2BA.%26aulast%3DThurston%26aufirst%3DD.%2BE.%26atitle%3DSequence-selective%2520recognition%2520of%2520duplex%2520DNA%2520through%2520covalent%2520interstrand%2520cross-linking%253A%2520Kinetic%2520and%2520molecular%2520modeling%2520studies%2520with%2520pyrrolobenzodiazepine%2520dimers%26jtitle%3DBiochemistry%26date%3D2003%26volume%3D42%26spage%3D8232%26epage%3D8239%26doi%3D10.1021%2Fbi034313t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit17b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Gregson, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gullick, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamaguchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corcoran, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartley, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guille, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurston, D. E.</span></span> <span> </span><span class="NLM_article-title">Linker length modulates DNA cross-linking reactivity and cytotoxic potency of C8/C8′ ether-linked C2-exo-unsaturated pyrrolo[2,1-c][1,4]benzodiazepine(PBD) dimers</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">1161</span>– <span class="NLM_lpage">1174</span>, <span class="refDoi"> DOI: 10.1021/jm030897l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030897l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnvFWhsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1161-1174&author=S.+J.+Gregsonauthor=P.+W.+Howardauthor=D.+R.+Gullickauthor=A.+Hamaguchiauthor=K.+E.+Corcoranauthor=N.+A.+Brooksauthor=J.+A.+Hartleyauthor=T.+C.+Jenkinsauthor=S.+Patelauthor=M.+J.+Guilleauthor=D.+E.+Thurston&title=Linker+length+modulates+DNA+cross-linking+reactivity+and+cytotoxic+potency+of+C8%2FC8%E2%80%B2+ether-linked+C2-exo-unsaturated+pyrrolo%5B2%2C1-c%5D%5B1%2C4%5Dbenzodiazepine%28PBD%29+dimers&doi=10.1021%2Fjm030897l"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17bR"><div class="casContent"><span class="casTitleNuber">17b</span><div class="casTitle"><span class="NLM_cas:atitle">Linker Length Modulates DNA Cross-Linking Reactivity and Cytotoxic Potency of C8/C8' Ether-Linked C2-exo-Unsaturated Pyrrolo[2,1-c][1,4]benzodiazepine (PBD) Dimers</span></div><div class="casAuthors">Gregson, Stephen J.; Howard, Philip W.; Gullick, Darren R.; Hamaguchi, Anzu; Corcoran, Kathryn E.; Brooks, Natalie A.; Hartley, John A.; Jenkins, Terence C.; Patel, Sejal; Guille, Matthew J.; Thurston, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1161-1174</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A C2/C2'-exo-unsatd. pyrrolo[2,1-c][1,4]benzodiazepine (PBD) dimer (DRG-16) with a C8-O(CH2)nO-C8' diether linkage (n = 5) has been synthesized that shows markedly superior in vitro cytotoxic potency (e.g., >3400-fold in IGROV1 ovarian cells) and interstrand DNA crosslinking reactivity (>10-fold) compared to the shorter homolog (SJG-136; n = 3).  In contrast, for the C-ring unsubstituted series, the corresponding n = 5 dimer is generally less cytotoxic and has a lower interstrand crosslinking reactivity compared to its shorter n = 3 homolog.  Dimer DRG-16 cross-links DNA with >10-fold efficiency compared to 4a, and also inhibits the activity of the restriction endonuclease BamH1 more efficiently.  The C2-exo-unsatd. PBD dimers 4a,b are not only more effective than their C-ring satd. counterparts in terms of induced ΔTm shift, but they also exert this effect more rapidly.  Mol. modeling shows a rank order of DRG-16 (n = 5) > SJG-136 (n = 3) in terms of binding energy toward duplexes contg. embedded target 5'-GAT1-2C cross-link sequences, reflecting the superior fit of the C2-exo-unsatd. rather than satd. C-rings of the PBD dimers.  A novel synthesis of core synthetic building blocks for PBD dimers via stepwise Mitsunobu reaction and nitration with Cu(NO3)2 is also reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrv_FYScSSSFLVg90H21EOLACvtfcHk0lhkpnqGhpeyrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnvFWhsQ%253D%253D&md5=ed9b4a4a43930d3316188bbd9e50401b</span></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=10.1021%2Fjm030897l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030897l%26sid%3Dliteratum%253Aachs%26aulast%3DGregson%26aufirst%3DS.%2BJ.%26aulast%3DHoward%26aufirst%3DP.%2BW.%26aulast%3DGullick%26aufirst%3DD.%2BR.%26aulast%3DHamaguchi%26aufirst%3DA.%26aulast%3DCorcoran%26aufirst%3DK.%2BE.%26aulast%3DBrooks%26aufirst%3DN.%2BA.%26aulast%3DHartley%26aufirst%3DJ.%2BA.%26aulast%3DJenkins%26aufirst%3DT.%2BC.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DGuille%26aufirst%3DM.%2BJ.%26aulast%3DThurston%26aufirst%3DD.%2BE.%26atitle%3DLinker%2520length%2520modulates%2520DNA%2520cross-linking%2520reactivity%2520and%2520cytotoxic%2520potency%2520of%2520C8%252FC8%25E2%2580%25B2%2520ether-linked%2520C2-exo-unsaturated%2520pyrrolo%255B2%252C1-c%255D%255B1%252C4%255Dbenzodiazepine%2528PBD%2529%2520dimers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D1161%26epage%3D1174%26doi%3D10.1021%2Fjm030897l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gregson, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masterson, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pillow, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, G.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raab, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, G. D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunzner-Toste, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safina, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darwish, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozak, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">dela Cruz-Chuh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flygare, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, P. W.</span></span> <span> </span><span class="NLM_article-title">Pyrrolobenzodiazepine dimer antibody–drug conjugates: Synthesis and evaluation of noncleavable drug-linkers</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">9490</span>– <span class="NLM_lpage">9507</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00736</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00736" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslOns7%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=9490-9507&author=S.+J.+Gregsonauthor=L.+A.+Mastersonauthor=B.+Weiauthor=T.+H.+Pillowauthor=S.+D.+Spencerauthor=G.-D.+Kangauthor=S.-F.+Yuauthor=H.+Raabauthor=J.+Lauauthor=G.+Liauthor=G.+D.+L.+Phillipsauthor=J.+Gunzner-Tosteauthor=B.+S.+Safinaauthor=R.+Ohriauthor=M.+Darwishauthor=K.+R.+Kozakauthor=J.+dela+Cruz-Chuhauthor=A.+Polsonauthor=J.+A.+Flygareauthor=P.+W.+Howard&title=Pyrrolobenzodiazepine+dimer+antibody%E2%80%93drug+conjugates%3A+Synthesis+and+evaluation+of+noncleavable+drug-linkers&doi=10.1021%2Facs.jmedchem.7b00736"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrrolobenzodiazepine Dimer Antibody-Drug Conjugates: Synthesis and Evaluation of Noncleavable Drug-Linkers</span></div><div class="casAuthors">Gregson, Stephen J.; Masterson, Luke A.; Wei, Binqing; Pillow, Thomas H.; Spencer, Susan D.; Kang, Gyoung-Dong; Yu, Shang-Fan; Raab, Helga; Lau, Jeffrey; Li, Guangmin; Lewis Phillips, Gail D.; Gunzner-Toste, Janet; Safina, Brian S.; Ohri, Rachana; Darwish, Martine; Kozak, Katherine R.; dela Cruz-Chuh, Josefa; Polson, Andrew; Flygare, John A.; Howard, Philip W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9490-9507</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Three rationally designed pyrrolobenzodiazepine (PBD) drug-linkers have been synthesized via intermediate, (11S,11'S,11aS,11'aS)-10,10'-bis(1,1-dimethylethyl) (11S,11aS,11'S,11a'S)-di-tert-Bu 8,8'-[(5-iodo-1,3-phenylene)bis(methyleneoxy)]bis[2,3,11,11a-tetrahydro-7-methoxy-2-methylene-5-oxo-11-[(tetrahydro-2H-pyran-2-yl)oxy]-1H-pyrrolo[2,1-c][1,4]benzodiazepine-10(5H)-carboxylate [1630094-65-3](19) for use in antibody-drug conjugates (ADCs).  They lack a cleavable trigger in the linker and consist of a maleimide for cysteine antibody conjugation, a hydrophilic spacer, and either an alkyne, triazole, or piperazine link to the PBD.  In vitro IC50 values were 11-48 ng/mL in HER2 3+ SK-BR-3 and KPL-4 (triazole conjugate, inactive) for the anti-HER2 ADCs (HER2 0 MCF7, all inactive) and 0.10-1.73 μg/mL (triazole conjugate, inactive) in CD22 3+ BJAB and WSU-DLCL2 for anti-CD22 ADCs (CD22 0 Jurkat, all inactive at low doses).  In vivo antitumor efficacy for the anti-HER2 ADCs in Founder 5 was obsd. with tumor stasis at 0.5-1 mg/kg, 1 mg/kg, and 3-6 mg/kg for three conjugates, resp.  Tumor stasis at 2 mg/kg was obsd. for anti-CD22 alkyne conjugate in WSU-DLCL2.  In summary, noncleavable PBD-ADCs exhibit potent activity, particularly in HER2 models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeLqWakvWPDLVg90H21EOLACvtfcHk0lhkpnqGhpeyrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslOns7%252FF&md5=99e06646a68d1395711428540c61884f</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00736%26sid%3Dliteratum%253Aachs%26aulast%3DGregson%26aufirst%3DS.%2BJ.%26aulast%3DMasterson%26aufirst%3DL.%2BA.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DPillow%26aufirst%3DT.%2BH.%26aulast%3DSpencer%26aufirst%3DS.%2BD.%26aulast%3DKang%26aufirst%3DG.-D.%26aulast%3DYu%26aufirst%3DS.-F.%26aulast%3DRaab%26aufirst%3DH.%26aulast%3DLau%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DPhillips%26aufirst%3DG.%2BD.%2BL.%26aulast%3DGunzner-Toste%26aufirst%3DJ.%26aulast%3DSafina%26aufirst%3DB.%2BS.%26aulast%3DOhri%26aufirst%3DR.%26aulast%3DDarwish%26aufirst%3DM.%26aulast%3DKozak%26aufirst%3DK.%2BR.%26aulast%3Ddela%2BCruz-Chuh%26aufirst%3DJ.%26aulast%3DPolson%26aufirst%3DA.%26aulast%3DFlygare%26aufirst%3DJ.%2BA.%26aulast%3DHoward%26aufirst%3DP.%2BW.%26atitle%3DPyrrolobenzodiazepine%2520dimer%2520antibody%25E2%2580%2593drug%2520conjugates%253A%2520Synthesis%2520and%2520evaluation%2520of%2520noncleavable%2520drug-linkers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D9490%26epage%3D9507%26doi%3D10.1021%2Facs.jmedchem.7b00736" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pillow, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruz-Chuh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozak, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadowsky, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, G. D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darwish, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hop, C. E. C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khojasteh, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dragovich, P. S.</span></span> <span> </span><span class="NLM_article-title">Linker immolation determines cell killing activity of disulfide-linked pyrrolobenzodiazepine antibody–drug conjugates</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">988</span>– <span class="NLM_lpage">993</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00233</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00233" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtl2rsrfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=988-993&author=D.+Zhangauthor=T.+H.+Pillowauthor=Y.+Maauthor=J.+Cruz-Chuhauthor=K.+R.+Kozakauthor=J.+D.+Sadowskyauthor=G.+D.+L.+Phillipsauthor=J.+Guoauthor=M.+Darwishauthor=P.+Fanauthor=J.+Chenauthor=C.+Heauthor=T.+Wangauthor=H.+Yaoauthor=Z.+Xuauthor=J.+Chenauthor=J.+Waiauthor=Z.+Peiauthor=C.+E.+C.+A.+Hopauthor=S.+C.+Khojastehauthor=P.+S.+Dragovich&title=Linker+immolation+determines+cell+killing+activity+of+disulfide-linked+pyrrolobenzodiazepine+antibody%E2%80%93drug+conjugates&doi=10.1021%2Facsmedchemlett.6b00233"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Linker Immolation Determines Cell Killing Activity of Disulfide-Linked Pyrrolobenzodiazepine Antibody-Drug Conjugates</span></div><div class="casAuthors">Zhang, Donglu; Pillow, Thomas H.; Ma, Yong; Cruz-Chuh, Josefa dela; Kozak, Katherine R.; Sadowsky, Jack D.; Lewis Phillips, Gail D.; Guo, Jun; Darwish, Martine; Fan, Peter; Chen, Jingtian; He, Changrong; Wang, Tao; Yao, Hui; Xu, Zijin; Chen, Jinhua; Wai, John; Pei, Zhonghua; Hop, Cornelis E. C. A.; Khojasteh, S. Cyrus; Dragovich, Peter S.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">988-993</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Disulfide bonds could be valuable linkers for a variety of therapeutic applications requiring tunable cleavage between two parts of a mol. (e.g., antibody-drug conjugates).  The in vitro linker immolation of β-mercaptoethyl-carbamate disulfides and DNA alkylation properties of assocd. payloads were investigated to understand the determinant of cell killing potency of anti-CD22 linked pyrrolobenzodiazepine (PBD-dimer) conjugates.  Efficient immolation and release of a PBD-dimer with strong DNA alkylation properties were obsd. following disulfide cleavage of methyl- and cyclobutyl-substituted disulfide linkers.  However, the analogous cyclopropyl-contg. linker did not immolate, and the assocd. thiol-contg. product was a poor DNA alkylator.  As predicted from these in vitro assessments, the related anti-CD22 ADCs showed different target-dependent cell killing activities in WSU-DLCL2 and BJAB cell lines.  These results demonstrate how the in vitro immolation models can be used to help design efficacious ADCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp46OI06jaKILVg90H21EOLACvtfcHk0lgoLWICCLTz1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtl2rsrfN&md5=2a9dbd291d99f13b848047198f97bd7c</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00233%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DPillow%26aufirst%3DT.%2BH.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DCruz-Chuh%26aufirst%3DJ.%26aulast%3DKozak%26aufirst%3DK.%2BR.%26aulast%3DSadowsky%26aufirst%3DJ.%2BD.%26aulast%3DPhillips%26aufirst%3DG.%2BD.%2BL.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DDarwish%26aufirst%3DM.%26aulast%3DFan%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DHe%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DWai%26aufirst%3DJ.%26aulast%3DPei%26aufirst%3DZ.%26aulast%3DHop%26aufirst%3DC.%2BE.%2BC.%2BA.%26aulast%3DKhojasteh%26aufirst%3DS.%2BC.%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26atitle%3DLinker%2520immolation%2520determines%2520cell%2520killing%2520activity%2520of%2520disulfide-linked%2520pyrrolobenzodiazepine%2520antibody%25E2%2580%2593drug%2520conjugates%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D988%26epage%3D993%26doi%3D10.1021%2Facsmedchemlett.6b00233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kansy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senner, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gubernator, K.</span></span> <span> </span><span class="NLM_article-title">Physicochemical high throughput screening: Parallel artificial membrane permeation assay in the description of passive absorption processes</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">1007</span>– <span class="NLM_lpage">1010</span>, <span class="refDoi"> DOI: 10.1021/jm970530e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm970530e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADyaK1cXhs12kt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1998&pages=1007-1010&author=M.+Kansyauthor=F.+Sennerauthor=K.+Gubernator&title=Physicochemical+high+throughput+screening%3A+Parallel+artificial+membrane+permeation+assay+in+the+description+of+passive+absorption+processes&doi=10.1021%2Fjm970530e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Physicochemical High Throughput Screening: Parallel Artificial Membrane Permeation Assay in the Description of Passive Absorption Processes</span></div><div class="casAuthors">Kansy, Manfred; Senner, Frank; Gubernator, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1007-1010</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The majority of pharmaceutical discovery projects aim for an orally available form of a new therapeutic principle.  One obstacle for per oral treatment is intestinal absorption.  A simple predictive exptl. method to assess the potential of intestinal absorption is therefore highly welcome.  The authors describe here the PAMPA (Parallel Artificial Membrane Permeation Assay) method, a simple, robust, high throughput screen (HTS) which has been shown to be predictive for passive diffusion through membranes and thus for oral absorption.  In addn. PAMPA can deliver information in parallel on the lipophilicity, the ionization state and the soly. of a compd.  Therefore PAMPA complements HTS, combinatorial chem. and parallel synthesis efforts in preclin. pharmaceutical research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqcwCGodCr1rVg90H21EOLACvtfcHk0lgoLWICCLTz1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhs12kt70%253D&md5=85d8ab409313b583de52348eb4d895da</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm970530e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm970530e%26sid%3Dliteratum%253Aachs%26aulast%3DKansy%26aufirst%3DM.%26aulast%3DSenner%26aufirst%3DF.%26aulast%3DGubernator%26aufirst%3DK.%26atitle%3DPhysicochemical%2520high%2520throughput%2520screening%253A%2520Parallel%2520artificial%2520membrane%2520permeation%2520assay%2520in%2520the%2520description%2520of%2520passive%2520absorption%2520processes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1998%26volume%3D41%26spage%3D1007%26epage%3D1010%26doi%3D10.1021%2Fjm970530e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dubowchik, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firestone, R. A.</span></span> <span> </span><span class="NLM_article-title">Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">3341</span>– <span class="NLM_lpage">3346</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(98)00609-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1016%2FS0960-894X%2898%2900609-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=9873731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADyaK1cXotFagtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1998&pages=3341-3346&author=G.+M.+Dubowchikauthor=R.+A.+Firestone&title=Cathepsin+B-sensitive+dipeptide+prodrugs.+1.+A+model+study+of+structural+requirements+for+efficient+release+of+doxorubicin&doi=10.1016%2FS0960-894X%2898%2900609-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin</span></div><div class="casAuthors">Dubowchik, Gene M.; Firestone, Raymond A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">3341-3346</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A series of lysosomal protease-sensitive peptides attached to doxorubicin (DOX) was prepd. as model substrates for internalizing anticancer immunoconjugates and potential antimetastasis prodrugs.  Rates of cathepsin B-mediated release of free drug was measured for each, and human plasma stabilities for representative examples.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOzOf1WKrZurVg90H21EOLACvtfcHk0lgoLWICCLTz1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXotFagtbY%253D&md5=946bb31dc62701634c946beb1f1cc1bc</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2898%2900609-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252898%252900609-X%26sid%3Dliteratum%253Aachs%26aulast%3DDubowchik%26aufirst%3DG.%2BM.%26aulast%3DFirestone%26aufirst%3DR.%2BA.%26atitle%3DCathepsin%2520B-sensitive%2520dipeptide%2520prodrugs.%25201.%2520A%2520model%2520study%2520of%2520structural%2520requirements%2520for%2520efficient%2520release%2520of%2520doxorubicin%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1998%26volume%3D8%26spage%3D3341%26epage%3D3346%26doi%3D10.1016%2FS0960-894X%2898%2900609-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Gregson, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, G.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiavone, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sult, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vijayakrishnan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masterson, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Hooge, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snaith, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harper, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartley, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, P. W.</span></span> <span> </span><span class="NLM_article-title">Synthesis and evaluation of pyrrolobenzodiazepine dimer antibody–drug conjugates with dual β-glucuronide and dipeptide triggers</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>179</i></span>,  <span class="NLM_fpage">591</span>– <span class="NLM_lpage">607</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.06.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1016%2Fj.ejmech.2019.06.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=31279293" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlejs7%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=179&publication_year=2019&pages=591-607&author=S.+J.+Gregsonauthor=A.+M.+Barrettauthor=N.+V.+Patelauthor=G.-D.+Kangauthor=D.+Schiavoneauthor=E.+Sultauthor=C.+S.+Barryauthor=B.+Vijayakrishnanauthor=L.+R.+Adamsauthor=L.+A.+Mastersonauthor=F.+D%E2%80%99Hoogeauthor=M.+Snaithauthor=J.+Harperauthor=J.+A.+Hartleyauthor=P.+W.+Howard&title=Synthesis+and+evaluation+of+pyrrolobenzodiazepine+dimer+antibody%E2%80%93drug+conjugates+with+dual+%CE%B2-glucuronide+and+dipeptide+triggers&doi=10.1016%2Fj.ejmech.2019.06.044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22aR"><div class="casContent"><span class="casTitleNuber">22a</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of pyrrolobenzodiazepine dimer antibody-drug conjugates with dual β-glucuronide and dipeptide triggers</span></div><div class="casAuthors">Gregson, Stephen J.; Barrett, Allison M.; Patel, Neki V.; Kang, Gyoung-Dong; Schiavone, Davide; Sult, Erin; Barry, Conor S.; Vijayakrishnan, Balakumar; Adams, Lauren R.; Masterson, Luke A.; D'Hooge, Francois; Snaith, Mike; Harper, Jay; Hartley, John A.; Howard, Philip W.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">179</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">591-607</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Antibody-drug conjugates (ADCs) contg. pyrrolobenzodiazepine (PBD) dimers are currently being evaluated in human oncol. clin. trials with encouraging results.  To further improve the therapeutic window, next-generation PBD drug-linker design has focused on the inclusion of addnl. tumor-selective triggers and use of lower-potency PBDs. β-Glucuronidase is a well-known target for discovery prodrugs due to increased presence in tumor cells and microenvironment.  In this study, a β-glucuronidase cleavable cap was investigated at the PBD N10-position and compared with corresponding free imine ADCs.  SG3600 (glucuronide) ADCs showed in vitro and in vivo efficacy/tolerability comparable to SG3400 (imine) ADCs, and good 50% inhibitory concn. differentials were obsd. in vitro between control non-antigen-targeted ADCs and targeted ADCs.  Dependence on β-glucuronidase for SG3600 activity was demonstrated through CRISPRCas9 knockdown studies and addn. of exogenous β-glucuronidase.  SG3600 showed better serum stability, improved conjugation efficiency and was able to reach high drug-to-antibody ratio without aggregation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh2H0GqhcV97Vg90H21EOLACvtfcHk0liTjHftVj3CAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlejs7%252FL&md5=a188076bf4345dd812a58d671b72e02b</span></div><a href="/servlet/linkout?suffix=cit22a&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.06.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.06.044%26sid%3Dliteratum%253Aachs%26aulast%3DGregson%26aufirst%3DS.%2BJ.%26aulast%3DBarrett%26aufirst%3DA.%2BM.%26aulast%3DPatel%26aufirst%3DN.%2BV.%26aulast%3DKang%26aufirst%3DG.-D.%26aulast%3DSchiavone%26aufirst%3DD.%26aulast%3DSult%26aufirst%3DE.%26aulast%3DBarry%26aufirst%3DC.%2BS.%26aulast%3DVijayakrishnan%26aufirst%3DB.%26aulast%3DAdams%26aufirst%3DL.%2BR.%26aulast%3DMasterson%26aufirst%3DL.%2BA.%26aulast%3DD%25E2%2580%2599Hooge%26aufirst%3DF.%26aulast%3DSnaith%26aufirst%3DM.%26aulast%3DHarper%26aufirst%3DJ.%26aulast%3DHartley%26aufirst%3DJ.%2BA.%26aulast%3DHoward%26aufirst%3DP.%2BW.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520pyrrolobenzodiazepine%2520dimer%2520antibody%25E2%2580%2593drug%2520conjugates%2520with%2520dual%2520%25CE%25B2-glucuronide%2520and%2520dipeptide%2520triggers%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D179%26spage%3D591%26epage%3D607%26doi%3D10.1016%2Fj.ejmech.2019.06.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit22b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panuganti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dao-Pick, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banik, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsi, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandalam, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Junutula, J. R.</span></span> <span> </span><span class="NLM_article-title">CLT030, a leukemic stem cell-targeting CLL1 antibody–drug conjugate for treatment of acute myeloid leukemia</span>. <i>Blood Adv.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">1738</span>– <span class="NLM_lpage">1749</span>, <span class="refDoi"> DOI: 10.1182/bloodadvances.2018020107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1182%2Fbloodadvances.2018020107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=30037800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BC1MXlvVKnsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2018&pages=1738-1749&author=Y.-P.+Jiangauthor=B.+Y.+Liuauthor=Q.+Zhengauthor=S.+Panugantiauthor=R.+Chenauthor=J.+Zhuauthor=M.+Mishraauthor=J.+Huangauthor=T.+Dao-Pickauthor=S.+Royauthor=X.-X.+Zhaoauthor=J.+Linauthor=G.+Banikauthor=E.+D.+Hsiauthor=R.+Mandalamauthor=J.+R.+Junutula&title=CLT030%2C+a+leukemic+stem+cell-targeting+CLL1+antibody%E2%80%93drug+conjugate+for+treatment+of+acute+myeloid+leukemia&doi=10.1182%2Fbloodadvances.2018020107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22bR"><div class="casContent"><span class="casTitleNuber">22b</span><div class="casTitle"><span class="NLM_cas:atitle">CLT030, a leukemic stem cell-targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia</span></div><div class="casAuthors">Jiang, Ying-Ping; Liu, Bob Y.; Zheng, Quan; Panuganti, Swapna; Chen, Ruoying; Zhu, Jianyu; Mishra, Madhavi; Huang, Jianqing; Dao-Pick, Trang; Roy, Sharmili; Zhao, XiaoXian; Lin, Jeffrey; Banik, Gautam; Hsi, Eric D.; Mandalam, Ramkumar; Junutula, Jagath R.</div><div class="citationInfo"><span class="NLM_cas:title">Blood Advances</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1738-1749</span>CODEN:
                <span class="NLM_cas:coden">BALDBA</span>;
        ISSN:<span class="NLM_cas:issn">2473-9537</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The current std. of care for acute myeloid leukemia (AML) is largely ineffective with very high relapse rates and low survival rates, mostly due to the inability to eliminate a rare population of leukemic stem cells (LSCs) that initiate tumor growth and are resistant to std. chemotherapy.  RNA-sequencing anal. on isolated LSCs confirmed C-type lectin domain family 12 member A (CLL1, also known as CLEC12A) to be highly expressed on LSCs but not on normal hematopoietic stem cells (HSCs) or other healthy organ tissues.  Expression of CLL1 was consistent across different types of AML.  We developed CLT030 (CLL1-ADC), an antibody-drug conjugate (ADC) based on a humanized anti-CLL1 antibody with 2 engineered cysteine residues linked covalently via a cleavable linker to a highly potent DNA-binding payload, thus resulting in a site-specific and homogenous ADC product.  The ADC is designed to be stable in the bloodstream and to release its DNA-binding payload only after the ADC binds to CLL1-expressing tumor cells, is internalized, and the linker is cleaved in the lysosomal compartment.  CLL1-ADC inhibits in vitro LSC colony formation and demonstrates robust in vivo efficacy in AML cell tumor models and tumor growth inhibition in the AML patient-derived xenograft model.  CLL1-ADC demonstrated a reduced effect on differentiation of healthy normal human CD34+ cells to various lineages as obsd. in an in vitro colony formation assay and in an in vivo xenotransplantation model as compared with CD33-ADC.  These results demonstrate that CLL1-ADC could be an effective ADC therapeutic for the treatment of AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJOpDWvxxUWrVg90H21EOLACvtfcHk0liTjHftVj3CAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXlvVKnsb0%253D&md5=478d01c2c6e9930745d97ddecbbfcb4a</span></div><a href="/servlet/linkout?suffix=cit22b&amp;dbid=16384&amp;doi=10.1182%2Fbloodadvances.2018020107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fbloodadvances.2018020107%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DY.-P.%26aulast%3DLiu%26aufirst%3DB.%2BY.%26aulast%3DZheng%26aufirst%3DQ.%26aulast%3DPanuganti%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DR.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DMishra%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DDao-Pick%26aufirst%3DT.%26aulast%3DRoy%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DX.-X.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DBanik%26aufirst%3DG.%26aulast%3DHsi%26aufirst%3DE.%2BD.%26aulast%3DMandalam%26aufirst%3DR.%26aulast%3DJunutula%26aufirst%3DJ.%2BR.%26atitle%3DCLT030%252C%2520a%2520leukemic%2520stem%2520cell-targeting%2520CLL1%2520antibody%25E2%2580%2593drug%2520conjugate%2520for%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%2520Adv.%26date%3D2018%26volume%3D2%26spage%3D1738%26epage%3D1749%26doi%3D10.1182%2Fbloodadvances.2018020107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span> The mAb nomenclature
follows the EU convention described in the following:<span class="NLM_contrib-group"><span class="NLM_string-name">Edelman, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gall, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottlieb, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutishauser, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waxdal, M. J.</span></span> <span> </span><span class="NLM_article-title">The covalent structure of an entire γG immunoglobin molecule</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1969</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">78</span>– <span class="NLM_lpage">85</span>, <span class="refDoi"> DOI: 10.1073/pnas.63.1.78</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1073%2Fpnas.63.1.78" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=5257969" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADyaE3cXivFyjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=1969&pages=78-85&author=G.+M.+Edelmanauthor=B.+A.+Cunninghamauthor=W.+E.+Gallauthor=P.+D.+Gottliebauthor=U.+Rutishauserauthor=M.+J.+Waxdal&title=The+covalent+structure+of+an+entire+%CE%B3G+immunoglobin+molecule&doi=10.1073%2Fpnas.63.1.78"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent structure of an entire γG immunoglobulin molecule</span></div><div class="casAuthors">Edelman, Gerald M.; Cunningham, Bruce A.; Gall, W. Einar; Gottlieb, Paul D.; Rutishauser, Urs; Waxdal, Myron J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1969</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">78-85</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">The complete amino acid sequence of a human γGl immunoglobulin (Eu) has been detd. and the arrangement of all of the disulfide bonds has been established.  Comparison of the sequence with that of another myeloma protein (He) suggests that the variable regions of heavy and light chains are homologous and similar in length.  The const. portion of the heavy chain contains 3 homology regions each of which is similar in size and homologous to the const. region of the light chain.  Each variable region and each const. homology region contains 1 intrachain disulfide bond.  The half-cystines participating in the interchain bonds are all clustered within a stretch of 10 residues at the middle of the heavy chains.  These data support the hypothesis that immunoglobulins evolved by gene duplication after early divergence of V genes, which specified antigen-binding functions, and C genes, which specified other functions of antibody mols.  Each polypeptide chain may therefore be specified by 2 genes, V and C, which are fused to form a single gene (translocation hypothesis).  The internal homologies and symmetry of the mol. suggest that homology regions may have similar 3-dimensional structures each consisting of a compact domain which contributes to at least 1 active site (domain hypothesis).  Both hypotheses are in accord with the linear regional differentiation of function in antibody mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjqW9i9JX9g7Vg90H21EOLACvtfcHk0liTjHftVj3CAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE3cXivFyjtQ%253D%253D&md5=18ba9b6417ce609be8870e1d142e7fc9</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1073%2Fpnas.63.1.78&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.63.1.78%26sid%3Dliteratum%253Aachs%26aulast%3DEdelman%26aufirst%3DG.%2BM.%26aulast%3DCunningham%26aufirst%3DB.%2BA.%26aulast%3DGall%26aufirst%3DW.%2BE.%26aulast%3DGottlieb%26aufirst%3DP.%2BD.%26aulast%3DRutishauser%26aufirst%3DU.%26aulast%3DWaxdal%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520covalent%2520structure%2520of%2520an%2520entire%2520%25CE%25B3G%2520immunoglobin%2520molecule%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1969%26volume%3D63%26spage%3D78%26epage%3D85%26doi%3D10.1073%2Fpnas.63.1.78" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="note"><p class="first last">For a comparison of the EU and the alternate Kabat mAb nomenclature systems, see table S1 in ref <a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a>.</p></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ohri, R.</span>; <span class="NLM_string-name">Bhakta, S.</span>; <span class="NLM_string-name">Fourie-O’Donohue, A.</span>; <span class="NLM_string-name">Dela Cruz-Chuh, J.</span>; <span class="NLM_string-name">Tsai, S. P.</span>; <span class="NLM_string-name">Cook, R.</span>; <span class="NLM_string-name">Wei, B.</span>; <span class="NLM_string-name">Ng, C.</span>; <span class="NLM_string-name">Wong, A. W.</span>; <span class="NLM_string-name">Bos, A. B.</span>; <span class="NLM_string-name">Farahi, R.</span>; <span class="NLM_string-name">Bhakta, J.</span>; <span class="NLM_string-name">Pillow, T. H.</span>; <span class="NLM_string-name">Raab, H.</span>; <span class="NLM_string-name">Vandlen, R.</span>; <span class="NLM_string-name">Polakis, P.</span>; <span class="NLM_string-name">Liu, Y.</span>; <span class="NLM_string-name">Erickson, H.</span>; <span class="NLM_string-name">Junutula, J. R.</span>; <span class="NLM_string-name">Kozak, K. R.</span></span> <span> </span><span class="NLM_article-title">High-throughput cysteine scanning to identify stable antibody conjugation sites for maleimide- and disulfide-based linkers</span>.  <i>Bioconjugate Chem.</i> <span class="NLM_year">2018</span>,  <span class="NLM_volume">29</span>,  <span class="NLM_fpage">473</span>– <span class="NLM_lpage">485</span>.</span><div class="citationLinks">[<a href="/doi/10.1021/acs.bioconjchem.7b00791" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&pages=473-485&author=R.+Ohri&author=S.+Bhakta&author=A.+Fourie-O%E2%80%99Donohue&author=J.+Dela+Cruz-Chuh&author=S.+P.+Tsai&author=R.+Cook&author=B.+Wei&author=C.+Ng&author=A.+W.+Wong&author=A.+B.+Bos&author=R.+Farahi&author=J.+Bhakta&author=T.+H.+Pillow&author=H.+Raab&author=R.+Vandlen&author=P.+Polakis&author=Y.+Liu&author=H.+Erickson&author=J.+R.+Junutula&author=K.+R.+Kozak&title=Bioconjugate+Chem."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facs.bioconjchem.7b00791&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1021%252Facs.bioconjchem.7b00791%26sid%3Dliteratum%253Aachs%26aulast%3DOhri%26aufirst%3DR.%26atitle%3DHigh-throughput%2520cysteine%2520scanning%2520to%2520identify%2520stable%2520antibody%2520conjugation%2520sites%2520for%2520maleimide-%2520and%2520disulfide-based%2520linkers%26btitle%3DBioconjugate%2520Chem.%26date%3D2018%26volume%3D29%26spage%3D473%26epage%3D485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Loomis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garg, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yavlovich, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell-Massa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimitrov, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumenthal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puri, A.</span></span> <span> </span><span class="NLM_article-title">Specific targeting to B cells by lipid-based nanoparticles conjugated with a novel CD22-ScFv</span>. <i>Exp. Mol. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">238</span>– <span class="NLM_lpage">249</span>, <span class="refDoi"> DOI: 10.1016/j.yexmp.2010.01.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1016%2Fj.yexmp.2010.01.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=20122924" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksVenurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2010&pages=238-249&author=K.+Loomisauthor=B.+Smithauthor=Y.+Fengauthor=H.+Gargauthor=A.+Yavlovichauthor=R.+Campbell-Massaauthor=D.+S.+Dimitrovauthor=R.+Blumenthalauthor=X.+Xiaoauthor=A.+Puri&title=Specific+targeting+to+B+cells+by+lipid-based+nanoparticles+conjugated+with+a+novel+CD22-ScFv&doi=10.1016%2Fj.yexmp.2010.01.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Specific targeting to B cells by lipid-based nanoparticles conjugated with a novel CD22-ScFv</span></div><div class="casAuthors">Loomis, Kristin; Smith, Brandon; Feng, Yang; Garg, Himanshu; Yavlovich, Amichai; Campbell-Massa, Ryan; Dimitrov, Dimiter S.; Blumenthal, Robert; Xiao, Xiao-Dong; Puri, Anu</div><div class="citationInfo"><span class="NLM_cas:title">Experimental and Molecular Pathology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">238-249</span>CODEN:
                <span class="NLM_cas:coden">EXMPA6</span>;
        ISSN:<span class="NLM_cas:issn">0014-4800</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The CD22 antigen is a viable target for therapeutic intervention for B-cell lymphomas.  Several therapeutic anti-CD22 antibodies as well as an anti-CD22-based immunotoxin (HA22) are currently under investigation in clin. settings.  Coupling of anti-CD22 reagents with a nano-drug delivery vehicle is projected to significantly improve treatment efficacies.  Therefore, the authors generated a mutant of the targeting segment of HA22 (a CD22 scFv) to increase its sol. expression (mut-HA22), and conjugated it to the surface of sonicated liposomes to generate immunoliposomes (mut-HA22-liposomes).  The authors examd. liposome binding and uptake by CD22+ B-lymphocytes (BJAB) by using calcein and/or rhodamine PE-labeled liposomes.  The authors also tested the effect of targeting on cellular toxicity with doxorubicin-loaded liposomes.  The authors report that: (i) Binding of mut-HA22-liposomes to BJAB cells was significantly greater than liposomes not conjugated with mut-HA22 (control liposomes), and mut-HA22-liposomes bind to and are taken in by BJAB cells in a dose and temp.-dependent manner, resp.; (ii) This binding occurred via the interaction with the cellular CD22 as pre-incubation of the cells with mut-HA22 blocked subsequent liposome binding; (iii) Intracellular localization of mut-HA22-liposomes at 37° but not at 4° indicated that the authors' targeted liposomes were taken up through an energy dependent process via receptor-mediated endocytosis; and (iv) Mut-HA22-liposomes loaded with doxorubicin exhibited at least 2-3-fold more accumulation of doxorubicin in BJAB cells as compared to control liposomes.  Moreover, these liposomes showed at least a 2-4-fold enhanced killing of BJAB or Raji cells (CD22+), but not SUP-T1 cells (CD22-).  Taken together these data suggest that these 2nd-generation liposomes may serve as promising carriers for targeted drug delivery to treat patients suffering from B-cell lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGLlD1ZnVLgrVg90H21EOLACvtfcHk0ljFfTsPjMWT1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksVenurs%253D&md5=7f725efb496dc848496939550dbb143c</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.yexmp.2010.01.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yexmp.2010.01.006%26sid%3Dliteratum%253Aachs%26aulast%3DLoomis%26aufirst%3DK.%26aulast%3DSmith%26aufirst%3DB.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DGarg%26aufirst%3DH.%26aulast%3DYavlovich%26aufirst%3DA.%26aulast%3DCampbell-Massa%26aufirst%3DR.%26aulast%3DDimitrov%26aufirst%3DD.%2BS.%26aulast%3DBlumenthal%26aufirst%3DR.%26aulast%3DXiao%26aufirst%3DX.%26aulast%3DPuri%26aufirst%3DA.%26atitle%3DSpecific%2520targeting%2520to%2520B%2520cells%2520by%2520lipid-based%2520nanoparticles%2520conjugated%2520with%2520a%2520novel%2520CD22-ScFv%26jtitle%3DExp.%2520Mol.%2520Pathol.%26date%3D2010%26volume%3D88%26spage%3D238%26epage%3D249%26doi%3D10.1016%2Fj.yexmp.2010.01.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Shor, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerber, H.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sapra, P.</span></span> <span> </span><span class="NLM_article-title">Preclinical and clinical development of inotuzumab ozogamicin in hematological malignancies</span>. <i>Mol. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">107</span>– <span class="NLM_lpage">116</span>, <span class="refDoi"> DOI: 10.1016/j.molimm.2014.09.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1016%2Fj.molimm.2014.09.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=25304309" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1Kntr%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2015&pages=107-116&author=B.+Shorauthor=H.-P.+Gerberauthor=P.+Sapra&title=Preclinical+and+clinical+development+of+inotuzumab+ozogamicin+in+hematological+malignancies&doi=10.1016%2Fj.molimm.2014.09.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26aR"><div class="casContent"><span class="casTitleNuber">26a</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies</span></div><div class="casAuthors">Shor, Boris; Gerber, Hans-Peter; Sapra, Puja</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Immunology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">2_Part_A</span>),
    <span class="NLM_cas:pages">107-116</span>CODEN:
                <span class="NLM_cas:coden">MOIMD5</span>;
        ISSN:<span class="NLM_cas:issn">0161-5890</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Calicheamicin is a DNA-damaging agent that, following intracellular activation, binds to DNA in the minor groove and introduces double-strand DNA breaks, leading to G2/M arrest and subsequent cell death.  Importantly, the mechanism of action of calicheamicin is fundamentally different from the tubulin-binding class of cytotoxics targeting the mitotic spindle, which represent the most common class of payloads for antibody-drug conjugates (ADCs) currently undergoing clin. development.  Spindle poisons that target tubulin, including auristatins and maytansines, are most effective against rapidly proliferating cells.  In contrast, calicheamicin induces DNA double-strand breaks and apoptosis independent of cell cycle progression.  Such properties may be advantageous when targeting malignant cells that are not markedly different in their proliferation status compared to normal cells.  Here we review calicheamicin conjugates, with a particular focus on the preclin.- and clin. development of inotuzumab ozogamicin, targeting the CD22 antigen expressed on a large variety of hematol. malignancies.  In pre-clin. expts., inotuzumab ozogamicin potently induced tumor regressions in models of non-Hodgkin's lymphoma (NHL), either alone or in combination with the anti-CD20 antibody Rituximab.  Promising anti-tumor responses were obsd. in early stage clin. trials, where inotuzumab ozogamicin was administered either as single agent or in combination with Rituximab.  Consistent with the cell cycle independent mechanism of action of the calicheamicin payload, high rates of complete responses were obsd. in less aggressive forms of lymphomas, including follicular lymphoma (FL) and relapsed, diffuse large B-cell lymphoma (DLBCL).Inotuzumab ozogamicin is currently being tested in phase III clin. trials in acute lymphocytic leukemia (ALL).  Particular focus is dedicated to reviewing the pre-clin. and clin. data generated with this compd. in NHL and to outline future focus areas for pre-clin.- and clin. research of inotuzumab ozogamicin, and the calicheamicin class of antibody-drug conjugates more generally.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1fLDErK7NWbVg90H21EOLACvtfcHk0ljFfTsPjMWT1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1Kntr%252FE&md5=29b4ae34952bdc12101c43cbe3777e48</span></div><a href="/servlet/linkout?suffix=cit26a&amp;dbid=16384&amp;doi=10.1016%2Fj.molimm.2014.09.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molimm.2014.09.014%26sid%3Dliteratum%253Aachs%26aulast%3DShor%26aufirst%3DB.%26aulast%3DGerber%26aufirst%3DH.-P.%26aulast%3DSapra%26aufirst%3DP.%26atitle%3DPreclinical%2520and%2520clinical%2520development%2520of%2520inotuzumab%2520ozogamicin%2520in%2520hematological%2520malignancies%26jtitle%3DMol.%2520Immunol.%26date%3D2015%26volume%3D67%26spage%3D107%26epage%3D116%26doi%3D10.1016%2Fj.molimm.2014.09.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit26b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Polson, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calemine-Fenaux, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Sauvage, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eaton, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkins, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frantz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuji, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harden, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingle, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kljavin, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeppen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prabhu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raab, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slaga, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephan, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scales, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandlen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wranik, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebens, A.</span></span> <span> </span><span class="NLM_article-title">Antibody-drug conjugates for the treatment of non–Hodgkin’s lymphoma: Target and linker-drug selection</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">2358</span>– <span class="NLM_lpage">2364</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-08-2250</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1158%2F0008-5472.CAN-08-2250" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=19258515" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtFyqtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=2358-2364&author=A.+G.+Polsonauthor=J.+Calemine-Fenauxauthor=P.+Chanauthor=W.+Changauthor=E.+Christensenauthor=S.+Clarkauthor=F.+J.+de+Sauvageauthor=D.+Eatonauthor=K.+Elkinsauthor=J.+M.+Elliottauthor=G.+Frantzauthor=R.+N.+Fujiauthor=A.+Grayauthor=K.+Hardenauthor=G.+S.+Ingleauthor=N.+M.+Kljavinauthor=H.+Koeppenauthor=C.+Nelsonauthor=S.+Prabhuauthor=H.+Raabauthor=S.+Rossauthor=D.+S.+Slagaauthor=J.-P.+Stephanauthor=S.+J.+Scalesauthor=S.+D.+Spencerauthor=R.+Vandlenauthor=B.+Wranikauthor=S.-F.+Yuauthor=B.+Zhengauthor=A.+Ebens&title=Antibody-drug+conjugates+for+the+treatment+of+non%E2%80%93Hodgkin%E2%80%99s+lymphoma%3A+Target+and+linker-drug+selection&doi=10.1158%2F0008-5472.CAN-08-2250"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26bR"><div class="casContent"><span class="casTitleNuber">26b</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-Drug Conjugates for the Treatment of Non-Hodgkin's Lymphoma: Target and Linker-Drug Selection</span></div><div class="casAuthors">Polson, Andrew G.; Calemine-Fenaux, Jill; Chan, Pamela; Chang, Wesley; Christensen, Erin; Clark, Suzanna; de Sauvage, Frederic J.; Eaton, Dan; Elkins, Kristi; Elliott, J. Michael; Frantz, Gretchen; Fuji, Reina N.; Gray, Alane; Harden, Kristin; Ingle, Gladys S.; Kljavin, Noelyn M.; Koeppen, Hartmut; Nelson, Christopher; Prabhu, Saileta; Raab, Helga; Ross, Sarajane; Stephan, Jean-Philippe; Scales, Suzie J.; Spencer, Susan D.; Vandlen, Richard; Wranik, Bernd; Yu, Shang-Fan; Zheng, Bing; Ebens, Allen</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2358-2364</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Antibody-drug conjugates (ADC), potent cytotoxic drugs covalently linked to antibodies via chem. linkers, provide a means to increase the effectiveness of chemotherapy by targeting the drug to neoplastic cells while reducing side effects.  Here, the authors systematically examine the potential targets and linker-drug combinations that could provide an optimal ADC for the treatment for non-Hodgkin's lymphoma.  The authors identified seven antigens (CD19, CD20, CD21, CD22, CD72, CD79b, and CD180) for potential treatment of non-Hodgkin's lymphoma with ADCs.  ADCs with cleavable linkers mediated in vivo efficacy via all these targets; ADCs with uncleavable linkers were only effective when targeted to CD22 and CD79b.  In target-independent safety studies in rats, the uncleavable linker ADCs showed reduced toxicity, presumably due to the reduced release of free drug or other toxic metabolites into the circulation.  Thus, the authors' data suggest that ADCs with cleavable linkers work on a broad range of targets, and for specific targets, ADCs with uncleavable linkers provide a promising opportunity to improve the therapeutic window for ADCs in humans. [Cancer Res 2009;69(6):2358-64].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqh0r17kwsTobVg90H21EOLACvtfcHk0ljFfTsPjMWT1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtFyqtb4%253D&md5=060457635dda4dafe14446e5a4815a07</span></div><a href="/servlet/linkout?suffix=cit26b&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-2250&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-2250%26sid%3Dliteratum%253Aachs%26aulast%3DPolson%26aufirst%3DA.%2BG.%26aulast%3DCalemine-Fenaux%26aufirst%3DJ.%26aulast%3DChan%26aufirst%3DP.%26aulast%3DChang%26aufirst%3DW.%26aulast%3DChristensen%26aufirst%3DE.%26aulast%3DClark%26aufirst%3DS.%26aulast%3Dde%2BSauvage%26aufirst%3DF.%2BJ.%26aulast%3DEaton%26aufirst%3DD.%26aulast%3DElkins%26aufirst%3DK.%26aulast%3DElliott%26aufirst%3DJ.%2BM.%26aulast%3DFrantz%26aufirst%3DG.%26aulast%3DFuji%26aufirst%3DR.%2BN.%26aulast%3DGray%26aufirst%3DA.%26aulast%3DHarden%26aufirst%3DK.%26aulast%3DIngle%26aufirst%3DG.%2BS.%26aulast%3DKljavin%26aufirst%3DN.%2BM.%26aulast%3DKoeppen%26aufirst%3DH.%26aulast%3DNelson%26aufirst%3DC.%26aulast%3DPrabhu%26aufirst%3DS.%26aulast%3DRaab%26aufirst%3DH.%26aulast%3DRoss%26aufirst%3DS.%26aulast%3DSlaga%26aufirst%3DD.%2BS.%26aulast%3DStephan%26aufirst%3DJ.-P.%26aulast%3DScales%26aufirst%3DS.%2BJ.%26aulast%3DSpencer%26aufirst%3DS.%2BD.%26aulast%3DVandlen%26aufirst%3DR.%26aulast%3DWranik%26aufirst%3DB.%26aulast%3DYu%26aufirst%3DS.-F.%26aulast%3DZheng%26aufirst%3DB.%26aulast%3DEbens%26aufirst%3DA.%26atitle%3DAntibody-drug%2520conjugates%2520for%2520the%2520treatment%2520of%2520non%25E2%2580%2593Hodgkin%25E2%2580%2599s%2520lymphoma%253A%2520Target%2520and%2520linker-drug%2520selection%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D2358%26epage%3D2364%26doi%3D10.1158%2F0008-5472.CAN-08-2250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Rinnerthaler, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gampenrieder, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greil, R.</span></span> <span> </span><span class="NLM_article-title">HER2 directed antibody–drug-conjugates beyond T-DM1 in breast cancer</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1115</span>, <span class="refDoi"> DOI: 10.3390/ijms20051115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.3390%2Fijms20051115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFOntLzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=1115&author=G.+Rinnerthalerauthor=S.+P.+Gampenriederauthor=R.+Greil&title=HER2+directed+antibody%E2%80%93drug-conjugates+beyond+T-DM1+in+breast+cancer&doi=10.3390%2Fijms20051115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27aR"><div class="casContent"><span class="casTitleNuber">27a</span><div class="casTitle"><span class="NLM_cas:atitle">HER2 directed antibody-drug-conjugates beyond T-DM1 in breast cancer</span></div><div class="casAuthors">Rinnerthaler, Gabriel; Gampenrieder, Simon Peter; Greil, Richard</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1115</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Since the discovery of the human epidermal growth factor receptor 2 (HER2) as an oncogenic driver in a subset of breast cancers and the development of HER2 directed therapies, the prognosis of HER2 amplified breast cancers has improved meaningfully.  Next to monoclonal anti-HER2 antibodies and tyrosine kinase inhibitors, the antibody-drug conjugate T-DM1 is a pillar of targeted treatment of advanced HER2-pos. breast cancers.  Currently, several HER2 directed antibody-drug conjugates are under clin. investigation for HER2 amplified but also HER2 expressing but not amplified breast tumors.  In this article, we review the current preclin. and clin. evidence of the investigational drugs A166, ALT-P7, ARX788, DHES0815A, DS-8201a, RC48, SYD985, MEDI4276 and XMT-1522.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquqRM0dTtznbVg90H21EOLACvtfcHk0ljjOP7i357B5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFOntLzP&md5=82e9b955a030e75b9faee476a7553b30</span></div><a href="/servlet/linkout?suffix=cit27a&amp;dbid=16384&amp;doi=10.3390%2Fijms20051115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms20051115%26sid%3Dliteratum%253Aachs%26aulast%3DRinnerthaler%26aufirst%3DG.%26aulast%3DGampenrieder%26aufirst%3DS.%2BP.%26aulast%3DGreil%26aufirst%3DR.%26atitle%3DHER2%2520directed%2520antibody%25E2%2580%2593drug-conjugates%2520beyond%2520T-DM1%2520in%2520breast%2520cancer%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2019%26volume%3D20%26spage%3D1115%26doi%3D10.3390%2Fijms20051115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit27b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, B.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yadav, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sliwkowski, M. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crocker, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacap, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, G. D. L.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of acquired resistance to trastuzumab emtansine in breast cancer cells</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1441</span>– <span class="NLM_lpage">1453</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-17-0296</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1158%2F1535-7163.MCT-17-0296" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=29695635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1alur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=1441-1453&author=G.+Liauthor=J.+Guoauthor=B.-Q.+Shenauthor=D.+B.+Yadavauthor=M.+X.+Sliwkowskiauthor=L.+M.+Crockerauthor=J.+A.+Lacapauthor=G.+D.+L.+Phillips&title=Mechanisms+of+acquired+resistance+to+trastuzumab+emtansine+in+breast+cancer+cells&doi=10.1158%2F1535-7163.MCT-17-0296"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27bR"><div class="casContent"><span class="casTitleNuber">27b</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells</span></div><div class="casAuthors">Li, Guangmin; Guo, Jun; Shen, Ben-Quan; Yadav, Daniela Bumbaca; Sliwkowski, Mark X.; Crocker, Lisa M.; Lacap, Jennifer A.; Phillips, Gail D. Lewis</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1441-1453</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The receptor tyrosine kinase HER2 is overexpressed in approx. 20% of breast cancer, and its amplification is assocd. with reduced survival.  Trastuzumab emtansine (Kadcyla, T-DM1), an antibody-drug conjugate that is comprised of trastuzumab covalently linked to the antimitotic agent DM1 through a stable linker, was designed to selectively deliver DM1 to HER2-overexpressing tumor cells.  T-DM1 is approved for the treatment of patients with HER2-pos. metastatic breast cancer following progression on trastuzumab and a taxane.  Despite the improvement in clin. outcome, many patients who initially respond to T-DM1 treatment eventually develop progressive disease.  The mechanisms that contribute to T-DM1 resistance are not fully understood.  To this end, we developed T-DM1-resistant in vitro models to examine the mechanisms of acquired T-DM1 resistance.  We demonstrate that decreased HER2 and upregulation of MDR1 contribute to T-DM1 resistance in KPL-4 T-DM1-resistant cells.  In contrast, both loss of SLC46A3 and PTEN deficiency play a role in conferring resistance in BT-474M1 T-DM1-resistant cells.  Our data suggest that these two cell lines acquire resistance through distinct mechanisms.  Furthermore, we show that the KPL-4 T-DM1 resistance can be overcome by treatment with an inhibitor of MDR1, whereas a PI3K inhibitor can rescue PTEN loss-induced resistance in T-DM1-resistant BT-474M1 cells.  Our results provide a rationale for developing therapeutic strategies to enhance T-DM1 clin. efficacy by combining T-DM1 and other inhibitors that target signaling transduction or resistance pathways.  Mol Cancer Ther; 17(7); 1441-53. ©2018 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozzBxmVx-2OLVg90H21EOLACvtfcHk0ljjOP7i357B5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1alur%252FP&md5=057dd2cfaed751fad7cb7a57ff1cfe79</span></div><a href="/servlet/linkout?suffix=cit27b&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-17-0296&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-17-0296%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DG.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DShen%26aufirst%3DB.-Q.%26aulast%3DYadav%26aufirst%3DD.%2BB.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26aulast%3DCrocker%26aufirst%3DL.%2BM.%26aulast%3DLacap%26aufirst%3DJ.%2BA.%26aulast%3DPhillips%26aufirst%3DG.%2BD.%2BL.%26atitle%3DMechanisms%2520of%2520acquired%2520resistance%2520to%2520trastuzumab%2520emtansine%2520in%2520breast%2520cancer%2520cells%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2018%26volume%3D17%26spage%3D1441%26epage%3D1453%26doi%3D10.1158%2F1535-7163.MCT-17-0296" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit27c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, G. D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dugger, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crocker, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsons, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mai, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blättler, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chari, R. V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, W. L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeppen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwall, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenkare-Mitra, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sliwkowski, M. X.</span></span> <span> </span><span class="NLM_article-title">Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">9280</span>– <span class="NLM_lpage">9290</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1158%2F0008-5472.CAN-08-1776" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=19010901" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=9280-9290&author=G.+D.+L.+Phillipsauthor=G.+Liauthor=D.+L.+Duggerauthor=L.+M.+Crockerauthor=K.+L.+Parsonsauthor=E.+Maiauthor=W.+A.+Bl%C3%A4ttlerauthor=J.+M.+Lambertauthor=R.+V.+J.+Chariauthor=R.+J.+Lutzauthor=W.+L.+T.+Wongauthor=F.+S.+Jacobsonauthor=H.+Koeppenauthor=R.+H.+Schwallauthor=S.+R.+Kenkare-Mitraauthor=S.+D.+Spencerauthor=M.+X.+Sliwkowski&title=Targeting+HER2-positive+breast+cancer+with+trastuzumab-DM1%2C+an+antibody-cytotoxic+drug+conjugate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27c&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-1776&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-1776%26sid%3Dliteratum%253Aachs%26aulast%3DPhillips%26aufirst%3DG.%2BD.%2BL.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DDugger%26aufirst%3DD.%2BL.%26aulast%3DCrocker%26aufirst%3DL.%2BM.%26aulast%3DParsons%26aufirst%3DK.%2BL.%26aulast%3DMai%26aufirst%3DE.%26aulast%3DBl%25C3%25A4ttler%26aufirst%3DW.%2BA.%26aulast%3DLambert%26aufirst%3DJ.%2BM.%26aulast%3DChari%26aufirst%3DR.%2BV.%2BJ.%26aulast%3DLutz%26aufirst%3DR.%2BJ.%26aulast%3DWong%26aufirst%3DW.%2BL.%2BT.%26aulast%3DJacobson%26aufirst%3DF.%2BS.%26aulast%3DKoeppen%26aufirst%3DH.%26aulast%3DSchwall%26aufirst%3DR.%2BH.%26aulast%3DKenkare-Mitra%26aufirst%3DS.%2BR.%26aulast%3DSpencer%26aufirst%3DS.%2BD.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26atitle%3DTargeting%2520HER2-positive%2520breast%2520cancer%2520with%2520trastuzumab-DM1%252C%2520an%2520antibody-cytotoxic%2520drug%2520conjugate%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D9280%26epage%3D9290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kinneer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meekin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiberghien, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tai, Y.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phipps, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiefer, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rebelatto, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimasi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriarty, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadopoulos, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sridhar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregson, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wick, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masterson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbst, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tice, D. A.</span></span> <span> </span><span class="NLM_article-title">SLC46A3 as a potential predictive biomarker for antibody–drug conjugates bearing noncleavable linked maytansinoid and pyrrolobenzodiazepine warheads</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">6570</span>– <span class="NLM_lpage">6582</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-18-1300</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1158%2F1078-0432.CCR-18-1300" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=30131388" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1ait7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=6570-6582&author=K.+Kinneerauthor=J.+Meekinauthor=A.+C.+Tiberghienauthor=Y.-T.+Taiauthor=S.+Phippsauthor=C.+M.+Kieferauthor=M.+C.+Rebelattoauthor=N.+Dimasiauthor=A.+Moriartyauthor=K.+P.+Papadopoulosauthor=S.+Sridharauthor=S.+J.+Gregsonauthor=M.+J.+Wickauthor=L.+Mastersonauthor=K.+C.+Andersonauthor=R.+Herbstauthor=P.+W.+Howardauthor=D.+A.+Tice&title=SLC46A3+as+a+potential+predictive+biomarker+for+antibody%E2%80%93drug+conjugates+bearing+noncleavable+linked+maytansinoid+and+pyrrolobenzodiazepine+warheads&doi=10.1158%2F1078-0432.CCR-18-1300"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">SLC46A3 as a potential predictive biomarker for antibody-drug conjugates bearing noncleavable linked maytansinoid and pyrrolobenzodiazepine warheads</span></div><div class="casAuthors">Kinneer, Krista; Meekin, John; Tiberghien, Arnaud C.; Tai, Yu-Tzu; Phipps, Sandrina; Kiefer, Christine Mione; Rebelatto, Marlon C.; Dimasi, Nazzareno; Moriarty, Alyssa; Papadopoulos, Kyriakos P.; Sridhar, Sriram; Gregson, Stephen J.; Wick, Michael J.; Masterson, Luke; Anderson, Kenneth C.; Herbst, Ronald; Howard, Philip W.; Tice, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6570-6582</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Antibody-drug conjugates (ADC) utilizing noncleavable linker drugs have been approved for clin. use, and several are in development targeting solid and hematol. malignancies including multiple myeloma.  Currently, there are no reliable biomarkers of activity for these ADCs other than presence of the targeted antigen.  We obsd. that certain cell lines are innately resistant to such ADCs, and sought to uncover the underlying mechanism of resistance.  Exptl. Design: The expression of 43 lysosomal membrane target genes was evaluated in cell lines resistant to ADCs bearing the noncleavable linker, pyrrolobenzodiazepine payload SG3376, in vitro.  The functional relevance of SLC46A3, a lysosomal transporter of noncleavable ADC catabolites whose expression uniquely correlated with SG3376 resistance, was assessed using EPHA2-, HER2-, and BCMA-targeted ADCs and isogenic cells overexpressing or genetically inactivated for SLC46A3.  SLC46A3 expression was also examd. in patient-derived xenograft and in vitro models of acquired T-DM1 resistance and multiple myeloma bone marrow samples by RT-PCR.  Results: Loss of SLC46A3 expression was found to be a mechanism of innate and acquired resistance to ADCs bearing DM1 and SG3376.  Sensitivity was restored in refractory lines upon introduction of SLC46A3, suggesting that expression of SLC46A3 may be more predictive of activity than target antigen levels alone.  Interrogation of primary multiple myeloma samples indicated a range of SLC46A3 expression, including samples with undetectable levels like multiple myeloma cell lines resistant to BCMA-targeting DM1 and SG3376 ADCs.  Conclusions: Our findings support SLC46A3 as a potential patient selection biomarker with immediate relevance to clin. trials involving these ADCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogMBCbYdUVXbVg90H21EOLACvtfcHk0lgkK7BLxja7Mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1ait7%252FI&md5=e3b5550bd7a96683d9f3ccac137eeb66</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-18-1300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-18-1300%26sid%3Dliteratum%253Aachs%26aulast%3DKinneer%26aufirst%3DK.%26aulast%3DMeekin%26aufirst%3DJ.%26aulast%3DTiberghien%26aufirst%3DA.%2BC.%26aulast%3DTai%26aufirst%3DY.-T.%26aulast%3DPhipps%26aufirst%3DS.%26aulast%3DKiefer%26aufirst%3DC.%2BM.%26aulast%3DRebelatto%26aufirst%3DM.%2BC.%26aulast%3DDimasi%26aufirst%3DN.%26aulast%3DMoriarty%26aufirst%3DA.%26aulast%3DPapadopoulos%26aufirst%3DK.%2BP.%26aulast%3DSridhar%26aufirst%3DS.%26aulast%3DGregson%26aufirst%3DS.%2BJ.%26aulast%3DWick%26aufirst%3DM.%2BJ.%26aulast%3DMasterson%26aufirst%3DL.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26aulast%3DHerbst%26aufirst%3DR.%26aulast%3DHoward%26aufirst%3DP.%2BW.%26aulast%3DTice%26aufirst%3DD.%2BA.%26atitle%3DSLC46A3%2520as%2520a%2520potential%2520predictive%2520biomarker%2520for%2520antibody%25E2%2580%2593drug%2520conjugates%2520bearing%2520noncleavable%2520linked%2520maytansinoid%2520and%2520pyrrolobenzodiazepine%2520warheads%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D24%26spage%3D6570%26epage%3D6582%26doi%3D10.1158%2F1078-0432.CCR-18-1300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Erickson, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, P. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widdison, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovtun, Y. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrett, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldmacher, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blättler, W. A.</span></span> <span> </span><span class="NLM_article-title">Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">4426</span>– <span class="NLM_lpage">4433</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-05-4489</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1158%2F0008-5472.CAN-05-4489" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=16618769" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BD28XjsFSlurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=4426-4433&author=H.+K.+Ericksonauthor=P.+U.+Parkauthor=W.+C.+Widdisonauthor=Y.+V.+Kovtunauthor=L.+M.+Garrettauthor=K.+Hoffmanauthor=R.+J.+Lutzauthor=V.+S.+Goldmacherauthor=W.+A.+Bl%C3%A4ttler&title=Antibody-maytansinoid+conjugates+are+activated+in+targeted+cancer+cells+by+lysosomal+degradation+and+linker-dependent+intracellular+processing&doi=10.1158%2F0008-5472.CAN-05-4489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-Maytansinoid Conjugates Are Activated in Targeted Cancer Cells by Lysosomal Degradation and Linker-Dependent Intracellular Processing</span></div><div class="casAuthors">Erickson, Hans K.; Park, Peter U.; Widdison, Wayne C.; Kovtun, Yelena V.; Garrett, Lisa M.; Hoffman, Karen; Lutz, Robert J.; Goldmacher, Victor S.; Blaettler, Walter A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4426-4433</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Antibody-drug conjugates are targeted anticancer agents consisting of a cytotoxic drug covalently linked to a monoclonal antibody for tumor antigen-specific activity.  Once bound to the target cell-surface antigen, the conjugate must be processed to release an active form of the drug, which can reach its intracellular target.  Here, we used both biol. and biochem. methods to better define this process for antibody-maytansinoid conjugates.  In particular, we examd. the metabolic fate in cells of huC242-maytansinoid conjugates contg. either a disulfide linker (huC242-SPDB-DM4) or a thioether linker (huC242-SMCC-DM1).  Using cell cycle anal. combined with lysosomal inhibitors, we showed that lysosomal processing is required for the activity of antibody-maytansinoid conjugates, irresp. of the linker.  We also identified and characterized the released maytansinoid mols. from these conjugates, and measured their rate of release compared with the kinetics of cell cycle arrest.  Both conjugates are efficiently degraded in lysosomes to yield metabolites consisting of the intact maytansinoid drug and linker attached to lysine.  The lysine adduct is the sole metabolite from the thioether-linked conjugate.  However, the lysine metabolite generated from the disulfide-linked conjugate is reduced and S-methylated to yield the lipophilic and potently cytotoxic metabolite, S-methyl-DM4.  These findings provide insight into the mechanism of action of antibody-maytansinoid conjugates in general, and more specifically, identify a biochem. mechanism that may account for the significantly enhanced antitumor efficacy obsd. with disulfide-linked conjugates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZZDy7Sl_BxrVg90H21EOLACvtfcHk0lgkK7BLxja7Mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjsFSlurs%253D&md5=aaf42c96e596e17a7896a265d5e1d158</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-05-4489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-05-4489%26sid%3Dliteratum%253Aachs%26aulast%3DErickson%26aufirst%3DH.%2BK.%26aulast%3DPark%26aufirst%3DP.%2BU.%26aulast%3DWiddison%26aufirst%3DW.%2BC.%26aulast%3DKovtun%26aufirst%3DY.%2BV.%26aulast%3DGarrett%26aufirst%3DL.%2BM.%26aulast%3DHoffman%26aufirst%3DK.%26aulast%3DLutz%26aufirst%3DR.%2BJ.%26aulast%3DGoldmacher%26aufirst%3DV.%2BS.%26aulast%3DBl%25C3%25A4ttler%26aufirst%3DW.%2BA.%26atitle%3DAntibody-maytansinoid%2520conjugates%2520are%2520activated%2520in%2520targeted%2520cancer%2520cells%2520by%2520lysosomal%2520degradation%2520and%2520linker-dependent%2520intracellular%2520processing%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D4426%26epage%3D4433%26doi%3D10.1158%2F0008-5472.CAN-05-4489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Gschwantler-Kaulich, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grunt, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muhr, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kölbl, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singer, C. F.</span></span> <span> </span><span class="NLM_article-title">HER specific TKIs exert their antineoplastic effects on breast cancer cell lines through the involvement of STAT5 and JNK</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">e0146311</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0146311</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1371%2Fjournal.pone.0146311" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=26735495" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFOrt7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=e0146311&author=D.+Gschwantler-Kaulichauthor=T.+W.+Gruntauthor=D.+Muhrauthor=R.+Wagnerauthor=H.+K%C3%B6lblauthor=C.+F.+Singer&title=HER+specific+TKIs+exert+their+antineoplastic+effects+on+breast+cancer+cell+lines+through+the+involvement+of+STAT5+and+JNK&doi=10.1371%2Fjournal.pone.0146311"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30aR"><div class="casContent"><span class="casTitleNuber">30a</span><div class="casTitle"><span class="NLM_cas:atitle">HER specific TKIs exert their antineoplastic effects on breast cancer cell lines through the involvement of STAT5 and JNK</span></div><div class="casAuthors">Gschwantler-Kaulich, Daphne; Grunt, Thomas W.; Muhr, Daniela; Wagner, Renate; Koelbl, Heinz; Singer, Christian F.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">e0146311/1-e0146311/14</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background: HER-targeted tyrosine kinase inhibitors (TKIs) have demonstrated pro-apoptotic and antiproliferative effects in vitro and in vivo.  The exact pathways through which TKIs exert their antineoplastic effects are, however, still not completely understood.  Methods: Using Milliplex assays, we have investigated the effects of the three panHER-TKIs lapatinib, canertinib and afatinib on signal transduction cascade activation in SKBR3, T47D and Jurkat neoplastic cell lines.  The growth-inhibitory effect of blockade of HER and of JNK and STAT5 signaling was measured by proliferation- and apoptosis-assays using formazan dye labeling of viable cells, Western blotting for cleaved PARP-1 and immunolabeling for active caspase 3, resp.  Results: All three HER-TKIs clearly inhibited proliferation and increased apoptosis in HER2 overexpressing SKBR3 cells, while their effect was less pronounced on HER2 moderately expressing T47D cells where they exerted only a weak antiproliferative and essentially no pro-apoptotic effect.  Remarkably, phosphorylation/activation of JNK and STAT5A/B were inhibited by HER-TKIs only in the sensitive, but not in the resistant cells.  In contrast, phosphorylation/activation of ERK/MAPK, STAT3, CREB, p70 S6 kinase, IkBa, and p38 were equally affected by HER-TKIs in both cell lines.  Moreover, we demonstrated that direct pharmacol. blockade of JNK and STAT5 abrogates cell growth in both HER-TKI-sensitive as well as -resistant breast cancer cells, resp.  Conclusion: We have shown that HER-TKIs exert a HER2 expression-dependent anti-cancer effect in breast cancer cell lines.  This involves blockade of JNK and STAT5A/B signaling, which have been found to be required for in vitro growth of these cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-6nSZtFrwObVg90H21EOLACvtfcHk0lgkK7BLxja7Mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFOrt7rI&md5=69dcc793d89d145e860123cbc765dc62</span></div><a href="/servlet/linkout?suffix=cit30a&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0146311&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0146311%26sid%3Dliteratum%253Aachs%26aulast%3DGschwantler-Kaulich%26aufirst%3DD.%26aulast%3DGrunt%26aufirst%3DT.%2BW.%26aulast%3DMuhr%26aufirst%3DD.%26aulast%3DWagner%26aufirst%3DR.%26aulast%3DK%25C3%25B6lbl%26aufirst%3DH.%26aulast%3DSinger%26aufirst%3DC.%2BF.%26atitle%3DHER%2520specific%2520TKIs%2520exert%2520their%2520antineoplastic%2520effects%2520on%2520breast%2520cancer%2520cell%2520lines%2520through%2520the%2520involvement%2520of%2520STAT5%2520and%2520JNK%26jtitle%3DPLoS%2520One%26date%3D2016%26volume%3D11%26spage%3De0146311%26doi%3D10.1371%2Fjournal.pone.0146311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit30b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Pop, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poe, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venturi, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shelton, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pop, I. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerber, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girard, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.-y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behrens, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Canales, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wistuba, I. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minna, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tedder, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitetta, E. S.</span></span> <span> </span><span class="NLM_article-title">A reevaluation of CD22 expression in human lung cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">263</span>– <span class="NLM_lpage">271</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-13-1436</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1158%2F0008-5472.CAN-13-1436" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=24395821" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BC2cXislKjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=263-271&author=L.+M.+Popauthor=S.+Barmanauthor=C.+Shaoauthor=J.+C.+Poeauthor=G.+M.+Venturiauthor=J.+M.+Sheltonauthor=I.+V.+Popauthor=D.+E.+Gerberauthor=L.+Girardauthor=X.-y.+Liuauthor=C.+Behrensauthor=J.+Rodriguez-Canalesauthor=H.+Liuauthor=I.+I.+Wistubaauthor=J.+A.+Richardsonauthor=J.+D.+Minnaauthor=T.+F.+Tedderauthor=E.+S.+Vitetta&title=A+reevaluation+of+CD22+expression+in+human+lung+cancer&doi=10.1158%2F0008-5472.CAN-13-1436"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30bR"><div class="casContent"><span class="casTitleNuber">30b</span><div class="casTitle"><span class="NLM_cas:atitle">A Reevaluation of CD22 Expression in Human Lung Cancer</span></div><div class="casAuthors">Pop, Laurentiu M.; Barman, Stephen; Shao, Chunli; Poe, Jonathan C.; Venturi, Guglielmo M.; Shelton, John M.; Pop, Iliodora V.; Gerber, David E.; Girard, Luc; Liu, Xiao-yun; Behrens, Carmen; Rodriguez-Canales, Jaime; Liu, Hui; Wistuba, Ignacio I.; Richardson, James A.; Minna, John D.; Tedder, Thomas F.; Vitetta, Ellen S.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">263-271</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">CD22 is a transmembrane glycoprotein expressed by mature B cells.  It inhibits signal transduction by the B-cell receptor and its coreceptor CD19.  Recent reports indicate that most human lung cancer cells and cell lines express CD22, making it an important new therapeutic target for lung cancer.  The objective of our studies was to independently validate these results with the goal of testing the efficacy of our CD22 immunotoxins on lung cancer cell lines.  As detd. by quant. real-time PCR anal., we found that levels of CD22 mRNA in a panel of human lung cancer cell lines were 200 to 60,000-fold lower than those obsd. in the human CD22+ Burkitt lymphoma cells, Daudi.  Using flow cytometry with a panel of CD22 monoclonal antibodies and Western blot analyses, we could not detect surface or intracellular expression of CD22 protein in a panel of lung cancer cell lines.  In addn., the in vitro proliferation of the lung tumor cell lines was not affected by either CD22 antibodies or our highly potent anti-CD22 immunotoxin.  In contrast, CD22+ Daudi cells expressed high levels of CD22 mRNA and protein, and were sensitive to our CD22 immunotoxin.  Importantly, primary non-small cell lung cancers from more than 250 patient specimens did not express detectable levels of CD22 protein as assessed by immuno- histochem.  We conclude that CD22 is not expressed at measurable levels on the surface of lung cancer cells, and that these cells cannot be killed by anti-CD22 immunotoxins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotB4GVT3xpJLVg90H21EOLACvtfcHk0liDhnBQMRUiVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXislKjtQ%253D%253D&md5=0f46bf3c127f3373917bd24fd899b1d6</span></div><a href="/servlet/linkout?suffix=cit30b&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-13-1436&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-13-1436%26sid%3Dliteratum%253Aachs%26aulast%3DPop%26aufirst%3DL.%2BM.%26aulast%3DBarman%26aufirst%3DS.%26aulast%3DShao%26aufirst%3DC.%26aulast%3DPoe%26aufirst%3DJ.%2BC.%26aulast%3DVenturi%26aufirst%3DG.%2BM.%26aulast%3DShelton%26aufirst%3DJ.%2BM.%26aulast%3DPop%26aufirst%3DI.%2BV.%26aulast%3DGerber%26aufirst%3DD.%2BE.%26aulast%3DGirard%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DX.-y.%26aulast%3DBehrens%26aufirst%3DC.%26aulast%3DRodriguez-Canales%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DWistuba%26aufirst%3DI.%2BI.%26aulast%3DRichardson%26aufirst%3DJ.%2BA.%26aulast%3DMinna%26aufirst%3DJ.%2BD.%26aulast%3DTedder%26aufirst%3DT.%2BF.%26aulast%3DVitetta%26aufirst%3DE.%2BS.%26atitle%3DA%2520reevaluation%2520of%2520CD22%2520expression%2520in%2520human%2520lung%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2014%26volume%3D74%26spage%3D263%26epage%3D271%26doi%3D10.1158%2F0008-5472.CAN-13-1436" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaumont, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span> <span> </span><span class="NLM_article-title">Volume of distribution in drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">5691</span>– <span class="NLM_lpage">5698</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00201</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00201" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BC2MXltFSlsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=5691-5698&author=D.+A.+Smithauthor=K.+Beaumontauthor=T.+S.+Maurerauthor=L.+Di&title=Volume+of+distribution+in+drug+design&doi=10.1021%2Facs.jmedchem.5b00201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Volume of Distribution in Drug Design</span></div><div class="casAuthors">Smith, Dennis A.; Beaumont, Kevin; Maurer, Tristan S.; Di, Li</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5691-5698</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Vol. of distribution is one of the most important pharmacokinetic properties of a drug candidate.  It is a major determinant of half-life and dosing frequency of a drug.  For a similar log P, a basic mol. will tend to exhibit higher vol. of distribution than a neutral mol.  Acids often exhibit low vols. of distribution.  Although a design strategy against vol. of distribution can be advantageous in achieving desirable dosing regimen, it must be well-directed in order to avoid detrimental effects to other important properties.  Strategies to increase vol. of distribution include adding lipophilicity and introducing basic functional groups in a way that does not increase metabolic clearance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP7QwgPahf4bVg90H21EOLACvtfcHk0liDhnBQMRUiVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXltFSlsb0%253D&md5=2c7289b3602a8edef2d9ef0e6a82e483</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00201%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DBeaumont%26aufirst%3DK.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26aulast%3DDi%26aufirst%3DL.%26atitle%3DVolume%2520of%2520distribution%2520in%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D5691%26epage%3D5698%26doi%3D10.1021%2Facs.jmedchem.5b00201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaidyanathan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koumarianou, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDougald, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pruszynski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lahoutte, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyerly, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalutsky, M. R.</span></span> <span> </span><span class="NLM_article-title"><i>N</i>-Succinimidyl guanidinomethyl iodobenzoate protein radiohalogenation agents: Influence of isomeric substitution on radiolabeling and target cell residualization</span>. <i>Nucl. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">802</span>– <span class="NLM_lpage">812</span>, <span class="refDoi"> DOI: 10.1016/j.nucmedbio.2014.07.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1016%2Fj.nucmedbio.2014.07.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=25156548" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVKntrjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2014&pages=802-812&author=J.+Choiauthor=G.+Vaidyanathanauthor=E.+Koumarianouauthor=D.+McDougaldauthor=M.+Pruszynskiauthor=T.+Osadaauthor=T.+Lahoutteauthor=H.+K.+Lyerlyauthor=M.+R.+Zalutsky&title=N-Succinimidyl+guanidinomethyl+iodobenzoate+protein+radiohalogenation+agents%3A+Influence+of+isomeric+substitution+on+radiolabeling+and+target+cell+residualization&doi=10.1016%2Fj.nucmedbio.2014.07.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">N-Succinimidyl guanidinomethyl iodobenzoate protein radiohalogenation agents: Influence of isomeric substitution on radiolabeling and target cell residualization</span></div><div class="casAuthors">Choi, Jaeyeon; Vaidyanathan, Ganesan; Koumarianou, Eftychia; McDougald, Darryl; Pruszynski, Marek; Osada, Takuya; Lahoutte, Tony; Lyerly, H. Kim; Zalutsky, Michael R.</div><div class="citationInfo"><span class="NLM_cas:title">Nuclear Medicine and Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">802-812</span>CODEN:
                <span class="NLM_cas:coden">NMBIEO</span>;
        ISSN:<span class="NLM_cas:issn">0969-8051</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">N-succinimidyl 4-guanidinomethyl-3-[*I]iodobenzoate ([*I]SGMIB) has shown promise for the radioiodination of monoclonal antibodies (mAbs) and other proteins that undergo extensive internalization after receptor binding, enhancing tumor targeting compared to direct electrophilic radioiodination.  However, radiochem. yields for [131I]SGMIB synthesis are low, which we hypothesize is due to steric hindrance from the Boc-protected guanidinomethyl group ortho to the tin moiety.  To overcome this, we developed the isomeric compd., N-succinimidyl 3-guanidinomethyl-5-[131I]iodobenzoate (iso-[131I]SGMIB) wherein this bulky group was moved from ortho to meta position.  Boc2-iso-SGMIB std. and its tin precursor, N-succinimidyl 3-((1,2-bis(tert-butoxycarbonyl)guanidino)methyl)-5-(trimethylstannyl)benzoate (Boc2-iso-SGMTB), were synthesized using two disparate routes, and iso-[*I]SGMIB synthesized from the tin precursor.  Two HER2-targeted vectors - trastuzumab (Tras) and a nanobody 5 F7 (Nb) - were labeled using iso-[*I]SGMIB and [*I]SGMIB.  Paired-label internalization assays in vitro with both proteins, and biodistribution in vivo with trastuzumab, labeled using the two isomeric prosthetic agents were performed.  When the reactions were performed under identical conditions, radioiodination yields for the synthesis of Boc2-iso-[131I]SGMIB were significantly higher than those for Boc2-[131I]SGMIB (70.7 ± 2.0% vs 56.5 ± 5.5%).  With both Nb and trastuzumab, conjugation efficiency also was higher with iso-[131I]SGMIB than with [131I]SGMIB (Nb, 33.1 ± 7.1% vs 28.9 ± 13.0%; Tras, 45.1 ± 4.5% vs 34.8 ± 10.3%); however, the differences were not statistically significant.  Internalization assays performed on BT474 cells with 5 F7 Nb indicated similar residualizing capacity over 6 h; however, at 24 h, radioactivity retained intracellularly for iso-[131I]SGMIB-Nb was lower than for [125I]SGMIB-Nb (46.4 ± 1.3% vs 56.5 ± 2.5%); similar results were obtained using Tras.  Likewise, a paired-label biodistribution of Tras labeled using iso-[125I]SGMIB and [131I]SGMIB indicated an up to 22% tumor uptake advantage at later time points for [131I]SGMIB-Tras.  Given the higher labeling efficiency obtained with iso-SGMIB, this residualizing agent might be of value for use with shorter half-life radiohalogens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8pMUf48-sTbVg90H21EOLACvtfcHk0liDhnBQMRUiVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVKntrjJ&md5=a798e0bcb0c6ea4efd4fe0dd46147d8c</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.nucmedbio.2014.07.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nucmedbio.2014.07.005%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DJ.%26aulast%3DVaidyanathan%26aufirst%3DG.%26aulast%3DKoumarianou%26aufirst%3DE.%26aulast%3DMcDougald%26aufirst%3DD.%26aulast%3DPruszynski%26aufirst%3DM.%26aulast%3DOsada%26aufirst%3DT.%26aulast%3DLahoutte%26aufirst%3DT.%26aulast%3DLyerly%26aufirst%3DH.%2BK.%26aulast%3DZalutsky%26aufirst%3DM.%2BR.%26atitle%3DN-Succinimidyl%2520guanidinomethyl%2520iodobenzoate%2520protein%2520radiohalogenation%2520agents%253A%2520Influence%2520of%2520isomeric%2520substitution%2520on%2520radiolabeling%2520and%2520target%2520cell%2520residualization%26jtitle%3DNucl.%2520Med.%2520Biol.%26date%3D2014%26volume%3D41%26spage%3D802%26epage%3D812%26doi%3D10.1016%2Fj.nucmedbio.2014.07.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kanwal, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mujahid, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasool, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizwan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, S. A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rashid, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nasir, N. M.</span></span> <span> </span><span class="NLM_article-title">Palladium and copper catalyzed Sonogashira cross coupling an excellent methodology for C-C bond formation over 17 years: A review</span>. <i>Catalysts</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">443</span>, <span class="refDoi"> DOI: 10.3390/catal10040443</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.3390%2Fcatal10040443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtValsrjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=443&author=I.+Kanwalauthor=A.+Mujahidauthor=N.+Rasoolauthor=K.+Rizwanauthor=A.+Malikauthor=G.+Ahmadauthor=S.+A.+A.+Shahauthor=U.+Rashidauthor=N.+M.+Nasir&title=Palladium+and+copper+catalyzed+Sonogashira+cross+coupling+an+excellent+methodology+for+C-C+bond+formation+over+17+years%3A+A+review&doi=10.3390%2Fcatal10040443"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33aR"><div class="casContent"><span class="casTitleNuber">33a</span><div class="casTitle"><span class="NLM_cas:atitle">Palladium and copper catalyzed Sonogashira cross coupling has been an excellent methodology for C-C bond formation for 17 years: a review</span></div><div class="casAuthors">Kanwal, Iram; Mujahid, Aqsa; Rasool, Nasir; Rizwan, Komal; Malik, Ayesha; Ahmad, Gulraiz; Shah, Syed Adnan Ali; Rashid, Umer; Nasir, Nadiah Mad</div><div class="citationInfo"><span class="NLM_cas:title">Catalysts</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">443</span>CODEN:
                <span class="NLM_cas:coden">CATACJ</span>;
        ISSN:<span class="NLM_cas:issn">2073-4344</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Developments in the palladium and copper catalyzed Sonogashira cross coupling achieved in recent years concerning substrates, different catalyst systems and reaction conditions was dicussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1Qetr_rYnRbVg90H21EOLACvtfcHk0lg10VeZSeLSZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtValsrjM&md5=4ed5b5330346580ee28619f48c98994f</span></div><a href="/servlet/linkout?suffix=cit33a&amp;dbid=16384&amp;doi=10.3390%2Fcatal10040443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcatal10040443%26sid%3Dliteratum%253Aachs%26aulast%3DKanwal%26aufirst%3DI.%26aulast%3DMujahid%26aufirst%3DA.%26aulast%3DRasool%26aufirst%3DN.%26aulast%3DRizwan%26aufirst%3DK.%26aulast%3DMalik%26aufirst%3DA.%26aulast%3DAhmad%26aufirst%3DG.%26aulast%3DShah%26aufirst%3DS.%2BA.%2BA.%26aulast%3DRashid%26aufirst%3DU.%26aulast%3DNasir%26aufirst%3DN.%2BM.%26atitle%3DPalladium%2520and%2520copper%2520catalyzed%2520Sonogashira%2520cross%2520coupling%2520an%2520excellent%2520methodology%2520for%2520C-C%2520bond%2520formation%2520over%252017%2520years%253A%2520A%2520review%26jtitle%3DCatalysts%26date%3D2020%26volume%3D10%26spage%3D443%26doi%3D10.3390%2Fcatal10040443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit33b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chinchilla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nájera, C.</span></span> <span> </span><span class="NLM_article-title">Recent advances in Sonogashira reactions</span>. <i>Chem. Soc. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">5084</span>– <span class="NLM_lpage">5121</span>, <span class="refDoi"> DOI: 10.1039/c1cs15071e</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1039%2Fc1cs15071e" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=21655588" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtF2jtbvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2011&pages=5084-5121&author=R.+Chinchillaauthor=C.+N%C3%A1jera&title=Recent+advances+in+Sonogashira+reactions&doi=10.1039%2Fc1cs15071e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33bR"><div class="casContent"><span class="casTitleNuber">33b</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in Sonogashira reactions</span></div><div class="casAuthors">Chinchilla, Rafael; Najera, Carmen</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">5084-5121</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review with 352 refs. discusses the Sonogashira reaction of alkynes and aryl halides to yield aryl alkynes and, in particular, the development of catalysts for Sonogashira reactions.  The mechanism of the Sonogashira reaction, the use of supported and unsupported palladium complexes with phosphines, nitrogen-contg. (imine and pyridine) ligands, ligands contg. phosphorus, nitrogen, and oxygen, and N-heterocyclic carbenes as catalysts, the use of palladacycles, ligand-free palladium species, and palladium nanoparticles as catalysts, and the use of other metals as catalysts or cocatalysts for Sonogashira coupling reactions are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRRxM3DrQgRrVg90H21EOLACvtfcHk0lg10VeZSeLSZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtF2jtbvE&md5=daa28257436731bf1fc800f0d1ce46f3</span></div><a href="/servlet/linkout?suffix=cit33b&amp;dbid=16384&amp;doi=10.1039%2Fc1cs15071e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc1cs15071e%26sid%3Dliteratum%253Aachs%26aulast%3DChinchilla%26aufirst%3DR.%26aulast%3DN%25C3%25A1jera%26aufirst%3DC.%26atitle%3DRecent%2520advances%2520in%2520Sonogashira%2520reactions%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2011%26volume%3D40%26spage%3D5084%26epage%3D5121%26doi%3D10.1039%2Fc1cs15071e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adhikari, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zacharias, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadowsky, J.</span></span> <span> </span><span class="NLM_article-title">Site-specific conjugation to Cys-engineered THIOMAB antibodies</span>. <i>Methods Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>2078</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">69</span>, <span class="refDoi"> DOI: 10.1007/978-1-4939-9929-3_4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1007%2F978-1-4939-9929-3_4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=31643049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnsVOmtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2078&publication_year=2020&pages=51-69&author=P.+Adhikariauthor=N.+Zachariasauthor=R.+Ohriauthor=J.+Sadowsky&title=Site-specific+conjugation+to+Cys-engineered+THIOMAB+antibodies&doi=10.1007%2F978-1-4939-9929-3_4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Site-Specific Conjugation to Cys-Engineered THIOMAB Antibodies</span></div><div class="casAuthors">Adhikari, Pragya; Zacharias, Neelie; Ohri, Rachana; Sadowsky, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">2078</span>
        (<span class="NLM_cas:issue">Antibody-Drug Conjugates</span>),
    <span class="NLM_cas:pages">51-69</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1940-6029</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Antibodies bearing engineered cysteine residues (termed THIOMAB antibodies) enable the site-selective attachment of a drug, label or other payload for specific delivery to certain tissues (e.g., tumors).  This Chapter describes detailed methods we have developed and optimized for the conjugation, purifn. and anal. of THIOMAB antibody drug conjugates (TDCs).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrUk7y1MvJF7Vg90H21EOLACvtfcHk0lg10VeZSeLSZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnsVOmtLY%253D&md5=aac9db6d1b978df97066912e9d1e9e2a</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1007%2F978-1-4939-9929-3_4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-4939-9929-3_4%26sid%3Dliteratum%253Aachs%26aulast%3DAdhikari%26aufirst%3DP.%26aulast%3DZacharias%26aufirst%3DN.%26aulast%3DOhri%26aufirst%3DR.%26aulast%3DSadowsky%26aufirst%3DJ.%26atitle%3DSite-specific%2520conjugation%2520to%2520Cys-engineered%2520THIOMAB%2520antibodies%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2020%26volume%3D2078%26spage%3D51%26epage%3D69%26doi%3D10.1007%2F978-1-4939-9929-3_4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tohma, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kita, Y.</span></span> <span> </span><span class="NLM_article-title">Hypervalent iodine reagents for the oxidation of alcohols and their application to complex molecule synthesis</span>. <i>Adv. Synth. Catal.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>346</i></span>,  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">124</span>, <span class="refDoi"> DOI: 10.1002/adsc.200303203</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1002%2Fadsc.200303203" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjt1ensLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=346&publication_year=2004&pages=111-124&author=H.+Tohmaauthor=Y.+Kita&title=Hypervalent+iodine+reagents+for+the+oxidation+of+alcohols+and+their+application+to+complex+molecule+synthesis&doi=10.1002%2Fadsc.200303203"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Hypervalent iodine reagents for the oxidation of alcohols and their application to complex molecule synthesis</span></div><div class="casAuthors">Tohma, Hirofumi; Kita, Yasuyuki</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Synthesis & Catalysis</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">346</span>
        (<span class="NLM_cas:issue">2+3</span>),
    <span class="NLM_cas:pages">111-124</span>CODEN:
                <span class="NLM_cas:coden">ASCAF7</span>;
        ISSN:<span class="NLM_cas:issn">1615-4150</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Hypervalent iodine(V) derivs. such as 2-iodoxybenzoic acid (IBX) and Dess-Martin periodinane [DMP; 1,1,1-tris(acetyloxy)-1,1-dihydro-1,2-benziodoxol-3-(1H)-one] are used widely for the oxidn. of alcs. to aldehydes and ketones during the last decade because of their high chemoselectivity, mild reactivity, and high yielding process.  This review focuses on the recent progress in the oxidn. of alcs. to carbonyl compds. using IBX, DMP, and other hypervalent iodine reagents, and their application to total syntheses of a variety of complex natural products.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDc0KufQbayLVg90H21EOLACvtfcHk0lg10VeZSeLSZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjt1ensLY%253D&md5=b7fde1a6d554fb1550dc43f3eb575d48</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1002%2Fadsc.200303203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fadsc.200303203%26sid%3Dliteratum%253Aachs%26aulast%3DTohma%26aufirst%3DH.%26aulast%3DKita%26aufirst%3DY.%26atitle%3DHypervalent%2520iodine%2520reagents%2520for%2520the%2520oxidation%2520of%2520alcohols%2520and%2520their%2520application%2520to%2520complex%2520molecule%2520synthesis%26jtitle%3DAdv.%2520Synth.%2520Catal.%26date%3D2004%26volume%3D346%26spage%3D111%26epage%3D124%26doi%3D10.1002%2Fadsc.200303203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="note"><p class="first last">For alternate preparations of dibromide <b>46</b>, see:</p></div><div class="NLM_citation" id="cit36a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Duchêne, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vögtle, F.</span></span> <span> </span><span class="NLM_article-title">A hydrocarbon skeleton with twelve identical functional groups. Synthesis of a dodeca host compound</span>. <i>Synthesis</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>1986</i></span>,  <span class="NLM_fpage">659</span>– <span class="NLM_lpage">661</span>, <span class="refDoi"> DOI: 10.1055/s-1986-31738</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1055%2Fs-1986-31738" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1986&publication_year=1986&pages=659-661&author=K.-H.+Duch%C3%AAneauthor=F.+V%C3%B6gtle&title=A+hydrocarbon+skeleton+with+twelve+identical+functional+groups.+Synthesis+of+a+dodeca+host+compound&doi=10.1055%2Fs-1986-31738"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36a&amp;dbid=16384&amp;doi=10.1055%2Fs-1986-31738&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-1986-31738%26sid%3Dliteratum%253Aachs%26aulast%3DDuch%25C3%25AAne%26aufirst%3DK.-H.%26aulast%3DV%25C3%25B6gtle%26aufirst%3DF.%26atitle%3DA%2520hydrocarbon%2520skeleton%2520with%2520twelve%2520identical%2520functional%2520groups.%2520Synthesis%2520of%2520a%2520dodeca%2520host%2520compound%26jtitle%3DSynthesis%26date%3D1986%26volume%3D1986%26spage%3D659%26epage%3D661%26doi%3D10.1055%2Fs-1986-31738" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit36b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Dash, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satapathy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaillard, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maguire, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosmane, N. S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and properties of carborane-appended C3-symmetrical extended π systems</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">6578</span>– <span class="NLM_lpage">6587</span>, <span class="refDoi"> DOI: 10.1021/ja101845m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja101845m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvVaiu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2010&pages=6578-6587&author=B.+P.+Dashauthor=R.+Satapathyauthor=E.+R.+Gaillardauthor=J.+A.+Maguireauthor=N.+S.+Hosmane&title=Synthesis+and+properties+of+carborane-appended+C3-symmetrical+extended+%CF%80+systems&doi=10.1021%2Fja101845m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36bR"><div class="casContent"><span class="casTitleNuber">36b</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Properties of Carborane-Appended C3-Symmetrical Extended π Systems</span></div><div class="casAuthors">Dash, Barada Prasanna; Satapathy, Rashmirekha; Gaillard, Elizabeth R.; Maguire, John A.; Hosmane, Narayan S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6578-6587</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">C3-sym. π-conjugated compds. contg. three to six o-carborane clusters were synthesized by employing Pd-catalyzed Suzuki coupling reactions and Pd-catalyzed acetylation reactions, followed by Si tetrachloride mediated trimerization reactions.  Carborane-contg. extended trimers emit blue light.  Incorporation of o-carborane clusters into extended π-conjugated systems led to 22-70% enhancement of their relative fluorescence quantum yields.  Decapitation of o-carborane clusters made these extended trimers water sol., and their aq. solns. also are fluorescent, but with a reduced fluorescence intensity.  The carborane-appended π-conjugated compds. are extremely thermally stable, and for some of these compds. only 10% mass loss occurred at temps. close to 500°.  The DSC thermograms of smaller Ccage-appended trimers indicate the occurrence of solid-solid phase transitions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7pLA4S9d_47Vg90H21EOLACvtfcHk0ljOiOXdSiG7SA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvVaiu7g%253D&md5=c56e1721fbb1bc04e84c14b5ef88ea60</span></div><a href="/servlet/linkout?suffix=cit36b&amp;dbid=16384&amp;doi=10.1021%2Fja101845m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja101845m%26sid%3Dliteratum%253Aachs%26aulast%3DDash%26aufirst%3DB.%2BP.%26aulast%3DSatapathy%26aufirst%3DR.%26aulast%3DGaillard%26aufirst%3DE.%2BR.%26aulast%3DMaguire%26aufirst%3DJ.%2BA.%26aulast%3DHosmane%26aufirst%3DN.%2BS.%26atitle%3DSynthesis%2520and%2520properties%2520of%2520carborane-appended%2520C3-symmetrical%2520extended%2520%25CF%2580%2520systems%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2010%26volume%3D132%26spage%3D6578%26epage%3D6587%26doi%3D10.1021%2Fja101845m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit36c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sookcharoenpinyo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrand, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brotherhood, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crump, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, A. P.</span></span> <span> </span><span class="NLM_article-title">High-affinity disaccharide binding by tricyclic synthetic lectins</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">4586</span>– <span class="NLM_lpage">4590</span>, <span class="refDoi"> DOI: 10.1002/anie.201200447</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1002%2Fanie.201200447" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvVGlt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2012&pages=4586-4590&author=B.+Sookcharoenpinyoauthor=E.+Kleinauthor=Y.+Ferrandauthor=D.+B.+Walkerauthor=P.+R.+Brotherhoodauthor=C.+Keauthor=M.+P.+Crumpauthor=A.+P.+Davis&title=High-affinity+disaccharide+binding+by+tricyclic+synthetic+lectins&doi=10.1002%2Fanie.201200447"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36cR"><div class="casContent"><span class="casTitleNuber">36c</span><div class="casTitle"><span class="NLM_cas:atitle">High-Affinity Disaccharide Binding by Tricyclic Synthetic Lectins</span></div><div class="casAuthors">Sookcharoenpinyo, Bunyarithi; Klein, Emmanuel; Ferrand, Yann; Walker, D. Barney; Brotherhood, Peter R.; Ke, Chengfeng; Crump, Matthew P.; Davis, Anthony P.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4586-4590, S4586/1-S4586/79</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Carbohydrate recognition mediates a wide range of biol. processes, including protein folding and trafficking, cell-cell recognition, infection by pathogenic organisms, and many aspects of the immune response.  Mols. capable of selective carbohydrate binding are therefore valuable as tools for biol. research, and potentially as medicinal agents.  There are many saccharide-binding proteins - notably the group known as lectins - but they often exhibit low affinities and less-than-ideal selectivities.  Moreover, they are generally too unstable and toxic for medical use.  Opportunities thus exist for synthetic systems, provided they can compete with lectins in terms of binding strength and selectivity.  The present study provides evidence that tricyclic synthetic lectins are capable of high-affinity disaccharide binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEPMTEToNGQrVg90H21EOLACvtfcHk0ljOiOXdSiG7SA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvVGlt74%253D&md5=9432aa4533c8cc60670c08e3cbfa3f20</span></div><a href="/servlet/linkout?suffix=cit36c&amp;dbid=16384&amp;doi=10.1002%2Fanie.201200447&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201200447%26sid%3Dliteratum%253Aachs%26aulast%3DSookcharoenpinyo%26aufirst%3DB.%26aulast%3DKlein%26aufirst%3DE.%26aulast%3DFerrand%26aufirst%3DY.%26aulast%3DWalker%26aufirst%3DD.%2BB.%26aulast%3DBrotherhood%26aufirst%3DP.%2BR.%26aulast%3DKe%26aufirst%3DC.%26aulast%3DCrump%26aufirst%3DM.%2BP.%26aulast%3DDavis%26aufirst%3DA.%2BP.%26atitle%3DHigh-affinity%2520disaccharide%2520binding%2520by%2520tricyclic%2520synthetic%2520lectins%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2012%26volume%3D51%26spage%3D4586%26epage%3D4590%26doi%3D10.1002%2Fanie.201200447" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dragovich, P.</span>; <span class="NLM_string-name">Pei, Z.</span>; <span class="NLM_string-name">Pillow, T.</span>; <span class="NLM_string-name">Sadowsky, J.</span>; <span class="NLM_string-name">Verma, V.</span>; <span class="NLM_string-name">Zhang, D.</span></span> <span> </span><span class="NLM_article-title">Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof. International patent application</span>, <span class="NLM_year">2018</span>, <span class="NLM_patent">WO 201831662</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=P.+Dragovich&author=Z.+Pei&author=T.+Pillow&author=J.+Sadowsky&author=V.+Verma&author=D.+Zhang&title=Pyrrolobenzodiazepine+prodrugs+and+antibody+conjugates+thereof.+International+patent+application"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDragovich%26aufirst%3DP.%26atitle%3DPyrrolobenzodiazepine%2520prodrugs%2520and%2520antibody%2520conjugates%2520thereof.%2520International%2520patent%2520application%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rettig, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weingarth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langel, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisz, K.</span></span> <span> </span><span class="NLM_article-title">Solution structure of a covalently bound pyrrolo[2,1-c][1,4]benzodiazepinebenzimidazole hybrid to a 10mer DNA duplex</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">12223</span>– <span class="NLM_lpage">12232</span>, <span class="refDoi"> DOI: 10.1021/bi901655t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi901655t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVKhs7nF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2009&pages=12223-12232&author=M.+Rettigauthor=M.+Weingarthauthor=W.+Langelauthor=A.+Kamalauthor=P.+P.+Kumarauthor=K.+Weisz&title=Solution+structure+of+a+covalently+bound+pyrrolo%5B2%2C1-c%5D%5B1%2C4%5Dbenzodiazepinebenzimidazole+hybrid+to+a+10mer+DNA+duplex&doi=10.1021%2Fbi901655t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Solution Structure of a Covalently Bound Pyrrolo[2,1-c][1,4]benzodiazepine-Benzimidazole Hybrid to a 10mer DNA Duplex</span></div><div class="casAuthors">Rettig, Michael; Weingarth, Markus; Langel, Walter; Kamal, Ahmed; Kumar, P. Praveen; Weisz, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">12223-12232</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A pyrrolo[2,1-c][1,4]benzodiazepine-benzimidazole hybrid (PBD-BIMZ) derived from the tricyclic anticancer PBD antibiotics can covalently bind to a guanine base at its exocyclic 2-amino group in double-helical DNA.  Through the formation of stable DNA adducts, these hybrids have previously been shown to have significant anticancer activity in a no. of cell lines.  Here, the three-dimensional soln. structure of the complex formed between the self-complementary DNA decamer 5'-AACAATTGTT-3' and PBD-BIMZ has been investigated by two-dimensional NMR spectroscopy and NOE distance restraint mol. dynamics simulations.  Refinements using an explicit solvation model yielded a complex structure that is in good agreement with the NMR structural data.  Successful convergence is indicated by an av. mutual root-mean-square deviation of <1 Å for three final representative structures selected by clustering methods from the mol. dynamics trajectories at 300 K.  The ligand binds in an (11S,11aS) configuration to one of the two sym. located guanine bases of the duplex and is oriented with its benzimidazole moiety toward the 5'-end of the modified guanine.  It is accommodated within the minor groove covering the centrally located 6 bp.  Conformational and helical parameters of the DNA adduct are typical of a B-like duplex, and more significant helical distortions by the covalent binding of PBD-BIMZ are mostly confined to the covalent binding site and the junction between complexed and noncomplexed DNA segments.  In contrast to the overall well-detd. conformation of the bound hybrid, its terminal N-methylpiperazine ring appears to adopt various conformations assocd. with increased flexibility.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo37xfG6Wuv3bVg90H21EOLACvtfcHk0ljOiOXdSiG7SA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVKhs7nF&md5=ae48ee51140a5b74afd2d583558414cb</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fbi901655t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi901655t%26sid%3Dliteratum%253Aachs%26aulast%3DRettig%26aufirst%3DM.%26aulast%3DWeingarth%26aufirst%3DM.%26aulast%3DLangel%26aufirst%3DW.%26aulast%3DKamal%26aufirst%3DA.%26aulast%3DKumar%26aufirst%3DP.%2BP.%26aulast%3DWeisz%26aufirst%3DK.%26atitle%3DSolution%2520structure%2520of%2520a%2520covalently%2520bound%2520pyrrolo%255B2%252C1-c%255D%255B1%252C4%255Dbenzodiazepinebenzimidazole%2520hybrid%2520to%2520a%252010mer%2520DNA%2520duplex%26jtitle%3DBiochemistry%26date%3D2009%26volume%3D48%26spage%3D12223%26epage%3D12232%26doi%3D10.1021%2Fbi901655t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7a','cit7b'],'ref8':['cit8a','cit8b'],'ref9':['cit9a','cit9b'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12a','cit12b','cit12c','cit12d'],'ref13':['cit13a','cit13b'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16a','cit16b'],'ref17':['cit17a','cit17b'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22a','cit22b'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26a','cit26b'],'ref27':['cit27a','cit27b','cit27c'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30a','cit30b'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33a','cit33b'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36a','cit36b','cit36c'],'ref37':['cit37'],'ref38':['cit38']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/medium/jm0c00691_0020.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/large/jm0c00691_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00691&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/medium/jm0c00691_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/large/jm0c00691_0001.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Representative cytotoxic PBD-dimers employed as ADC payloads.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/large/jm0c00691_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00691&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/medium/jm0c00691_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/large/jm0c00691_0002.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Alkyne-containing PBD-dimer linker drug employed in our previous studies (ref <a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/large/jm0c00691_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00691&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/medium/jm0c00691_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/large/jm0c00691_0003.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Composite model of compounds <b>5</b>–<b>9</b> binding to the DNA minor groove. The pink atom indicates the location of ionizable groups attached to the terminus of the central phenyl-alkyne moiety.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/large/jm0c00691_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00691&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/medium/jm0c00691_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/large/jm0c00691_0004.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Reference compound <b>10</b> employed in DNA alkylation assessments as an inactive control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/large/jm0c00691_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00691&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/medium/jm0c00691_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/large/jm0c00691_0005.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. <i>In vitro</i> antiproliferation activities of PBD-dimer conjugates as a function of cell line. Antiproliferation data are taken from <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>. The targeted antigen expressed by each cell line (CD22 or HER2) is listed below each name. p<i>K</i><sub>a</sub> values refer to the R-group appended to each PBD-dimer payload and were calculated using the MoKa software package (version 2.6.6); red = acidic, blue = basic (conjugate acid). (*) Control ADC (<b>16a</b>) IC<sub>50</sub> was weaker than typically observed; see <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> for additional details.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/large/jm0c00691_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00691&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/medium/jm0c00691_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/large/jm0c00691_0006.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Structure of control conjugates <b>16a</b> (CD22) and <b>16b</b> (HER2). Star symbol = second copy of the attached linker drug.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/large/jm0c00691_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00691&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/medium/jm0c00691_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/large/jm0c00691_0007.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. BJAB or KPL4 <i>in vitro</i> antiproliferation activities of PBD-dimer conjugates as a function of free payload <i>in vitro</i> antiproliferation potency. Antiproliferation data are taken from <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>. The targeted antigen expressed by each cell line (CD22 or HER2) is listed below each name. p<i>K</i><sub>a</sub> values refer to the R-group appended to each PBD-dimer payload and were calculated using the MoKa software package (version 2.6.6); red = acidic, blue = basic (conjugate acid). (*) Control ADC (<b>16a</b>) IC<sub>50</sub> was weaker than typically observed; see <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> for additional details.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/large/jm0c00691_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00691&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/medium/jm0c00691_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/large/jm0c00691_0008.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. <i>In vivo</i> activity of conjugates <b>11a</b>, <b>12a</b>, and <b>13a</b> in the WSU-DLCL2 xenograft model. (A) Efficacy (tumor growth inhibition). (B) Impact on mouse body weights. Blue traces, <b>11a</b>; red traces, <b>12a</b>; green traces, <b>13a</b>; black traces, vehicle control. Numbers next to traces indicate doses of each conjugate (in mg/kg) that were administered once IV at the day 0 time point. Group mean tumor volumes or body weight changes (±SEM) are plotted over the duration of the study (<i>n</i> = 8/group). See <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a> for additional details.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/large/jm0c00691_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00691&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/medium/jm0c00691_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/large/jm0c00691_0009.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. <i>In vivo</i> activity of conjugates <b>11a</b>, <b>11b</b>, <b>13a</b>, and <b>13b</b> in the WSU-DLCL2 xenograft model. (A) Efficacy (tumor growth inhibition). (B) Impact on mouse body weights. Blue traces (solid line), <b>11a</b>; blue traces (dotted line), <b>11b</b>; green traces (solid line), <b>13a</b>; green traces (dotted line), <b>13b</b>; black traces, vehicle control. Numbers next to traces indicate doses of each conjugate (in mg/kg) that were administered once IV at the day 0 time point. Group mean tumor volumes (± SEM) are plotted over the duration of the study (<i>n</i> = 5/group). See <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a> for additional details.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/large/jm0c00691_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00691&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/medium/jm0c00691_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/large/jm0c00691_0010.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. <i>In vivo</i> activity of conjugates <b>13a</b>, <b>14a</b>, and <b>15a</b> in the WSU-DLCL2 xenograft model. (A) Efficacy (tumor growth inhibition). (B) Impact on mouse body weights. Green traces, <b>13a</b>; orange traces, <b>14a</b>; purple traces, <b>15a</b>; black traces, vehicle control. Numbers next to traces indicate doses of each conjugate (in mg/kg) that were administered once IV at the day 0 time point. Group mean tumor volumes (± SEM) are plotted over the duration of the study (<i>n</i> = 5/group). See <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a> for additional details.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/large/jm0c00691_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00691&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/medium/jm0c00691_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/large/jm0c00691_0011.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Unconjugated PBD-Dimers <b>5</b>–<b>9</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/large/jm0c00691_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00691&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) alkyne, Et<sub>2</sub>NH, Pd(Ph<sub>3</sub>P)<sub>4</sub>, CuI, DMF, 100 °C, 10–20 min, 40–67%; (b) TFA, 0–15 °C, 1 h, 15–80%; (c) Et<sub>3</sub>N, MsCl, DCM, 15 °C, 0.5 h; (d) LiBr, THF, 10 °C, 16 h, 94%; (e) Na<sub>2</sub>SO<sub>3</sub>, 3:1 MeOH/H<sub>2</sub>O, 60 °C, 6 h, 31%. THP = 2-tetrahydropyran.</p></p></figure><figure data-id="sch2" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/medium/jm0c00691_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/large/jm0c00691_0012.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Preparation of Antibody–Drug Conjugates <b>11a</b>–<b>15a</b> and <b>11b</b>–<b>15b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/large/jm0c00691_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00691&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) DMF, Tris pH 6.5 to 7.5, 25 °C, 3–24 h.</p></p></figure><figure data-id="sch3" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/medium/jm0c00691_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/large/jm0c00691_0013.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Preparation of Linker Drugs <b>31</b>–<b>35</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/large/jm0c00691_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00691&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Fe, NH<sub>4</sub>Cl, 2:1 EtOH/H<sub>2</sub>O, 80 °C, 2 h, 100%; (b) Boc<sub>2</sub>O, THF, 75 °C, 3 h, 36%; (c) Et<sub>3</sub>N, triphosgene, 4 Å sieves, DCM, 25 °C, 1 h, then Boc-Val-Cit-PAB–OH, DMF, 25 °C, 16 h, 81%; (d) HOAc, 3:1 THF/H<sub>2</sub>O, 25 °C, 16 h, 79%; (e) IBX, DMSO, 38 °C, 16 h, 43%; (f) alkyne, Et<sub>2</sub>NH, Pd(Ph<sub>3</sub>P)<sub>4</sub>, CuI, DMF, 25 °C, 12–48 h, 25–61%; (g) TFA, 0 °C, 1 h; (h) MC-OSu, (<i>i</i>-Pr)<sub>2</sub>NEt, DMF, 25 °C, 10–72 h, 15–32%. TBS = Si(CH<sub>3</sub>)<sub>2</sub>tBu.</p></p></figure><figure data-id="sch4" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/medium/jm0c00691_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/large/jm0c00691_0014.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Preparation of Intermediates <b>17</b> and <b>36</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/large/jm0c00691_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00691&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaBH<sub>4</sub>, CaCl<sub>2</sub>, EtOH, 0–25 °C, 2 h, 72%; (b) CBr<sub>4</sub>, PPh<sub>3</sub>, DCM, 0–25 °C, 12 h, 35%; (c) <i>n</i>-Bu<sub>4</sub>NI, K<sub>2</sub>CO<sub>3</sub>, DMF, 60 °C, 6 h, 63%; (d) NaClO<sub>2</sub>, NaH<sub>2</sub>PO<sub>4</sub>·2H<sub>2</sub>O, H<sub>2</sub>O<sub>2</sub>, THF, 25–45 °C, 4 h, 93%; (e) HNO<sub>3</sub>, 25 °C, 16 h, 58%; (f) oxalyl chloride, DCM, 25 °C, 4 h, then <b>50</b>, Et<sub>3</sub>N, −40 to 0 °C, crude; (g) LiOH·2H<sub>2</sub>O, 1:1 THF/H<sub>2</sub>O, 25 °C, 3 h, 50% over 2 steps; (h) TBSCl, imidazole, DMF, 0–25 °C, 3 h, 67%; (i) Fe, NH<sub>4</sub>Cl, 2:1 EtOH/H<sub>2</sub>O, 90 °C, 2 h, 78%; (j) Boc<sub>2</sub>O, THF, 90 °C, 6 h, 99%; (k) HOAc, 2:1 THF/H<sub>2</sub>O, 18 °C, 48 h, 90%; (l) DMP, DCM, 14 °C, 16 h, 53%. TBS = Si(CH<sub>3</sub>)<sub>2</sub>tBu.</p></p></figure><figure data-id="sch5" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/medium/jm0c00691_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/large/jm0c00691_0015.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Preparation of Alkynes <b>20</b>, <b>21</b>, and <b>42</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00691/20200903/images/large/jm0c00691_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00691&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaI, DMSO, 0–20 °C, 2 h, then NaCN, 80 °C, 2 h, 54%; (b) Et<sub>3</sub>N·HCl, NaN<sub>3</sub>, toluene, 25–115 °C, 10 h, 52%; (c) <i>n</i>-BuLi, (<i>i</i>-Pr)<sub>2</sub>NH, THF, −78 to 50 °C, 45 min, then (3-bromoprop-1-yn-1-yl)trimethylsilane, 20 °C, 3 h, 23%; (d) <i>n</i>-Bu<sub>4</sub>NF, THF, 20 °C, 20 min, 99%; (e) Na<sub>2</sub>SO<sub>3</sub>, 1:1 MeOH/H<sub>2</sub>O, 80 °C, 8 h, 98%.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i61">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78022" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78022" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 38 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mantaj, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, P. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurston, D. E.</span></span> <span> </span><span class="NLM_article-title">From anthramycin to pyrrolobenzodiazepine (PBD)-containing antibody–drug conjugates (ADCs)</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">462</span>– <span class="NLM_lpage">488</span>, <span class="refDoi"> DOI: 10.1002/anie.201510610</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1002%2Fanie.201510610" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVGitrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=462-488&author=J.+Mantajauthor=P.+J.+M.+Jacksonauthor=K.+M.+Rahmanauthor=D.+E.+Thurston&title=From+anthramycin+to+pyrrolobenzodiazepine+%28PBD%29-containing+antibody%E2%80%93drug+conjugates+%28ADCs%29&doi=10.1002%2Fanie.201510610"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">From Anthramycin to Pyrrolobenzodiazepine (PBD)-Containing Antibody-Drug Conjugates (ADCs)</span></div><div class="casAuthors">Mantaj, Julia; Jackson, Paul J. M.; Rahman, Khondaker M.; Thurston, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">462-488</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) are a family of sequence-selective DNA minor-groove binding agents that form a covalent aminal bond between their C11-position and the C2-NH2 groups of guanine bases.  The first example of a PBD monomer, the natural product anthramycin, was discovered in the 1960s, and the best known PBD dimer, SJG-136 (also known as SG2000, NSC 694501 or BN2629), was synthesized in the 1990s and has recently completed Phase II clin. trials in patients with leukemia and ovarian cancer.  More recently, PBD dimer analogs are being attached to tumor-targeting antibodies to create antibody-drug conjugates (ADCs), a no. of which are now in clin. trials, with many others in pre-clin. development.  This Review maps the development from anthramycin to the first PBD dimers, and then to PBD-contg. ADCs, and explores both structure-activity relationships (SARs) and the biol. of PBDs, and the strategies for their use as payloads for ADCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9tjTimo4Cv7Vg90H21EOLACvtfcHk0lhqsFDLJJMtwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVGitrnO&md5=8a87ad3c033b2a20798c861accba46a6</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1002%2Fanie.201510610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201510610%26sid%3Dliteratum%253Aachs%26aulast%3DMantaj%26aufirst%3DJ.%26aulast%3DJackson%26aufirst%3DP.%2BJ.%2BM.%26aulast%3DRahman%26aufirst%3DK.%2BM.%26aulast%3DThurston%26aufirst%3DD.%2BE.%26atitle%3DFrom%2520anthramycin%2520to%2520pyrrolobenzodiazepine%2520%2528PBD%2529-containing%2520antibody%25E2%2580%2593drug%2520conjugates%2520%2528ADCs%2529%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2017%26volume%3D56%26spage%3D462%26epage%3D488%26doi%3D10.1002%2Fanie.201510610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">del Rosario, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leong, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, G. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vij, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, W.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalouni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadowsky, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendricks, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poon, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pillow, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schutten, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flygare, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polson, A. G.</span></span> <span> </span><span class="NLM_article-title">An Anti-CLL-1 antibody–drug conjugate for the treatment of acute myeloid leukemia</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1358</span>– <span class="NLM_lpage">1368</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-18-0333</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1158%2F1078-0432.CCR-18-0333" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=29959143" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlOmt7bE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2019&pages=1358-1368&author=B.+Zhengauthor=S.-F.+Yuauthor=G.+del+Rosarioauthor=S.+R.+Leongauthor=G.+Y.+Leeauthor=R.+Vijauthor=C.+Chiuauthor=W.-C.+Liangauthor=Y.+Wuauthor=C.+Chalouniauthor=J.+Sadowskyauthor=V.+Clarkauthor=A.+Hendricksauthor=K.+A.+Poonauthor=W.+Chuauthor=T.+Pillowauthor=M.+M.+Schuttenauthor=J.+Flygareauthor=A.+G.+Polson&title=An+Anti-CLL-1+antibody%E2%80%93drug+conjugate+for+the+treatment+of+acute+myeloid+leukemia&doi=10.1158%2F1078-0432.CCR-18-0333"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">An anti-CLL-I antibody-drug conjugate for the treatment of acute myeloid leukemia</span></div><div class="casAuthors">Zheng, Bing; Yu, Shang-Fan; del Rosario, Geoffrey; Leong, Steven R.; Lee, Genee Y.; Vij, Rajesh; Chiu, Cecilia; Liang, Wei-Ching; Wu, Yan; Chalouni, Cecile; Sadowsky, Jack; Clark, Vanessa; Hendricks, Angela; Poon, Kirsten Achilles; Chu, Wayne; Pillow, Thomas; Schutten, Melissa M.; Flygare, John; Polson, Andrew G.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1358</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The treatment of acute myeloid leukemia (AML) has not significantly changed in 40 years.  Cytarabine- and anthracycline-based chemotherapy induction regimens (7 + 3) remain the std. of care, and most patients have poor long-term survival.  The reapproval of Mylotarg, an anti-CD33-calicheamicin antibody-drug conjugate (ADC), has demonstrated ADCs as a clin. validated option to enhance the effectiveness of induction therapy.  We are interested in developing a next-generation ADC for AML to improve upon the initial success of Mylotarg.  Exptl. Design: The expression pattern of CLL-1 and its hematopoietic potential were investigated.  A novel anti-CLL-1-ADC, with a highly potent pyrrolobenzodiazepine (PBD) dimer conjugated through a self-immolative disulfide linker, was developed.  The efficacy and safety profiles of this ADC were evaluated in mouse xenograft models and in cynomolgus monkeys.  Results: We demonstrate that CLL-1 shares similar prevalence and trafficking properties that make CD33 an excellent ADC target for AML, but lacks expression on hematopoietic stem cells that hampers current CD33-targeted ADCs.  Our anti-CLL-1-ADC is highly effective at depleting tumor cells in AML xenograft models and lacks target independent toxicities at doses that depleted target monocytes and neutrophils in cynomolgus monkeys.  Conclusions: Collectively, our data suggest that an anti-CLL-1-ADC has the potential to become an effective and safer treatment for AML in humans, by reducing and allowing for faster recovery from initial cytopenias than the current generation of ADCs for AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJdzTurW_r4LVg90H21EOLACvtfcHk0lhqsFDLJJMtwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlOmt7bE&md5=c701a514d19baec87815539f0eaa9275</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-18-0333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-18-0333%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DB.%26aulast%3DYu%26aufirst%3DS.-F.%26aulast%3Ddel%2BRosario%26aufirst%3DG.%26aulast%3DLeong%26aufirst%3DS.%2BR.%26aulast%3DLee%26aufirst%3DG.%2BY.%26aulast%3DVij%26aufirst%3DR.%26aulast%3DChiu%26aufirst%3DC.%26aulast%3DLiang%26aufirst%3DW.-C.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DChalouni%26aufirst%3DC.%26aulast%3DSadowsky%26aufirst%3DJ.%26aulast%3DClark%26aufirst%3DV.%26aulast%3DHendricks%26aufirst%3DA.%26aulast%3DPoon%26aufirst%3DK.%2BA.%26aulast%3DChu%26aufirst%3DW.%26aulast%3DPillow%26aufirst%3DT.%26aulast%3DSchutten%26aufirst%3DM.%2BM.%26aulast%3DFlygare%26aufirst%3DJ.%26aulast%3DPolson%26aufirst%3DA.%2BG.%26atitle%3DAn%2520Anti-CLL-1%2520antibody%25E2%2580%2593drug%2520conjugate%2520for%2520the%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2019%26volume%3D25%26spage%3D1358%26epage%3D1368%26doi%3D10.1158%2F1078-0432.CCR-18-0333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pillow, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schutten, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadowsky, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poon, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solis, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Rosario, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Go, M. A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leipold, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamath, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masterson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregson, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunzner-Toste, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozak, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polakis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polson, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flygare, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Junutula, J. R.</span></span> <span> </span><span class="NLM_article-title">Modulating therapeutic activity and toxicity of pyrrolobenzodiazepine antibody–drug conjugates with self-immolative disulfide linkers</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">871</span>– <span class="NLM_lpage">878</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-16-0641</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1158%2F1535-7163.MCT-16-0641" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=28223423" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmvFemtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=871-878&author=T.+H.+Pillowauthor=M.+Schuttenauthor=S.-F.+Yuauthor=R.+Ohriauthor=J.+Sadowskyauthor=K.+A.+Poonauthor=W.+Solisauthor=F.+Zhongauthor=G.+Del+Rosarioauthor=M.+A.+T.+Goauthor=J.+Lauauthor=S.+Yeeauthor=J.+Heauthor=L.+Liuauthor=C.+Ngauthor=K.+Xuauthor=D.+D.+Leipoldauthor=A.+V.+Kamathauthor=D.+Zhangauthor=L.+Mastersonauthor=S.+J.+Gregsonauthor=P.+W.+Howardauthor=F.+Fangauthor=J.+Chenauthor=J.+Gunzner-Tosteauthor=K.+K.+Kozakauthor=S.+Spencerauthor=P.+Polakisauthor=A.+G.+Polsonauthor=J.+A.+Flygareauthor=J.+R.+Junutula&title=Modulating+therapeutic+activity+and+toxicity+of+pyrrolobenzodiazepine+antibody%E2%80%93drug+conjugates+with+self-immolative+disulfide+linkers&doi=10.1158%2F1535-7163.MCT-16-0641"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Modulating Therapeutic Activity and Toxicity of Pyrrolobenzodiazepine Antibody-Drug Conjugates with Self-Immolative Disulfide Linkers</span></div><div class="casAuthors">Pillow, Thomas H.; Schutten, Melissa; Yu, Shang-Fan; Ohri, Rachana; Sadowsky, Jack; Poon, Kirsten Achilles; Solis, Willy; Zhong, Fiona; Del Rosario, Geoffrey; Go, Mary Ann T.; Lau, Jeffrey; Yee, Sharon; He, Jintang; Liu, Luna; Ng, Carl; Xu, Keyang; Leipold, Douglas D.; Kamath, Amrita V.; Zhang, Donglu; Masterson, Luke; Gregson, Stephen J.; Howard, Philip W.; Fang, Fan; Chen, Jinhua; Gunzner-Toste, Janet; Kozak, Katherine K.; Spencer, Susan; Polakis, Paul; Polson, Andrew G.; Flygare, John A.; Junutula, Jagath R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">871-878</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A novel disulfide linker was designed to enable a direct connection between cytotoxic pyrrolobenzodiazepine (PBD) drugs and the cysteine on a targeting antibody for use in antibody-drug conjugates (ADCs).  ADCs composed of a cysteine-engineered antibody were armed with a PBD using a self-immolative disulfide linker.  Both the chem. linker and the antibody site were optimized for this new bioconjugation strategy to provide a highly stable and efficacious ADC.  This novel disulfide ADC was compared with a conjugate contg. the same PBD drug, but attached to the antibody via a peptide linker.  Both ADCs had similar efficacy in mice bearing human tumor xenografts.  Safety studies in rats revealed that the disulfide-linked ADC had a higher MTD than the peptide-linked ADC.  Overall, these data suggest that the novel self-immolative disulfide linker represents a valuable way to construct ADCs with equiv. efficacy and improved safety.  Mol Cancer Ther; 16(5); 871-8. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZP_imFtNeBrVg90H21EOLACvtfcHk0lh7Jb-8oMjY5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmvFemtrw%253D&md5=6bf9501951de0cfad9d890a4ef9492b1</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-16-0641&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-16-0641%26sid%3Dliteratum%253Aachs%26aulast%3DPillow%26aufirst%3DT.%2BH.%26aulast%3DSchutten%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DS.-F.%26aulast%3DOhri%26aufirst%3DR.%26aulast%3DSadowsky%26aufirst%3DJ.%26aulast%3DPoon%26aufirst%3DK.%2BA.%26aulast%3DSolis%26aufirst%3DW.%26aulast%3DZhong%26aufirst%3DF.%26aulast%3DDel%2BRosario%26aufirst%3DG.%26aulast%3DGo%26aufirst%3DM.%2BA.%2BT.%26aulast%3DLau%26aufirst%3DJ.%26aulast%3DYee%26aufirst%3DS.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DNg%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DK.%26aulast%3DLeipold%26aufirst%3DD.%2BD.%26aulast%3DKamath%26aufirst%3DA.%2BV.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DMasterson%26aufirst%3DL.%26aulast%3DGregson%26aufirst%3DS.%2BJ.%26aulast%3DHoward%26aufirst%3DP.%2BW.%26aulast%3DFang%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DGunzner-Toste%26aufirst%3DJ.%26aulast%3DKozak%26aufirst%3DK.%2BK.%26aulast%3DSpencer%26aufirst%3DS.%26aulast%3DPolakis%26aufirst%3DP.%26aulast%3DPolson%26aufirst%3DA.%2BG.%26aulast%3DFlygare%26aufirst%3DJ.%2BA.%26aulast%3DJunutula%26aufirst%3DJ.%2BR.%26atitle%3DModulating%2520therapeutic%2520activity%2520and%2520toxicity%2520of%2520pyrrolobenzodiazepine%2520antibody%25E2%2580%2593drug%2520conjugates%2520with%2520self-immolative%2520disulfide%2520linkers%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2017%26volume%3D16%26spage%3D871%26epage%3D878%26doi%3D10.1158%2F1535-7163.MCT-16-0641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bankovich, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aujay, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bheddah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escarpe, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hampl, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laysang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Molina, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pysz, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slingerland, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torgov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foord, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jassem, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badzio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czapiewski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harpole, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowlati, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massion, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Travis, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietanza, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poirier, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudin, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stull, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dylla, S. J.</span></span> <span> </span><span class="NLM_article-title">A DLL3-targeted antibody–drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells <i>in vivo</i></span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">302ra136</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.aac9459</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1126%2Fscitranslmed.aac9459" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=26311731" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=302ra136&author=L.+R.+Saundersauthor=A.+J.+Bankovichauthor=W.+C.+Andersonauthor=M.+A.+Aujayauthor=S.+Bheddahauthor=K.+A.+Blackauthor=R.+Desaiauthor=P.+A.+Escarpeauthor=J.+Hamplauthor=A.+Laysangauthor=D.+Liuauthor=J.+Lopez-Molinaauthor=M.+Miltonauthor=A.+Parkauthor=M.+A.+Pyszauthor=H.+Shaoauthor=B.+Slingerlandauthor=M.+Torgovauthor=S.+A.+Williamsauthor=O.+Foordauthor=P.+Howardauthor=J.+Jassemauthor=A.+Badzioauthor=P.+Czapiewskiauthor=D.+H.+Harpoleauthor=A.+Dowlatiauthor=P.+P.+Massionauthor=W.+D.+Travisauthor=M.+C.+Pietanzaauthor=J.+T.+Poirierauthor=C.+M.+Rudinauthor=R.+A.+Stullauthor=S.+J.+Dylla&title=A+DLL3-targeted+antibody%E2%80%93drug+conjugate+eradicates+high-grade+pulmonary+neuroendocrine+tumor-initiating+cells+in+vivo&doi=10.1126%2Fscitranslmed.aac9459"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aac9459&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aac9459%26sid%3Dliteratum%253Aachs%26aulast%3DSaunders%26aufirst%3DL.%2BR.%26aulast%3DBankovich%26aufirst%3DA.%2BJ.%26aulast%3DAnderson%26aufirst%3DW.%2BC.%26aulast%3DAujay%26aufirst%3DM.%2BA.%26aulast%3DBheddah%26aufirst%3DS.%26aulast%3DBlack%26aufirst%3DK.%2BA.%26aulast%3DDesai%26aufirst%3DR.%26aulast%3DEscarpe%26aufirst%3DP.%2BA.%26aulast%3DHampl%26aufirst%3DJ.%26aulast%3DLaysang%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DLopez-Molina%26aufirst%3DJ.%26aulast%3DMilton%26aufirst%3DM.%26aulast%3DPark%26aufirst%3DA.%26aulast%3DPysz%26aufirst%3DM.%2BA.%26aulast%3DShao%26aufirst%3DH.%26aulast%3DSlingerland%26aufirst%3DB.%26aulast%3DTorgov%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DS.%2BA.%26aulast%3DFoord%26aufirst%3DO.%26aulast%3DHoward%26aufirst%3DP.%26aulast%3DJassem%26aufirst%3DJ.%26aulast%3DBadzio%26aufirst%3DA.%26aulast%3DCzapiewski%26aufirst%3DP.%26aulast%3DHarpole%26aufirst%3DD.%2BH.%26aulast%3DDowlati%26aufirst%3DA.%26aulast%3DMassion%26aufirst%3DP.%2BP.%26aulast%3DTravis%26aufirst%3DW.%2BD.%26aulast%3DPietanza%26aufirst%3DM.%2BC.%26aulast%3DPoirier%26aufirst%3DJ.%2BT.%26aulast%3DRudin%26aufirst%3DC.%2BM.%26aulast%3DStull%26aufirst%3DR.%2BA.%26aulast%3DDylla%26aufirst%3DS.%2BJ.%26atitle%3DA%2520DLL3-targeted%2520antibody%25E2%2580%2593drug%2520conjugate%2520eradicates%2520high-grade%2520pulmonary%2520neuroendocrine%2520tumor-initiating%2520cells%2520in%2520vivo%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2015%26volume%3D7%26spage%3D302ra136%26doi%3D10.1126%2Fscitranslmed.aac9459" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sutherland, M. S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walter, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffrey, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sussman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyon, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrington, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klussman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westendorf, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernstein, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senter, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benjamin, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drachman, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEarchern, J. A.</span></span> <span> </span><span class="NLM_article-title">SGN-CD33A: a novel CD33-targeting antibody–drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>122</i></span>,  <span class="NLM_fpage">1455</span>– <span class="NLM_lpage">1463</span>, <span class="refDoi"> DOI: 10.1182/blood-2013-03-491506</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1182%2Fblood-2013-03-491506" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=23770776" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVSqu73F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2013&pages=1455-1463&author=M.+S.+K.+Sutherlandauthor=R.+B.+Walterauthor=S.+C.+Jeffreyauthor=P.+J.+Burkeauthor=C.+Yuauthor=H.+Kostnerauthor=I.+Stoneauthor=M.+C.+Ryanauthor=D.+Sussmanauthor=R.+P.+Lyonauthor=W.+Zengauthor=K.+H.+Harringtonauthor=K.+Klussmanauthor=L.+Westendorfauthor=D.+Meyerauthor=I.+D.+Bernsteinauthor=P.+D.+Senterauthor=D.+R.+Benjaminauthor=J.+G.+Drachmanauthor=J.+A.+McEarchern&title=SGN-CD33A%3A+a+novel+CD33-targeting+antibody%E2%80%93drug+conjugate+using+a+pyrrolobenzodiazepine+dimer+is+active+in+models+of+drug-resistant+AML&doi=10.1182%2Fblood-2013-03-491506"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML</span></div><div class="casAuthors">Sutherland, May S. Kung; Walter, Roland B.; Jeffrey, Scott C.; Burke, Patrick J.; Yu, Changpu; Kostner, Heather; Stone, Ivan; Ryan, Maureen C.; Sussman, Django; Lyon, Robert P.; Zeng, Weiping; Harrington, Kimberly H.; Klussman, Kerry; Westendorf, Lori; Meyer, David; Bernstein, Irwin D.; Senter, Peter D.; Benjamin, Dennis R.; Drachman, Jonathan G.; McEarchern, Julie A.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1455-1463</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Outcomes in acute myeloid leukemia (AML) remain unsatisfactory, and novel treatments are urgently needed.  One strategy explores antibodies and their drug conjugates, particularly those targeting CD33.  Emerging data with gemtuzumab ozogamicin (GO) demonstrate target validity and activity in some patients with AML, but efficacy is limited by heterogeneous drug conjugation, linker instability, and a high incidence of multidrug resistance.  We describe here the development of SGN-CD33A, a humanized anti-CD33 antibody with engineered cysteines conjugated to a highly potent, synthetic DNA crosslinking pyrrolobenzodiazepine dimer via a protease-cleavable linker.  The use of engineered cysteine residues at the sites of drug linker attachment results in a drug loading of approx. 2 pyrrolobenzodiazepine dimers per antibody.  In preclin. testing, SGN-CD33A is more potent than GO against a panel of AML cell lines and primary AML cells in vitro and in xenotransplantation studies in mice.  Unlike GO, antileukemic activity is obsd. with SGN-CD33A in AML models with the multidrug-resistant phenotype.  Mechanistic studies indicate that the cytotoxic effects of SGN-CD33A involve DNA damage with ensuing cell cycle arrest and apoptotic cell death.  Together, these data suggest that SGN-CD33A has CD33-directed antitumor activity and support clin. testing of this novel therapeutic in patients with AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBSMYK90zZNrVg90H21EOLACvtfcHk0lhoEOvSaa1lbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVSqu73F&md5=6f6d10edd544b91186ef2a8bfa9142dc</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1182%2Fblood-2013-03-491506&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2013-03-491506%26sid%3Dliteratum%253Aachs%26aulast%3DSutherland%26aufirst%3DM.%2BS.%2BK.%26aulast%3DWalter%26aufirst%3DR.%2BB.%26aulast%3DJeffrey%26aufirst%3DS.%2BC.%26aulast%3DBurke%26aufirst%3DP.%2BJ.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DKostner%26aufirst%3DH.%26aulast%3DStone%26aufirst%3DI.%26aulast%3DRyan%26aufirst%3DM.%2BC.%26aulast%3DSussman%26aufirst%3DD.%26aulast%3DLyon%26aufirst%3DR.%2BP.%26aulast%3DZeng%26aufirst%3DW.%26aulast%3DHarrington%26aufirst%3DK.%2BH.%26aulast%3DKlussman%26aufirst%3DK.%26aulast%3DWestendorf%26aufirst%3DL.%26aulast%3DMeyer%26aufirst%3DD.%26aulast%3DBernstein%26aufirst%3DI.%2BD.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26aulast%3DBenjamin%26aufirst%3DD.%2BR.%26aulast%3DDrachman%26aufirst%3DJ.%2BG.%26aulast%3DMcEarchern%26aufirst%3DJ.%2BA.%26atitle%3DSGN-CD33A%253A%2520a%2520novel%2520CD33-targeting%2520antibody%25E2%2580%2593drug%2520conjugate%2520using%2520a%2520pyrrolobenzodiazepine%2520dimer%2520is%2520active%2520in%2520models%2520of%2520drug-resistant%2520AML%26jtitle%3DBlood%26date%3D2013%26volume%3D122%26spage%3D1455%26epage%3D1463%26doi%3D10.1182%2Fblood-2013-03-491506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caimi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahl, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamadani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlo-Stella, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ungar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feingold, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ardeshna, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radford, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heffner, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, O. A.</span></span> <span> </span><span class="NLM_article-title">Safety and efficacy of ADCT-402 (loncastuximab tesirine), a novel antibody drug conjugate, in relapsed/refractory follicular lymphoma and mantle cell lymphoma: Interim results from the phase 1 first-in-human study</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>132</i></span> (<span class="NLM_issue">Suppl 1</span>),  <span class="NLM_fpage">2874</span>, <span class="refDoi"> DOI: 10.1182/blood-2018-99-118133</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1182%2Fblood-2018-99-118133" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2018&pages=2874&issue=Suppl+1&author=P.+Caimiauthor=B.+S.+Kahlauthor=M.+Hamadaniauthor=C.+Carlo-Stellaauthor=S.+Heauthor=D.+Ungarauthor=J.+Feingoldauthor=K.+M.+Ardeshnaauthor=J.+Radfordauthor=M.+Solhauthor=L.+Heffnerauthor=O.+A.+O%E2%80%99Connor&title=Safety+and+efficacy+of+ADCT-402+%28loncastuximab+tesirine%29%2C+a+novel+antibody+drug+conjugate%2C+in+relapsed%2Frefractory+follicular+lymphoma+and+mantle+cell+lymphoma%3A+Interim+results+from+the+phase+1+first-in-human+study&doi=10.1182%2Fblood-2018-99-118133"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1182%2Fblood-2018-99-118133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2018-99-118133%26sid%3Dliteratum%253Aachs%26aulast%3DCaimi%26aufirst%3DP.%26aulast%3DKahl%26aufirst%3DB.%2BS.%26aulast%3DHamadani%26aufirst%3DM.%26aulast%3DCarlo-Stella%26aufirst%3DC.%26aulast%3DHe%26aufirst%3DS.%26aulast%3DUngar%26aufirst%3DD.%26aulast%3DFeingold%26aufirst%3DJ.%26aulast%3DArdeshna%26aufirst%3DK.%2BM.%26aulast%3DRadford%26aufirst%3DJ.%26aulast%3DSolh%26aufirst%3DM.%26aulast%3DHeffner%26aufirst%3DL.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DO.%2BA.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520ADCT-402%2520%2528loncastuximab%2520tesirine%2529%252C%2520a%2520novel%2520antibody%2520drug%2520conjugate%252C%2520in%2520relapsed%252Frefractory%2520follicular%2520lymphoma%2520and%2520mantle%2520cell%2520lymphoma%253A%2520Interim%2520results%2520from%2520the%2520phase%25201%2520first-in-human%2520study%26jtitle%3DBlood%26date%3D2018%26volume%3D132%26issue%3DSuppl%25201%26spage%3D2874%26doi%3D10.1182%2Fblood-2018-99-118133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Zammarchi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Havenith, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chivers, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogg, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Britten, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dissanayake, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyrer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchinson, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masterson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartley, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Berkel, P. H.</span></span> <span> </span><span class="NLM_article-title">Preclinical activity of ADCT-601, a novel pyrrolobenzodiazepine (PBD) dimer-based antibody–drug conjugate (ADC) targeting AXL-expressing tumors</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span> (<span class="NLM_issue">13 Suppl</span>),  <span class="NLM_fpage">2792A</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2018-2792A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1158%2F1538-7445.AM2018-2792A" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=2792A&issue=13+Suppl&author=F.+Zammarchiauthor=K.+Havenithauthor=S.+Chiversauthor=P.+W.+Hoggauthor=C.+Brittenauthor=S.+Dissanayakeauthor=P.+Tyrerauthor=F.+Bertelliauthor=I.+Hutchinsonauthor=L.+Mastersonauthor=P.+Howardauthor=J.+A.+Hartleyauthor=P.+H.+van+Berkel&title=Preclinical+activity+of+ADCT-601%2C+a+novel+pyrrolobenzodiazepine+%28PBD%29+dimer-based+antibody%E2%80%93drug+conjugate+%28ADC%29+targeting+AXL-expressing+tumors&doi=10.1158%2F1538-7445.AM2018-2792A"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2018-2792A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2018-2792A%26sid%3Dliteratum%253Aachs%26aulast%3DZammarchi%26aufirst%3DF.%26aulast%3DHavenith%26aufirst%3DK.%26aulast%3DChivers%26aufirst%3DS.%26aulast%3DHogg%26aufirst%3DP.%2BW.%26aulast%3DBritten%26aufirst%3DC.%26aulast%3DDissanayake%26aufirst%3DS.%26aulast%3DTyrer%26aufirst%3DP.%26aulast%3DBertelli%26aufirst%3DF.%26aulast%3DHutchinson%26aufirst%3DI.%26aulast%3DMasterson%26aufirst%3DL.%26aulast%3DHoward%26aufirst%3DP.%26aulast%3DHartley%26aufirst%3DJ.%2BA.%26aulast%3Dvan%2BBerkel%26aufirst%3DP.%2BH.%26atitle%3DPreclinical%2520activity%2520of%2520ADCT-601%252C%2520a%2520novel%2520pyrrolobenzodiazepine%2520%2528PBD%2529%2520dimer-based%2520antibody%25E2%2580%2593drug%2520conjugate%2520%2528ADC%2529%2520targeting%2520AXL-expressing%2520tumors%26jtitle%3DCancer%2520Res.%26date%3D2018%26volume%3D78%26issue%3D13%2520Suppl%26spage%3D2792A%26doi%3D10.1158%2F1538-7445.AM2018-2792A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit7b"><span><span class="NLM_label">(b) </span> ADC Therapeutics
press release, January 16, 2019. <a href="https://www.globenewswire.com/news-release/2019/01/16/1696491/0/en/ADC-Therapeutics-Announces-First-Patient-Dosed-in-Phase-I-Clinical-Trial-of-ADCT-601-in-Advanced-Solid-Tumors.html" class="extLink">https://www.globenewswire.com/news-release/2019/01/16/1696491/0/en/ADC-Therapeutics-Announces-First-Patient-Dosed-in-Phase-I-Clinical-Trial-of-ADCT-601-in-Advanced-Solid-Tumors.html</a> (accessed July 7, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+ADC+Therapeutics%0Apress+release%2C+January+16%2C+2019.+https%3A%2F%2Fwww.globenewswire.com%2Fnews-release%2F2019%2F01%2F16%2F1696491%2F0%2Fen%2FADC-Therapeutics-Announces-First-Patient-Dosed-in-Phase-I-Clinical-Trial-of-ADCT-601-in-Advanced-Solid-Tumors.html+%28accessed+July+7%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kinneer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meekin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varkey, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurt, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flynn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hynes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezabeh, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wetzel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tai, Y.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbst, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tice, D.</span></span> <span> </span><span class="NLM_article-title">Preclinical evaluation of MEDI2228, a BCMA-targeting pyrrolobenzodiazepine-linked antibody drug conjugate for the treatment of multiple myeloma</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>130</i></span> (<span class="NLM_issue">Suppl 1</span>),  <span class="NLM_fpage">3153</span>, <span class="refDoi"> DOI: 10.1038/s41375-018-0278-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1038%2Fs41375-018-0278-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2019&pages=3153&issue=Suppl+1&author=K.+Kinneerauthor=J.+Meekinauthor=R.+Varkeyauthor=X.+Xiaoauthor=H.+Zhongauthor=S.+Breenauthor=E.+Hurtauthor=S.+Thomasauthor=M.+Flynnauthor=P.+Hynesauthor=B.+Bezabehauthor=C.+Chenauthor=L.+Wetzelauthor=R.+Chenauthor=Y.-T.+Taiauthor=K.+C.+Andersonauthor=R.+Herbstauthor=D.+Tice&title=Preclinical+evaluation+of+MEDI2228%2C+a+BCMA-targeting+pyrrolobenzodiazepine-linked+antibody+drug+conjugate+for+the+treatment+of+multiple+myeloma&doi=10.1038%2Fs41375-018-0278-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.1038%2Fs41375-018-0278-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41375-018-0278-7%26sid%3Dliteratum%253Aachs%26aulast%3DKinneer%26aufirst%3DK.%26aulast%3DMeekin%26aufirst%3DJ.%26aulast%3DVarkey%26aufirst%3DR.%26aulast%3DXiao%26aufirst%3DX.%26aulast%3DZhong%26aufirst%3DH.%26aulast%3DBreen%26aufirst%3DS.%26aulast%3DHurt%26aufirst%3DE.%26aulast%3DThomas%26aufirst%3DS.%26aulast%3DFlynn%26aufirst%3DM.%26aulast%3DHynes%26aufirst%3DP.%26aulast%3DBezabeh%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DWetzel%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DR.%26aulast%3DTai%26aufirst%3DY.-T.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26aulast%3DHerbst%26aufirst%3DR.%26aulast%3DTice%26aufirst%3DD.%26atitle%3DPreclinical%2520evaluation%2520of%2520MEDI2228%252C%2520a%2520BCMA-targeting%2520pyrrolobenzodiazepine-linked%2520antibody%2520drug%2520conjugate%2520for%2520the%2520treatment%2520of%2520multiple%2520myeloma%26jtitle%3DLeukemia%26date%3D2019%26volume%3D130%26issue%3DSuppl%25201%26spage%3D3153%26doi%3D10.1038%2Fs41375-018-0278-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit8b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group">ClinicalTrials.gov</span>, NCT03489525. <a href="https://clinicaltrials.gov/ct2/show/NCT03489525" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03489525</a> (accessed July 7, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+ClinicalTrials.gov%2C+NCT03489525.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03489525+%28accessed+July+7%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Flynn, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zammarchi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyrer, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akarca, A. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janghra, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Britten, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Havenith, C. E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, J.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiberghien, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masterson, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Hooge, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marafioti, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parren, P. W. H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Berkel, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartley, J. A.</span></span> <span> </span><span class="NLM_article-title">ADCT-301, a pyrrolobenzodiazepine (PBD) dimer-containing antibody–drug conjugate (ADC) Targeting CD25-expressing hematological malignancies</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">2709</span>– <span class="NLM_lpage">2721</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-16-0233</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1158%2F1535-7163.MCT-16-0233" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=27535974" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BC2sXovVOqsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=2709-2721&author=M.+J.+Flynnauthor=F.+Zammarchiauthor=P.+C.+Tyrerauthor=A.+U.+Akarcaauthor=N.+Janghraauthor=C.+E.+Brittenauthor=C.+E.+G.+Havenithauthor=J.-N.+Levyauthor=A.+Tiberghienauthor=L.+A.+Mastersonauthor=C.+Barryauthor=F.+D%E2%80%99Hoogeauthor=T.+Marafiotiauthor=P.+W.+H.+I.+Parrenauthor=D.+G.+Williamsauthor=P.+W.+Howardauthor=P.+H.+van+Berkelauthor=J.+A.+Hartley&title=ADCT-301%2C+a+pyrrolobenzodiazepine+%28PBD%29+dimer-containing+antibody%E2%80%93drug+conjugate+%28ADC%29+Targeting+CD25-expressing+hematological+malignancies&doi=10.1158%2F1535-7163.MCT-16-0233"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9aR"><div class="casContent"><span class="casTitleNuber">9a</span><div class="casTitle"><span class="NLM_cas:atitle">ADCT-301, a pyrrolobenzodiazepine (PBD) dimer-containing antibody-drug conjugate (ADC) targeting CD25-expressing hematological malignancies</span></div><div class="casAuthors">Flynn, Michael J.; Zammarchi, Francesca; Tyrer, Peter C.; Akarca, Ayse U.; Janghra, Narinder; Britten, Charles E.; Havenith, Carin E. G.; Levy, Jean-Noel; Tiberghien, Arnaud; Masterson, Luke A.; Barry, Conor; D'Hooge, Francois; Marafioti, Teresa; Parren, Paul W. H. I.; Williams, David G.; Howard, Philip W.; van Berkel, Patrick H.; Hartley, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2709-2721</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Despite the many advances in the treatment of hematol. malignancies over the past decade, outcomes in refractory lymphomas remain poor.  One potential strategy in this patient population is the specific targeting of IL2R-α (CD25), which is overexpressed on many lymphoma and leukemic cells, using antibody-drug conjugates (ADC).  ADCT-301 is an ADC composed of human IgG1 HuMax-TAC against CD25, stochastically conjugated through a dipeptide cleavable linker to a pyrrolobenzodiazepine (PBD) dimer warhead with a drug-antibody ratio (DAR) of 2.3.  ADCT-301 binds human CD25 with picomolar affinity.  ADCT-301 has highly potent and selective cytotoxicity against a panel of CD25-expressing human lymphoma cell lines.  Once internalized, the released warhead binds in the DNA minor groove and exerts its potent cytotoxic action via the formation of DNA interstrand cross-links.  A strong correlation between loss of viability and DNA cross-link formation is demonstrated.  DNA damage persists, resulting in phosphorylation of histone H2AX, cell-cycle arrest in G2-M, and apoptosis Bystander killing of CD25-neg. cells by ADCT-301 is also obsd.  In vivo, a single dose of ADCT-301 results in dose-dependent and targeted antitumor activity against both s.c. and disseminated CD25-pos. lymphoma models.  In xenografts of Karpas 299, which expressed both CD25 and CD30, marked superiority over brentuximab vedotin (Adcetris) is obsd.  Dose-dependent increases in DNA crosslinking, γ-H2AX, and PBD payload staining were obsd. in tumors in vivo indicating a role as relevant pharmacodynamic assays.  Together, these data support the clin. testing of this novel ADC in patients with CD25-expressing tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOYRWJCTYK9rVg90H21EOLACvtfcHk0lifS56LYACgag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXovVOqsro%253D&md5=f43190787d13ef897602016b3a607bc3</span></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-16-0233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-16-0233%26sid%3Dliteratum%253Aachs%26aulast%3DFlynn%26aufirst%3DM.%2BJ.%26aulast%3DZammarchi%26aufirst%3DF.%26aulast%3DTyrer%26aufirst%3DP.%2BC.%26aulast%3DAkarca%26aufirst%3DA.%2BU.%26aulast%3DJanghra%26aufirst%3DN.%26aulast%3DBritten%26aufirst%3DC.%2BE.%26aulast%3DHavenith%26aufirst%3DC.%2BE.%2BG.%26aulast%3DLevy%26aufirst%3DJ.-N.%26aulast%3DTiberghien%26aufirst%3DA.%26aulast%3DMasterson%26aufirst%3DL.%2BA.%26aulast%3DBarry%26aufirst%3DC.%26aulast%3DD%25E2%2580%2599Hooge%26aufirst%3DF.%26aulast%3DMarafioti%26aufirst%3DT.%26aulast%3DParren%26aufirst%3DP.%2BW.%2BH.%2BI.%26aulast%3DWilliams%26aufirst%3DD.%2BG.%26aulast%3DHoward%26aufirst%3DP.%2BW.%26aulast%3Dvan%2BBerkel%26aufirst%3DP.%2BH.%26aulast%3DHartley%26aufirst%3DJ.%2BA.%26atitle%3DADCT-301%252C%2520a%2520pyrrolobenzodiazepine%2520%2528PBD%2529%2520dimer-containing%2520antibody%25E2%2580%2593drug%2520conjugate%2520%2528ADC%2529%2520Targeting%2520CD25-expressing%2520hematological%2520malignancies%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26volume%3D15%26spage%3D2709%26epage%3D2721%26doi%3D10.1158%2F1535-7163.MCT-16-0233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit9b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hamadani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samaniego, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spira, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radford, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caimi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menne, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boni, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feingold, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wuerthner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horwitz, S. M.</span></span> <span> </span><span class="NLM_article-title">Phase 1 study of ADCT-301 (camidanlumab tesirine), a novel pyrrolobenzodiazepine-based antibody drug conjugate, in relapsed/refractory classical Hodgkin lymphoma</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>132</i></span> (<span class="NLM_issue">Suppl 1</span>),  <span class="NLM_fpage">928</span>, <span class="refDoi"> DOI: 10.1182/blood-2018-99-118198</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1182%2Fblood-2018-99-118198" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2018&pages=928&issue=Suppl+1&author=M.+Hamadaniauthor=G.+P.+Collinsauthor=F.+Samaniegoauthor=A.+I.+Spiraauthor=A.+Daviesauthor=J.+Radfordauthor=P.+Caimiauthor=T.+Menneauthor=J.+Boniauthor=H.+Cruzauthor=J.+Feingoldauthor=S.+Heauthor=J.+Wuerthnerauthor=S.+M.+Horwitz&title=Phase+1+study+of+ADCT-301+%28camidanlumab+tesirine%29%2C+a+novel+pyrrolobenzodiazepine-based+antibody+drug+conjugate%2C+in+relapsed%2Frefractory+classical+Hodgkin+lymphoma&doi=10.1182%2Fblood-2018-99-118198"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1182%2Fblood-2018-99-118198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2018-99-118198%26sid%3Dliteratum%253Aachs%26aulast%3DHamadani%26aufirst%3DM.%26aulast%3DCollins%26aufirst%3DG.%2BP.%26aulast%3DSamaniego%26aufirst%3DF.%26aulast%3DSpira%26aufirst%3DA.%2BI.%26aulast%3DDavies%26aufirst%3DA.%26aulast%3DRadford%26aufirst%3DJ.%26aulast%3DCaimi%26aufirst%3DP.%26aulast%3DMenne%26aufirst%3DT.%26aulast%3DBoni%26aufirst%3DJ.%26aulast%3DCruz%26aufirst%3DH.%26aulast%3DFeingold%26aufirst%3DJ.%26aulast%3DHe%26aufirst%3DS.%26aulast%3DWuerthner%26aufirst%3DJ.%26aulast%3DHorwitz%26aufirst%3DS.%2BM.%26atitle%3DPhase%25201%2520study%2520of%2520ADCT-301%2520%2528camidanlumab%2520tesirine%2529%252C%2520a%2520novel%2520pyrrolobenzodiazepine-based%2520antibody%2520drug%2520conjugate%252C%2520in%2520relapsed%252Frefractory%2520classical%2520Hodgkin%2520lymphoma%26jtitle%3DBlood%26date%3D2018%26volume%3D132%26issue%3DSuppl%25201%26spage%3D928%26doi%3D10.1182%2Fblood-2018-99-118198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Abbvie
press release</span>, August 29, 2019. <a href="https://news.abbvie.com/news/press-releases/abbvie-discontinues-rovalpituzumab-tesirine-rova-t-research-and-development-program.htm" class="extLink">https://news.abbvie.com/news/press-releases/abbvie-discontinues-rovalpituzumab-tesirine-rova-t-research-and-development-program.htm</a> (accessed July 7, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Abbvie%0Apress+release%2C+August+29%2C+2019.+https%3A%2F%2Fnews.abbvie.com%2Fnews%2Fpress-releases%2Fabbvie-discontinues-rovalpituzumab-tesirine-rova-t-research-and-development-program.htm+%28accessed+July+7%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3D%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Seattle
Genetics press release</span>, June 19, 2017. <a href="https://investor.seattlegenetics.com/press-releases/news-details/2017/Seattle-Genetics-Discontinues-Phase-3-CASCADE-Trial-of-Vadastuximab-Talirine-SGN-CD33A-in-Frontline-Acute-Myeloid-Leukemia/default.aspx" class="extLink">https://investor.seattlegenetics.com/press-releases/news-details/2017/Seattle-Genetics-Discontinues-Phase-3-CASCADE-Trial-of-Vadastuximab-Talirine-SGN-CD33A-in-Frontline-Acute-Myeloid-Leukemia/default.aspx</a> (accessed July 7, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Seattle%0AGenetics+press+release%2C+June+19%2C+2017.+https%3A%2F%2Finvestor.seattlegenetics.com%2Fpress-releases%2Fnews-details%2F2017%2FSeattle-Genetics-Discontinues-Phase-3-CASCADE-Trial-of-Vadastuximab-Talirine-SGN-CD33A-in-Frontline-Acute-Myeloid-Leukemia%2Fdefault.aspx+%28accessed+July+7%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3D%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Doronina, S. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendelsohn, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bovee, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerveny, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alley, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oflazoglu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toki, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanderson, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zabinski, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wahl, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senter, P. D.</span></span> <span> </span><span class="NLM_article-title">Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: Effects of linker technology on efficacy and toxicity</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">114</span>– <span class="NLM_lpage">124</span>, <span class="refDoi"> DOI: 10.1021/bc0502917</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc0502917" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlars7%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2006&pages=114-124&author=S.+O.+Doroninaauthor=B.+A.+Mendelsohnauthor=T.+D.+Boveeauthor=C.+G.+Cervenyauthor=S.+C.+Alleyauthor=D.+L.+Meyerauthor=E.+Oflazogluauthor=B.+E.+Tokiauthor=R.+J.+Sandersonauthor=R.+F.+Zabinskiauthor=A.+F.+Wahlauthor=P.+D.+Senter&title=Enhanced+activity+of+monomethylauristatin+F+through+monoclonal+antibody+delivery%3A+Effects+of+linker+technology+on+efficacy+and+toxicity&doi=10.1021%2Fbc0502917"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12aR"><div class="casContent"><span class="casTitleNuber">12a</span><div class="casTitle"><span class="NLM_cas:atitle">Enhanced Activity of Monomethylauristatin F through Monoclonal Antibody Delivery: Effects of Linker Technology on Efficacy and Toxicity</span></div><div class="casAuthors">Doronina, Svetlana O.; Mendelsohn, Brian A.; Bovee, Tim D.; Cerveny, Charles G.; Alley, Stephen C.; Meyer, Damon L.; Oflazoglu, Ezogelin; Toki, Brian E.; Sanderson, Russell J.; Zabinski, Roger F.; Wahl, Alan F.; Senter, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">114-124</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We have previously shown that antibody-drug conjugates (ADCs) consisting of cAC10 (anti-CD30) linked to the antimitotic agent monomethylauristatin E (MMAE) lead to potent in vitro and in vivo activities against antigen pos. tumor models.  MMAF is a new antimitotic auristatin deriv. with a charged C-terminal phenylalanine residue that attenuates its cytotoxic activity compared to its uncharged counterpart, MMAE, most likely due to impaired intracellular access.  In vitro cytotoxicity studies indicated that mAb-maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl-MMAF (mAb-L1-MMAF) conjugates were >2200-fold more potent than free MMAF on a large panel of CD30 pos. hematol. cell lines.  As with cAC10-L1-MMAE, the corresponding MMAF ADC induced cures and regressions of established xenograft tumors at well tolerated doses.  To further optimize the ADC, several new linkers were generated in which various components within the L1 linker were either altered or deleted.  One of the most promising linkers contained a noncleavable maleimidocaproyl (L4) spacer between the drug and the mAb.  CAC10-L4-MMAF was approx. as potent in vitro as cAC10-L1-MMAF against a large panel of cell lines and was equally potent in vivo.  Importantly, cAC10-L4-MMAF was tolerated at >3 times the MTD of cAC10-L1-MMAF.  LCMS studies indicated that drug released from cAC10-L4-MMAF was the cysteine-L4-MMAF adduct, which likely arises from mAb degrdn. within the lysosomes of target cells.  This new linker technol. appears to be ideally suited for drugs that are both relatively cell-impermeable and tolerant of substitution with amino acids.  Thus, alterations of the linker have pronounced impacts on toxicity and lead to new ADCs with greatly improved therapeutic indexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfwQJyn8sp0LVg90H21EOLACvtfcHk0lhT_fdEVuM5pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlars7%252FL&md5=92da0266f0a83c7680006ef94956c879</span></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=10.1021%2Fbc0502917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc0502917%26sid%3Dliteratum%253Aachs%26aulast%3DDoronina%26aufirst%3DS.%2BO.%26aulast%3DMendelsohn%26aufirst%3DB.%2BA.%26aulast%3DBovee%26aufirst%3DT.%2BD.%26aulast%3DCerveny%26aufirst%3DC.%2BG.%26aulast%3DAlley%26aufirst%3DS.%2BC.%26aulast%3DMeyer%26aufirst%3DD.%2BL.%26aulast%3DOflazoglu%26aufirst%3DE.%26aulast%3DToki%26aufirst%3DB.%2BE.%26aulast%3DSanderson%26aufirst%3DR.%2BJ.%26aulast%3DZabinski%26aufirst%3DR.%2BF.%26aulast%3DWahl%26aufirst%3DA.%2BF.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26atitle%3DEnhanced%2520activity%2520of%2520monomethylauristatin%2520F%2520through%2520monoclonal%2520antibody%2520delivery%253A%2520Effects%2520of%2520linker%2520technology%2520on%2520efficacy%2520and%2520toxicity%26jtitle%3DBioconjugate%2520Chem.%26date%3D2006%26volume%3D17%26spage%3D114%26epage%3D124%26doi%3D10.1021%2Fbc0502917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit12b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Maderna, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leverett, C. A.</span></span> <span> </span><span class="NLM_article-title">Recent advances in the development of new auristatins: Structural modifications and application in antibody drug conjugates</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1798</span>– <span class="NLM_lpage">1812</span>, <span class="refDoi"> DOI: 10.1021/mp500762u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp500762u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtVaht7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=1798-1812&author=A.+Madernaauthor=C.+A.+Leverett&title=Recent+advances+in+the+development+of+new+auristatins%3A+Structural+modifications+and+application+in+antibody+drug+conjugates&doi=10.1021%2Fmp500762u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12bR"><div class="casContent"><span class="casTitleNuber">12b</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Advances in the Development of New Auristatins: Structural Modifications and Application in Antibody Drug Conjugates</span></div><div class="casAuthors">Maderna, Andreas; Leverett, Carolyn A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1798-1812</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review. Dolastatin 10 is a powerful antineoplastic agent and microtubule inhibitor that was discovered by Pettit et al. and published in 1987.  Since then, many research groups have engaged in SAR studies of synthetic analogs, termed "auristatins".  It was eventually discovered that auristatins are of great value as payloads in antibody drug conjugates (ADCs), which led to the FDA-approved ADC brentuximab vedotin (Seattle Genetics).  Currently, over 30 ADCs in clin. trials employ auristatins as payloads, and there is a great interest in the research community, both on academic and industrial sides, to further study these analogs.  This review will provide an overview of the recent advancements in auristatin development spanning a time frame of about the past ten years.  The main focus will be to describe structural changes made to the auristatin peptide and their resulting biol. activities in tumor cell proliferation assays.  Selected ADC examples will also be described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxfsjeci8BurVg90H21EOLACvtfcHk0lhT_fdEVuM5pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtVaht7o%253D&md5=6ad39fd9b6f8d0eff5be442037981c62</span></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=10.1021%2Fmp500762u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp500762u%26sid%3Dliteratum%253Aachs%26aulast%3DMaderna%26aufirst%3DA.%26aulast%3DLeverett%26aufirst%3DC.%2BA.%26atitle%3DRecent%2520advances%2520in%2520the%2520development%2520of%2520new%2520auristatins%253A%2520Structural%2520modifications%2520and%2520application%2520in%2520antibody%2520drug%2520conjugates%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2015%26volume%3D12%26spage%3D1798%26epage%3D1812%26doi%3D10.1021%2Fmp500762u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit12c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emmerton, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyamoto, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setter, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholas, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okeley, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyon, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benjamin, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Law, C.-L.</span></span> <span> </span><span class="NLM_article-title">Intracellular released payload influences potency and bystander-killing effects of antibody–drug conjugates in preclinical models</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">2710</span>– <span class="NLM_lpage">2719</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-15-1795</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1158%2F0008-5472.CAN-15-1795" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=26921341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BC28XntVers74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=2710-2719&author=F.+Liauthor=K.+K.+Emmertonauthor=M.+Jonasauthor=X.+Zhangauthor=J.+B.+Miyamotoauthor=J.+R.+Setterauthor=N.+D.+Nicholasauthor=N.+M.+Okeleyauthor=R.+P.+Lyonauthor=D.+R.+Benjaminauthor=C.-L.+Law&title=Intracellular+released+payload+influences+potency+and+bystander-killing+effects+of+antibody%E2%80%93drug+conjugates+in+preclinical+models&doi=10.1158%2F0008-5472.CAN-15-1795"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12cR"><div class="casContent"><span class="casTitleNuber">12c</span><div class="casTitle"><span class="NLM_cas:atitle">Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models</span></div><div class="casAuthors">Li, Fu; Emmerton, Kim K.; Jonas, Mechthild; Zhang, Xinqun; Miyamoto, Jamie B.; Setter, Jocelyn R.; Nicholas, Nicole D.; Okeley, Nicole M.; Lyon, Robert P.; Benjamin, Dennis R.; Law, Che-Leung</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2710-2719</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Antibody-drug conjugates (ADC) comprise targeting antibodies armed with potent small-mol. payloads.  ADCs demonstrate specific cell killing in clinic, but the basis of their antitumor activity is not fully understood.  In this study, we investigated the degree to which payload release predicts ADC activity in vitro and in vivo.  ADCs were generated to target different receptors on the anaplastic large cell lymphoma line L-82, but delivered the same cytotoxic payload (monomethyl auristatin E, MMAE), and we found that the intracellular concn. of released MMAE correlated with in vitro ADC-mediated cytotoxicity independent of target expression or drug:antibody ratios.  Intratumoral MMAE concns. consistently correlated with the extent of tumor growth inhibition in tumor xenograft models.  In addn., we developed a robust admixed tumor model consisting of CD30+ and CD30- cancer cells to study how heterogeneity of target antigen expression, a phenomenon often obsd. in cancer specimens, affects the treatment response.  CD30-targeting ADC delivering membrane permeable MMAE or pyrrolobenzodiazepine dimers demonstrated potent bystander killing of neighboring CD30- cells.  In contrast, a less membrane permeable payload, MMAF, failed to mediate bystander killing in vivo, suggesting local diffusion and distribution of released payloads represents a potential mechanism of ADC-mediated bystander killing.  Collectively, our findings establish that the biophys. properties and amt. of released payloads are chief factors detg. the overall ADC potency and bystander killing.  Cancer Res; 76(9); 2710-9. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoylCMD1xAFdLVg90H21EOLACvtfcHk0lhT_fdEVuM5pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntVers74%253D&md5=bb7e7c2e6b4ea6f92d522d6c086454d2</span></div><a href="/servlet/linkout?suffix=cit12c&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-15-1795&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-15-1795%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DF.%26aulast%3DEmmerton%26aufirst%3DK.%2BK.%26aulast%3DJonas%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DMiyamoto%26aufirst%3DJ.%2BB.%26aulast%3DSetter%26aufirst%3DJ.%2BR.%26aulast%3DNicholas%26aufirst%3DN.%2BD.%26aulast%3DOkeley%26aufirst%3DN.%2BM.%26aulast%3DLyon%26aufirst%3DR.%2BP.%26aulast%3DBenjamin%26aufirst%3DD.%2BR.%26aulast%3DLaw%26aufirst%3DC.-L.%26atitle%3DIntracellular%2520released%2520payload%2520influences%2520potency%2520and%2520bystander-killing%2520effects%2520of%2520antibody%25E2%2580%2593drug%2520conjugates%2520in%2520preclinical%2520models%26jtitle%3DCancer%2520Res.%26date%3D2016%26volume%3D76%26spage%3D2710%26epage%3D2719%26doi%3D10.1158%2F0008-5472.CAN-15-1795" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit12d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hingorani, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doan, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camargo, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aguilera, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pizzo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scanderbeg, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, E. E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowy, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Advani, S. J.</span></span> <span> </span><span class="NLM_article-title">Precision chemoradiotherapy for HER2 tumors using antibody conjugates of an auristatin derivative with reduced cell permeability</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">157</span>– <span class="NLM_lpage">167</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-18-1302</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1158%2F1535-7163.MCT-18-1302" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=31597712" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkvVOlt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2020&pages=157-167&author=D.+V.+Hingoraniauthor=M.+K.+Doanauthor=M.+F.+Camargoauthor=J.+Aguileraauthor=S.+M.+Songauthor=D.+Pizzoauthor=D.+J.+Scanderbegauthor=E.+E.+W.+Cohenauthor=A.+M.+Lowyauthor=S.+R.+Adamsauthor=S.+J.+Advani&title=Precision+chemoradiotherapy+for+HER2+tumors+using+antibody+conjugates+of+an+auristatin+derivative+with+reduced+cell+permeability&doi=10.1158%2F1535-7163.MCT-18-1302"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12dR"><div class="casContent"><span class="casTitleNuber">12d</span><div class="casTitle"><span class="NLM_cas:atitle">Precision chemoradiotherapy for HER2 tumors using antibody conjugates of an Auristatin derivative with reduced cell permeability</span></div><div class="casAuthors">Hingorani, Dina V.; Doan, Matthew K.; Camargo, Maria F.; Aguilera, Joseph; Song, Seung M.; Pizzo, Donald; Scanderbeg, Daniel J.; Cohen, Ezra E. W.; Lowy, Andrew M.; Adams, Stephen R.; Advani, Sunil J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">157-167</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The most successful therapeutic strategies for locally advanced cancers continue to combine decades-old classical radiosensitizing chemotherapies with radiotherapy.  Mol. targeted radiosensitizers offer the potential to improve the therapeutic ratio by increasing tumor-specific kill while minimizing drug delivery and toxicity to surrounding normal tissue.  Auristatins are a potent class of anti-tubulins that sensitize cells to ionizing radiation damage and are chem. amenable to antibody conjugation.  To achieve tumor-selective radiosensitization, we synthesized and tested anti-HER2 antibody-drug conjugates of two auristatin derivs. with ionizing radiation.  Monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF) were attached to the anti-HER2 antibodies trastuzumab and pertuzumab through a cleavable linker.  While MMAE is cell permeable, MMAF has limited cell permeability as free drug resulting in diminished cytotoxicity and radiosensitization.  However, when attached to trastuzumab or pertuzumab, MMAF was as efficacious as MMAE in blocking HER2-expressing tumor cells in G -M.  Moreover, MMAF anti-HER2 conjugates selectively killed and radiosensitized HER2-rich tumor cells.  Importantly, when conjugated to targeting antibody, MMAF had the advantage of decreased bystander and off-target effects compared with MMAE.  In murine xenograft models, MMAF anti-HER2 antibody conjugates had less drug accumulated in the normal tissue surrounding tumors compared with MMAE.  Therapeutically, systemically injected MMAF anti-HER2 conjugates combined with focal ionizing radiation increased tumor control and improved survival of mice with HER2-rich tumor xenografts.  In summary, our results demonstrate the potential of cell-impermeable radiosensitizing warheads to improve the therapeutic ratio of radiotherapy by leveraging antibody-drug conjugate technol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr40_zxT2Tip7Vg90H21EOLACvtfcHk0lgW9bSZtIVeQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkvVOlt7k%253D&md5=47f7c763a14a2f6ccb3fbfd71f17971b</span></div><a href="/servlet/linkout?suffix=cit12d&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-18-1302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-18-1302%26sid%3Dliteratum%253Aachs%26aulast%3DHingorani%26aufirst%3DD.%2BV.%26aulast%3DDoan%26aufirst%3DM.%2BK.%26aulast%3DCamargo%26aufirst%3DM.%2BF.%26aulast%3DAguilera%26aufirst%3DJ.%26aulast%3DSong%26aufirst%3DS.%2BM.%26aulast%3DPizzo%26aufirst%3DD.%26aulast%3DScanderbeg%26aufirst%3DD.%2BJ.%26aulast%3DCohen%26aufirst%3DE.%2BE.%2BW.%26aulast%3DLowy%26aufirst%3DA.%2BM.%26aulast%3DAdams%26aufirst%3DS.%2BR.%26aulast%3DAdvani%26aufirst%3DS.%2BJ.%26atitle%3DPrecision%2520chemoradiotherapy%2520for%2520HER2%2520tumors%2520using%2520antibody%2520conjugates%2520of%2520an%2520auristatin%2520derivative%2520with%2520reduced%2520cell%2520permeability%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2020%26volume%3D19%26spage%3D157%26epage%3D167%26doi%3D10.1158%2F1535-7163.MCT-18-1302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Widdison, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponte, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coccia, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanieri, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setiady, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skaletskaya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salomon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fishkin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maloney, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovtun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veale, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilhelm, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Audette, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costoplus, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chari, R. V. J.</span></span> <span> </span><span class="NLM_article-title">Development of anilino-maytansinoid ADCs that efficiently release cytotoxic metabolites in cancer cells and induce high levels of bystander killing</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">2261</span>– <span class="NLM_lpage">2278</span>, <span class="refDoi"> DOI: 10.1021/acs.bioconjchem.5b00430</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.bioconjchem.5b00430" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVyis7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2015&pages=2261-2278&author=W.+C.+Widdisonauthor=J.+F.+Ponteauthor=J.+A.+Cocciaauthor=L.+Lanieriauthor=Y.+Setiadyauthor=L.+Dongauthor=A.+Skaletskayaauthor=E.+E.+Hongauthor=R.+Wuauthor=Q.+Qiuauthor=R.+Singhauthor=P.+Salomonauthor=N.+Fishkinauthor=L.+Harrisauthor=E.+K.+Maloneyauthor=Y.+Kovtunauthor=K.+Vealeauthor=S.+D.+Wilhelmauthor=C.+A.+Audetteauthor=J.+A.+Costoplusauthor=R.+V.+J.+Chari&title=Development+of+anilino-maytansinoid+ADCs+that+efficiently+release+cytotoxic+metabolites+in+cancer+cells+and+induce+high+levels+of+bystander+killing&doi=10.1021%2Facs.bioconjchem.5b00430"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13a</span><div class="casTitle"><span class="NLM_cas:atitle">Development of anilino-maytansinoid ADCs that efficiently release cytotoxic metabolites in cancer cells and induce high levels of bystander killing</span></div><div class="casAuthors">Widdison, Wayne C.; Ponte, Jose F.; Coccia, Jennifer A.; Lanieri, Leanne; Setiady, Yulius; Dong, Ling; Skaletskaya, Anna; Hong, E. Erica; Wu, Rui; Qiu, Qifeng; Singh, Rajeeva; Salomon, Paulin; Fishkin, Nathan; Harris, Luke; Maloney, Erin K.; Kovtun, Yelena; Veale, Karen; Wilhelm, Sharon D.; Audette, Charlene A.; Costoplus, Juliet A.; Chari, Ravi V. J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2261-2278</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Antibody anilino maytansinoid conjugates (AaMCs) have been prepd. in which a maytansinoid bearing an aniline group was linked through the aniline amine to a dipeptide, which in turn was covalently attached to a desired monoclonal antibody.  Several such conjugates were prepd. utilizing different dipeptides in the linkage including Gly-Gly, L-Val-L-Cit, and all four stereoisomers of the Ala-Ala dipeptide.  The properties of AaMCs could be altered by the choice of dipeptide in the linker.  Each of the AaMCs, except the AaMC bearing a D-Ala-D-Ala peptide linker, displayed more bystander killing in vitro than maytansinoid ADCs that utilize disulfide linkers.  In mouse models, the anti-CanAg AaMC bearing a D-Ala-L-Ala dipeptide in the linker was shown to be more efficacious against heterogeneous HT-29 xenografts than maytansinoid ADCs that utilize disulfide linkers, while both types of the conjugates displayed similar tolerabilities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDe0CRN4quKLVg90H21EOLACvtfcHk0lgW9bSZtIVeQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVyis7rI&md5=b71d9ed21705a302f01c167ca662141a</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1021%2Facs.bioconjchem.5b00430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.bioconjchem.5b00430%26sid%3Dliteratum%253Aachs%26aulast%3DWiddison%26aufirst%3DW.%2BC.%26aulast%3DPonte%26aufirst%3DJ.%2BF.%26aulast%3DCoccia%26aufirst%3DJ.%2BA.%26aulast%3DLanieri%26aufirst%3DL.%26aulast%3DSetiady%26aufirst%3DY.%26aulast%3DDong%26aufirst%3DL.%26aulast%3DSkaletskaya%26aufirst%3DA.%26aulast%3DHong%26aufirst%3DE.%2BE.%26aulast%3DWu%26aufirst%3DR.%26aulast%3DQiu%26aufirst%3DQ.%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DSalomon%26aufirst%3DP.%26aulast%3DFishkin%26aufirst%3DN.%26aulast%3DHarris%26aufirst%3DL.%26aulast%3DMaloney%26aufirst%3DE.%2BK.%26aulast%3DKovtun%26aufirst%3DY.%26aulast%3DVeale%26aufirst%3DK.%26aulast%3DWilhelm%26aufirst%3DS.%2BD.%26aulast%3DAudette%26aufirst%3DC.%2BA.%26aulast%3DCostoplus%26aufirst%3DJ.%2BA.%26aulast%3DChari%26aufirst%3DR.%2BV.%2BJ.%26atitle%3DDevelopment%2520of%2520anilino-maytansinoid%2520ADCs%2520that%2520efficiently%2520release%2520cytotoxic%2520metabolites%2520in%2520cancer%2520cells%2520and%2520induce%2520high%2520levels%2520of%2520bystander%2520killing%26jtitle%3DBioconjugate%2520Chem.%26date%3D2015%26volume%3D26%26spage%3D2261%26epage%3D2278%26doi%3D10.1021%2Facs.bioconjchem.5b00430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit13b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Costoplus, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veale, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponte, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanieri, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setiady, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skaletskaya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartle, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salomon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maloney, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovtun, Y. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ab, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chari, R. V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widdison, W. C.</span></span> <span> </span><span class="NLM_article-title">Peptide-cleavable self-immolative maytansinoid antibody–drug conjugates designed to provide improved bystander killing</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1393</span>– <span class="NLM_lpage">1399</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00310</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00310" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVGgtLzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1393-1399&author=J.+A.+Costoplusauthor=K.+H.+Vealeauthor=Q.+Qiuauthor=J.+F.+Ponteauthor=L.+Lanieriauthor=Y.+Setiadyauthor=L.+Dongauthor=A.+Skaletskayaauthor=L.+M.+Bartleauthor=P.+Salomonauthor=R.+Wuauthor=E.+K.+Maloneyauthor=Y.+V.+Kovtunauthor=O.+Abauthor=K.+Laiauthor=R.+V.+J.+Chariauthor=W.+C.+Widdison&title=Peptide-cleavable+self-immolative+maytansinoid+antibody%E2%80%93drug+conjugates+designed+to+provide+improved+bystander+killing&doi=10.1021%2Facsmedchemlett.9b00310"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13b</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide-Cleavable Self-immolative Maytansinoid Antibody-Drug Conjugates Designed To Provide Improved Bystander Killing</span></div><div class="casAuthors">Costoplus, Juliet A.; Veale, Karen H.; Qiu, Qifeng; Ponte, Jose F.; Lanieri, Leanne; Setiady, Yulius; Dong, Ling; Skaletskaya, Anna; Bartle, Laura M.; Salomon, Paulin; Wu, Rui; Maloney, Erin K.; Kovtun, Yelena V.; Ab, Olga; Lai, Kate; Chari, Ravi V. J.; Widdison, Wayne C.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1393-1399</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new type of antibody-drug conjugate (ADC) has been prepd. that contains a sulfur-bearing maytansinoid attached to an antibody via a highly stable tripeptide linker.  Once internalized by cells, proteases in catabolic vesicles cleave the peptide of the ADC's linker causing self-immolation that releases a thiol-bearing metabolite, which is then S-methylated.  Conjugates were prepd. with peptide linkers contg. only alanyl residues, which were all L isomers or had a single D residue in one of the three positions.  A D-alanyl residue in the linker did not significantly impair a conjugate's cytotoxicity or bystander killing unless it was directly attached to the immolative moiety.  Increasing the no. of methylene units in the maytansinoid side chain of a conjugate did not typically affect an ADC's cytotoxicity to targeted cells but did increase bystander killing activity.  ADCs with the highest in vitro bystander killing were then evaluated in vivo in mice, where they displayed improved efficacy compared to previously described types of maytansinoid conjugates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVorbrpE2efbVg90H21EOLACvtfcHk0lib8wOXRXtl0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVGgtLzI&md5=5bbc21126af25e33a52971fbeef6be32</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00310%26sid%3Dliteratum%253Aachs%26aulast%3DCostoplus%26aufirst%3DJ.%2BA.%26aulast%3DVeale%26aufirst%3DK.%2BH.%26aulast%3DQiu%26aufirst%3DQ.%26aulast%3DPonte%26aufirst%3DJ.%2BF.%26aulast%3DLanieri%26aufirst%3DL.%26aulast%3DSetiady%26aufirst%3DY.%26aulast%3DDong%26aufirst%3DL.%26aulast%3DSkaletskaya%26aufirst%3DA.%26aulast%3DBartle%26aufirst%3DL.%2BM.%26aulast%3DSalomon%26aufirst%3DP.%26aulast%3DWu%26aufirst%3DR.%26aulast%3DMaloney%26aufirst%3DE.%2BK.%26aulast%3DKovtun%26aufirst%3DY.%2BV.%26aulast%3DAb%26aufirst%3DO.%26aulast%3DLai%26aufirst%3DK.%26aulast%3DChari%26aufirst%3DR.%2BV.%2BJ.%26aulast%3DWiddison%26aufirst%3DW.%2BC.%26atitle%3DPeptide-cleavable%2520self-immolative%2520maytansinoid%2520antibody%25E2%2580%2593drug%2520conjugates%2520designed%2520to%2520provide%2520improved%2520bystander%2520killing%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D1393%26epage%3D1399%26doi%3D10.1021%2Facsmedchemlett.9b00310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ogitani, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagihara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oitate, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naito, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agatsuma, T.</span></span> <span> </span><span class="NLM_article-title">Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody–drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity</span>. <i>Cancer Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">1039</span>– <span class="NLM_lpage">1046</span>, <span class="refDoi"> DOI: 10.1111/cas.12966</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1111%2Fcas.12966" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=27166974" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVahu7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2016&pages=1039-1046&author=Y.+Ogitaniauthor=K.+Hagiharaauthor=M.+Oitateauthor=H.+Naitoauthor=T.+Agatsuma&title=Bystander+killing+effect+of+DS-8201a%2C+a+novel+anti-human+epidermal+growth+factor+receptor+2+antibody%E2%80%93drug+conjugate%2C+in+tumors+with+human+epidermal+growth+factor+receptor+2+heterogeneity&doi=10.1111%2Fcas.12966"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity</span></div><div class="casAuthors">Ogitani, Yusuke; Hagihara, Katsunobu; Oitate, Masataka; Naito, Hiroyuki; Agatsuma, Toshinori</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1039-1046</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1349-7006</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Antibody-drug conjugates deliver anticancer agents selectively and efficiently to tumor tissue and have significant antitumor efficacy with a wide therapeutic window.  DS-8201a is a human epidermal growth factor receptor 2 (HER2)-targeting antibody-drug conjugate prepd. using a novel linker-payload system with a potent topoisomerase I inhibitor, exatecan deriv. (DX-8951 deriv., DXd).  It was effective against trastuzumab emtansine (T-DM1)-insensitive patient-derived xenograft models with both high and low HER2 expression.  In this study, the bystander killing effect of DS-8201a was evaluated and compared with that of T-DM1.  We confirmed that the payload of DS-8201a, DXd (1), was highly membrane-permeable whereas that of T-DM1, Lys-SMCC-DM1, had a low level of permeability.  Under a coculture condition of HER2-pos. KPL-4 cells and neg. MDA-MB-468 cells in vitro, DS-8201a killed both cells, whereas T-DM1 and an antibody-drug conjugate with a low permeable payload, anti-HER2-DXd (2), did not.  In vivo evaluation was carried out using mice inoculated with a mixt. of HER2-pos. NCI-N87 cells and HER2-neg. MDA-MB-468-Luc cells by using an in vivo imaging system.  In vivo, DS-8201a reduced the luciferase signal of the mice, indicating suppression of the MDA-MB-468-Luc population; however, T-DM1 and anti-HER2-DXd (2) did not.  Furthermore, it was confirmed that DS-8201a was not effective against MDA-MB-468-Luc tumors inoculated at the opposite side of the NCI-N87 tumor, suggesting that the bystander killing effect of DS-8201a is obsd. only in cells neighboring HER2-pos. cells, indicating low concern in terms of systemic toxicity.  These results indicated that DS-8201a has a potent bystander effect due to a highly membrane-permeable payload and is beneficial in treating tumors with HER2 heterogeneity that are unresponsive to T-DM1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroroEcCVHueLVg90H21EOLACvtfcHk0lib8wOXRXtl0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVahu7zO&md5=1e65fee32e1333a1c446aff844a7c67d</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1111%2Fcas.12966&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcas.12966%26sid%3Dliteratum%253Aachs%26aulast%3DOgitani%26aufirst%3DY.%26aulast%3DHagihara%26aufirst%3DK.%26aulast%3DOitate%26aufirst%3DM.%26aulast%3DNaito%26aufirst%3DH.%26aulast%3DAgatsuma%26aufirst%3DT.%26atitle%3DBystander%2520killing%2520effect%2520of%2520DS-8201a%252C%2520a%2520novel%2520anti-human%2520epidermal%2520growth%2520factor%2520receptor%25202%2520antibody%25E2%2580%2593drug%2520conjugate%252C%2520in%2520tumors%2520with%2520human%2520epidermal%2520growth%2520factor%2520receptor%25202%2520heterogeneity%26jtitle%3DCancer%2520Sci.%26date%3D2016%26volume%3D107%26spage%3D1039%26epage%3D1046%26doi%3D10.1111%2Fcas.12966" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="note"><p class="first last">For a related example that accomplishes indolinobenzodiazepine ADC payload modification via an attached linker, see:</p></div><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reid, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Archer, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shizuka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilhelm, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoder, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fishkin, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maloney, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salomon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ab, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sikka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chari, R. V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. L.</span></span> <span> </span><span class="NLM_article-title">Effect of linker stereochemistry on the activity of indolinobenzodiazepine containing antibody–drug conjugates (ADCs)</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1193</span>– <span class="NLM_lpage">1197</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00240</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00240" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlGjs7fP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1193-1197&author=E.+E.+Reidauthor=K.+E.+Archerauthor=M.+Shizukaauthor=A.+Wilhelmauthor=N.+C.+Yoderauthor=C.+Baiauthor=N.+E.+Fishkinauthor=L.+Harrisauthor=E.+K.+Maloneyauthor=P.+Salomonauthor=E.+Hongauthor=R.+Wuauthor=O.+Abauthor=S.+Jinauthor=K.+C.+Laiauthor=S.+Sikkaauthor=R.+V.+J.+Chariauthor=M.+L.+Miller&title=Effect+of+linker+stereochemistry+on+the+activity+of+indolinobenzodiazepine+containing+antibody%E2%80%93drug+conjugates+%28ADCs%29&doi=10.1021%2Facsmedchemlett.9b00240"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of Linker Stereochemistry on the Activity of Indolinobenzodiazepine Containing Antibody-Drug Conjugates (ADCs)</span></div><div class="casAuthors">Reid, Emily E.; Archer, Katie E.; Shizuka, Manami; Wilhelm, Alan; Yoder, Nicholas C.; Bai, Chen; Fishkin, Nathan E.; Harris, Luke; Maloney, Erin K.; Salomon, Paulin; Hong, Erica; Wu, Rui; Ab, Olga; Jin, Shan; Lai, Katharine C.; Sikka, Surina; Chari, Ravi V. J.; Miller, Michael L.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1193-1197</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Antibody-drug conjugates (ADCs) that incorporate potent indolinobenzodiazepine DNA alkylators as the payload component are currently undergoing clin. evaluation.  In one ADC design, the payload mols. are linked to the antibody through a peptidase-labile L-Ala-L-Ala linker.  In order to det. the role of amino acid stereochem. on antitumor activity and tolerability, we incorporated L- and D-alanyl groups in the dipeptide, synthesized all four diastereomers, and prepd. and tested the corresponding ADCs.  Results of our preclin. evaluation showed that the L-Ala-L-Ala configuration provided the ADC with the highest therapeutic index (antitumor activity vs toxicity).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5N94m19c_tLVg90H21EOLACvtfcHk0lib8wOXRXtl0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlGjs7fP&md5=72540be91ff42af39669c697c9b0f162</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00240&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00240%26sid%3Dliteratum%253Aachs%26aulast%3DReid%26aufirst%3DE.%2BE.%26aulast%3DArcher%26aufirst%3DK.%2BE.%26aulast%3DShizuka%26aufirst%3DM.%26aulast%3DWilhelm%26aufirst%3DA.%26aulast%3DYoder%26aufirst%3DN.%2BC.%26aulast%3DBai%26aufirst%3DC.%26aulast%3DFishkin%26aufirst%3DN.%2BE.%26aulast%3DHarris%26aufirst%3DL.%26aulast%3DMaloney%26aufirst%3DE.%2BK.%26aulast%3DSalomon%26aufirst%3DP.%26aulast%3DHong%26aufirst%3DE.%26aulast%3DWu%26aufirst%3DR.%26aulast%3DAb%26aufirst%3DO.%26aulast%3DJin%26aufirst%3DS.%26aulast%3DLai%26aufirst%3DK.%2BC.%26aulast%3DSikka%26aufirst%3DS.%26aulast%3DChari%26aufirst%3DR.%2BV.%2BJ.%26aulast%3DMiller%26aufirst%3DM.%2BL.%26atitle%3DEffect%2520of%2520linker%2520stereochemistry%2520on%2520the%2520activity%2520of%2520indolinobenzodiazepine%2520containing%2520antibody%25E2%2580%2593drug%2520conjugates%2520%2528ADCs%2529%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D1193%26epage%3D1197%26doi%3D10.1021%2Facsmedchemlett.9b00240" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Cailleau, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arora, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, G.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masterson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartley, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harper, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, P. W.</span></span> <span> </span><span class="NLM_article-title">Potentiation of PBD dimers by lipophilicity manipulation</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">741</span>– <span class="NLM_lpage">752</span>, <span class="refDoi"> DOI: 10.2174/1568026619666190401112517</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.2174%2F1568026619666190401112517" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=30931859" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVKksb%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=741-752&author=T.+Cailleauauthor=L.+R.+Adamsauthor=N.+Aroraauthor=G.-D.+Kangauthor=L.+Mastersonauthor=N.+Patelauthor=J.+A.+Hartleyauthor=S.+Maoauthor=J.+Harperauthor=P.+W.+Howard&title=Potentiation+of+PBD+dimers+by+lipophilicity+manipulation&doi=10.2174%2F1568026619666190401112517"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16aR"><div class="casContent"><span class="casTitleNuber">16a</span><div class="casTitle"><span class="NLM_cas:atitle">Potentiation of PBD Dimers by Lipophilicity Manipulation</span></div><div class="casAuthors">Cailleau, Thais; Adams, Lauren R.; Arora, Neha; Kang, Gyoung-Dong; Masterson, Luke; Patel, Neki; Hartley, John A.; Mao, Shenlan; Harper, Jay; Howard, Philip W.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">741-752</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Pyrrolobenzodiazepine (PBD) dimers are highly potent DNA crosslinking agents used as warheads in Antibody Drug Conjugates (ADCs) for cancer therapy.  We propose to investigate the correlation existing between the lipophilicity of those mols. and their activity (both in vitro and in vivo) as well as any effect obsd. during conjugation.  Reaction progress was monitored by Thin-Layer Chromatog. (TLC) using Merck Kieselgel 60 F254 silica gel, with a fluorescent indicator on aluminum plates.  Visualisation of TLC was achieved with UV light or iodine vapor unless otherwise stated.  Flash chromatog. was performed using Merck Kieselgel 60 F254 silica gel.  We have successfully designed and synthesized a novel PBD warhead (SG3312) with enhanced physicochem. properties.  The warhead also displayed increased potency in vitro.  After overcoming some epimerization issues, the synthesis of enantiomerically pure payload was achieved (SG3259) and fulfilled our criteria for a simplified and more efficient conjugation.  No addn. of propylene glycol was required, and high DAR and excellent monomeric purity were achieved.  The ADC (Herceptin-maia-SG3259) has been shown to release the active warhead (SG3312) upon exposure to Cathepsin B and demonstrated encouraging activity both in vitro and in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSrjP6i6JKr7Vg90H21EOLACvtfcHk0lics8tc-MAyEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVKksb%252FO&md5=eda97c8d8802c46b15b325c2ef2bbf33</span></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=10.2174%2F1568026619666190401112517&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026619666190401112517%26sid%3Dliteratum%253Aachs%26aulast%3DCailleau%26aufirst%3DT.%26aulast%3DAdams%26aufirst%3DL.%2BR.%26aulast%3DArora%26aufirst%3DN.%26aulast%3DKang%26aufirst%3DG.-D.%26aulast%3DMasterson%26aufirst%3DL.%26aulast%3DPatel%26aufirst%3DN.%26aulast%3DHartley%26aufirst%3DJ.%2BA.%26aulast%3DMao%26aufirst%3DS.%26aulast%3DHarper%26aufirst%3DJ.%26aulast%3DHoward%26aufirst%3DP.%2BW.%26atitle%3DPotentiation%2520of%2520PBD%2520dimers%2520by%2520lipophilicity%2520manipulation%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2019%26volume%3D19%26spage%3D741%26epage%3D752%26doi%3D10.2174%2F1568026619666190401112517" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit16b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kinneer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meekin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiberghien, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tai, Y.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phipps, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiefer, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rebelatto, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimasi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriarty, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadopoulos, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sridhar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregson, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wick, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masterson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbst, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tice, D. A.</span></span> <span> </span><span class="NLM_article-title">SLC46A3 as a potential predictive biomarker for antibody–drug conjugates bearing noncleavable linked maytansinoid and pyrrolobenzodiazepine warheads</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">6570</span>– <span class="NLM_lpage">6582</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-18-1300</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1158%2F1078-0432.CCR-18-1300" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=30131388" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1ait7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=6570-6582&author=K.+Kinneerauthor=J.+Meekinauthor=A.+C.+Tiberghienauthor=Y.-T.+Taiauthor=S.+Phippsauthor=C.+M.+Kieferauthor=M.+C.+Rebelattoauthor=N.+Dimasiauthor=A.+Moriartyauthor=K.+P.+Papadopoulosauthor=S.+Sridharauthor=S.+J.+Gregsonauthor=M.+J.+Wickauthor=L.+Mastersonauthor=K.+C.+Andersonauthor=R.+Herbstauthor=P.+W.+Howardauthor=D.+A.+Tice&title=SLC46A3+as+a+potential+predictive+biomarker+for+antibody%E2%80%93drug+conjugates+bearing+noncleavable+linked+maytansinoid+and+pyrrolobenzodiazepine+warheads&doi=10.1158%2F1078-0432.CCR-18-1300"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16bR"><div class="casContent"><span class="casTitleNuber">16b</span><div class="casTitle"><span class="NLM_cas:atitle">SLC46A3 as a potential predictive biomarker for antibody-drug conjugates bearing noncleavable linked maytansinoid and pyrrolobenzodiazepine warheads</span></div><div class="casAuthors">Kinneer, Krista; Meekin, John; Tiberghien, Arnaud C.; Tai, Yu-Tzu; Phipps, Sandrina; Kiefer, Christine Mione; Rebelatto, Marlon C.; Dimasi, Nazzareno; Moriarty, Alyssa; Papadopoulos, Kyriakos P.; Sridhar, Sriram; Gregson, Stephen J.; Wick, Michael J.; Masterson, Luke; Anderson, Kenneth C.; Herbst, Ronald; Howard, Philip W.; Tice, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6570-6582</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Antibody-drug conjugates (ADC) utilizing noncleavable linker drugs have been approved for clin. use, and several are in development targeting solid and hematol. malignancies including multiple myeloma.  Currently, there are no reliable biomarkers of activity for these ADCs other than presence of the targeted antigen.  We obsd. that certain cell lines are innately resistant to such ADCs, and sought to uncover the underlying mechanism of resistance.  Exptl. Design: The expression of 43 lysosomal membrane target genes was evaluated in cell lines resistant to ADCs bearing the noncleavable linker, pyrrolobenzodiazepine payload SG3376, in vitro.  The functional relevance of SLC46A3, a lysosomal transporter of noncleavable ADC catabolites whose expression uniquely correlated with SG3376 resistance, was assessed using EPHA2-, HER2-, and BCMA-targeted ADCs and isogenic cells overexpressing or genetically inactivated for SLC46A3.  SLC46A3 expression was also examd. in patient-derived xenograft and in vitro models of acquired T-DM1 resistance and multiple myeloma bone marrow samples by RT-PCR.  Results: Loss of SLC46A3 expression was found to be a mechanism of innate and acquired resistance to ADCs bearing DM1 and SG3376.  Sensitivity was restored in refractory lines upon introduction of SLC46A3, suggesting that expression of SLC46A3 may be more predictive of activity than target antigen levels alone.  Interrogation of primary multiple myeloma samples indicated a range of SLC46A3 expression, including samples with undetectable levels like multiple myeloma cell lines resistant to BCMA-targeting DM1 and SG3376 ADCs.  Conclusions: Our findings support SLC46A3 as a potential patient selection biomarker with immediate relevance to clin. trials involving these ADCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogMBCbYdUVXbVg90H21EOLACvtfcHk0lics8tc-MAyEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1ait7%252FI&md5=e3b5550bd7a96683d9f3ccac137eeb66</span></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-18-1300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-18-1300%26sid%3Dliteratum%253Aachs%26aulast%3DKinneer%26aufirst%3DK.%26aulast%3DMeekin%26aufirst%3DJ.%26aulast%3DTiberghien%26aufirst%3DA.%2BC.%26aulast%3DTai%26aufirst%3DY.-T.%26aulast%3DPhipps%26aufirst%3DS.%26aulast%3DKiefer%26aufirst%3DC.%2BM.%26aulast%3DRebelatto%26aufirst%3DM.%2BC.%26aulast%3DDimasi%26aufirst%3DN.%26aulast%3DMoriarty%26aufirst%3DA.%26aulast%3DPapadopoulos%26aufirst%3DK.%2BP.%26aulast%3DSridhar%26aufirst%3DS.%26aulast%3DGregson%26aufirst%3DS.%2BJ.%26aulast%3DWick%26aufirst%3DM.%2BJ.%26aulast%3DMasterson%26aufirst%3DL.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26aulast%3DHerbst%26aufirst%3DR.%26aulast%3DHoward%26aufirst%3DP.%2BW.%26aulast%3DTice%26aufirst%3DD.%2BA.%26atitle%3DSLC46A3%2520as%2520a%2520potential%2520predictive%2520biomarker%2520for%2520antibody%25E2%2580%2593drug%2520conjugates%2520bearing%2520noncleavable%2520linked%2520maytansinoid%2520and%2520pyrrolobenzodiazepine%2520warheads%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D24%26spage%3D6570%26epage%3D6582%26doi%3D10.1158%2F1078-0432.CCR-18-1300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Smellie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bose, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartley, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurston, D. E.</span></span> <span> </span><span class="NLM_article-title">Sequence-selective recognition of duplex DNA through covalent interstrand cross-linking: Kinetic and molecular modeling studies with pyrrolobenzodiazepine dimers</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">8232</span>– <span class="NLM_lpage">8239</span>, <span class="refDoi"> DOI: 10.1021/bi034313t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi034313t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BD3sXksF2kt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2003&pages=8232-8239&author=M.+Smellieauthor=D.+S.+Boseauthor=A.+S.+Thompsonauthor=T.+C.+Jenkinsauthor=J.+A.+Hartleyauthor=D.+E.+Thurston&title=Sequence-selective+recognition+of+duplex+DNA+through+covalent+interstrand+cross-linking%3A+Kinetic+and+molecular+modeling+studies+with+pyrrolobenzodiazepine+dimers&doi=10.1021%2Fbi034313t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17aR"><div class="casContent"><span class="casTitleNuber">17a</span><div class="casTitle"><span class="NLM_cas:atitle">Sequence-Selective Recognition of Duplex DNA through Covalent Interstrand Cross-Linking: Kinetic and Molecular Modeling Studies with Pyrrolobenzodiazepine Dimers</span></div><div class="casAuthors">Smellie, Melissa; Bose, Deravander S.; Thompson, Andrew S.; Jenkins, Terence C.; Hartley, John A.; Thurston, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">8232-8239</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Members of a homologous series of pyrrolo[2,1-c][1,4]benzodiazepine (PBD) dimers with C8-O-(CH2)n-O-C8' diether linkages (n = 3-6) have been studied for their ability to interact with oligonucleotide duplexes contg. potential target binding sites.  The results confirm earlier predictions that the n = 3 analog (DSB-120) will covalently bind to a 5'-Pu-GATC-Py sequence by crosslinking opposite-strand guanines sepd. by 2 bp.  Preference for this DNA sequence is shown using oligonucleotides with altered bases between and/or flanking these guanines.  The more extended PBD dimer (n = 5) can span an extra base pair and cross-link the 5'-Pu-GA(T/A)TC-Py sequence.  The ability of each homolog to cross-link linear plasmid DNA has been detd., with a rank order that correlates with the reported order of in vitro cytotoxicity: n = 3 > n = 5 > n = 6 > n = 4.  The n = 3 homolog is >300-fold more efficient at crosslinking DNA than the clin. used crosslinking agent melphalan under the same conditions.  Kinetic studies reveal that the n = 3 and 5 dimers achieve faster crosslinking to plasmid DNA (108 and 81% crosslinking h-1 μM-1 at 37°, resp.), whereas the n = 4 and 6 homologs are significantly less efficient at 10.3 and 23% crosslinking h-1 μM-1, resp.  Alternating activity for the odd n and even n dimers is probably due to configurational factors governed by the spatial sepn. of the PBD subunits and the flexible character of the tethering linkage.  Mol. modeling confirms the order of crosslinking reactivity, and highlights the role of linker length in dictating sequence recognition for this class of DNA-reactive agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZzUk-f-x3ebVg90H21EOLACvtfcHk0lics8tc-MAyEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXksF2kt78%253D&md5=ab688aab96a5be2bedb9e01933f80eed</span></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=10.1021%2Fbi034313t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi034313t%26sid%3Dliteratum%253Aachs%26aulast%3DSmellie%26aufirst%3DM.%26aulast%3DBose%26aufirst%3DD.%2BS.%26aulast%3DThompson%26aufirst%3DA.%2BS.%26aulast%3DJenkins%26aufirst%3DT.%2BC.%26aulast%3DHartley%26aufirst%3DJ.%2BA.%26aulast%3DThurston%26aufirst%3DD.%2BE.%26atitle%3DSequence-selective%2520recognition%2520of%2520duplex%2520DNA%2520through%2520covalent%2520interstrand%2520cross-linking%253A%2520Kinetic%2520and%2520molecular%2520modeling%2520studies%2520with%2520pyrrolobenzodiazepine%2520dimers%26jtitle%3DBiochemistry%26date%3D2003%26volume%3D42%26spage%3D8232%26epage%3D8239%26doi%3D10.1021%2Fbi034313t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit17b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Gregson, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gullick, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamaguchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corcoran, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartley, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guille, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurston, D. E.</span></span> <span> </span><span class="NLM_article-title">Linker length modulates DNA cross-linking reactivity and cytotoxic potency of C8/C8′ ether-linked C2-exo-unsaturated pyrrolo[2,1-c][1,4]benzodiazepine(PBD) dimers</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">1161</span>– <span class="NLM_lpage">1174</span>, <span class="refDoi"> DOI: 10.1021/jm030897l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030897l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnvFWhsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1161-1174&author=S.+J.+Gregsonauthor=P.+W.+Howardauthor=D.+R.+Gullickauthor=A.+Hamaguchiauthor=K.+E.+Corcoranauthor=N.+A.+Brooksauthor=J.+A.+Hartleyauthor=T.+C.+Jenkinsauthor=S.+Patelauthor=M.+J.+Guilleauthor=D.+E.+Thurston&title=Linker+length+modulates+DNA+cross-linking+reactivity+and+cytotoxic+potency+of+C8%2FC8%E2%80%B2+ether-linked+C2-exo-unsaturated+pyrrolo%5B2%2C1-c%5D%5B1%2C4%5Dbenzodiazepine%28PBD%29+dimers&doi=10.1021%2Fjm030897l"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17bR"><div class="casContent"><span class="casTitleNuber">17b</span><div class="casTitle"><span class="NLM_cas:atitle">Linker Length Modulates DNA Cross-Linking Reactivity and Cytotoxic Potency of C8/C8' Ether-Linked C2-exo-Unsaturated Pyrrolo[2,1-c][1,4]benzodiazepine (PBD) Dimers</span></div><div class="casAuthors">Gregson, Stephen J.; Howard, Philip W.; Gullick, Darren R.; Hamaguchi, Anzu; Corcoran, Kathryn E.; Brooks, Natalie A.; Hartley, John A.; Jenkins, Terence C.; Patel, Sejal; Guille, Matthew J.; Thurston, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1161-1174</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A C2/C2'-exo-unsatd. pyrrolo[2,1-c][1,4]benzodiazepine (PBD) dimer (DRG-16) with a C8-O(CH2)nO-C8' diether linkage (n = 5) has been synthesized that shows markedly superior in vitro cytotoxic potency (e.g., >3400-fold in IGROV1 ovarian cells) and interstrand DNA crosslinking reactivity (>10-fold) compared to the shorter homolog (SJG-136; n = 3).  In contrast, for the C-ring unsubstituted series, the corresponding n = 5 dimer is generally less cytotoxic and has a lower interstrand crosslinking reactivity compared to its shorter n = 3 homolog.  Dimer DRG-16 cross-links DNA with >10-fold efficiency compared to 4a, and also inhibits the activity of the restriction endonuclease BamH1 more efficiently.  The C2-exo-unsatd. PBD dimers 4a,b are not only more effective than their C-ring satd. counterparts in terms of induced ΔTm shift, but they also exert this effect more rapidly.  Mol. modeling shows a rank order of DRG-16 (n = 5) > SJG-136 (n = 3) in terms of binding energy toward duplexes contg. embedded target 5'-GAT1-2C cross-link sequences, reflecting the superior fit of the C2-exo-unsatd. rather than satd. C-rings of the PBD dimers.  A novel synthesis of core synthetic building blocks for PBD dimers via stepwise Mitsunobu reaction and nitration with Cu(NO3)2 is also reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrv_FYScSSSFLVg90H21EOLACvtfcHk0lhF5XD1KLWxEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnvFWhsQ%253D%253D&md5=ed9b4a4a43930d3316188bbd9e50401b</span></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=10.1021%2Fjm030897l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030897l%26sid%3Dliteratum%253Aachs%26aulast%3DGregson%26aufirst%3DS.%2BJ.%26aulast%3DHoward%26aufirst%3DP.%2BW.%26aulast%3DGullick%26aufirst%3DD.%2BR.%26aulast%3DHamaguchi%26aufirst%3DA.%26aulast%3DCorcoran%26aufirst%3DK.%2BE.%26aulast%3DBrooks%26aufirst%3DN.%2BA.%26aulast%3DHartley%26aufirst%3DJ.%2BA.%26aulast%3DJenkins%26aufirst%3DT.%2BC.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DGuille%26aufirst%3DM.%2BJ.%26aulast%3DThurston%26aufirst%3DD.%2BE.%26atitle%3DLinker%2520length%2520modulates%2520DNA%2520cross-linking%2520reactivity%2520and%2520cytotoxic%2520potency%2520of%2520C8%252FC8%25E2%2580%25B2%2520ether-linked%2520C2-exo-unsaturated%2520pyrrolo%255B2%252C1-c%255D%255B1%252C4%255Dbenzodiazepine%2528PBD%2529%2520dimers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D1161%26epage%3D1174%26doi%3D10.1021%2Fjm030897l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gregson, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masterson, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pillow, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, G.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raab, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, G. D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunzner-Toste, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safina, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darwish, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozak, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">dela Cruz-Chuh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flygare, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, P. W.</span></span> <span> </span><span class="NLM_article-title">Pyrrolobenzodiazepine dimer antibody–drug conjugates: Synthesis and evaluation of noncleavable drug-linkers</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">9490</span>– <span class="NLM_lpage">9507</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00736</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00736" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslOns7%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=9490-9507&author=S.+J.+Gregsonauthor=L.+A.+Mastersonauthor=B.+Weiauthor=T.+H.+Pillowauthor=S.+D.+Spencerauthor=G.-D.+Kangauthor=S.-F.+Yuauthor=H.+Raabauthor=J.+Lauauthor=G.+Liauthor=G.+D.+L.+Phillipsauthor=J.+Gunzner-Tosteauthor=B.+S.+Safinaauthor=R.+Ohriauthor=M.+Darwishauthor=K.+R.+Kozakauthor=J.+dela+Cruz-Chuhauthor=A.+Polsonauthor=J.+A.+Flygareauthor=P.+W.+Howard&title=Pyrrolobenzodiazepine+dimer+antibody%E2%80%93drug+conjugates%3A+Synthesis+and+evaluation+of+noncleavable+drug-linkers&doi=10.1021%2Facs.jmedchem.7b00736"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrrolobenzodiazepine Dimer Antibody-Drug Conjugates: Synthesis and Evaluation of Noncleavable Drug-Linkers</span></div><div class="casAuthors">Gregson, Stephen J.; Masterson, Luke A.; Wei, Binqing; Pillow, Thomas H.; Spencer, Susan D.; Kang, Gyoung-Dong; Yu, Shang-Fan; Raab, Helga; Lau, Jeffrey; Li, Guangmin; Lewis Phillips, Gail D.; Gunzner-Toste, Janet; Safina, Brian S.; Ohri, Rachana; Darwish, Martine; Kozak, Katherine R.; dela Cruz-Chuh, Josefa; Polson, Andrew; Flygare, John A.; Howard, Philip W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9490-9507</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Three rationally designed pyrrolobenzodiazepine (PBD) drug-linkers have been synthesized via intermediate, (11S,11'S,11aS,11'aS)-10,10'-bis(1,1-dimethylethyl) (11S,11aS,11'S,11a'S)-di-tert-Bu 8,8'-[(5-iodo-1,3-phenylene)bis(methyleneoxy)]bis[2,3,11,11a-tetrahydro-7-methoxy-2-methylene-5-oxo-11-[(tetrahydro-2H-pyran-2-yl)oxy]-1H-pyrrolo[2,1-c][1,4]benzodiazepine-10(5H)-carboxylate [1630094-65-3](19) for use in antibody-drug conjugates (ADCs).  They lack a cleavable trigger in the linker and consist of a maleimide for cysteine antibody conjugation, a hydrophilic spacer, and either an alkyne, triazole, or piperazine link to the PBD.  In vitro IC50 values were 11-48 ng/mL in HER2 3+ SK-BR-3 and KPL-4 (triazole conjugate, inactive) for the anti-HER2 ADCs (HER2 0 MCF7, all inactive) and 0.10-1.73 μg/mL (triazole conjugate, inactive) in CD22 3+ BJAB and WSU-DLCL2 for anti-CD22 ADCs (CD22 0 Jurkat, all inactive at low doses).  In vivo antitumor efficacy for the anti-HER2 ADCs in Founder 5 was obsd. with tumor stasis at 0.5-1 mg/kg, 1 mg/kg, and 3-6 mg/kg for three conjugates, resp.  Tumor stasis at 2 mg/kg was obsd. for anti-CD22 alkyne conjugate in WSU-DLCL2.  In summary, noncleavable PBD-ADCs exhibit potent activity, particularly in HER2 models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeLqWakvWPDLVg90H21EOLACvtfcHk0lhF5XD1KLWxEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslOns7%252FF&md5=99e06646a68d1395711428540c61884f</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00736%26sid%3Dliteratum%253Aachs%26aulast%3DGregson%26aufirst%3DS.%2BJ.%26aulast%3DMasterson%26aufirst%3DL.%2BA.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DPillow%26aufirst%3DT.%2BH.%26aulast%3DSpencer%26aufirst%3DS.%2BD.%26aulast%3DKang%26aufirst%3DG.-D.%26aulast%3DYu%26aufirst%3DS.-F.%26aulast%3DRaab%26aufirst%3DH.%26aulast%3DLau%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DPhillips%26aufirst%3DG.%2BD.%2BL.%26aulast%3DGunzner-Toste%26aufirst%3DJ.%26aulast%3DSafina%26aufirst%3DB.%2BS.%26aulast%3DOhri%26aufirst%3DR.%26aulast%3DDarwish%26aufirst%3DM.%26aulast%3DKozak%26aufirst%3DK.%2BR.%26aulast%3Ddela%2BCruz-Chuh%26aufirst%3DJ.%26aulast%3DPolson%26aufirst%3DA.%26aulast%3DFlygare%26aufirst%3DJ.%2BA.%26aulast%3DHoward%26aufirst%3DP.%2BW.%26atitle%3DPyrrolobenzodiazepine%2520dimer%2520antibody%25E2%2580%2593drug%2520conjugates%253A%2520Synthesis%2520and%2520evaluation%2520of%2520noncleavable%2520drug-linkers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D9490%26epage%3D9507%26doi%3D10.1021%2Facs.jmedchem.7b00736" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pillow, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruz-Chuh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozak, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadowsky, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, G. D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darwish, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hop, C. E. C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khojasteh, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dragovich, P. S.</span></span> <span> </span><span class="NLM_article-title">Linker immolation determines cell killing activity of disulfide-linked pyrrolobenzodiazepine antibody–drug conjugates</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">988</span>– <span class="NLM_lpage">993</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00233</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00233" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtl2rsrfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=988-993&author=D.+Zhangauthor=T.+H.+Pillowauthor=Y.+Maauthor=J.+Cruz-Chuhauthor=K.+R.+Kozakauthor=J.+D.+Sadowskyauthor=G.+D.+L.+Phillipsauthor=J.+Guoauthor=M.+Darwishauthor=P.+Fanauthor=J.+Chenauthor=C.+Heauthor=T.+Wangauthor=H.+Yaoauthor=Z.+Xuauthor=J.+Chenauthor=J.+Waiauthor=Z.+Peiauthor=C.+E.+C.+A.+Hopauthor=S.+C.+Khojastehauthor=P.+S.+Dragovich&title=Linker+immolation+determines+cell+killing+activity+of+disulfide-linked+pyrrolobenzodiazepine+antibody%E2%80%93drug+conjugates&doi=10.1021%2Facsmedchemlett.6b00233"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Linker Immolation Determines Cell Killing Activity of Disulfide-Linked Pyrrolobenzodiazepine Antibody-Drug Conjugates</span></div><div class="casAuthors">Zhang, Donglu; Pillow, Thomas H.; Ma, Yong; Cruz-Chuh, Josefa dela; Kozak, Katherine R.; Sadowsky, Jack D.; Lewis Phillips, Gail D.; Guo, Jun; Darwish, Martine; Fan, Peter; Chen, Jingtian; He, Changrong; Wang, Tao; Yao, Hui; Xu, Zijin; Chen, Jinhua; Wai, John; Pei, Zhonghua; Hop, Cornelis E. C. A.; Khojasteh, S. Cyrus; Dragovich, Peter S.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">988-993</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Disulfide bonds could be valuable linkers for a variety of therapeutic applications requiring tunable cleavage between two parts of a mol. (e.g., antibody-drug conjugates).  The in vitro linker immolation of β-mercaptoethyl-carbamate disulfides and DNA alkylation properties of assocd. payloads were investigated to understand the determinant of cell killing potency of anti-CD22 linked pyrrolobenzodiazepine (PBD-dimer) conjugates.  Efficient immolation and release of a PBD-dimer with strong DNA alkylation properties were obsd. following disulfide cleavage of methyl- and cyclobutyl-substituted disulfide linkers.  However, the analogous cyclopropyl-contg. linker did not immolate, and the assocd. thiol-contg. product was a poor DNA alkylator.  As predicted from these in vitro assessments, the related anti-CD22 ADCs showed different target-dependent cell killing activities in WSU-DLCL2 and BJAB cell lines.  These results demonstrate how the in vitro immolation models can be used to help design efficacious ADCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp46OI06jaKILVg90H21EOLACvtfcHk0ljBAV3tU-9kCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtl2rsrfN&md5=2a9dbd291d99f13b848047198f97bd7c</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00233%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DPillow%26aufirst%3DT.%2BH.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DCruz-Chuh%26aufirst%3DJ.%26aulast%3DKozak%26aufirst%3DK.%2BR.%26aulast%3DSadowsky%26aufirst%3DJ.%2BD.%26aulast%3DPhillips%26aufirst%3DG.%2BD.%2BL.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DDarwish%26aufirst%3DM.%26aulast%3DFan%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DHe%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DWai%26aufirst%3DJ.%26aulast%3DPei%26aufirst%3DZ.%26aulast%3DHop%26aufirst%3DC.%2BE.%2BC.%2BA.%26aulast%3DKhojasteh%26aufirst%3DS.%2BC.%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26atitle%3DLinker%2520immolation%2520determines%2520cell%2520killing%2520activity%2520of%2520disulfide-linked%2520pyrrolobenzodiazepine%2520antibody%25E2%2580%2593drug%2520conjugates%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D988%26epage%3D993%26doi%3D10.1021%2Facsmedchemlett.6b00233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kansy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senner, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gubernator, K.</span></span> <span> </span><span class="NLM_article-title">Physicochemical high throughput screening: Parallel artificial membrane permeation assay in the description of passive absorption processes</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">1007</span>– <span class="NLM_lpage">1010</span>, <span class="refDoi"> DOI: 10.1021/jm970530e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm970530e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADyaK1cXhs12kt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1998&pages=1007-1010&author=M.+Kansyauthor=F.+Sennerauthor=K.+Gubernator&title=Physicochemical+high+throughput+screening%3A+Parallel+artificial+membrane+permeation+assay+in+the+description+of+passive+absorption+processes&doi=10.1021%2Fjm970530e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Physicochemical High Throughput Screening: Parallel Artificial Membrane Permeation Assay in the Description of Passive Absorption Processes</span></div><div class="casAuthors">Kansy, Manfred; Senner, Frank; Gubernator, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1007-1010</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The majority of pharmaceutical discovery projects aim for an orally available form of a new therapeutic principle.  One obstacle for per oral treatment is intestinal absorption.  A simple predictive exptl. method to assess the potential of intestinal absorption is therefore highly welcome.  The authors describe here the PAMPA (Parallel Artificial Membrane Permeation Assay) method, a simple, robust, high throughput screen (HTS) which has been shown to be predictive for passive diffusion through membranes and thus for oral absorption.  In addn. PAMPA can deliver information in parallel on the lipophilicity, the ionization state and the soly. of a compd.  Therefore PAMPA complements HTS, combinatorial chem. and parallel synthesis efforts in preclin. pharmaceutical research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqcwCGodCr1rVg90H21EOLACvtfcHk0ljBAV3tU-9kCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhs12kt70%253D&md5=85d8ab409313b583de52348eb4d895da</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm970530e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm970530e%26sid%3Dliteratum%253Aachs%26aulast%3DKansy%26aufirst%3DM.%26aulast%3DSenner%26aufirst%3DF.%26aulast%3DGubernator%26aufirst%3DK.%26atitle%3DPhysicochemical%2520high%2520throughput%2520screening%253A%2520Parallel%2520artificial%2520membrane%2520permeation%2520assay%2520in%2520the%2520description%2520of%2520passive%2520absorption%2520processes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1998%26volume%3D41%26spage%3D1007%26epage%3D1010%26doi%3D10.1021%2Fjm970530e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dubowchik, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firestone, R. A.</span></span> <span> </span><span class="NLM_article-title">Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">3341</span>– <span class="NLM_lpage">3346</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(98)00609-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1016%2FS0960-894X%2898%2900609-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=9873731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADyaK1cXotFagtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1998&pages=3341-3346&author=G.+M.+Dubowchikauthor=R.+A.+Firestone&title=Cathepsin+B-sensitive+dipeptide+prodrugs.+1.+A+model+study+of+structural+requirements+for+efficient+release+of+doxorubicin&doi=10.1016%2FS0960-894X%2898%2900609-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin</span></div><div class="casAuthors">Dubowchik, Gene M.; Firestone, Raymond A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">3341-3346</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A series of lysosomal protease-sensitive peptides attached to doxorubicin (DOX) was prepd. as model substrates for internalizing anticancer immunoconjugates and potential antimetastasis prodrugs.  Rates of cathepsin B-mediated release of free drug was measured for each, and human plasma stabilities for representative examples.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOzOf1WKrZurVg90H21EOLACvtfcHk0ljBAV3tU-9kCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXotFagtbY%253D&md5=946bb31dc62701634c946beb1f1cc1bc</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2898%2900609-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252898%252900609-X%26sid%3Dliteratum%253Aachs%26aulast%3DDubowchik%26aufirst%3DG.%2BM.%26aulast%3DFirestone%26aufirst%3DR.%2BA.%26atitle%3DCathepsin%2520B-sensitive%2520dipeptide%2520prodrugs.%25201.%2520A%2520model%2520study%2520of%2520structural%2520requirements%2520for%2520efficient%2520release%2520of%2520doxorubicin%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1998%26volume%3D8%26spage%3D3341%26epage%3D3346%26doi%3D10.1016%2FS0960-894X%2898%2900609-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Gregson, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, G.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiavone, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sult, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vijayakrishnan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masterson, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Hooge, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snaith, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harper, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartley, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, P. W.</span></span> <span> </span><span class="NLM_article-title">Synthesis and evaluation of pyrrolobenzodiazepine dimer antibody–drug conjugates with dual β-glucuronide and dipeptide triggers</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>179</i></span>,  <span class="NLM_fpage">591</span>– <span class="NLM_lpage">607</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.06.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1016%2Fj.ejmech.2019.06.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=31279293" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlejs7%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=179&publication_year=2019&pages=591-607&author=S.+J.+Gregsonauthor=A.+M.+Barrettauthor=N.+V.+Patelauthor=G.-D.+Kangauthor=D.+Schiavoneauthor=E.+Sultauthor=C.+S.+Barryauthor=B.+Vijayakrishnanauthor=L.+R.+Adamsauthor=L.+A.+Mastersonauthor=F.+D%E2%80%99Hoogeauthor=M.+Snaithauthor=J.+Harperauthor=J.+A.+Hartleyauthor=P.+W.+Howard&title=Synthesis+and+evaluation+of+pyrrolobenzodiazepine+dimer+antibody%E2%80%93drug+conjugates+with+dual+%CE%B2-glucuronide+and+dipeptide+triggers&doi=10.1016%2Fj.ejmech.2019.06.044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22aR"><div class="casContent"><span class="casTitleNuber">22a</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of pyrrolobenzodiazepine dimer antibody-drug conjugates with dual β-glucuronide and dipeptide triggers</span></div><div class="casAuthors">Gregson, Stephen J.; Barrett, Allison M.; Patel, Neki V.; Kang, Gyoung-Dong; Schiavone, Davide; Sult, Erin; Barry, Conor S.; Vijayakrishnan, Balakumar; Adams, Lauren R.; Masterson, Luke A.; D'Hooge, Francois; Snaith, Mike; Harper, Jay; Hartley, John A.; Howard, Philip W.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">179</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">591-607</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Antibody-drug conjugates (ADCs) contg. pyrrolobenzodiazepine (PBD) dimers are currently being evaluated in human oncol. clin. trials with encouraging results.  To further improve the therapeutic window, next-generation PBD drug-linker design has focused on the inclusion of addnl. tumor-selective triggers and use of lower-potency PBDs. β-Glucuronidase is a well-known target for discovery prodrugs due to increased presence in tumor cells and microenvironment.  In this study, a β-glucuronidase cleavable cap was investigated at the PBD N10-position and compared with corresponding free imine ADCs.  SG3600 (glucuronide) ADCs showed in vitro and in vivo efficacy/tolerability comparable to SG3400 (imine) ADCs, and good 50% inhibitory concn. differentials were obsd. in vitro between control non-antigen-targeted ADCs and targeted ADCs.  Dependence on β-glucuronidase for SG3600 activity was demonstrated through CRISPRCas9 knockdown studies and addn. of exogenous β-glucuronidase.  SG3600 showed better serum stability, improved conjugation efficiency and was able to reach high drug-to-antibody ratio without aggregation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh2H0GqhcV97Vg90H21EOLACvtfcHk0lgmbORGC2cJqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlejs7%252FL&md5=a188076bf4345dd812a58d671b72e02b</span></div><a href="/servlet/linkout?suffix=cit22a&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.06.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.06.044%26sid%3Dliteratum%253Aachs%26aulast%3DGregson%26aufirst%3DS.%2BJ.%26aulast%3DBarrett%26aufirst%3DA.%2BM.%26aulast%3DPatel%26aufirst%3DN.%2BV.%26aulast%3DKang%26aufirst%3DG.-D.%26aulast%3DSchiavone%26aufirst%3DD.%26aulast%3DSult%26aufirst%3DE.%26aulast%3DBarry%26aufirst%3DC.%2BS.%26aulast%3DVijayakrishnan%26aufirst%3DB.%26aulast%3DAdams%26aufirst%3DL.%2BR.%26aulast%3DMasterson%26aufirst%3DL.%2BA.%26aulast%3DD%25E2%2580%2599Hooge%26aufirst%3DF.%26aulast%3DSnaith%26aufirst%3DM.%26aulast%3DHarper%26aufirst%3DJ.%26aulast%3DHartley%26aufirst%3DJ.%2BA.%26aulast%3DHoward%26aufirst%3DP.%2BW.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520pyrrolobenzodiazepine%2520dimer%2520antibody%25E2%2580%2593drug%2520conjugates%2520with%2520dual%2520%25CE%25B2-glucuronide%2520and%2520dipeptide%2520triggers%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D179%26spage%3D591%26epage%3D607%26doi%3D10.1016%2Fj.ejmech.2019.06.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit22b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panuganti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dao-Pick, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banik, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsi, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandalam, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Junutula, J. R.</span></span> <span> </span><span class="NLM_article-title">CLT030, a leukemic stem cell-targeting CLL1 antibody–drug conjugate for treatment of acute myeloid leukemia</span>. <i>Blood Adv.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">1738</span>– <span class="NLM_lpage">1749</span>, <span class="refDoi"> DOI: 10.1182/bloodadvances.2018020107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1182%2Fbloodadvances.2018020107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=30037800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BC1MXlvVKnsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2018&pages=1738-1749&author=Y.-P.+Jiangauthor=B.+Y.+Liuauthor=Q.+Zhengauthor=S.+Panugantiauthor=R.+Chenauthor=J.+Zhuauthor=M.+Mishraauthor=J.+Huangauthor=T.+Dao-Pickauthor=S.+Royauthor=X.-X.+Zhaoauthor=J.+Linauthor=G.+Banikauthor=E.+D.+Hsiauthor=R.+Mandalamauthor=J.+R.+Junutula&title=CLT030%2C+a+leukemic+stem+cell-targeting+CLL1+antibody%E2%80%93drug+conjugate+for+treatment+of+acute+myeloid+leukemia&doi=10.1182%2Fbloodadvances.2018020107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22bR"><div class="casContent"><span class="casTitleNuber">22b</span><div class="casTitle"><span class="NLM_cas:atitle">CLT030, a leukemic stem cell-targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia</span></div><div class="casAuthors">Jiang, Ying-Ping; Liu, Bob Y.; Zheng, Quan; Panuganti, Swapna; Chen, Ruoying; Zhu, Jianyu; Mishra, Madhavi; Huang, Jianqing; Dao-Pick, Trang; Roy, Sharmili; Zhao, XiaoXian; Lin, Jeffrey; Banik, Gautam; Hsi, Eric D.; Mandalam, Ramkumar; Junutula, Jagath R.</div><div class="citationInfo"><span class="NLM_cas:title">Blood Advances</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1738-1749</span>CODEN:
                <span class="NLM_cas:coden">BALDBA</span>;
        ISSN:<span class="NLM_cas:issn">2473-9537</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The current std. of care for acute myeloid leukemia (AML) is largely ineffective with very high relapse rates and low survival rates, mostly due to the inability to eliminate a rare population of leukemic stem cells (LSCs) that initiate tumor growth and are resistant to std. chemotherapy.  RNA-sequencing anal. on isolated LSCs confirmed C-type lectin domain family 12 member A (CLL1, also known as CLEC12A) to be highly expressed on LSCs but not on normal hematopoietic stem cells (HSCs) or other healthy organ tissues.  Expression of CLL1 was consistent across different types of AML.  We developed CLT030 (CLL1-ADC), an antibody-drug conjugate (ADC) based on a humanized anti-CLL1 antibody with 2 engineered cysteine residues linked covalently via a cleavable linker to a highly potent DNA-binding payload, thus resulting in a site-specific and homogenous ADC product.  The ADC is designed to be stable in the bloodstream and to release its DNA-binding payload only after the ADC binds to CLL1-expressing tumor cells, is internalized, and the linker is cleaved in the lysosomal compartment.  CLL1-ADC inhibits in vitro LSC colony formation and demonstrates robust in vivo efficacy in AML cell tumor models and tumor growth inhibition in the AML patient-derived xenograft model.  CLL1-ADC demonstrated a reduced effect on differentiation of healthy normal human CD34+ cells to various lineages as obsd. in an in vitro colony formation assay and in an in vivo xenotransplantation model as compared with CD33-ADC.  These results demonstrate that CLL1-ADC could be an effective ADC therapeutic for the treatment of AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJOpDWvxxUWrVg90H21EOLACvtfcHk0lgmbORGC2cJqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXlvVKnsb0%253D&md5=478d01c2c6e9930745d97ddecbbfcb4a</span></div><a href="/servlet/linkout?suffix=cit22b&amp;dbid=16384&amp;doi=10.1182%2Fbloodadvances.2018020107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fbloodadvances.2018020107%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DY.-P.%26aulast%3DLiu%26aufirst%3DB.%2BY.%26aulast%3DZheng%26aufirst%3DQ.%26aulast%3DPanuganti%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DR.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DMishra%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DDao-Pick%26aufirst%3DT.%26aulast%3DRoy%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DX.-X.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DBanik%26aufirst%3DG.%26aulast%3DHsi%26aufirst%3DE.%2BD.%26aulast%3DMandalam%26aufirst%3DR.%26aulast%3DJunutula%26aufirst%3DJ.%2BR.%26atitle%3DCLT030%252C%2520a%2520leukemic%2520stem%2520cell-targeting%2520CLL1%2520antibody%25E2%2580%2593drug%2520conjugate%2520for%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%2520Adv.%26date%3D2018%26volume%3D2%26spage%3D1738%26epage%3D1749%26doi%3D10.1182%2Fbloodadvances.2018020107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span> The mAb nomenclature
follows the EU convention described in the following:<span class="NLM_contrib-group"><span class="NLM_string-name">Edelman, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gall, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottlieb, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutishauser, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waxdal, M. J.</span></span> <span> </span><span class="NLM_article-title">The covalent structure of an entire γG immunoglobin molecule</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1969</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">78</span>– <span class="NLM_lpage">85</span>, <span class="refDoi"> DOI: 10.1073/pnas.63.1.78</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1073%2Fpnas.63.1.78" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=5257969" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADyaE3cXivFyjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=1969&pages=78-85&author=G.+M.+Edelmanauthor=B.+A.+Cunninghamauthor=W.+E.+Gallauthor=P.+D.+Gottliebauthor=U.+Rutishauserauthor=M.+J.+Waxdal&title=The+covalent+structure+of+an+entire+%CE%B3G+immunoglobin+molecule&doi=10.1073%2Fpnas.63.1.78"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent structure of an entire γG immunoglobulin molecule</span></div><div class="casAuthors">Edelman, Gerald M.; Cunningham, Bruce A.; Gall, W. Einar; Gottlieb, Paul D.; Rutishauser, Urs; Waxdal, Myron J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1969</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">78-85</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">The complete amino acid sequence of a human γGl immunoglobulin (Eu) has been detd. and the arrangement of all of the disulfide bonds has been established.  Comparison of the sequence with that of another myeloma protein (He) suggests that the variable regions of heavy and light chains are homologous and similar in length.  The const. portion of the heavy chain contains 3 homology regions each of which is similar in size and homologous to the const. region of the light chain.  Each variable region and each const. homology region contains 1 intrachain disulfide bond.  The half-cystines participating in the interchain bonds are all clustered within a stretch of 10 residues at the middle of the heavy chains.  These data support the hypothesis that immunoglobulins evolved by gene duplication after early divergence of V genes, which specified antigen-binding functions, and C genes, which specified other functions of antibody mols.  Each polypeptide chain may therefore be specified by 2 genes, V and C, which are fused to form a single gene (translocation hypothesis).  The internal homologies and symmetry of the mol. suggest that homology regions may have similar 3-dimensional structures each consisting of a compact domain which contributes to at least 1 active site (domain hypothesis).  Both hypotheses are in accord with the linear regional differentiation of function in antibody mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjqW9i9JX9g7Vg90H21EOLACvtfcHk0lgmbORGC2cJqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE3cXivFyjtQ%253D%253D&md5=18ba9b6417ce609be8870e1d142e7fc9</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1073%2Fpnas.63.1.78&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.63.1.78%26sid%3Dliteratum%253Aachs%26aulast%3DEdelman%26aufirst%3DG.%2BM.%26aulast%3DCunningham%26aufirst%3DB.%2BA.%26aulast%3DGall%26aufirst%3DW.%2BE.%26aulast%3DGottlieb%26aufirst%3DP.%2BD.%26aulast%3DRutishauser%26aufirst%3DU.%26aulast%3DWaxdal%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520covalent%2520structure%2520of%2520an%2520entire%2520%25CE%25B3G%2520immunoglobin%2520molecule%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1969%26volume%3D63%26spage%3D78%26epage%3D85%26doi%3D10.1073%2Fpnas.63.1.78" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="note"><p class="first last">For a comparison of the EU and the alternate Kabat mAb nomenclature systems, see table S1 in ref <a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a>.</p></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ohri, R.</span>; <span class="NLM_string-name">Bhakta, S.</span>; <span class="NLM_string-name">Fourie-O’Donohue, A.</span>; <span class="NLM_string-name">Dela Cruz-Chuh, J.</span>; <span class="NLM_string-name">Tsai, S. P.</span>; <span class="NLM_string-name">Cook, R.</span>; <span class="NLM_string-name">Wei, B.</span>; <span class="NLM_string-name">Ng, C.</span>; <span class="NLM_string-name">Wong, A. W.</span>; <span class="NLM_string-name">Bos, A. B.</span>; <span class="NLM_string-name">Farahi, R.</span>; <span class="NLM_string-name">Bhakta, J.</span>; <span class="NLM_string-name">Pillow, T. H.</span>; <span class="NLM_string-name">Raab, H.</span>; <span class="NLM_string-name">Vandlen, R.</span>; <span class="NLM_string-name">Polakis, P.</span>; <span class="NLM_string-name">Liu, Y.</span>; <span class="NLM_string-name">Erickson, H.</span>; <span class="NLM_string-name">Junutula, J. R.</span>; <span class="NLM_string-name">Kozak, K. R.</span></span> <span> </span><span class="NLM_article-title">High-throughput cysteine scanning to identify stable antibody conjugation sites for maleimide- and disulfide-based linkers</span>.  <i>Bioconjugate Chem.</i> <span class="NLM_year">2018</span>,  <span class="NLM_volume">29</span>,  <span class="NLM_fpage">473</span>– <span class="NLM_lpage">485</span>.</span><div class="citationLinks">[<a href="/doi/10.1021/acs.bioconjchem.7b00791" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&pages=473-485&author=R.+Ohri&author=S.+Bhakta&author=A.+Fourie-O%E2%80%99Donohue&author=J.+Dela+Cruz-Chuh&author=S.+P.+Tsai&author=R.+Cook&author=B.+Wei&author=C.+Ng&author=A.+W.+Wong&author=A.+B.+Bos&author=R.+Farahi&author=J.+Bhakta&author=T.+H.+Pillow&author=H.+Raab&author=R.+Vandlen&author=P.+Polakis&author=Y.+Liu&author=H.+Erickson&author=J.+R.+Junutula&author=K.+R.+Kozak&title=Bioconjugate+Chem."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facs.bioconjchem.7b00791&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1021%252Facs.bioconjchem.7b00791%26sid%3Dliteratum%253Aachs%26aulast%3DOhri%26aufirst%3DR.%26atitle%3DHigh-throughput%2520cysteine%2520scanning%2520to%2520identify%2520stable%2520antibody%2520conjugation%2520sites%2520for%2520maleimide-%2520and%2520disulfide-based%2520linkers%26btitle%3DBioconjugate%2520Chem.%26date%3D2018%26volume%3D29%26spage%3D473%26epage%3D485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Loomis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garg, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yavlovich, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell-Massa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimitrov, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumenthal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puri, A.</span></span> <span> </span><span class="NLM_article-title">Specific targeting to B cells by lipid-based nanoparticles conjugated with a novel CD22-ScFv</span>. <i>Exp. Mol. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">238</span>– <span class="NLM_lpage">249</span>, <span class="refDoi"> DOI: 10.1016/j.yexmp.2010.01.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1016%2Fj.yexmp.2010.01.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=20122924" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksVenurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2010&pages=238-249&author=K.+Loomisauthor=B.+Smithauthor=Y.+Fengauthor=H.+Gargauthor=A.+Yavlovichauthor=R.+Campbell-Massaauthor=D.+S.+Dimitrovauthor=R.+Blumenthalauthor=X.+Xiaoauthor=A.+Puri&title=Specific+targeting+to+B+cells+by+lipid-based+nanoparticles+conjugated+with+a+novel+CD22-ScFv&doi=10.1016%2Fj.yexmp.2010.01.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Specific targeting to B cells by lipid-based nanoparticles conjugated with a novel CD22-ScFv</span></div><div class="casAuthors">Loomis, Kristin; Smith, Brandon; Feng, Yang; Garg, Himanshu; Yavlovich, Amichai; Campbell-Massa, Ryan; Dimitrov, Dimiter S.; Blumenthal, Robert; Xiao, Xiao-Dong; Puri, Anu</div><div class="citationInfo"><span class="NLM_cas:title">Experimental and Molecular Pathology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">238-249</span>CODEN:
                <span class="NLM_cas:coden">EXMPA6</span>;
        ISSN:<span class="NLM_cas:issn">0014-4800</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The CD22 antigen is a viable target for therapeutic intervention for B-cell lymphomas.  Several therapeutic anti-CD22 antibodies as well as an anti-CD22-based immunotoxin (HA22) are currently under investigation in clin. settings.  Coupling of anti-CD22 reagents with a nano-drug delivery vehicle is projected to significantly improve treatment efficacies.  Therefore, the authors generated a mutant of the targeting segment of HA22 (a CD22 scFv) to increase its sol. expression (mut-HA22), and conjugated it to the surface of sonicated liposomes to generate immunoliposomes (mut-HA22-liposomes).  The authors examd. liposome binding and uptake by CD22+ B-lymphocytes (BJAB) by using calcein and/or rhodamine PE-labeled liposomes.  The authors also tested the effect of targeting on cellular toxicity with doxorubicin-loaded liposomes.  The authors report that: (i) Binding of mut-HA22-liposomes to BJAB cells was significantly greater than liposomes not conjugated with mut-HA22 (control liposomes), and mut-HA22-liposomes bind to and are taken in by BJAB cells in a dose and temp.-dependent manner, resp.; (ii) This binding occurred via the interaction with the cellular CD22 as pre-incubation of the cells with mut-HA22 blocked subsequent liposome binding; (iii) Intracellular localization of mut-HA22-liposomes at 37° but not at 4° indicated that the authors' targeted liposomes were taken up through an energy dependent process via receptor-mediated endocytosis; and (iv) Mut-HA22-liposomes loaded with doxorubicin exhibited at least 2-3-fold more accumulation of doxorubicin in BJAB cells as compared to control liposomes.  Moreover, these liposomes showed at least a 2-4-fold enhanced killing of BJAB or Raji cells (CD22+), but not SUP-T1 cells (CD22-).  Taken together these data suggest that these 2nd-generation liposomes may serve as promising carriers for targeted drug delivery to treat patients suffering from B-cell lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGLlD1ZnVLgrVg90H21EOLACvtfcHk0li232IJcPacQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksVenurs%253D&md5=7f725efb496dc848496939550dbb143c</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.yexmp.2010.01.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yexmp.2010.01.006%26sid%3Dliteratum%253Aachs%26aulast%3DLoomis%26aufirst%3DK.%26aulast%3DSmith%26aufirst%3DB.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DGarg%26aufirst%3DH.%26aulast%3DYavlovich%26aufirst%3DA.%26aulast%3DCampbell-Massa%26aufirst%3DR.%26aulast%3DDimitrov%26aufirst%3DD.%2BS.%26aulast%3DBlumenthal%26aufirst%3DR.%26aulast%3DXiao%26aufirst%3DX.%26aulast%3DPuri%26aufirst%3DA.%26atitle%3DSpecific%2520targeting%2520to%2520B%2520cells%2520by%2520lipid-based%2520nanoparticles%2520conjugated%2520with%2520a%2520novel%2520CD22-ScFv%26jtitle%3DExp.%2520Mol.%2520Pathol.%26date%3D2010%26volume%3D88%26spage%3D238%26epage%3D249%26doi%3D10.1016%2Fj.yexmp.2010.01.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Shor, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerber, H.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sapra, P.</span></span> <span> </span><span class="NLM_article-title">Preclinical and clinical development of inotuzumab ozogamicin in hematological malignancies</span>. <i>Mol. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">107</span>– <span class="NLM_lpage">116</span>, <span class="refDoi"> DOI: 10.1016/j.molimm.2014.09.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1016%2Fj.molimm.2014.09.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=25304309" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1Kntr%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2015&pages=107-116&author=B.+Shorauthor=H.-P.+Gerberauthor=P.+Sapra&title=Preclinical+and+clinical+development+of+inotuzumab+ozogamicin+in+hematological+malignancies&doi=10.1016%2Fj.molimm.2014.09.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26aR"><div class="casContent"><span class="casTitleNuber">26a</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies</span></div><div class="casAuthors">Shor, Boris; Gerber, Hans-Peter; Sapra, Puja</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Immunology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">2_Part_A</span>),
    <span class="NLM_cas:pages">107-116</span>CODEN:
                <span class="NLM_cas:coden">MOIMD5</span>;
        ISSN:<span class="NLM_cas:issn">0161-5890</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Calicheamicin is a DNA-damaging agent that, following intracellular activation, binds to DNA in the minor groove and introduces double-strand DNA breaks, leading to G2/M arrest and subsequent cell death.  Importantly, the mechanism of action of calicheamicin is fundamentally different from the tubulin-binding class of cytotoxics targeting the mitotic spindle, which represent the most common class of payloads for antibody-drug conjugates (ADCs) currently undergoing clin. development.  Spindle poisons that target tubulin, including auristatins and maytansines, are most effective against rapidly proliferating cells.  In contrast, calicheamicin induces DNA double-strand breaks and apoptosis independent of cell cycle progression.  Such properties may be advantageous when targeting malignant cells that are not markedly different in their proliferation status compared to normal cells.  Here we review calicheamicin conjugates, with a particular focus on the preclin.- and clin. development of inotuzumab ozogamicin, targeting the CD22 antigen expressed on a large variety of hematol. malignancies.  In pre-clin. expts., inotuzumab ozogamicin potently induced tumor regressions in models of non-Hodgkin's lymphoma (NHL), either alone or in combination with the anti-CD20 antibody Rituximab.  Promising anti-tumor responses were obsd. in early stage clin. trials, where inotuzumab ozogamicin was administered either as single agent or in combination with Rituximab.  Consistent with the cell cycle independent mechanism of action of the calicheamicin payload, high rates of complete responses were obsd. in less aggressive forms of lymphomas, including follicular lymphoma (FL) and relapsed, diffuse large B-cell lymphoma (DLBCL).Inotuzumab ozogamicin is currently being tested in phase III clin. trials in acute lymphocytic leukemia (ALL).  Particular focus is dedicated to reviewing the pre-clin. and clin. data generated with this compd. in NHL and to outline future focus areas for pre-clin.- and clin. research of inotuzumab ozogamicin, and the calicheamicin class of antibody-drug conjugates more generally.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1fLDErK7NWbVg90H21EOLACvtfcHk0li232IJcPacQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1Kntr%252FE&md5=29b4ae34952bdc12101c43cbe3777e48</span></div><a href="/servlet/linkout?suffix=cit26a&amp;dbid=16384&amp;doi=10.1016%2Fj.molimm.2014.09.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molimm.2014.09.014%26sid%3Dliteratum%253Aachs%26aulast%3DShor%26aufirst%3DB.%26aulast%3DGerber%26aufirst%3DH.-P.%26aulast%3DSapra%26aufirst%3DP.%26atitle%3DPreclinical%2520and%2520clinical%2520development%2520of%2520inotuzumab%2520ozogamicin%2520in%2520hematological%2520malignancies%26jtitle%3DMol.%2520Immunol.%26date%3D2015%26volume%3D67%26spage%3D107%26epage%3D116%26doi%3D10.1016%2Fj.molimm.2014.09.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit26b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Polson, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calemine-Fenaux, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Sauvage, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eaton, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkins, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frantz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuji, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harden, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingle, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kljavin, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeppen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prabhu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raab, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slaga, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephan, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scales, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandlen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wranik, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebens, A.</span></span> <span> </span><span class="NLM_article-title">Antibody-drug conjugates for the treatment of non–Hodgkin’s lymphoma: Target and linker-drug selection</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">2358</span>– <span class="NLM_lpage">2364</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-08-2250</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1158%2F0008-5472.CAN-08-2250" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=19258515" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtFyqtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=2358-2364&author=A.+G.+Polsonauthor=J.+Calemine-Fenauxauthor=P.+Chanauthor=W.+Changauthor=E.+Christensenauthor=S.+Clarkauthor=F.+J.+de+Sauvageauthor=D.+Eatonauthor=K.+Elkinsauthor=J.+M.+Elliottauthor=G.+Frantzauthor=R.+N.+Fujiauthor=A.+Grayauthor=K.+Hardenauthor=G.+S.+Ingleauthor=N.+M.+Kljavinauthor=H.+Koeppenauthor=C.+Nelsonauthor=S.+Prabhuauthor=H.+Raabauthor=S.+Rossauthor=D.+S.+Slagaauthor=J.-P.+Stephanauthor=S.+J.+Scalesauthor=S.+D.+Spencerauthor=R.+Vandlenauthor=B.+Wranikauthor=S.-F.+Yuauthor=B.+Zhengauthor=A.+Ebens&title=Antibody-drug+conjugates+for+the+treatment+of+non%E2%80%93Hodgkin%E2%80%99s+lymphoma%3A+Target+and+linker-drug+selection&doi=10.1158%2F0008-5472.CAN-08-2250"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26bR"><div class="casContent"><span class="casTitleNuber">26b</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-Drug Conjugates for the Treatment of Non-Hodgkin's Lymphoma: Target and Linker-Drug Selection</span></div><div class="casAuthors">Polson, Andrew G.; Calemine-Fenaux, Jill; Chan, Pamela; Chang, Wesley; Christensen, Erin; Clark, Suzanna; de Sauvage, Frederic J.; Eaton, Dan; Elkins, Kristi; Elliott, J. Michael; Frantz, Gretchen; Fuji, Reina N.; Gray, Alane; Harden, Kristin; Ingle, Gladys S.; Kljavin, Noelyn M.; Koeppen, Hartmut; Nelson, Christopher; Prabhu, Saileta; Raab, Helga; Ross, Sarajane; Stephan, Jean-Philippe; Scales, Suzie J.; Spencer, Susan D.; Vandlen, Richard; Wranik, Bernd; Yu, Shang-Fan; Zheng, Bing; Ebens, Allen</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2358-2364</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Antibody-drug conjugates (ADC), potent cytotoxic drugs covalently linked to antibodies via chem. linkers, provide a means to increase the effectiveness of chemotherapy by targeting the drug to neoplastic cells while reducing side effects.  Here, the authors systematically examine the potential targets and linker-drug combinations that could provide an optimal ADC for the treatment for non-Hodgkin's lymphoma.  The authors identified seven antigens (CD19, CD20, CD21, CD22, CD72, CD79b, and CD180) for potential treatment of non-Hodgkin's lymphoma with ADCs.  ADCs with cleavable linkers mediated in vivo efficacy via all these targets; ADCs with uncleavable linkers were only effective when targeted to CD22 and CD79b.  In target-independent safety studies in rats, the uncleavable linker ADCs showed reduced toxicity, presumably due to the reduced release of free drug or other toxic metabolites into the circulation.  Thus, the authors' data suggest that ADCs with cleavable linkers work on a broad range of targets, and for specific targets, ADCs with uncleavable linkers provide a promising opportunity to improve the therapeutic window for ADCs in humans. [Cancer Res 2009;69(6):2358-64].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqh0r17kwsTobVg90H21EOLACvtfcHk0lh5-jM6BX7Z-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtFyqtb4%253D&md5=060457635dda4dafe14446e5a4815a07</span></div><a href="/servlet/linkout?suffix=cit26b&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-2250&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-2250%26sid%3Dliteratum%253Aachs%26aulast%3DPolson%26aufirst%3DA.%2BG.%26aulast%3DCalemine-Fenaux%26aufirst%3DJ.%26aulast%3DChan%26aufirst%3DP.%26aulast%3DChang%26aufirst%3DW.%26aulast%3DChristensen%26aufirst%3DE.%26aulast%3DClark%26aufirst%3DS.%26aulast%3Dde%2BSauvage%26aufirst%3DF.%2BJ.%26aulast%3DEaton%26aufirst%3DD.%26aulast%3DElkins%26aufirst%3DK.%26aulast%3DElliott%26aufirst%3DJ.%2BM.%26aulast%3DFrantz%26aufirst%3DG.%26aulast%3DFuji%26aufirst%3DR.%2BN.%26aulast%3DGray%26aufirst%3DA.%26aulast%3DHarden%26aufirst%3DK.%26aulast%3DIngle%26aufirst%3DG.%2BS.%26aulast%3DKljavin%26aufirst%3DN.%2BM.%26aulast%3DKoeppen%26aufirst%3DH.%26aulast%3DNelson%26aufirst%3DC.%26aulast%3DPrabhu%26aufirst%3DS.%26aulast%3DRaab%26aufirst%3DH.%26aulast%3DRoss%26aufirst%3DS.%26aulast%3DSlaga%26aufirst%3DD.%2BS.%26aulast%3DStephan%26aufirst%3DJ.-P.%26aulast%3DScales%26aufirst%3DS.%2BJ.%26aulast%3DSpencer%26aufirst%3DS.%2BD.%26aulast%3DVandlen%26aufirst%3DR.%26aulast%3DWranik%26aufirst%3DB.%26aulast%3DYu%26aufirst%3DS.-F.%26aulast%3DZheng%26aufirst%3DB.%26aulast%3DEbens%26aufirst%3DA.%26atitle%3DAntibody-drug%2520conjugates%2520for%2520the%2520treatment%2520of%2520non%25E2%2580%2593Hodgkin%25E2%2580%2599s%2520lymphoma%253A%2520Target%2520and%2520linker-drug%2520selection%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D2358%26epage%3D2364%26doi%3D10.1158%2F0008-5472.CAN-08-2250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Rinnerthaler, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gampenrieder, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greil, R.</span></span> <span> </span><span class="NLM_article-title">HER2 directed antibody–drug-conjugates beyond T-DM1 in breast cancer</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1115</span>, <span class="refDoi"> DOI: 10.3390/ijms20051115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.3390%2Fijms20051115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFOntLzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=1115&author=G.+Rinnerthalerauthor=S.+P.+Gampenriederauthor=R.+Greil&title=HER2+directed+antibody%E2%80%93drug-conjugates+beyond+T-DM1+in+breast+cancer&doi=10.3390%2Fijms20051115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27aR"><div class="casContent"><span class="casTitleNuber">27a</span><div class="casTitle"><span class="NLM_cas:atitle">HER2 directed antibody-drug-conjugates beyond T-DM1 in breast cancer</span></div><div class="casAuthors">Rinnerthaler, Gabriel; Gampenrieder, Simon Peter; Greil, Richard</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1115</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Since the discovery of the human epidermal growth factor receptor 2 (HER2) as an oncogenic driver in a subset of breast cancers and the development of HER2 directed therapies, the prognosis of HER2 amplified breast cancers has improved meaningfully.  Next to monoclonal anti-HER2 antibodies and tyrosine kinase inhibitors, the antibody-drug conjugate T-DM1 is a pillar of targeted treatment of advanced HER2-pos. breast cancers.  Currently, several HER2 directed antibody-drug conjugates are under clin. investigation for HER2 amplified but also HER2 expressing but not amplified breast tumors.  In this article, we review the current preclin. and clin. evidence of the investigational drugs A166, ALT-P7, ARX788, DHES0815A, DS-8201a, RC48, SYD985, MEDI4276 and XMT-1522.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquqRM0dTtznbVg90H21EOLACvtfcHk0lh5-jM6BX7Z-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFOntLzP&md5=82e9b955a030e75b9faee476a7553b30</span></div><a href="/servlet/linkout?suffix=cit27a&amp;dbid=16384&amp;doi=10.3390%2Fijms20051115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms20051115%26sid%3Dliteratum%253Aachs%26aulast%3DRinnerthaler%26aufirst%3DG.%26aulast%3DGampenrieder%26aufirst%3DS.%2BP.%26aulast%3DGreil%26aufirst%3DR.%26atitle%3DHER2%2520directed%2520antibody%25E2%2580%2593drug-conjugates%2520beyond%2520T-DM1%2520in%2520breast%2520cancer%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2019%26volume%3D20%26spage%3D1115%26doi%3D10.3390%2Fijms20051115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit27b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, B.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yadav, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sliwkowski, M. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crocker, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacap, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, G. D. L.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of acquired resistance to trastuzumab emtansine in breast cancer cells</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1441</span>– <span class="NLM_lpage">1453</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-17-0296</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1158%2F1535-7163.MCT-17-0296" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=29695635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1alur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=1441-1453&author=G.+Liauthor=J.+Guoauthor=B.-Q.+Shenauthor=D.+B.+Yadavauthor=M.+X.+Sliwkowskiauthor=L.+M.+Crockerauthor=J.+A.+Lacapauthor=G.+D.+L.+Phillips&title=Mechanisms+of+acquired+resistance+to+trastuzumab+emtansine+in+breast+cancer+cells&doi=10.1158%2F1535-7163.MCT-17-0296"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27bR"><div class="casContent"><span class="casTitleNuber">27b</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells</span></div><div class="casAuthors">Li, Guangmin; Guo, Jun; Shen, Ben-Quan; Yadav, Daniela Bumbaca; Sliwkowski, Mark X.; Crocker, Lisa M.; Lacap, Jennifer A.; Phillips, Gail D. Lewis</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1441-1453</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The receptor tyrosine kinase HER2 is overexpressed in approx. 20% of breast cancer, and its amplification is assocd. with reduced survival.  Trastuzumab emtansine (Kadcyla, T-DM1), an antibody-drug conjugate that is comprised of trastuzumab covalently linked to the antimitotic agent DM1 through a stable linker, was designed to selectively deliver DM1 to HER2-overexpressing tumor cells.  T-DM1 is approved for the treatment of patients with HER2-pos. metastatic breast cancer following progression on trastuzumab and a taxane.  Despite the improvement in clin. outcome, many patients who initially respond to T-DM1 treatment eventually develop progressive disease.  The mechanisms that contribute to T-DM1 resistance are not fully understood.  To this end, we developed T-DM1-resistant in vitro models to examine the mechanisms of acquired T-DM1 resistance.  We demonstrate that decreased HER2 and upregulation of MDR1 contribute to T-DM1 resistance in KPL-4 T-DM1-resistant cells.  In contrast, both loss of SLC46A3 and PTEN deficiency play a role in conferring resistance in BT-474M1 T-DM1-resistant cells.  Our data suggest that these two cell lines acquire resistance through distinct mechanisms.  Furthermore, we show that the KPL-4 T-DM1 resistance can be overcome by treatment with an inhibitor of MDR1, whereas a PI3K inhibitor can rescue PTEN loss-induced resistance in T-DM1-resistant BT-474M1 cells.  Our results provide a rationale for developing therapeutic strategies to enhance T-DM1 clin. efficacy by combining T-DM1 and other inhibitors that target signaling transduction or resistance pathways.  Mol Cancer Ther; 17(7); 1441-53. ©2018 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozzBxmVx-2OLVg90H21EOLACvtfcHk0lgdL4cynSOADg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1alur%252FP&md5=057dd2cfaed751fad7cb7a57ff1cfe79</span></div><a href="/servlet/linkout?suffix=cit27b&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-17-0296&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-17-0296%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DG.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DShen%26aufirst%3DB.-Q.%26aulast%3DYadav%26aufirst%3DD.%2BB.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26aulast%3DCrocker%26aufirst%3DL.%2BM.%26aulast%3DLacap%26aufirst%3DJ.%2BA.%26aulast%3DPhillips%26aufirst%3DG.%2BD.%2BL.%26atitle%3DMechanisms%2520of%2520acquired%2520resistance%2520to%2520trastuzumab%2520emtansine%2520in%2520breast%2520cancer%2520cells%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2018%26volume%3D17%26spage%3D1441%26epage%3D1453%26doi%3D10.1158%2F1535-7163.MCT-17-0296" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit27c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, G. D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dugger, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crocker, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsons, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mai, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blättler, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chari, R. V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, W. L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeppen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwall, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenkare-Mitra, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sliwkowski, M. X.</span></span> <span> </span><span class="NLM_article-title">Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">9280</span>– <span class="NLM_lpage">9290</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1158%2F0008-5472.CAN-08-1776" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=19010901" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=9280-9290&author=G.+D.+L.+Phillipsauthor=G.+Liauthor=D.+L.+Duggerauthor=L.+M.+Crockerauthor=K.+L.+Parsonsauthor=E.+Maiauthor=W.+A.+Bl%C3%A4ttlerauthor=J.+M.+Lambertauthor=R.+V.+J.+Chariauthor=R.+J.+Lutzauthor=W.+L.+T.+Wongauthor=F.+S.+Jacobsonauthor=H.+Koeppenauthor=R.+H.+Schwallauthor=S.+R.+Kenkare-Mitraauthor=S.+D.+Spencerauthor=M.+X.+Sliwkowski&title=Targeting+HER2-positive+breast+cancer+with+trastuzumab-DM1%2C+an+antibody-cytotoxic+drug+conjugate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27c&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-1776&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-1776%26sid%3Dliteratum%253Aachs%26aulast%3DPhillips%26aufirst%3DG.%2BD.%2BL.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DDugger%26aufirst%3DD.%2BL.%26aulast%3DCrocker%26aufirst%3DL.%2BM.%26aulast%3DParsons%26aufirst%3DK.%2BL.%26aulast%3DMai%26aufirst%3DE.%26aulast%3DBl%25C3%25A4ttler%26aufirst%3DW.%2BA.%26aulast%3DLambert%26aufirst%3DJ.%2BM.%26aulast%3DChari%26aufirst%3DR.%2BV.%2BJ.%26aulast%3DLutz%26aufirst%3DR.%2BJ.%26aulast%3DWong%26aufirst%3DW.%2BL.%2BT.%26aulast%3DJacobson%26aufirst%3DF.%2BS.%26aulast%3DKoeppen%26aufirst%3DH.%26aulast%3DSchwall%26aufirst%3DR.%2BH.%26aulast%3DKenkare-Mitra%26aufirst%3DS.%2BR.%26aulast%3DSpencer%26aufirst%3DS.%2BD.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26atitle%3DTargeting%2520HER2-positive%2520breast%2520cancer%2520with%2520trastuzumab-DM1%252C%2520an%2520antibody-cytotoxic%2520drug%2520conjugate%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D9280%26epage%3D9290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kinneer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meekin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiberghien, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tai, Y.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phipps, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiefer, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rebelatto, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimasi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriarty, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadopoulos, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sridhar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregson, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wick, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masterson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbst, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tice, D. A.</span></span> <span> </span><span class="NLM_article-title">SLC46A3 as a potential predictive biomarker for antibody–drug conjugates bearing noncleavable linked maytansinoid and pyrrolobenzodiazepine warheads</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">6570</span>– <span class="NLM_lpage">6582</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-18-1300</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1158%2F1078-0432.CCR-18-1300" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=30131388" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1ait7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=6570-6582&author=K.+Kinneerauthor=J.+Meekinauthor=A.+C.+Tiberghienauthor=Y.-T.+Taiauthor=S.+Phippsauthor=C.+M.+Kieferauthor=M.+C.+Rebelattoauthor=N.+Dimasiauthor=A.+Moriartyauthor=K.+P.+Papadopoulosauthor=S.+Sridharauthor=S.+J.+Gregsonauthor=M.+J.+Wickauthor=L.+Mastersonauthor=K.+C.+Andersonauthor=R.+Herbstauthor=P.+W.+Howardauthor=D.+A.+Tice&title=SLC46A3+as+a+potential+predictive+biomarker+for+antibody%E2%80%93drug+conjugates+bearing+noncleavable+linked+maytansinoid+and+pyrrolobenzodiazepine+warheads&doi=10.1158%2F1078-0432.CCR-18-1300"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">SLC46A3 as a potential predictive biomarker for antibody-drug conjugates bearing noncleavable linked maytansinoid and pyrrolobenzodiazepine warheads</span></div><div class="casAuthors">Kinneer, Krista; Meekin, John; Tiberghien, Arnaud C.; Tai, Yu-Tzu; Phipps, Sandrina; Kiefer, Christine Mione; Rebelatto, Marlon C.; Dimasi, Nazzareno; Moriarty, Alyssa; Papadopoulos, Kyriakos P.; Sridhar, Sriram; Gregson, Stephen J.; Wick, Michael J.; Masterson, Luke; Anderson, Kenneth C.; Herbst, Ronald; Howard, Philip W.; Tice, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6570-6582</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Antibody-drug conjugates (ADC) utilizing noncleavable linker drugs have been approved for clin. use, and several are in development targeting solid and hematol. malignancies including multiple myeloma.  Currently, there are no reliable biomarkers of activity for these ADCs other than presence of the targeted antigen.  We obsd. that certain cell lines are innately resistant to such ADCs, and sought to uncover the underlying mechanism of resistance.  Exptl. Design: The expression of 43 lysosomal membrane target genes was evaluated in cell lines resistant to ADCs bearing the noncleavable linker, pyrrolobenzodiazepine payload SG3376, in vitro.  The functional relevance of SLC46A3, a lysosomal transporter of noncleavable ADC catabolites whose expression uniquely correlated with SG3376 resistance, was assessed using EPHA2-, HER2-, and BCMA-targeted ADCs and isogenic cells overexpressing or genetically inactivated for SLC46A3.  SLC46A3 expression was also examd. in patient-derived xenograft and in vitro models of acquired T-DM1 resistance and multiple myeloma bone marrow samples by RT-PCR.  Results: Loss of SLC46A3 expression was found to be a mechanism of innate and acquired resistance to ADCs bearing DM1 and SG3376.  Sensitivity was restored in refractory lines upon introduction of SLC46A3, suggesting that expression of SLC46A3 may be more predictive of activity than target antigen levels alone.  Interrogation of primary multiple myeloma samples indicated a range of SLC46A3 expression, including samples with undetectable levels like multiple myeloma cell lines resistant to BCMA-targeting DM1 and SG3376 ADCs.  Conclusions: Our findings support SLC46A3 as a potential patient selection biomarker with immediate relevance to clin. trials involving these ADCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogMBCbYdUVXbVg90H21EOLACvtfcHk0liFSpsV0zU4nQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1ait7%252FI&md5=e3b5550bd7a96683d9f3ccac137eeb66</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-18-1300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-18-1300%26sid%3Dliteratum%253Aachs%26aulast%3DKinneer%26aufirst%3DK.%26aulast%3DMeekin%26aufirst%3DJ.%26aulast%3DTiberghien%26aufirst%3DA.%2BC.%26aulast%3DTai%26aufirst%3DY.-T.%26aulast%3DPhipps%26aufirst%3DS.%26aulast%3DKiefer%26aufirst%3DC.%2BM.%26aulast%3DRebelatto%26aufirst%3DM.%2BC.%26aulast%3DDimasi%26aufirst%3DN.%26aulast%3DMoriarty%26aufirst%3DA.%26aulast%3DPapadopoulos%26aufirst%3DK.%2BP.%26aulast%3DSridhar%26aufirst%3DS.%26aulast%3DGregson%26aufirst%3DS.%2BJ.%26aulast%3DWick%26aufirst%3DM.%2BJ.%26aulast%3DMasterson%26aufirst%3DL.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26aulast%3DHerbst%26aufirst%3DR.%26aulast%3DHoward%26aufirst%3DP.%2BW.%26aulast%3DTice%26aufirst%3DD.%2BA.%26atitle%3DSLC46A3%2520as%2520a%2520potential%2520predictive%2520biomarker%2520for%2520antibody%25E2%2580%2593drug%2520conjugates%2520bearing%2520noncleavable%2520linked%2520maytansinoid%2520and%2520pyrrolobenzodiazepine%2520warheads%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D24%26spage%3D6570%26epage%3D6582%26doi%3D10.1158%2F1078-0432.CCR-18-1300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Erickson, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, P. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widdison, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovtun, Y. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrett, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldmacher, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blättler, W. A.</span></span> <span> </span><span class="NLM_article-title">Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">4426</span>– <span class="NLM_lpage">4433</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-05-4489</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1158%2F0008-5472.CAN-05-4489" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=16618769" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BD28XjsFSlurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=4426-4433&author=H.+K.+Ericksonauthor=P.+U.+Parkauthor=W.+C.+Widdisonauthor=Y.+V.+Kovtunauthor=L.+M.+Garrettauthor=K.+Hoffmanauthor=R.+J.+Lutzauthor=V.+S.+Goldmacherauthor=W.+A.+Bl%C3%A4ttler&title=Antibody-maytansinoid+conjugates+are+activated+in+targeted+cancer+cells+by+lysosomal+degradation+and+linker-dependent+intracellular+processing&doi=10.1158%2F0008-5472.CAN-05-4489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-Maytansinoid Conjugates Are Activated in Targeted Cancer Cells by Lysosomal Degradation and Linker-Dependent Intracellular Processing</span></div><div class="casAuthors">Erickson, Hans K.; Park, Peter U.; Widdison, Wayne C.; Kovtun, Yelena V.; Garrett, Lisa M.; Hoffman, Karen; Lutz, Robert J.; Goldmacher, Victor S.; Blaettler, Walter A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4426-4433</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Antibody-drug conjugates are targeted anticancer agents consisting of a cytotoxic drug covalently linked to a monoclonal antibody for tumor antigen-specific activity.  Once bound to the target cell-surface antigen, the conjugate must be processed to release an active form of the drug, which can reach its intracellular target.  Here, we used both biol. and biochem. methods to better define this process for antibody-maytansinoid conjugates.  In particular, we examd. the metabolic fate in cells of huC242-maytansinoid conjugates contg. either a disulfide linker (huC242-SPDB-DM4) or a thioether linker (huC242-SMCC-DM1).  Using cell cycle anal. combined with lysosomal inhibitors, we showed that lysosomal processing is required for the activity of antibody-maytansinoid conjugates, irresp. of the linker.  We also identified and characterized the released maytansinoid mols. from these conjugates, and measured their rate of release compared with the kinetics of cell cycle arrest.  Both conjugates are efficiently degraded in lysosomes to yield metabolites consisting of the intact maytansinoid drug and linker attached to lysine.  The lysine adduct is the sole metabolite from the thioether-linked conjugate.  However, the lysine metabolite generated from the disulfide-linked conjugate is reduced and S-methylated to yield the lipophilic and potently cytotoxic metabolite, S-methyl-DM4.  These findings provide insight into the mechanism of action of antibody-maytansinoid conjugates in general, and more specifically, identify a biochem. mechanism that may account for the significantly enhanced antitumor efficacy obsd. with disulfide-linked conjugates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZZDy7Sl_BxrVg90H21EOLACvtfcHk0liFSpsV0zU4nQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjsFSlurs%253D&md5=aaf42c96e596e17a7896a265d5e1d158</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-05-4489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-05-4489%26sid%3Dliteratum%253Aachs%26aulast%3DErickson%26aufirst%3DH.%2BK.%26aulast%3DPark%26aufirst%3DP.%2BU.%26aulast%3DWiddison%26aufirst%3DW.%2BC.%26aulast%3DKovtun%26aufirst%3DY.%2BV.%26aulast%3DGarrett%26aufirst%3DL.%2BM.%26aulast%3DHoffman%26aufirst%3DK.%26aulast%3DLutz%26aufirst%3DR.%2BJ.%26aulast%3DGoldmacher%26aufirst%3DV.%2BS.%26aulast%3DBl%25C3%25A4ttler%26aufirst%3DW.%2BA.%26atitle%3DAntibody-maytansinoid%2520conjugates%2520are%2520activated%2520in%2520targeted%2520cancer%2520cells%2520by%2520lysosomal%2520degradation%2520and%2520linker-dependent%2520intracellular%2520processing%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D4426%26epage%3D4433%26doi%3D10.1158%2F0008-5472.CAN-05-4489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Gschwantler-Kaulich, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grunt, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muhr, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kölbl, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singer, C. F.</span></span> <span> </span><span class="NLM_article-title">HER specific TKIs exert their antineoplastic effects on breast cancer cell lines through the involvement of STAT5 and JNK</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">e0146311</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0146311</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1371%2Fjournal.pone.0146311" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=26735495" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFOrt7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=e0146311&author=D.+Gschwantler-Kaulichauthor=T.+W.+Gruntauthor=D.+Muhrauthor=R.+Wagnerauthor=H.+K%C3%B6lblauthor=C.+F.+Singer&title=HER+specific+TKIs+exert+their+antineoplastic+effects+on+breast+cancer+cell+lines+through+the+involvement+of+STAT5+and+JNK&doi=10.1371%2Fjournal.pone.0146311"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30aR"><div class="casContent"><span class="casTitleNuber">30a</span><div class="casTitle"><span class="NLM_cas:atitle">HER specific TKIs exert their antineoplastic effects on breast cancer cell lines through the involvement of STAT5 and JNK</span></div><div class="casAuthors">Gschwantler-Kaulich, Daphne; Grunt, Thomas W.; Muhr, Daniela; Wagner, Renate; Koelbl, Heinz; Singer, Christian F.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">e0146311/1-e0146311/14</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background: HER-targeted tyrosine kinase inhibitors (TKIs) have demonstrated pro-apoptotic and antiproliferative effects in vitro and in vivo.  The exact pathways through which TKIs exert their antineoplastic effects are, however, still not completely understood.  Methods: Using Milliplex assays, we have investigated the effects of the three panHER-TKIs lapatinib, canertinib and afatinib on signal transduction cascade activation in SKBR3, T47D and Jurkat neoplastic cell lines.  The growth-inhibitory effect of blockade of HER and of JNK and STAT5 signaling was measured by proliferation- and apoptosis-assays using formazan dye labeling of viable cells, Western blotting for cleaved PARP-1 and immunolabeling for active caspase 3, resp.  Results: All three HER-TKIs clearly inhibited proliferation and increased apoptosis in HER2 overexpressing SKBR3 cells, while their effect was less pronounced on HER2 moderately expressing T47D cells where they exerted only a weak antiproliferative and essentially no pro-apoptotic effect.  Remarkably, phosphorylation/activation of JNK and STAT5A/B were inhibited by HER-TKIs only in the sensitive, but not in the resistant cells.  In contrast, phosphorylation/activation of ERK/MAPK, STAT3, CREB, p70 S6 kinase, IkBa, and p38 were equally affected by HER-TKIs in both cell lines.  Moreover, we demonstrated that direct pharmacol. blockade of JNK and STAT5 abrogates cell growth in both HER-TKI-sensitive as well as -resistant breast cancer cells, resp.  Conclusion: We have shown that HER-TKIs exert a HER2 expression-dependent anti-cancer effect in breast cancer cell lines.  This involves blockade of JNK and STAT5A/B signaling, which have been found to be required for in vitro growth of these cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-6nSZtFrwObVg90H21EOLACvtfcHk0liFSpsV0zU4nQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFOrt7rI&md5=69dcc793d89d145e860123cbc765dc62</span></div><a href="/servlet/linkout?suffix=cit30a&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0146311&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0146311%26sid%3Dliteratum%253Aachs%26aulast%3DGschwantler-Kaulich%26aufirst%3DD.%26aulast%3DGrunt%26aufirst%3DT.%2BW.%26aulast%3DMuhr%26aufirst%3DD.%26aulast%3DWagner%26aufirst%3DR.%26aulast%3DK%25C3%25B6lbl%26aufirst%3DH.%26aulast%3DSinger%26aufirst%3DC.%2BF.%26atitle%3DHER%2520specific%2520TKIs%2520exert%2520their%2520antineoplastic%2520effects%2520on%2520breast%2520cancer%2520cell%2520lines%2520through%2520the%2520involvement%2520of%2520STAT5%2520and%2520JNK%26jtitle%3DPLoS%2520One%26date%3D2016%26volume%3D11%26spage%3De0146311%26doi%3D10.1371%2Fjournal.pone.0146311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit30b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Pop, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poe, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venturi, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shelton, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pop, I. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerber, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girard, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.-y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behrens, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Canales, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wistuba, I. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minna, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tedder, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitetta, E. S.</span></span> <span> </span><span class="NLM_article-title">A reevaluation of CD22 expression in human lung cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">263</span>– <span class="NLM_lpage">271</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-13-1436</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1158%2F0008-5472.CAN-13-1436" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=24395821" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BC2cXislKjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=263-271&author=L.+M.+Popauthor=S.+Barmanauthor=C.+Shaoauthor=J.+C.+Poeauthor=G.+M.+Venturiauthor=J.+M.+Sheltonauthor=I.+V.+Popauthor=D.+E.+Gerberauthor=L.+Girardauthor=X.-y.+Liuauthor=C.+Behrensauthor=J.+Rodriguez-Canalesauthor=H.+Liuauthor=I.+I.+Wistubaauthor=J.+A.+Richardsonauthor=J.+D.+Minnaauthor=T.+F.+Tedderauthor=E.+S.+Vitetta&title=A+reevaluation+of+CD22+expression+in+human+lung+cancer&doi=10.1158%2F0008-5472.CAN-13-1436"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30bR"><div class="casContent"><span class="casTitleNuber">30b</span><div class="casTitle"><span class="NLM_cas:atitle">A Reevaluation of CD22 Expression in Human Lung Cancer</span></div><div class="casAuthors">Pop, Laurentiu M.; Barman, Stephen; Shao, Chunli; Poe, Jonathan C.; Venturi, Guglielmo M.; Shelton, John M.; Pop, Iliodora V.; Gerber, David E.; Girard, Luc; Liu, Xiao-yun; Behrens, Carmen; Rodriguez-Canales, Jaime; Liu, Hui; Wistuba, Ignacio I.; Richardson, James A.; Minna, John D.; Tedder, Thomas F.; Vitetta, Ellen S.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">263-271</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">CD22 is a transmembrane glycoprotein expressed by mature B cells.  It inhibits signal transduction by the B-cell receptor and its coreceptor CD19.  Recent reports indicate that most human lung cancer cells and cell lines express CD22, making it an important new therapeutic target for lung cancer.  The objective of our studies was to independently validate these results with the goal of testing the efficacy of our CD22 immunotoxins on lung cancer cell lines.  As detd. by quant. real-time PCR anal., we found that levels of CD22 mRNA in a panel of human lung cancer cell lines were 200 to 60,000-fold lower than those obsd. in the human CD22+ Burkitt lymphoma cells, Daudi.  Using flow cytometry with a panel of CD22 monoclonal antibodies and Western blot analyses, we could not detect surface or intracellular expression of CD22 protein in a panel of lung cancer cell lines.  In addn., the in vitro proliferation of the lung tumor cell lines was not affected by either CD22 antibodies or our highly potent anti-CD22 immunotoxin.  In contrast, CD22+ Daudi cells expressed high levels of CD22 mRNA and protein, and were sensitive to our CD22 immunotoxin.  Importantly, primary non-small cell lung cancers from more than 250 patient specimens did not express detectable levels of CD22 protein as assessed by immuno- histochem.  We conclude that CD22 is not expressed at measurable levels on the surface of lung cancer cells, and that these cells cannot be killed by anti-CD22 immunotoxins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotB4GVT3xpJLVg90H21EOLACvtfcHk0lizHoujEsFOJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXislKjtQ%253D%253D&md5=0f46bf3c127f3373917bd24fd899b1d6</span></div><a href="/servlet/linkout?suffix=cit30b&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-13-1436&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-13-1436%26sid%3Dliteratum%253Aachs%26aulast%3DPop%26aufirst%3DL.%2BM.%26aulast%3DBarman%26aufirst%3DS.%26aulast%3DShao%26aufirst%3DC.%26aulast%3DPoe%26aufirst%3DJ.%2BC.%26aulast%3DVenturi%26aufirst%3DG.%2BM.%26aulast%3DShelton%26aufirst%3DJ.%2BM.%26aulast%3DPop%26aufirst%3DI.%2BV.%26aulast%3DGerber%26aufirst%3DD.%2BE.%26aulast%3DGirard%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DX.-y.%26aulast%3DBehrens%26aufirst%3DC.%26aulast%3DRodriguez-Canales%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DWistuba%26aufirst%3DI.%2BI.%26aulast%3DRichardson%26aufirst%3DJ.%2BA.%26aulast%3DMinna%26aufirst%3DJ.%2BD.%26aulast%3DTedder%26aufirst%3DT.%2BF.%26aulast%3DVitetta%26aufirst%3DE.%2BS.%26atitle%3DA%2520reevaluation%2520of%2520CD22%2520expression%2520in%2520human%2520lung%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2014%26volume%3D74%26spage%3D263%26epage%3D271%26doi%3D10.1158%2F0008-5472.CAN-13-1436" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaumont, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span> <span> </span><span class="NLM_article-title">Volume of distribution in drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">5691</span>– <span class="NLM_lpage">5698</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00201</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00201" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BC2MXltFSlsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=5691-5698&author=D.+A.+Smithauthor=K.+Beaumontauthor=T.+S.+Maurerauthor=L.+Di&title=Volume+of+distribution+in+drug+design&doi=10.1021%2Facs.jmedchem.5b00201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Volume of Distribution in Drug Design</span></div><div class="casAuthors">Smith, Dennis A.; Beaumont, Kevin; Maurer, Tristan S.; Di, Li</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5691-5698</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Vol. of distribution is one of the most important pharmacokinetic properties of a drug candidate.  It is a major determinant of half-life and dosing frequency of a drug.  For a similar log P, a basic mol. will tend to exhibit higher vol. of distribution than a neutral mol.  Acids often exhibit low vols. of distribution.  Although a design strategy against vol. of distribution can be advantageous in achieving desirable dosing regimen, it must be well-directed in order to avoid detrimental effects to other important properties.  Strategies to increase vol. of distribution include adding lipophilicity and introducing basic functional groups in a way that does not increase metabolic clearance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP7QwgPahf4bVg90H21EOLACvtfcHk0lizHoujEsFOJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXltFSlsb0%253D&md5=2c7289b3602a8edef2d9ef0e6a82e483</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00201%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DBeaumont%26aufirst%3DK.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26aulast%3DDi%26aufirst%3DL.%26atitle%3DVolume%2520of%2520distribution%2520in%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D5691%26epage%3D5698%26doi%3D10.1021%2Facs.jmedchem.5b00201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaidyanathan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koumarianou, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDougald, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pruszynski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lahoutte, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyerly, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalutsky, M. R.</span></span> <span> </span><span class="NLM_article-title"><i>N</i>-Succinimidyl guanidinomethyl iodobenzoate protein radiohalogenation agents: Influence of isomeric substitution on radiolabeling and target cell residualization</span>. <i>Nucl. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">802</span>– <span class="NLM_lpage">812</span>, <span class="refDoi"> DOI: 10.1016/j.nucmedbio.2014.07.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1016%2Fj.nucmedbio.2014.07.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=25156548" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVKntrjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2014&pages=802-812&author=J.+Choiauthor=G.+Vaidyanathanauthor=E.+Koumarianouauthor=D.+McDougaldauthor=M.+Pruszynskiauthor=T.+Osadaauthor=T.+Lahoutteauthor=H.+K.+Lyerlyauthor=M.+R.+Zalutsky&title=N-Succinimidyl+guanidinomethyl+iodobenzoate+protein+radiohalogenation+agents%3A+Influence+of+isomeric+substitution+on+radiolabeling+and+target+cell+residualization&doi=10.1016%2Fj.nucmedbio.2014.07.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">N-Succinimidyl guanidinomethyl iodobenzoate protein radiohalogenation agents: Influence of isomeric substitution on radiolabeling and target cell residualization</span></div><div class="casAuthors">Choi, Jaeyeon; Vaidyanathan, Ganesan; Koumarianou, Eftychia; McDougald, Darryl; Pruszynski, Marek; Osada, Takuya; Lahoutte, Tony; Lyerly, H. Kim; Zalutsky, Michael R.</div><div class="citationInfo"><span class="NLM_cas:title">Nuclear Medicine and Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">802-812</span>CODEN:
                <span class="NLM_cas:coden">NMBIEO</span>;
        ISSN:<span class="NLM_cas:issn">0969-8051</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">N-succinimidyl 4-guanidinomethyl-3-[*I]iodobenzoate ([*I]SGMIB) has shown promise for the radioiodination of monoclonal antibodies (mAbs) and other proteins that undergo extensive internalization after receptor binding, enhancing tumor targeting compared to direct electrophilic radioiodination.  However, radiochem. yields for [131I]SGMIB synthesis are low, which we hypothesize is due to steric hindrance from the Boc-protected guanidinomethyl group ortho to the tin moiety.  To overcome this, we developed the isomeric compd., N-succinimidyl 3-guanidinomethyl-5-[131I]iodobenzoate (iso-[131I]SGMIB) wherein this bulky group was moved from ortho to meta position.  Boc2-iso-SGMIB std. and its tin precursor, N-succinimidyl 3-((1,2-bis(tert-butoxycarbonyl)guanidino)methyl)-5-(trimethylstannyl)benzoate (Boc2-iso-SGMTB), were synthesized using two disparate routes, and iso-[*I]SGMIB synthesized from the tin precursor.  Two HER2-targeted vectors - trastuzumab (Tras) and a nanobody 5 F7 (Nb) - were labeled using iso-[*I]SGMIB and [*I]SGMIB.  Paired-label internalization assays in vitro with both proteins, and biodistribution in vivo with trastuzumab, labeled using the two isomeric prosthetic agents were performed.  When the reactions were performed under identical conditions, radioiodination yields for the synthesis of Boc2-iso-[131I]SGMIB were significantly higher than those for Boc2-[131I]SGMIB (70.7 ± 2.0% vs 56.5 ± 5.5%).  With both Nb and trastuzumab, conjugation efficiency also was higher with iso-[131I]SGMIB than with [131I]SGMIB (Nb, 33.1 ± 7.1% vs 28.9 ± 13.0%; Tras, 45.1 ± 4.5% vs 34.8 ± 10.3%); however, the differences were not statistically significant.  Internalization assays performed on BT474 cells with 5 F7 Nb indicated similar residualizing capacity over 6 h; however, at 24 h, radioactivity retained intracellularly for iso-[131I]SGMIB-Nb was lower than for [125I]SGMIB-Nb (46.4 ± 1.3% vs 56.5 ± 2.5%); similar results were obtained using Tras.  Likewise, a paired-label biodistribution of Tras labeled using iso-[125I]SGMIB and [131I]SGMIB indicated an up to 22% tumor uptake advantage at later time points for [131I]SGMIB-Tras.  Given the higher labeling efficiency obtained with iso-SGMIB, this residualizing agent might be of value for use with shorter half-life radiohalogens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8pMUf48-sTbVg90H21EOLACvtfcHk0liPsbRRj5MD1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVKntrjJ&md5=a798e0bcb0c6ea4efd4fe0dd46147d8c</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.nucmedbio.2014.07.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nucmedbio.2014.07.005%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DJ.%26aulast%3DVaidyanathan%26aufirst%3DG.%26aulast%3DKoumarianou%26aufirst%3DE.%26aulast%3DMcDougald%26aufirst%3DD.%26aulast%3DPruszynski%26aufirst%3DM.%26aulast%3DOsada%26aufirst%3DT.%26aulast%3DLahoutte%26aufirst%3DT.%26aulast%3DLyerly%26aufirst%3DH.%2BK.%26aulast%3DZalutsky%26aufirst%3DM.%2BR.%26atitle%3DN-Succinimidyl%2520guanidinomethyl%2520iodobenzoate%2520protein%2520radiohalogenation%2520agents%253A%2520Influence%2520of%2520isomeric%2520substitution%2520on%2520radiolabeling%2520and%2520target%2520cell%2520residualization%26jtitle%3DNucl.%2520Med.%2520Biol.%26date%3D2014%26volume%3D41%26spage%3D802%26epage%3D812%26doi%3D10.1016%2Fj.nucmedbio.2014.07.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kanwal, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mujahid, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasool, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizwan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, S. A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rashid, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nasir, N. M.</span></span> <span> </span><span class="NLM_article-title">Palladium and copper catalyzed Sonogashira cross coupling an excellent methodology for C-C bond formation over 17 years: A review</span>. <i>Catalysts</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">443</span>, <span class="refDoi"> DOI: 10.3390/catal10040443</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.3390%2Fcatal10040443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtValsrjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=443&author=I.+Kanwalauthor=A.+Mujahidauthor=N.+Rasoolauthor=K.+Rizwanauthor=A.+Malikauthor=G.+Ahmadauthor=S.+A.+A.+Shahauthor=U.+Rashidauthor=N.+M.+Nasir&title=Palladium+and+copper+catalyzed+Sonogashira+cross+coupling+an+excellent+methodology+for+C-C+bond+formation+over+17+years%3A+A+review&doi=10.3390%2Fcatal10040443"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33aR"><div class="casContent"><span class="casTitleNuber">33a</span><div class="casTitle"><span class="NLM_cas:atitle">Palladium and copper catalyzed Sonogashira cross coupling has been an excellent methodology for C-C bond formation for 17 years: a review</span></div><div class="casAuthors">Kanwal, Iram; Mujahid, Aqsa; Rasool, Nasir; Rizwan, Komal; Malik, Ayesha; Ahmad, Gulraiz; Shah, Syed Adnan Ali; Rashid, Umer; Nasir, Nadiah Mad</div><div class="citationInfo"><span class="NLM_cas:title">Catalysts</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">443</span>CODEN:
                <span class="NLM_cas:coden">CATACJ</span>;
        ISSN:<span class="NLM_cas:issn">2073-4344</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Developments in the palladium and copper catalyzed Sonogashira cross coupling achieved in recent years concerning substrates, different catalyst systems and reaction conditions was dicussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1Qetr_rYnRbVg90H21EOLACvtfcHk0liPsbRRj5MD1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtValsrjM&md5=4ed5b5330346580ee28619f48c98994f</span></div><a href="/servlet/linkout?suffix=cit33a&amp;dbid=16384&amp;doi=10.3390%2Fcatal10040443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcatal10040443%26sid%3Dliteratum%253Aachs%26aulast%3DKanwal%26aufirst%3DI.%26aulast%3DMujahid%26aufirst%3DA.%26aulast%3DRasool%26aufirst%3DN.%26aulast%3DRizwan%26aufirst%3DK.%26aulast%3DMalik%26aufirst%3DA.%26aulast%3DAhmad%26aufirst%3DG.%26aulast%3DShah%26aufirst%3DS.%2BA.%2BA.%26aulast%3DRashid%26aufirst%3DU.%26aulast%3DNasir%26aufirst%3DN.%2BM.%26atitle%3DPalladium%2520and%2520copper%2520catalyzed%2520Sonogashira%2520cross%2520coupling%2520an%2520excellent%2520methodology%2520for%2520C-C%2520bond%2520formation%2520over%252017%2520years%253A%2520A%2520review%26jtitle%3DCatalysts%26date%3D2020%26volume%3D10%26spage%3D443%26doi%3D10.3390%2Fcatal10040443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit33b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chinchilla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nájera, C.</span></span> <span> </span><span class="NLM_article-title">Recent advances in Sonogashira reactions</span>. <i>Chem. Soc. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">5084</span>– <span class="NLM_lpage">5121</span>, <span class="refDoi"> DOI: 10.1039/c1cs15071e</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1039%2Fc1cs15071e" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=21655588" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtF2jtbvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2011&pages=5084-5121&author=R.+Chinchillaauthor=C.+N%C3%A1jera&title=Recent+advances+in+Sonogashira+reactions&doi=10.1039%2Fc1cs15071e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33bR"><div class="casContent"><span class="casTitleNuber">33b</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in Sonogashira reactions</span></div><div class="casAuthors">Chinchilla, Rafael; Najera, Carmen</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">5084-5121</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review with 352 refs. discusses the Sonogashira reaction of alkynes and aryl halides to yield aryl alkynes and, in particular, the development of catalysts for Sonogashira reactions.  The mechanism of the Sonogashira reaction, the use of supported and unsupported palladium complexes with phosphines, nitrogen-contg. (imine and pyridine) ligands, ligands contg. phosphorus, nitrogen, and oxygen, and N-heterocyclic carbenes as catalysts, the use of palladacycles, ligand-free palladium species, and palladium nanoparticles as catalysts, and the use of other metals as catalysts or cocatalysts for Sonogashira coupling reactions are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRRxM3DrQgRrVg90H21EOLACvtfcHk0lhhBT1yal9ljA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtF2jtbvE&md5=daa28257436731bf1fc800f0d1ce46f3</span></div><a href="/servlet/linkout?suffix=cit33b&amp;dbid=16384&amp;doi=10.1039%2Fc1cs15071e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc1cs15071e%26sid%3Dliteratum%253Aachs%26aulast%3DChinchilla%26aufirst%3DR.%26aulast%3DN%25C3%25A1jera%26aufirst%3DC.%26atitle%3DRecent%2520advances%2520in%2520Sonogashira%2520reactions%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2011%26volume%3D40%26spage%3D5084%26epage%3D5121%26doi%3D10.1039%2Fc1cs15071e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adhikari, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zacharias, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadowsky, J.</span></span> <span> </span><span class="NLM_article-title">Site-specific conjugation to Cys-engineered THIOMAB antibodies</span>. <i>Methods Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>2078</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">69</span>, <span class="refDoi"> DOI: 10.1007/978-1-4939-9929-3_4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1007%2F978-1-4939-9929-3_4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=31643049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnsVOmtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2078&publication_year=2020&pages=51-69&author=P.+Adhikariauthor=N.+Zachariasauthor=R.+Ohriauthor=J.+Sadowsky&title=Site-specific+conjugation+to+Cys-engineered+THIOMAB+antibodies&doi=10.1007%2F978-1-4939-9929-3_4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Site-Specific Conjugation to Cys-Engineered THIOMAB Antibodies</span></div><div class="casAuthors">Adhikari, Pragya; Zacharias, Neelie; Ohri, Rachana; Sadowsky, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">2078</span>
        (<span class="NLM_cas:issue">Antibody-Drug Conjugates</span>),
    <span class="NLM_cas:pages">51-69</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1940-6029</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Antibodies bearing engineered cysteine residues (termed THIOMAB antibodies) enable the site-selective attachment of a drug, label or other payload for specific delivery to certain tissues (e.g., tumors).  This Chapter describes detailed methods we have developed and optimized for the conjugation, purifn. and anal. of THIOMAB antibody drug conjugates (TDCs).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrUk7y1MvJF7Vg90H21EOLACvtfcHk0lhhBT1yal9ljA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnsVOmtLY%253D&md5=aac9db6d1b978df97066912e9d1e9e2a</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1007%2F978-1-4939-9929-3_4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-4939-9929-3_4%26sid%3Dliteratum%253Aachs%26aulast%3DAdhikari%26aufirst%3DP.%26aulast%3DZacharias%26aufirst%3DN.%26aulast%3DOhri%26aufirst%3DR.%26aulast%3DSadowsky%26aufirst%3DJ.%26atitle%3DSite-specific%2520conjugation%2520to%2520Cys-engineered%2520THIOMAB%2520antibodies%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2020%26volume%3D2078%26spage%3D51%26epage%3D69%26doi%3D10.1007%2F978-1-4939-9929-3_4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tohma, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kita, Y.</span></span> <span> </span><span class="NLM_article-title">Hypervalent iodine reagents for the oxidation of alcohols and their application to complex molecule synthesis</span>. <i>Adv. Synth. Catal.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>346</i></span>,  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">124</span>, <span class="refDoi"> DOI: 10.1002/adsc.200303203</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1002%2Fadsc.200303203" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjt1ensLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=346&publication_year=2004&pages=111-124&author=H.+Tohmaauthor=Y.+Kita&title=Hypervalent+iodine+reagents+for+the+oxidation+of+alcohols+and+their+application+to+complex+molecule+synthesis&doi=10.1002%2Fadsc.200303203"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Hypervalent iodine reagents for the oxidation of alcohols and their application to complex molecule synthesis</span></div><div class="casAuthors">Tohma, Hirofumi; Kita, Yasuyuki</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Synthesis & Catalysis</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">346</span>
        (<span class="NLM_cas:issue">2+3</span>),
    <span class="NLM_cas:pages">111-124</span>CODEN:
                <span class="NLM_cas:coden">ASCAF7</span>;
        ISSN:<span class="NLM_cas:issn">1615-4150</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Hypervalent iodine(V) derivs. such as 2-iodoxybenzoic acid (IBX) and Dess-Martin periodinane [DMP; 1,1,1-tris(acetyloxy)-1,1-dihydro-1,2-benziodoxol-3-(1H)-one] are used widely for the oxidn. of alcs. to aldehydes and ketones during the last decade because of their high chemoselectivity, mild reactivity, and high yielding process.  This review focuses on the recent progress in the oxidn. of alcs. to carbonyl compds. using IBX, DMP, and other hypervalent iodine reagents, and their application to total syntheses of a variety of complex natural products.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDc0KufQbayLVg90H21EOLACvtfcHk0lhhBT1yal9ljA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjt1ensLY%253D&md5=b7fde1a6d554fb1550dc43f3eb575d48</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1002%2Fadsc.200303203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fadsc.200303203%26sid%3Dliteratum%253Aachs%26aulast%3DTohma%26aufirst%3DH.%26aulast%3DKita%26aufirst%3DY.%26atitle%3DHypervalent%2520iodine%2520reagents%2520for%2520the%2520oxidation%2520of%2520alcohols%2520and%2520their%2520application%2520to%2520complex%2520molecule%2520synthesis%26jtitle%3DAdv.%2520Synth.%2520Catal.%26date%3D2004%26volume%3D346%26spage%3D111%26epage%3D124%26doi%3D10.1002%2Fadsc.200303203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="note"><p class="first last">For alternate preparations of dibromide <b>46</b>, see:</p></div><div class="NLM_citation" id="rightTab-cit36a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Duchêne, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vögtle, F.</span></span> <span> </span><span class="NLM_article-title">A hydrocarbon skeleton with twelve identical functional groups. Synthesis of a dodeca host compound</span>. <i>Synthesis</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>1986</i></span>,  <span class="NLM_fpage">659</span>– <span class="NLM_lpage">661</span>, <span class="refDoi"> DOI: 10.1055/s-1986-31738</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1055%2Fs-1986-31738" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1986&publication_year=1986&pages=659-661&author=K.-H.+Duch%C3%AAneauthor=F.+V%C3%B6gtle&title=A+hydrocarbon+skeleton+with+twelve+identical+functional+groups.+Synthesis+of+a+dodeca+host+compound&doi=10.1055%2Fs-1986-31738"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36a&amp;dbid=16384&amp;doi=10.1055%2Fs-1986-31738&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-1986-31738%26sid%3Dliteratum%253Aachs%26aulast%3DDuch%25C3%25AAne%26aufirst%3DK.-H.%26aulast%3DV%25C3%25B6gtle%26aufirst%3DF.%26atitle%3DA%2520hydrocarbon%2520skeleton%2520with%2520twelve%2520identical%2520functional%2520groups.%2520Synthesis%2520of%2520a%2520dodeca%2520host%2520compound%26jtitle%3DSynthesis%26date%3D1986%26volume%3D1986%26spage%3D659%26epage%3D661%26doi%3D10.1055%2Fs-1986-31738" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit36b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Dash, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satapathy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaillard, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maguire, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosmane, N. S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and properties of carborane-appended C3-symmetrical extended π systems</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">6578</span>– <span class="NLM_lpage">6587</span>, <span class="refDoi"> DOI: 10.1021/ja101845m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja101845m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvVaiu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2010&pages=6578-6587&author=B.+P.+Dashauthor=R.+Satapathyauthor=E.+R.+Gaillardauthor=J.+A.+Maguireauthor=N.+S.+Hosmane&title=Synthesis+and+properties+of+carborane-appended+C3-symmetrical+extended+%CF%80+systems&doi=10.1021%2Fja101845m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36bR"><div class="casContent"><span class="casTitleNuber">36b</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Properties of Carborane-Appended C3-Symmetrical Extended π Systems</span></div><div class="casAuthors">Dash, Barada Prasanna; Satapathy, Rashmirekha; Gaillard, Elizabeth R.; Maguire, John A.; Hosmane, Narayan S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6578-6587</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">C3-sym. π-conjugated compds. contg. three to six o-carborane clusters were synthesized by employing Pd-catalyzed Suzuki coupling reactions and Pd-catalyzed acetylation reactions, followed by Si tetrachloride mediated trimerization reactions.  Carborane-contg. extended trimers emit blue light.  Incorporation of o-carborane clusters into extended π-conjugated systems led to 22-70% enhancement of their relative fluorescence quantum yields.  Decapitation of o-carborane clusters made these extended trimers water sol., and their aq. solns. also are fluorescent, but with a reduced fluorescence intensity.  The carborane-appended π-conjugated compds. are extremely thermally stable, and for some of these compds. only 10% mass loss occurred at temps. close to 500°.  The DSC thermograms of smaller Ccage-appended trimers indicate the occurrence of solid-solid phase transitions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7pLA4S9d_47Vg90H21EOLACvtfcHk0lg0pwOzCh33lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvVaiu7g%253D&md5=c56e1721fbb1bc04e84c14b5ef88ea60</span></div><a href="/servlet/linkout?suffix=cit36b&amp;dbid=16384&amp;doi=10.1021%2Fja101845m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja101845m%26sid%3Dliteratum%253Aachs%26aulast%3DDash%26aufirst%3DB.%2BP.%26aulast%3DSatapathy%26aufirst%3DR.%26aulast%3DGaillard%26aufirst%3DE.%2BR.%26aulast%3DMaguire%26aufirst%3DJ.%2BA.%26aulast%3DHosmane%26aufirst%3DN.%2BS.%26atitle%3DSynthesis%2520and%2520properties%2520of%2520carborane-appended%2520C3-symmetrical%2520extended%2520%25CF%2580%2520systems%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2010%26volume%3D132%26spage%3D6578%26epage%3D6587%26doi%3D10.1021%2Fja101845m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit36c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sookcharoenpinyo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrand, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brotherhood, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crump, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, A. P.</span></span> <span> </span><span class="NLM_article-title">High-affinity disaccharide binding by tricyclic synthetic lectins</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">4586</span>– <span class="NLM_lpage">4590</span>, <span class="refDoi"> DOI: 10.1002/anie.201200447</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=10.1002%2Fanie.201200447" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvVGlt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2012&pages=4586-4590&author=B.+Sookcharoenpinyoauthor=E.+Kleinauthor=Y.+Ferrandauthor=D.+B.+Walkerauthor=P.+R.+Brotherhoodauthor=C.+Keauthor=M.+P.+Crumpauthor=A.+P.+Davis&title=High-affinity+disaccharide+binding+by+tricyclic+synthetic+lectins&doi=10.1002%2Fanie.201200447"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36cR"><div class="casContent"><span class="casTitleNuber">36c</span><div class="casTitle"><span class="NLM_cas:atitle">High-Affinity Disaccharide Binding by Tricyclic Synthetic Lectins</span></div><div class="casAuthors">Sookcharoenpinyo, Bunyarithi; Klein, Emmanuel; Ferrand, Yann; Walker, D. Barney; Brotherhood, Peter R.; Ke, Chengfeng; Crump, Matthew P.; Davis, Anthony P.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4586-4590, S4586/1-S4586/79</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Carbohydrate recognition mediates a wide range of biol. processes, including protein folding and trafficking, cell-cell recognition, infection by pathogenic organisms, and many aspects of the immune response.  Mols. capable of selective carbohydrate binding are therefore valuable as tools for biol. research, and potentially as medicinal agents.  There are many saccharide-binding proteins - notably the group known as lectins - but they often exhibit low affinities and less-than-ideal selectivities.  Moreover, they are generally too unstable and toxic for medical use.  Opportunities thus exist for synthetic systems, provided they can compete with lectins in terms of binding strength and selectivity.  The present study provides evidence that tricyclic synthetic lectins are capable of high-affinity disaccharide binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEPMTEToNGQrVg90H21EOLACvtfcHk0lg0pwOzCh33lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvVGlt74%253D&md5=9432aa4533c8cc60670c08e3cbfa3f20</span></div><a href="/servlet/linkout?suffix=cit36c&amp;dbid=16384&amp;doi=10.1002%2Fanie.201200447&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201200447%26sid%3Dliteratum%253Aachs%26aulast%3DSookcharoenpinyo%26aufirst%3DB.%26aulast%3DKlein%26aufirst%3DE.%26aulast%3DFerrand%26aufirst%3DY.%26aulast%3DWalker%26aufirst%3DD.%2BB.%26aulast%3DBrotherhood%26aufirst%3DP.%2BR.%26aulast%3DKe%26aufirst%3DC.%26aulast%3DCrump%26aufirst%3DM.%2BP.%26aulast%3DDavis%26aufirst%3DA.%2BP.%26atitle%3DHigh-affinity%2520disaccharide%2520binding%2520by%2520tricyclic%2520synthetic%2520lectins%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2012%26volume%3D51%26spage%3D4586%26epage%3D4590%26doi%3D10.1002%2Fanie.201200447" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dragovich, P.</span>; <span class="NLM_string-name">Pei, Z.</span>; <span class="NLM_string-name">Pillow, T.</span>; <span class="NLM_string-name">Sadowsky, J.</span>; <span class="NLM_string-name">Verma, V.</span>; <span class="NLM_string-name">Zhang, D.</span></span> <span> </span><span class="NLM_article-title">Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof. International patent application</span>, <span class="NLM_year">2018</span>, <span class="NLM_patent">WO 201831662</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=P.+Dragovich&author=Z.+Pei&author=T.+Pillow&author=J.+Sadowsky&author=V.+Verma&author=D.+Zhang&title=Pyrrolobenzodiazepine+prodrugs+and+antibody+conjugates+thereof.+International+patent+application"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDragovich%26aufirst%3DP.%26atitle%3DPyrrolobenzodiazepine%2520prodrugs%2520and%2520antibody%2520conjugates%2520thereof.%2520International%2520patent%2520application%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rettig, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weingarth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langel, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisz, K.</span></span> <span> </span><span class="NLM_article-title">Solution structure of a covalently bound pyrrolo[2,1-c][1,4]benzodiazepinebenzimidazole hybrid to a 10mer DNA duplex</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">12223</span>– <span class="NLM_lpage">12232</span>, <span class="refDoi"> DOI: 10.1021/bi901655t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi901655t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVKhs7nF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2009&pages=12223-12232&author=M.+Rettigauthor=M.+Weingarthauthor=W.+Langelauthor=A.+Kamalauthor=P.+P.+Kumarauthor=K.+Weisz&title=Solution+structure+of+a+covalently+bound+pyrrolo%5B2%2C1-c%5D%5B1%2C4%5Dbenzodiazepinebenzimidazole+hybrid+to+a+10mer+DNA+duplex&doi=10.1021%2Fbi901655t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Solution Structure of a Covalently Bound Pyrrolo[2,1-c][1,4]benzodiazepine-Benzimidazole Hybrid to a 10mer DNA Duplex</span></div><div class="casAuthors">Rettig, Michael; Weingarth, Markus; Langel, Walter; Kamal, Ahmed; Kumar, P. Praveen; Weisz, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">12223-12232</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A pyrrolo[2,1-c][1,4]benzodiazepine-benzimidazole hybrid (PBD-BIMZ) derived from the tricyclic anticancer PBD antibiotics can covalently bind to a guanine base at its exocyclic 2-amino group in double-helical DNA.  Through the formation of stable DNA adducts, these hybrids have previously been shown to have significant anticancer activity in a no. of cell lines.  Here, the three-dimensional soln. structure of the complex formed between the self-complementary DNA decamer 5'-AACAATTGTT-3' and PBD-BIMZ has been investigated by two-dimensional NMR spectroscopy and NOE distance restraint mol. dynamics simulations.  Refinements using an explicit solvation model yielded a complex structure that is in good agreement with the NMR structural data.  Successful convergence is indicated by an av. mutual root-mean-square deviation of <1 Å for three final representative structures selected by clustering methods from the mol. dynamics trajectories at 300 K.  The ligand binds in an (11S,11aS) configuration to one of the two sym. located guanine bases of the duplex and is oriented with its benzimidazole moiety toward the 5'-end of the modified guanine.  It is accommodated within the minor groove covering the centrally located 6 bp.  Conformational and helical parameters of the DNA adduct are typical of a B-like duplex, and more significant helical distortions by the covalent binding of PBD-BIMZ are mostly confined to the covalent binding site and the junction between complexed and noncomplexed DNA segments.  In contrast to the overall well-detd. conformation of the bound hybrid, its terminal N-methylpiperazine ring appears to adopt various conformations assocd. with increased flexibility.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo37xfG6Wuv3bVg90H21EOLACvtfcHk0lgkora4EfAtcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVKhs7nF&md5=ae48ee51140a5b74afd2d583558414cb</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fbi901655t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi901655t%26sid%3Dliteratum%253Aachs%26aulast%3DRettig%26aufirst%3DM.%26aulast%3DWeingarth%26aufirst%3DM.%26aulast%3DLangel%26aufirst%3DW.%26aulast%3DKamal%26aufirst%3DA.%26aulast%3DKumar%26aufirst%3DP.%2BP.%26aulast%3DWeisz%26aufirst%3DK.%26atitle%3DSolution%2520structure%2520of%2520a%2520covalently%2520bound%2520pyrrolo%255B2%252C1-c%255D%255B1%252C4%255Dbenzodiazepinebenzimidazole%2520hybrid%2520to%2520a%252010mer%2520DNA%2520duplex%26jtitle%3DBiochemistry%26date%3D2009%26volume%3D48%26spage%3D12223%26epage%3D12232%26doi%3D10.1021%2Fbi901655t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i58"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00691">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_68776"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c00691?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00691</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">95% confidence intervals for <a class="ref showTableEvent internalNav" href="#tbl1">Table <a class="ref showTableEvent internalNav" href="#tbl1">1</a></a> IC<sub>50</sub> data, antiproliferation activity of compounds <b>5</b>–<b>9</b> against a panel of cancer cell lines, 95% confidence intervals for <a class="ref showTableEvent internalNav" href="#tbl2">Table <a class="ref showTableEvent internalNav" href="#tbl2">2</a></a> IC<sub>50</sub> data, CD22 expression in WSU-DLCL2 cells, <i>in vivo</i> stability for conjugates <b>11a</b> and <b>13a</b>, and conjugate characterization data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00691/suppl_file/jm0c00691_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings of <a class="ref showTableEvent internalNav" href="#tbl1">Table <a class="ref showTableEvent internalNav" href="#tbl1">1</a></a> compounds (<b>5</b>–<b>10</b>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00691/suppl_file/jm0c00691_si_002.csv">CSV</a>)</p></li><li><p class="inline">Molecular formula strings of new compounds in <a class="ref internalNav" href="#sch1">Schemes 1</a>–<a class="ref internalNav" href="#sch5">5</a> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00691/suppl_file/jm0c00691_si_003.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00691/suppl_file/jm0c00691_si_001.pdf">jm0c00691_si_001.pdf (615.34 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00691/suppl_file/jm0c00691_si_002.csv">jm0c00691_si_002.csv (1.03 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00691/suppl_file/jm0c00691_si_003.csv">jm0c00691_si_003.csv (5.4 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c00691&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-17%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c00691%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c00691" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679900d0ebf82308","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
